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Hyperactivity of the classical renin angiotensin system (cRAS) (ACE-1/Ang-II/AT1R) within the 
brain exerts damaging effects and contributes to the pathogenesis of Alzheimer’s disease (AD). 
Alternative ‘downstream’ regulatory RAS pathways: the non-classical RAS axis (ACE-2/Ang (1-
7)/MasR) and the alternative regulatory RAS axis (rRAS) (APA/Ang-III/APN/Ang-IV/IRAP) have 
recently been discovered that counter-regulate the damaging effects of cRAS signalling, whilst also 
regulating synaptic function and boosting learning and memory. Despite a strong association of an 
imbalance in brain RAS pathways in relation to AD pathology and cognitive decline, the role of 
ACE-1 and the involvement of the other rRAS pathways in relation to AD pathogenesis remains 
unclear. This thesis describes a series of investigations of both cRAS and rRAS, and non-classical 
RAS components, in AD in post-mortem brain tissue aimed to test the general hypothesis that 
alterations of both the classical and regulatory axes of brain RAS can influence AD pathogenesis and 
are related to vascular dysfunction.  
 
For this thesis I have studied mid-frontal cortex (Brodmann area 8/9) from post-mortem confirmed 
AD cases (n= 70) and age-matched controls (n= 48) that were matched closely for age-at-death and 
post-mortem delay (PMD). I developed specific ACE-1 N-domain and C-domain activity assays 
using immunocapture-based fluorogenic substrates. I measured the level of angiotensin peptides 
(Ang-I and Ang (1-7)) and characterised the expression, enzyme activity and distribution of rRAS 
receptors including MasR, Ang-IV, and IRAP by ELISA and immunohistochemistry. I used 
previously measured markers of disease pathology (parenchymal Aβ/Tau and insoluble Aβ40 and 42) 
and measured markers of cerebrovascular dysfunction including brain ischaemia (VEGF) and tissue 
oxygenation (MAG:PLP1 ratio) and examined the relationship between alterations of brain RAS 
components with these markers. I also explored the novel non-AT1R and non-AT2R receptor 




Divergent ACE-1 C-domain (increased) and N-domain (reduced) enzyme activity was observed in 
AD that potentially favours Ang-II production and limits Aβ clearance and provides further insight 
into the complex role of ACE-1 in AD. These data potentially indicate that C-domain ACEIs may 
have greater therapeutic benefit for AD. Ang-I level was reduced and the ratio of Ang-II:Ang-I was 
increased in AD - as would be expected with overactivation of ACE-1. Changes were observed in 
mid-frontal cortex in the rRAS pathways indicative of dysregulation in AD: the Ang-II:Ang (1-7) 
ratio, a proxy marker of ACE-2 activity, was reduced in AD; IRAP activity was also reduced in AD, 
however, other components of the rRAS pathways including Ang (1-7), and MasR and Ang-IV and 
IRAP protein level remained unchanged in AD (although they were related to ischaemic damage).  
Interestingly, the non-AT1R and non-AT2R binding protein (neurolysin), previously not studied in 
AD, was reduced in relation to disease severity and ischaemia in AD.  
 
In conclusion, these data support recent findings within the field that indicate that regulatory RAS 
pathways are dysfunctional in AD associated with disease pathology and vascular function. This 
thesis also offers insights into novel RAS components, such as neurolysin and neurotensin and their 
involvement in AD, that will require further investigation. The RAS remains a pivotal and complex 
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Dementia is characterised clinically by a progressive decline in higher cognitive functions, such as 
thinking, memory, planning, problem-solving and associated behavioural impairment, that together 
significantly affects a patient’s daily functioning activities (1). Dementia is a multi-aetiological 
syndrome that mainly affects the elderly and is caused by different neurodegenerative diseases 
including Alzheimer’s disease (AD), vascular dementia (VaD), mixed dementia, dementia with Lewy 
bodies (DLB), Fronto-temporal dementia (FTD), Parkinson’s disease dementia (PDD) and less 
common causes including Huntington’s disease and Creutzfeldt-Jakob disease and multiple sclerosis 
(2). One of the early symptoms of dementia is impairment of short-term memory. As dementia 
progresses, a variety of symptoms including progressive cognitive impairment, disorientation, 
confusion, mood swings and transient behavioural issues, language impairment, difficulties in 
movement and progressive disabilities occur (3). The severity and duration of these symptoms vary 
amongst people with different types of dementia and at different stages of the disease. 
 
1.1.1 Types of Dementia 
	
	
AD is the most common type of dementia and accounts for 60-80% of all dementia cases (Figure 1.1) 
(4). AD was first described in 1906 when Alois Alzheimer observed the unusual clinical symptoms of 
his patient (Auguste Deter) that included loss of memory, hallucination, disorientation and delusions 
(5). Seventy years later, AD, which was now widely recognized as a common type of dementia also 
became recognised as a major cause of death (6). Early clinical symptoms of AD are forgetfulness and 
short-term memory loss, which together are known as mild cognitive impairment (MCI). Other 
symptoms such as apathy and depression appear later (7). In addition to these clinical symptoms, AD 
has the two distinct neuropathological hallmarks that differentiate it from other types of dementia; 
extracellular accumulation of amyloid beta (Aβ) plaques that triggers an intracellular accumulation of 
neurofibrillary tangles (NFTs) and intiates a series of pathological events attributed to neurotoxicity in 




Figure 1.1 Types of dementia. 
Pie chart showing the estimated percentages of different types of dementia.  
AD - Alzheimer’s disease; VaD - Vascular dementia; Mixed dementia (a condition when more than 
one type of dementia co-occur; DLB - Dementia with Lewy bodies; FTD - Fronto-temporal dementia; 
PDD - Parkinson’s disease dementia; Others include numerous less common causes of dementia 
Huntington’s disease and Creutzfeldt-Jakob disease, multiple sclerosis, infections, metabolic disease 
and tumours (sourced and adapted from Alzheimer’s Society UK, 2015)(7).   
 
The second most common type of dementia is VaD and accounts for 15-20% of all dementia cases (7). 
Early symptoms that first appear in patients with VaD include impaired judgement, poor planning and 
impaired ability to organise that are called executive cognitive functions, in contrast to deficits in 
memory and language functions observed in AD (8). The underlying mechanisms of VaD are 
associated with ischaemic tissue damage as a result of reduced cerebral blood flow (CBF) either by 
blocked or damaged blood vessel that result in infarcts or haemorrhage (9). VaD is divided into several 
sub-categories that include: multi-infarction dementia, strategic infarction dementia, haemorrhagic 
dementia, mixed dementia, subcortical ischaemic vascular dementia (SIVD) and other forms of VaD 
(10, 11). There is evidence that many forms of dementia also have vascular abnormalities and thus of 
all the dementias, VaD is possibly one of the biggest contributors to co-morbidity and mixed 
dementias (11-13).  
 
DLB, as a singular cause of dementia, accounts for approximately 5% of all dementia cases (7). DLB 
is characterised neuropathologically by abnormal accumulation of alpha-synuclein in cortical neurons 
	 3 
associated with brain atrophy (14). In addition to the common clinical symptoms of AD, patients with 
DLB also have disturbances in sleep pattern, visual hallucinations, gait imbalance and other 
parkinsonian movement abnormalities (15). If the onset of movement disorders precedes dementia by 
twelve months, likely as a result of alpha-synuclein aggregation in the substantia nigra resulting in 
degeneration of the dopaminergic neurons, it is diagnosed as PDD, which accounts for approximately 
2% of all cases of dementia. Both clinical diagnosis and neuropathological assessment are required to 
differentiate between DLB and PDD (16). 
Dementia with more than one cause is known as mixed dementia and has been suggested to account 
for about 10% of all other dementia types (7). However as mentioned, many people with dementia also 
have vascular changes or dysfunction that are also associated with VaD and so mixed dementia is 
likely to be under recognised. The most common combination of mixed dementia is AD-VaD, this is 
followed by AD-DLB, and then AD-VaD-DLB. VaD-DLB is less commonly observed (12). Mixed 
dementia is increased with age and is more prevalent in older people (age 85 or older) (17, 18).  
FTD is a heterogenous neurodegenerative group of dementias with different clinical and pathological 
characteristics compared to AD and accounts for about 2% of all dementia cases (7, 19). FTD is 
characterised pathologically by atrophy of both frontal and temporal lobes, neuronal loss and gliosis 
and spongiosis due to abnormal aggregation of protein inclusions that mainly comprise tau protein or 
the transactive response DNA-binding protein 43kDa (TDP-43) (20). FTD is divided into three 
subgroups that include FTD-tauopathies such as Pick’s disease, corticobasal degeneration, argyrophilic 
grain disease and others such as FTD-ubiquitin and FTD-without tau or ubiquitin (19). FTD tends to 
affect people at a younger age where approximately 60% of people with FTD are aged between 40-60 
years old (21). Early symptoms of patients with FTD include behavioural and personality changes and 
language impairment, while memory function is spared at the early stage of the disease (4).  
There are other less common causes of dementia such as Huntington’s disease and Creutzfeldt-Jakob 







1.1.2 Prevalence of Dementia 
 
Dementia is considered as a major cause of death and a global health burden with around 50 million 
people suffering from dementia worldwide (22). Every 3 seconds someone develops dementia and 
every year there are around 10 million new cases globally (23). This number has been predicted by 
some researchers to double every 20 years, reaching 75 million in 2030 and 131.5 million in 2050 (24). 
Currently, around 850,000 people in the UK are estimated to have dementia where the incidence of 
dementia has been predicted to rise to over 1 million by 2025 and over 2 million by 2051 (7). A recent 
modelling study estimated the number of people that will have dementia in the UK by 2040 is more 
than 1.2 million with an increase by 57% from 2016 (25). However, more recent research and findings 
are pointing to a slowing in incidence rates although there will still be high prevalence of AD with an 
increasingly ageing population and the current absence of any disease-modifying treatments (26, 27).  
 
AD is the most common form of dementia accounting for between 60-80% of all dementia cases (4). 
The prevalence of AD increases with age and ranges from ~1% in 60-64 year olds compared to ~30% 
in the 90-94 year olds (2). The majority of AD cases, between 95-99%, are regarded as sporadic in 
origin (SAD) also known as late-onset AD (LOAD) (28), whereas 1-5% of AD cases are familial 
(FAD) (early-onset, EOAD) (3).	 
 
	
1.2 Alzheimer’s disease  
 
AD is a complex, progressive chronic neurodegenerative disorder. Characterised clinically by 
cognitive decline associated with behavioural impairment and neuropathologically by the presence of 
cortical extracellular senile Aβ plaques and intracellular NFTs. In addition, AD has a complex 
aetiology including a combination of genetic and lifestyle factors (29). 
 
1.2.1 Neuropathology of AD 
 
Multiple macroscopic changes are visible in the AD brain that include cortical atrophy predominantly 
affecting the frontal and medial temporal lobes, widening of the sulci and enlargement of the lateral 
and third ventricles. These changes can be detected clinically by a magnetic resonance imaging (MRI) 
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scan (30). Cortical micro-infarcts and white matter changes, associated with cerebrovascular disease, 
may also be present (29).  
At a microscopic level, the two major and most commonly referred to pathological hallmarks of AD 
are extracellular Aβ plaques and intracellular NFTs (31). Aβ plaques are extracellular proteinaceous 
deposits primarily formed from abnormal accumulation of the Aβ peptide derived from the sequential 
enzymatic actions of β- and γ- secretase on the transmembrane amyloid precursor protein (APP). 
Plaques are characterised as either being diffuse (composed mainly of Aβ42 and thought to be the 
earliest form of amyloid deposits (32), or neuritic (senile) that contain a central core of fibrillar 
amyloid peptide (Aβ40 and Aβ42), which is surrounded by dystrophic neurites, reactive astrocytes and 
microglial cells (33). Both forms of amyloid plaques have been thought to play a significant role in the 
pathogenesis of AD, but more recently the presence of (more neurotoxic) soluble oligomeric forms has 
been attributed with the greatest levels of neurotoxicity in the brain in AD (34). 
 
NFTs are composed of intracellular aggregated phosphorylated tau. Tau is a microtubule-associated 
protein that normally plays a physiological role in microtubule stabilisation (35). However, in AD 
there is an imbalance in the hyperphosphorylation state of tau (36). Hyperphosphorylated tau impairs 
axonal transport and synaptic function (37). The levels of hyperphosphorylated tau proteins are 
increased in the AD brain (35). The distribution of NFTs is important in the post-mortem diagnosis of 
AD (38). Studies indicate a synergistic role of Aβ and tau in AD (39-41). However, much uncertainty 
still exists about the relationship between the Aβ and tau proteins and their interaction in AD.  
 
A third, less often referred to, but arguably as common as senile plaques and tangles, is cerebral 
amyloid angiopathy (CAA) that contributes to AD pathogenesis. CAA affects around 90% of elderly 
with AD and approximately 30% of normal elderly (42, 43). Accumulation of Aβ in and around 
cerebral blood vessels can alter blood-brain barrier (BBB) integrity and limit blood supply (44), or can 
increase risk of haemorrhage which is another risk factor for dementia (45). The exact mechanisms of 





1.2.2 Pathological hypotheses of Alzheimer’s disease 
 
1.2.2.1 The amyloid cascade hypothesis  
 
The amyloid cascade hypothesis, perhaps the most widely accepted and predicted cause of AD 
pathogenesis, states that the accumulation of Aβ is central to the pathogenesis of AD and triggers a 
series of downstream events that ultimately result in nerve cell injury/death and cognitive impairment 
(Figure 1.2) (46). This pathogenic cascade starts when there is accumulation and increased levels of 
pathogenic Aβ42 (either oligomeric or fibrillar) or an increase in the ratio of Aβ42:40. Elevated Aβ 
causes a subsequent cascade resulting in tissue damage such as activation of microglia and astrocytes, 
altered ionic homeostasis and oxidative injury in neurons and activation of kinases, which lead to 
hyperphosphorylation of the tau protein, synaptic dysfunction, and ultimately neuronal death (47, 48). 
Several imaging and brain biomarker studies, and recent disease-modelling studies indicate that 
abnormal accumulation of Aβ in the brain begins up to 10-20 years before the onset of AD clinical 





Figure 1.2 The amyloid (Aβ) cascade hypothesis of AD pathogenesis. 
The figure illustrates the proposed sequence of major pathogenic effects of Aβ accumulation leading to 
AD. The pathogenic sequence is initiated by accumulation of Aβ42 that alters tau phosphorylation, 
activates inflammation, oxidative stress and other neurotoxic events and leads to synaptic remodelling 
and neuronal death. More recently, the direct neurotoxic effects of oligomeric Aβ, indicated by the 
curved orange arrow have been recognised. Aβ42 - Amyloid beta 42. NFTs - Neurofibrillary tangles 
(adapted from Selkoe and Hardy. 2016)(48). 
 
 
1.2.2.1.1 Aβ Production 
 
The Aβ peptide is a product of the proteolytic cleavage of APP, an integral trans-membrane 
glycoprotein consisting of a large extracellular N-terminus and a smaller cytoplasmic C-terminus (51). 
APP usually comprises 770 amino acids and is encoded for by APP located on chromosome 21 (52). 
APP can be cleaved by α-secretase that includes members of the ADAM (a disintegrin and 
metalloproteinase) family enzymes (ADAM 9, ADAM 10 and TAC (tumor necrosis factor-α 
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convertase, ADAM 17); β-secretase (BACE1) and γ-secretase (made up of presenilins (presenilin-
1(PSEN1) and presenilin-1(PSEN2)), nicastrin, anterior pharynx defective 1 (Aph-1) and presenilin 
enhancer 2 (Pen-2) (53-55).  
 
When APP is hydrolysed by α-secretase at residues 16–17 of the Aβ domain, a large non-pathogenic 
peptide known as soluble N-terminal ectodomain of APP (sAPPα) and a C-terminal fragment (C83) 
are generated. These non-pathogenic fragments are further cleaved by γ-secretase to produce the APP 
intracellular domain (AICD) and a 3-kDa peptide (P3) – collectively this pathway is called non-
amyloidogenic processing. Toxic amyloidogenic processing of APP, generates heterogeneous 
polypeptides with 40 to 42 amino acids are produced in the brain when APP is first hydrolysed by β-
secretase to produce a soluble fragment of APP (sAPPβ) and the C-terminal fragment (C99) followed 
by cleavage by γ-secretase (Figure 1.3) (56). Autosomal dominant mutations in APP that are located 
within the Aβ sequence increase the production and aggregation of Aβ, and account for around 10% of 
mutations in FAD (57). The remaining 90% of identified mutations in FAD are located in PSEN1 and 
PSEN 2 that are linked to increased production of Aβ42 or those that increase the ratio of Aβ42/Aβ40 
in humans (48, 58). 
 
 
Figure 1.3 APP processing showing the amyloidogenic and non-amyloidogenic pathways. 
APP is cleaved by β-secretase (BACE1) to produce sAPPβ followed by cleavage of the sAPPβ 
fragment by γ-secretase (presenilins, nicastrin, Aph-1, and Pen-2) to produce Aβ and AICD 
(amyloidogenic pathway). APP is cleaved by α-secretases (ADAM 19, ADAM 10, TACE) to produce 
sAPPα followed by cleavage of the soluble fragment by γ-secretase to release AICD and P3 (non-
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amyloidogenic pathway). APP - amyloid precursor protein, Aβ - Amyloid beta, sAPPβ - soluble 
fragment of APP β, C99 - C-terminal fragment 99, AICD - APP intracellular domain, sAPPα - soluble 




1.2.2.1.2 Aβ aggregation 
 
Soluble Aβ monomers aggregate in a dynamic, reversible process into small soluble multimers that can 
be converted by further oligomerisation to form micelles and protofibrils. In the final irreversible step 
of this process, protofibrils undergo conformational change to form insoluble fibrils that aggregate and 
form the Aβ plaque (Figure 1.4) (59, 60). The most common species of Aβ that are produced and 
aggregate during plaque formation are Aβ40 and Aβ42 (61). The ratio of Aβ40:Aβ42 in brain tissue is 
predicted to be approximately 9:1 in the healthy non-diseased individuals (62). In contrast to Aβ40, 
Aβ42 is highly insoluble, amyloidogenic and deposits in the parenchyma as senile plaques. Aβ42 also 
more-readily forms neurotoxic oligomeric aggregates that impair neuronal synaptic function, trigger 
the inflammatory responses through activation of microglia and astrocytes and alters neuronal activity 
leading to loss of neurons (63-65). Aβ43 is an early depositing Aβ species in both SAD and FAD and 
is potently amyloidogenic and toxic (66, 67), while Aβ40 is less prone to aggregation and may actually 
be an anti-amyloidogenic form of Aβ in addition to be the major amyloid species found in CAA (68).  
 
Figure 1.4 The Aβ Aggregation process. 
Soluble Aβ monomers readily aggregate to form small soluble multimers followed by more aggregated 
forms such as micelles and protofibrils. Protofibrils undergo conformational changes to form insoluble 
fibrils that deposit in the extracellular space as plaques. The process then becomes irreversible 
(adapted from Walsh and Selkoe. 2007) (61).  
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1.2.2.1.3 Aβ clearance  
 
Accumulation of Aβ in the brain may result from either increased neuronal production of Aβ or 
reduced clearance of Aβ as a result of defective transport across the BBB or decreased degradation by 
proteolytic Aβ degrading enzymes (69). Previous studies indicate that accumulation of Aβ in SAD and 
CAA is due to impaired clearance rather than overproduction of Aβ peptides that leads to Aβ peptide 
deposition (70). There are several clearance routes of Aβ from the brain: bulk flow of interstitial fluid 
(ISF) into the cerebral spinal fluid (CSF); transport across the BBB that is mediated by a series of 
clearance receptors such as low-density lipoprotein receptor-related protein 1 (LRP1), very low-
density lipoprotein receptor (VLDLR) and P-glycoprotein (71); the uptake and phagocytosis of Aβ by 
microglial or astrocytic phagocytosis in the early stage of AD (72). Dysfunction of these clearance 
pathways has been shown to increase Aβ accumulation in the brain associated with cognitive 
impairment in AD (73, 74). The routes of Aβ clearance that are proposed to be impaired in AD are 
illustrated in (Figure 1.5).  
 
Proteolytic degradation of Aβ involves multiple enzymes known to cleave at a single or multiple sites 
within Aβ such as neprilysin (NEP), insulin-degrading enzyme (IDE), endothelin converting enzymes 
(ECE-1 and ECE-2), angiotensin converting enzyme (ACE-1 and ACE-2), plasmin and matrix 
metalloproteinases (MMP-2, MMP-3 and MMP-9) (75). Alterations of the level and activity of these 
Aβ degrading enzymes have been linked to reduced Aβ metabolism (76-78). In vitro studies showed 
that the Aβ degrading enzymes cleave the full-length Aβ to produce small peptide fragments, which 
are less neurotoxic and thus more easily cleared (71). ACE-2 was recently reported to convert Aβ43 
(earliest and potent amyloidogenic form of Aβ) to Aβ42, which in turn is converted to a shorter and 
less toxic form, Aβ40, by ACE-1 (79), which indicate that the combined effects of ACE-1 and ACE-2 
in degradation of Aβ are protective in AD. All degrading enzymes are thought to be able to cleave 
monomeric Aβ but only few appear to degrade oligomeric and fibrillar forms of Aβ including NEP, 
plasmin and MMP-2 and MMP-9 (80). Knowing the important roles of these degrading enzymes on 
Aβ metabolism makes them an interesting therapeutic target for AD. 
 
ACE-1 has been reported to degrade both Aβ40 and Aβ42 and convert the neurotoxic Aβ42 into less 
toxic form Aβ40 in vitro (81-83). Several earlier genetic studies showed a strong association between 
ACE-1 and AD and found that the ACE indel polymorphism (I/I) increased risk of LOAD (84-90). In 
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human studies, both ACE-1 level and activity are increased in AD (78, 91, 92). The potential role of 




Figure 1.5 Metabolism of Aβ in AD brain.  
The metabolic processing of Aβ is impaired in AD. Accumulation of Aβ in brain tissue may result 
from either increased production of Aβ (due to genetic mutation in APP or decreased Aβ clearance 
(from several routes including: impaired bulk flow of the interstitial fluid (ISF) into the cerebral spinal 
fluid (CSF), the uptake of Aβ by microglial or astrocytic phagocytosis in the early stage of AD; 
receptor-facilitated transport of Aβ across the BBB or via enzymatic degradation of Aβ (e.g. NEP, 
IDE, ECE-1, -2, ACE-1,-2, plasmin, MMP-2, -3, -9). BBB - blood brain barrier; NFTs - neurofibrillary 
tangles; APP - amyloid precursor protein; NEP - neprilysin; IDE - insulin degrading enzyme; ECE-1; 
ECE-2 - Endothelin converting enzymes 1 and 2; ACE-1, ACE-2 - angiotensin II converting enzymes 
1 and 2. Downward pointing blue arrows = decrease, Upward pointing blue arrow = increase (adapted 
from Huang and Mucke. 2012) (69). 
 
 
1.2.2.2 The Tau hypothesis  
 
NFTs are composed of abnormally hyperphosphorylated tau proteins and defined as one of the 
pathological hallmarks of AD (93, 94). The tau hypothesis proposes that abnormal accumulation and 
distribution of hyperphosphorylated tau proteins is closely linked to the progression of AD and related 
to cognitive decline (95). Based on this abnormal distribution, AD has been described as having six 
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disease stages known as Braak tangle stages (96) (Figure 1.6). In the human adult brain, six isoforms 
of tau are expressed and these play an important role in the stability of microtubules (97). Under 
pathological conditions, tau proteins undergo many modifications including phosphorylation that can 
be triggered by the accumulation of Aβ, and the activation of kinases such as Glycogen synthase 
kinase 3β (GSK3β) that are involved in tau phosphorylation (98-100). The hyperphosphorylated tau 
proteins have increased propensity to aggregate and form NFTs and therefore affect the synaptic and 
axonal transport functions of neurons (37, 101). Several studies have shown that Aβ aggregation 
precedes and accelerates tau pathology in AD both in vitro and in vivo (39, 102-104). However, the 
pathophysiological conditions of tau proteins in relation to AD pathogenesis are not fully understood. 
 
 
Figure 1.6 Stages of tau pathology in the development of AD. 
The distribution and spread of NFTs in human brain tissue can be used to describe disease-stage 
severity into six stages. In the Braak tangle stage I-II, NFTs accumulate in the transentorhinal region. 
In stage III-IV they spread to the neocortic association areas and then extend to the primary and 




1.2.2.3 The cholinergic hypothesis  
 
The cholinergic hypothesis was the first established hypothesis of AD based on findings of dysfunction 
and loss of cholinergic neurons (106). Early studies identified cholinergic dysfunction as an early 
hallmark of AD (107). Acetylcholine, the major neurotransmitter of the cholinergic system, which has 
been implicated in several brain physiological functions such as learning, memory, attention, stress 
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response, sleep and processing of sensory information (108). Cholinergic dysfunction was associated 
with cognitive impairment in AD. Post-mortem brain tissue from AD patients showed reduced activity 
of choline acetyltransferase, reduced acetylcholine synthesis, choline uptake and acetylcholine release 
(35). Currently available drugs that have been approved by the food and drug administration (FDA) for 
AD treatment that were discovered and developed from research on the cholinergic hypothesis include 
tacrine, donepezil, rivastigmine and galantamine (109). Although there is currently no cure for AD, 




1.2.2.4 The vascular hypothesis  
 
The vascular hypothesis, is currently gaining a new popularity but this hypothesis, which has been 
around for several decades proposes and states that reduced cerebral perfusion and vascular 
dysfunction play a significant role in AD pathogenesis (110), particularly in the early stages of disease 
(111-113). Most AD cases have evidence of vascular lesions including CAA and SVD (43, 45). Data 
from several studies highlighted the relationship between cerebrovascular diseases on the production 
and clearance process of Aβ peptide (114) and more recently Tau (115). Cerebral hypoxia or ischaemia 
caused by cerebrovascular diseases may also contribute to neurodegeneration in AD through several 
pathways, including acceleration of Aβ deposition, neuronal or synaptic dysfunction, and white matter 
changes (116, 117) (Figure 1.7). Results from multifactorial data-driven analysis suggest that brain 
vascular dysregulation including reduced CBF and BBB breakdown are early pathological changes in 




Figure 1.7 The vascular hypothesis for AD pathogenesis. 
According to vascular hypothesis, the presence of one or more vascular risk factors including BBB 
dysfunction and a reduction in cerebral blood flow can lead to either increased accumulation of Aβ or 
reduced Aβ clearance that can exacerbate the toxic effects of Aβ (adapted from Zlokovic. 2011) (117). 
HTN - hypertension, DM - diabetic mellitus, CVD - cardiovascular diseases, BBB - blood brain 
barrier, Aβ - amyloid beta. 
 
 
1.2.2.5 The inflammation hypothesis 
 
 
Neuroinflammation is considered as a hallmark of AD. Dysfunctional microglia and astrocytes are 
believed to play a central role in the inflammatory process of AD (119, 120). The role of the 
inflammatory system in AD is further supported by more recent Genome Wide Association Studies 
(GWAS) studies that have identified that genetic variants in genes that regulate inflammation, such as 
triggering receptor expressed on myeloid cells-2 (TREM2), increase AD risk (121-123). In the early 
stages of AD, accumulation of Aβ is proposed to activate microglia and lead to the increased secretion 
of pro-inflammatory cytokines (72, 124). Activated microglia, TREM2 and the complement system 
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contribute to neurotoxicity and synapse loss associated with dysregulated proinflammatory cascades 
(125, 126). Targeting the inflammatory system is currently under investigation as a therapeutic 
approach for the treatment of AD (127-129).  
 
 
1.2.3 Common Risk factors for AD 
 
 
AD is a multifactorial neurodegenerative disease and advanced age remains the greatest non-
modifiable risk factor for AD (130, 131). The risk of AD is increased with age with the largest 
incidence rates observed after the sixth decade of life (4, 132). As the ageing population is growing 
globally, the number of aged people aged 60 years or over has been predicted to double by 2050 and as 
a result the incidence of AD has been estimated to increase dramatically (131).  
 
 
1.2.3.1 Genetic Risk factors 
 
The known causative genetic mutations for FAD (or EOAD) are in genes that encode proteins 
involved in the processing of APP including APP (encoding amyloid precursor protein) on 
chromosome 21, PSEN1 (encoding presenilin 1) on chromosome 14, PSEN2 (encoding presenilin 2) 
on chromosome 1. There are 32 APP, 221 PSEN1 and 19 PSEN2 gene mutations associated with 
autosomal-dominant FAD (133). These genetic mutations lead to accelerated Aβ40 and Aβ42 
production, or increased Aβ42:Aβ40, all of which are proposed as diagnostic biomarkers of FAD (134, 
135).  
 
In contrast, the most common form of AD, the SAD (or LOAD) is thought to be mainly caused by the 
interaction between several susceptibility genes and environmental risk factors (29). Among all of the 
known susceptibility genes that are associated with increased risk of AD, the APOE gene (encoding 
apolipoprotein E (ApoE)) is the strongest genetic risk factor and accounts for 50% of the genetic cause 
of AD (136-138). ApoE is a cholesterol transporter and plays a key role in regulating cholesterol 
metabolism in brain tissue (139). APOE is located in chromosome 19 and in humans there are three 
ApoE isoforms coded for by three alleles of APOE, ε2, ε3 and ε4 (140). The level of APOE expression 
has been associated with the different APOE genotypes, with ε4 associated with the lowest APOE 
expression (141). People carrying a single APOE ε4 allele have two to three fold increased risk of AD, 
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while having two APOE ε4 alleles increase the risk five-fold (142). Studies have found that patients 
with an APOE ε4 allele have more Aβ deposition, increased Aβ oligomer level, reduced level and 
activity of Aβ degrading enzymes and greater hippocampal volume loss (76, 143-145).  
 
The major GWAS have identified several novel susceptibility genes for LOAD (Table 1.1). The ten 
genes that reached genome-wide significance in most GWAS studies are APOE ε4, BIN1, CLU, 
ABCA7, CR1, PICALM, MS4A6A, CD33, MS4A4E and CD2AP. A number of these susceptibility 
genes are clustered together and are involved in three main biological pathways related to AD that 
include APP processing and lipid metabolism (APOE, CLU, ABCA7) (29, 146-148), immune response 
(CLU, CR1, ABCA7, CD33, MS4A6A, MS4A4E, CD2AP) (29, 146, 148-150) and endocytosis (BIN1, 
PICALM) (149-152). Most recently, a large GWAS study has confirmed twenty previously identified 
risk loci (APOE ε2, ε3 and ε4, BIN1, CLU, ABCA7, CR1, PICALM, MS4A6A, CD33, MS4A4E, 
CD2AP, INPP5D, HLA-DQB1, TREM2, NYAP1, EPHA1, PTK2B, ECHDC3, SPI1, SORL1, FERMT2, 
SLC24A4, CASS4) and identified four novel genome-wide loci for LOAD (IQCK, ACE1 ADAM10, 
ADAMTS1) that have been implicated in immune system, lipid metabolism, tau bindings protein and 
APP processing (153).  
 
Table 1.1 Summary of the sporadic AD susceptibility genes implicate in APP processing, lipid 
metabolism, immunity and tau processing.  
Gene 
 
Chromosome Polymorphism Protein 
APOE ε2/3/4 
 
19 APOE_e2/3/4 apolipoprotein E 
BIN1 
 
2 rs744373 bridging integrator 1 
CLU 
 
8 rs11136000 clustrin 
ABCA7 19 rs3764650 ATP-binding cassette transporter A7 
CR1 1 rs3813861 
 
complement receptor one 
PICALM 11 rs541458 
 
phosphatidylinositol binding clathrin 
assembly protein 
MS4A6A 11 rs610932 
 
membrane-spanning 4-domain, subfamily 
A, member 6A 
CD33 19 rs3865444 
 
CD33 molecule (sialic acid–binding 
immunoglobulin (Ig)–like lectin) 
MS4A4E 11 rs670139 
 
membrane-spanning 4-domain, subfamily 
A, member 4E 





2 rs10933431 inositol polyphosphate-5-phosphatase, 
145 kDa 
HLA-DQB1 6 rs78738018 major histocompatibility complex class II, 
DQ beta 1 
TREM2 
 
6 rs75932628 triggering receptor expressed on myeloid 
cells-2 
NYAP1 7 rs12539172 neuronal tyrosine phosphorylated 
phosphoinositide-3-kinase adaptor 1 
EPHA1 
 
7 rs11762262 ephrin receptor A1 
PTK2B 
 
8 rs73223431 protein tyrosine kinase 2 beta 
ECDH3 
 
10 rs7920721 enoyl CoA hydratase domain containing 3 
SPI1 
 
11 rs3740688 transcription factor PU.1 




14 rs17125924 fermitin family member 




20 rs6024870 cas scaffolding protein family member 4 
IQCK 
 
16 rs7185636 IQ motif containing K 
ACE1 
 
17 rs138190086 angiotensin-converting enzyme 1 
ADAM10 
 
15 rs593742 a disintegrin and metalloproteinase 10 
ADAMTS1 21 rs2830500 a disintegrin and metalloprotease domain 
with TSP repeats protein-1 
 
 
ACE, the gene that encodes ACE-1, is one of the most studied susceptibility genes for LOAD. First 
reported by Kehoe et al. (84) who found that an insertion (I)/ deletion (D) polymorphism (indel) within 
intron 16 of ACE on chromosome 17q23 was associated with increased AD risk. Since then, several 
studies replicated this finding and supported the strong relationship between the ACE indel 
polymorphism (I/I) and increased risk of LOAD (85, 86, 88, 89, 154, 155). As mentioned, ACE-1 is 
one of the Aβ degrading enzymes and genetic variation in ACE has been associated with Aβ level, 
particularly soluble Aβ species. Miners et al. (90) found that (II) genotype and other nearby proxy 
SNPs were associated with increased levels of soluble Aβ in AD. The rarer ACE polymorphism 
(rs138190086) on chromosome 17 was also more recently reported as a new genome-wide significance 
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loci implicated in Aβ processing (153). Together these genetic studies strongly suggest an association 
between ACE indel polymorphism and increased risk of AD that may also link to Aβ pathogenesis and 
thus have helped to generate renewed interest in the role of ACE in AD pathogenesis and implications 
with respect to the therapeutic intervention of AD.  
 
Modifiable lifestyle factors such as midlife hypertension, midlife diabetes, stroke, obesity, high 
cholesterol level and smoking also increase the risk of AD (156-161). Among all the cardiovascular 
risk factors, hypertension seems to be the most common risk factor for AD (162). Recently, numerous 
studies have focused on describing the role of hypertension in causing or increasing the progression of 
AD (163-165). Based on the previously published literature, there is considerable evidence to support a 
strong association between hypertension and AD. However, to date, potential mechanisms that explain 
a pathophysiological link between hypertension and the development or progression of AD are less 
clear. Therefore, explaining how the primary regulatory system of blood pressure might alter the 
progression of AD will provide important insights into the mechanisms between these two diseases 
and potentially provide important data to inform therapeutic strategies.   
 
Based on epidemiological studies, several preventable lifestyle risk factors have been found to increase 
the risk of cognitive impairment and AD such as head trauma, depression, sleep disturbances (166-
171). Several observational and randomized controlled trials have also shown that achievable life 
adjustments, such as maintaining an active lifestyle including regular physical activity, a balanced diet, 
cognitive training and social engagement are all associated with a decreased risk of cognitive 
impairment and lower incidence of AD (172-178). It is important to consider these preventable risk 






The clinical diagnosis of AD is mainly based on clinical symptoms that are measured by a variety of 
cognitive assessment tests, some of which include the measurement of different cognitive domains 
(179). However, the sensitivity of some screening tools, such as the Mini Mental State Examination 
(MMSE) to detect MCI is limited (180). Other cognitive screening tools such as the Montreal 
Cognitive Assessment (MoCA) has been found to be able to detect early cases of MCI and are more 
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sensitive than MMSE to disturbance to executive function, which can be attributed to vascular issues 
(181).  
 
In addition to the memory tests, there are numbers of neuroimaging procedures that are increasingly 
used, depending on availability, to detect the brain changes and accumulation of Aβ within the brain. 
This includes MRI to look at brain atrophy, or the use of F-florbetapir or C Pittsburgh compound B 
(PiB) positron emission tomography (PET) to assess amyloid burden, whilst single photon emission 
computed tomography (SPECT) is another modality that allows assessment of brain structural change 
(182-185). Together these neuroimaging tools could be used as an early detection method of AD in 
people at high risk. CSF biomarkers (Aβ, tau) are also considered to be of use to help facilitate earlier 
and more accurate diagnosis of AD and help differentiate it from other types of dementia (186). Both 
plasma level of Aβ and tau have also been proposed but have, as yet, to be shown to be reliable as 
diagnostic biomarkers (187). All of these diagnostic approaches are included in the Alzheimer’s 
Disease and Related Disorders Association (ADRDA) guidelines, which take into account clinical 
symptoms, cognitive results, neurological assessment and biomarkers (188).  
 
Overall, the accuracy of clinical diagnosis of AD has been shown to vary somewhat and can range, 
according to various groups from 80% to 100%. Yet, it is more realistic and acknowledged that post-
mortem neuropathological examination is in fact the most accurate diagnostic test for AD among all 
these diagnostic approaches and is likely to be the only one that can confirm with the greatest accuracy 
the diagnosis of AD and other dementias (16). In post-mortem diagnosis, the brain tissue is examined 
at both macroscopic and microscopic levels and is assessed according to specific criteria of the 
Consortium to Establish a Registry for Alzheimer’s disease (CERAD), which is based on semi-
quantitative assessment of the density of neocortical neuritic plaques (NP) (189), in addition to the use 
of Braak staging for distribution of NFTs recommended by the National Institute on Aging and the 
Alzheimer’s Association (NIA-RI) (190). This information is viewed alongside the clinical medical 







None of the currently available pharmacological drugs slow or stop the progression of AD. Six drugs 
are clinically available for the symptomatic treatment of AD including cholinesterase inhibitors 
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(rivastigmine, galantamine, donepezil) (191-193) and the N-methyl-D-aspartate (NMDA) receptor 
antagonist (memantine). Memantine combined with donepezil and tacrine have also been approved by 
the FDA (194). All cholinesterase inhibitors are approved for the treatment of mild to moderate stages 
of AD and help facilitate synaptic transmission due to increasing the level of the neurotransmitter 
acetylcholine. However, cholinesterase inhibitors may not benefit mild cognitive impairment (195). 
Memantine was originally developed for use in more severe (moderate to late) stages of AD and works 
by preventing the excitotoxicity of glutamate and inhibiting tau hyperphosphorylation and aggregation 
(196). Although, 244 drugs for Alzheimer’s have been tested in registered clinical trials, memantine is 
the only drug that successfully completed clinical trials and is approved by the FDA (197).  
In more recent years there have been several clinical trials and efforts to investigate drugs that target 
Aβ, tau and inflammation (3, 198). However, most of these Aβ-focussed targeting approaches have 
been unsuccessful. With continually growing knowledge about the pathogenesis of AD and the 
potential role of modifiable risk factors, particularly in the early stages of disease, many researchers 
are now focusing on modulating vascular risk factors of AD and exploring new and what some might 
view as alternative new therapeutic approaches. Examples of which include ongoing efforts to re-
position anti-hypertensive drugs that include angiotensin converting enzyme inhibitors (ACEIs) and 
angiotensin-II receptor blockers (ARBs) (56). Other non-pharmacological approaches have also been 
attempted and some have been found to relieve behavioural symptoms and improve cognitive function 
such as exercise and cognitive stimulation (199-201). Thus far, the available pharmacological and non-
pharmacological approaches for AD, which may be beneficial are still unable to cure or prevent AD, 
but some may be able to slow or halt the progression of the disease. Thus, there is now a strong focus 
on the need for developing effective disease-modifying treatment for AD, whilst research will continue 
to find the earliest triggers for AD that will then lead to the potential identification of a cure. 
  
1.3 Relationship between hypertension and AD 
 
One possible therapeutic approach to prevent and slow progression of AD has been suggested to 
involve maintaining a healthy and normal blood pressure (202). Meta-analysis of secondary 
investigations in cardiovascular clinical trials and observational research of populations has showed 
evidence that high blood pressure was associated with subsequent cognitive decline (203, 204). The 
Framingham study was one of the first study to find a positive association between high blood pressure 
and cognitive decline (205). Several other longitudinal studies have replicated this positive observation 
of a relationship (206-211). Several epidemiological studies have reported a strong relationship 
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between mid-life hypertension and increase risk of AD in later life (206, 212-215). However, some 
longitudinal studies showed either no significant association or a negative association between 
hypertension and AD (216-218).  
 
There is also some debate about whether mid-life hypertension increased risk of AD or late-life 
hypertension is more strongly associated with reduced risk of AD. Some studies indicated that late-life 
hypertension could be protective against cognitive decline and reduce the risk of AD (162, 219). This 
physiological compensatory mechanism of increase blood pressure in elderly may help maintain 
adequate CBF and normal cognition. Although the previous studies revealed divergent effects of high 
blood pressure with respect to increased risk of AD, which could be due to an age-dependent effect of 
hypertension on AD pathogenesis. Most recently, post hoc analysis of data from a randomized trial 
(NILVAD) indicated that mild-moderate AD patients with blood pressure variability had a greater 
deterioration in cognitive decline that was associated with progression of AD (220). 
 
The effect of hypertension on brain cerebrovascular homeostasis has been investigated by several 
studies. Hypertension may increase the risk of AD by disturbing the integrity of the BBB, resulting in 
the accumulation of Aβ in brain tissue (116). Hypertension also causes white matter lesions (WML) 
and is associated with cognitive impairment (221, 222). Hypertension has also been shown to increase 
blood vessel fibrosis resulting in narrowing and stiffness of the blood vessel walls that leads to reduced 
cerebral blood flow and WML (223-227). An association between mid-life hypertension and increased 
rate of progression of vascular brain injury and worsening cognitive function has been reported (159). 
Beauchet et al. (228) has shown using meta-analysis that high blood pressure is associated with 
reduced cortical and hippocampal brain volumes. Several potential pathological mechanisms that 
might explain how hypertension and vascular dysfunction and damage might lead to cognitive decline 






Figure 1.8 Proposed underlying mechanisms of the relationship between hypertension and AD. 
Hypertension leads to both vascular dysfunction and brain structure abnormalities such as white matter 
lesions, and neuronal dysfunction, through direct and indirect effects of increased Aβ production and 
reduced Aβ and tau clearance. In turn, accumulation of AD pathological hallmarks may lead to 
synaptic dysfunction and neuronal loss that both result in cognitive impairment and AD. BBB - blood 
brain barrier, CBF - cerebral blood flow, WML - white matter lesion, Aβ - amyloid beta, AD - 
Alzheimer’s disease. Down pointed red arrows = decrease, Up pointed red arrow = increase (adapted 
from Iadecola and Gottesman. 2019) (229). 
 
Further evidence of the relationship between hypertension and AD pathogenesis is reported in several 
post-mortem studies, in vivo neuroimaging studies and experimental studies. In post-mortem brain 
tissue, accumulation of AD pathological hallmarks, including Aβ plaques and NFTs, was greater in 
hypertensive elderly patients (230-233). In vivo PET scan studies have found that Aβ accumulation is 
associated with higher blood pressure, both systolic and diastolic, in normal, mild cognitive 
impairment and AD patients (234-237). Induced hypertension in experimental animal models 
following administration of the vasoconstrictor, angiotensin II (Ang-II) has also been shown to 
increase microvascular accumulation of Aβ and neuronal deposition of phosphorylated tau (p-tau), 
suggesting a role of Ang-II on APP processing and Aβ production (238, 239). Moreover, the 
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relationship between hypertension and AD biomarkers was observed. In elderly patients, high pulse 
pressure was associated with increased levels of p-tau in CSF and decreased Aβ42 level (240, 241).  
In several observational studies, treatment with anti-hypertensive drugs was associated with 
improvement of cognitive function. The first prospective randomised study (FOCUS study) found that 
anti-hypertensive drugs (felodipine, a calcium channel blocker and enalapril, an ACEI) in elderly 
patients with cognitive impairment resulted in significant improvement in overall cognitive function at 
12 and 24 weeks (242). Moreover, the SCOPE study showed a trend in risk reduction of dementia in 
elderly patients that received angiotensin receptor antagonists (candesartan and cilexetil) (243). More 




1.4 The Renin Angiotensin System (RAS) 
 
The RAS is a complex enzymatic and peptide system that acts either locally or centrally to maintain 
body fluid homeostasis, control blood pressure and regulate hormone secretion (244). The first 
understanding of the RAS was gathered from its function in the periphery. The RAS involves the 
synthesis and release of angiotensinogen (AGT) by hepatocytes into the circulation. AGT is the only 
known substrate of renin. The latter, an acid protease enzyme that is synthesised and released from the 
juxtaglomerular apparatus of the kidney into the circulation in response to a reduction in peripheral 
blood pressure, cleaves AGT 10 amino acids from the N-terminus to generate angiotensin I (Ang-I) 
(245). Centerally, AGT and renin are produced within neurons and astrocytes (246). Ang-I, in turn, is 
hydrolysed by ACE-1 (a member of the M2 metalloprotease family), at the C-terminus to form 
angiotensin II (Ang-II). Ang-II is the main effector of the classical RAS pathway but more recently has 
been identified to have central functions where it exerts neuro-damaging effects by interaction with the 
angiotensin II type-1 receptor (AT1R) or protective effects by binding to angiotensin II type-2 receptor 
(AT2R) (247). This ACE-I/Ang-II/AT1R pathway is now more commonly known as the classical axis 
of RAS or classical RAS (cRAS). Hyperactivity of cRAS has traditionally been viewed to contribute to 
pathogenesis of cardiovascular and renal diseases associated with hypertension (248).  
 
It has more recently emerged that cRAS is counter-regulated by activation of the non-classical axis of 
RAS or regulatory RAS (rRAS) pathways. These downstream pathways are involved in the 
metabolism of Ang-II. Angiotensin converting enzyme 2 (ACE-2) is the enzyme mainly involved in 
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the regulation of the rRAS (249, 250). ACE-2 is a zinc metallopeptidase comprising of 805 amino 
acids and shares 42% sequence identity with the catalytic regions of ACE-1 metalloprotease (250). 
The main role of ACE-2 is in the metabolism of Ang-II to generate angiotensin (1-7) (Ang (1-7)). 
ACE-2 is also capable of converting Ang-I to angiotensin (1-9) (Ang (1-9)) (251). Binding of Ang (1-
7) to the MAS receptor (MasR), a G-protein-coupled receptor that has been found within the brain 
(252), causes vasodilation through stimulation of bradykinin and nitric oxide release (253). It has also 
been shown to have other protective actions such as diuresis, anti-inflammatory, anti-proliferative and 
anti-fibrotic effects (254). This pathway is often termed the ACE-2/Ang (1-7)/MasR axis. 
Dysregulation of this pathway is associated with organ-specific diseases, such as hypertension 
(cardiovascular disease), stroke (cerebrovascular diseases) and AD (neurodegenerative disease) (255).  
 
Another regulatory pathway (Ang-III/APN/Ang-IV/IRAP) of cRAS involves the formation of 
angiotensin III (Ang-III) following cleavage of Ang-II by aminopeptidase A (APA). Ang-III binds to 
AT1R, as well as AT2R, and has similar actions to Ang-II such as vasoconstriction, stimulation of 
aldosterone secretion, cell growth, and inflammation through AT1R signalling (256). Ang-III can be 
subsequently cleaved by aminopeptidase N (APN) to form angiotensin IV (Ang-IV) (244). Ang-IV 
exerts actions on the central nervous system (CNS) via binding to angiotensin IV receptor (AT4R) 
(also called insulin regulated aminopeptidase (IRAP) and another AT4R binding site identified as c-
MET, a tyrosine kinase receptor), which includes improved learning and memory and protection from 
cerebral hypoxia (257). In addition to the classical and non-classical pathways there are a number of 
additional pathways and smaller angiotensin peptides (Figure 1.9). The current view of RAS is thus 
relatively complex with much to still learn about more recently identified angiotensins such Ang (1-9), 




Figure 1.9 The renin angiotensin system. 
A schematic of the enzymes, substrates and effector molecules related to RAS function. Angiotensin 
peptides in the brain are produced from angiotensinogen through several enzymatic pathways. 
Angiotensin-I (Ang-I) is formed by renin acting on angiotensinogen that is then converted into the 
main effector, angiotensin-II (Ang-II), by angiotensin II converting enzyme 1 (ACE-1) that acts on 
both AT1R and AT2R. This pathway was first identified and is known as the classical axis of RAS. 
Ang-II is converted into the active Ang (1-7) by angiotensin II converting enzyme 1 (ACE-2) that acts 
on both MasR and MrgD, this pathway is known as the non-classical regulatory axis of RAS. Ang-II 
can be converted to angiotensin III (Ang-III) by aminopeptidase A (APA) and is further converted into 
angiotensin IV (Ang-IV) by aminopeptidase N (APN). The resultant Ang-IV acts on AT4R (also 
referred to as Insulin-regulated aminopeptidase (IRAP)). These pathways giving rise to Ang (1-7) and 
Ang-IV from the cleavage of Ang-II are known as the alternative regulatory pathways of RAS (rRAS). 
Both Ang (1-7) and Ang-IV can be further converted into small inactive peptide fragments. Other but 
less involved components of the RAS include APB - Aminopeptidase B, ASAP - Aspartyl 
aminopeptidase, Carb-P - Carboxypeptidase B, DAP - dipepidyl aminopeptidases, PEP - prolyl 
endopeptidase PO - Proly oligopeptidase, NEP - Neprilysin (adapted from Puertas et al. 2013) (258). 
 
 
In addition to the well-known crucial role of the peripheral circulating RAS in the maintenance of fluid 
balance and regulation of blood pressure, several studies demonstrated the vital role of a local RAS in 
different tissues such as the brain, heart, kidney, peripheral blood vessels, adipose tissue, liver, 
endocrine tissue, reproductive tissues, immune cells, hematopoietic tissue and gastrointestinal tract 
(259-266). Dysregulation of the local RAS underlies various cardiovascular, renal, vascular and 
neurodegenerative disorders and can include inflammation, fibrosis and oxidative stress as well as 
other tissue-specific pathological conditions (267-269). It is now widely accepted that there is a fully 
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functioning local RAS within the brain (270). This comprises both the classical and regulatory 
pathways that are likely to function independently from, but also probably synchronously with, the 
peripheral RAS (253, 254). In the following sections I will discuss in more detail the role of the brain 
RAS and its importance and relevance to AD.  
 
1.4.1 The role of brain RAS in regulating blood pressure 
 
Most of the active components of brain RAS are involved in regulating blood pressure. Overactivity of 
cRAS in the brain is associated with hypertension. Several experimental studies have demonstrated the 
effect of Ang-II administration in increasing neuronal activity in brain areas responsible for 
cardiovascular regulation, osmoregulation and energy homeostasis (271). Through activation of AT1R, 
Ang-II was found to inhibit barosensitive neurons and increase blood pressure (BP) (272). 
Furthermore, Ang-II induces vasoconstriction, endothelial dysfunction, inflammation, growth and 
remodelling of the vasculature through several mechanisms that include, modulating sympathetic tone, 
stimulation of aldosterone secretion and sodium reabsorption (248). Intracerebroventricular (ICV) 
administration of ACEIs enhanced baroreceptor reflex sensitivity due to reduced production of Ang-II 
(273). Furthermore, similar to Ang-II, Ang-III binds to AT1R and contributes to increased blood 
pressure (274), whilst similarly both Ang-II and Ang-III were also found to bind to a recently 
discovered non-AT1R and non-AT2R site. Reduction of this binding protein, called neurolysin, was 
found in spontaneously hypertensive rats, suggesting the important role of this binding protein in the 
development of hypertension (275). On the other hand, rRAS in the brain, including ACE-2/Ang (1-
7)/MasR, exerts an anti-hypertensive effect. The effects of Ang (1-7) on blood pressure are also mainly 
effected via modulating the baroreflex (276). Several animal studies demonstrated the effect of long-
term administration of Ang (1-7) on reduced blood pressure and attenuated the development of 
hypertension (277-279). A MasR antagonist completely reversed the cerebroprotective effect of Ang 
(1-7) (280). Further support for the protective role of the rRAS in the brain was a recent study that 
showed that increased expression of ACE-2 reduced the development of neurogenic hypertension 
through reduced oxidative stress and inflammation (281).  
 
1.4.2 Involvement of brain RAS in inflammation 
 
The classical and non-classical axes of brain RAS are implicated in the inflammatory responses in 
brain tissue. ACE-1/Ang-II/AT1R is known as a proinflammatory axis due to the effect of the powerful 
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proinflammatory mediator Ang-II and its activation of AT1R (282). Ang-II mediates an inflammatory 
response through activation of several pathways that stimulate the production of prostaglandins and 
vascular endothelial cell growth factor (VEGF) (283), upregulates adhesion molecules and vascular 
cell adhesion molecules on vascular endothelial cells and smooth muscle cells, and activates 
monocytes (284, 285). In addition, Ang-II upregulates potent chemoattractants and activators of 
neutrophils (286), and mediates reactive oxygen species (ROS) production and nuclear factor- kappa B 
(NF-κB) activation (287). ARBs have been found to suppress the inflammatory responses mediated by 
Ang-II (288-291). On the other hand, the rRAS exerts anti-inflammatory effects mediated by the action 
of Ang (1-7) on MasR. Supporting evidence demonstrated that Ang (1-7) suppressed leukocyte 
migration, cytokine expression and release, and fibrogenic pathways. In the brain, ICV administration 
of Ang (1-7) in a stroke model in Sprague-Dawley rats (SDR) was associated with a reduction in 
oxidative stress, suppression of NF-κB activity and reduced levels of pro-inflammatory cytokines 
(292). Overexpression of ACE-2 in the paraventricular nucleus attenuated the increase in the 
expression of tumour necrosis factor alpha (TNF-a), interleukin (IL-1b) and (IL-6) that had been 
induced by Ang-II (293). Moreover, in the APOE knockout mouse, genetic ACE-2 deficiency 
enhanced vascular inflammation and atherosclerosis through increased gene expression of vascular 
cells adhesion molecules (VCAM), cytokines, chemokines and MMP (294). Activation of ACE-2/Ang 
(1-7)/MasR axis by ACE-2 activator, diminazene aceturate (DIZE) in the D-Galactose-Ovariectomized 
rat model of AD showed upregulation of ACE-2 and MasR expression along with downregulation of 
AT1R and inflammatory proteins such as glial fibrillary acidic protein (GFAP), NF-kB p65 and TNF-
a, indicating the anti-inflammatory role of the non-classical axis of brain RAS in AD (295). 
 
1.4.3 The role of brain RAS in cerebral hypoperfusion/ ischaemia  
 
AD is associated with cerebrovascular dysfunction such as cerebral hypoperfusion, CAA and BBB 
dysfunction (117, 296-299). Several experimental studies have revealed that hypoxic or ischaemic 
conditions are associated with increased amyloidogenic APP processing, stimulating the production 
and the accumulation of Aβ that dysregulates calcium homeostasis in both neurons and astrocytes, 
leading to neuronal cell death and activated microglia (300-304). Hypoperfusion is evident in the early 
stages of AD and is related to cognitive decline (118, 305-307). Moreover, cerebral ischaemia leads to 
cognitive decline in AD and aggravates cognitive deficiency induced by accumulation of Aβ (308-
310). The mechanism linking cerebral hypoperfusion/ischaemia and Aβ accumulation is related to 
interaction between Aβ degrading enzymes in both the brain endothelin system (ECE-1, ECE-2) and 
	 28 
RAS (ACE-1). Miners and colleagues (311) reviewed the evidence that indicates upregulation of ECE-
1, ECE-2 and ACE-1 activities are increased in the cerebral cortex in AD in human post-mortem brain 
tissue are associated with increased production of the potent vasoconstrictors (endothelin-1(ET-1) and 
Ang-II), which both result in reduced CBF and aggravated Aβ-related pathology (Figure 1.10). 
 
 
Figure 1.10 Possible mechanisms linking cerebral hypoperfusion/ischaemia and Aβ degrading 
enzymes in AD.  
Upregulation of ECE-1, ECE-2 and ACE-1 activities are a physiological feedback response of Aβ 
accumulation in AD. These result in increased production of vasoconstrictors (ET-1 and Ang-II) that 
lead to reduced CBF, increase Aβ production and accumulation mediated by reduced NEP activity in 
ischaemia that all aggravate Aβ-related pathology (adapted from Miners et al. 2014) (311). 
 
 
Recently, two novel methods to quantify ischaemic injury in post-mortem brain tissue have been 
developed. These involve the comparison of the levels of two myelin proteins, myelin-associated 
glycoprotein (MAG), which is highly susceptible to reduced tissue oxygenation, and proteolipid 
protein-1 (PLP1), which is relatively resistant to reduced tissue oxygenation and thus reduction in 
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MAG:PLP1 ratio would be indicative of ischaemic (reduced tissue oxygenation) injury (prior to death 
as the myelin proteins are resistant to PM-delay and have a slow turnover rate of several months). This 
was recently shown in the mid-frontal and medial parietal cortex (precuneus) in human post-mortem 
brain tissue in AD (312-315). A reduction in MAG:PLP1 is also related to increased  levels of VEGF, 
a potent angiogenic and neuroprotective factor that is upregulated in response to tissue hypoxia and is 
thus considered another independent sensitive marker of ischaemia. VEGF level has been shown to be 
increased in mid-frontal cortex and parahippocampal cortex in human post-mortem brain tissue in AD 
and was positively correlated with insoluble Aβ42 level and Aβ42:Aβ40 ratio (314). In addition, the 
reduction in cortical MAG:PLP1 ratio was inversely correlated with VEGF level (314, 315). Together 
these studies demonstrate an involvement of ischaemia in early AD pathogenesis. 
 
The ACE-1/Ang-II/AT1R pathway (also known as a pressor axis of brain RAS) is involved in 
cerebrovascular damage after stroke. Experimental studies have shown the association between 
increased Ang-II level and vascular damage following stroke (316). AT1R activation is linked to 
ischaemic damage through a change in cerebral nitric oxide synthase (NOS) in genetic hypertensive 
rats, while treatment with ARBs reduced the risk of cerebrovascular ischaemia and neuronal injury 
(317, 318). In addition, ARBs reduced infarct size and increased cerebral blood flow in an animal 
stroke model (319-324). Conversely, activation of the depressor or regulatory axis of brain RAS, i.e. 
the ACE-2/Ang (1-7)/MasR axis was found to induce baroreflex activity, reduce blood pressure and 
increase release of nitric oxide (NO) that protects cerebrovascular function during ischaemic injury 
(251). Several experimental studies demonstrated the cerebroprotective effects of centrally 
administered Ang (1-7) (325). ICV administration of Ang (1-7) in animal stroke models caused a 
reduction of the infarct size associated with increased neuron survival in the cortex and striatum (326, 
327). Ang (1-7) stimulates NO release and upregulates endothelial NOS (eNOS) expression (328). 
Chen and colleagues (329), demonstrated that overexpression of neuronal ACE-2 in an animal model 
with central Ang-II overproduction protected the brain from the ischaemic injury by changing the Ang 
(1-7)/Ang-II ratio. Supporting this protective effect of ACE-2, it has been shown that overexpression 
of ACE-2 reduced ischaemic neuronal damage such as cell swelling and death (330). Overexpression 
of ACE-2/Ang (1-7)/MasR has been shown after acute cerebral ischaemia as a compensatory 
mechanism to protect the brain (331). All these previous studies support the important role of the brain 
RAS in ischaemia and highlight the need to either block the effect of the pressor axis or activate the 
depressor axis as a therapeutic approach for cerebrovascular disorders.   
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1.5 The brain RAS and AD 
 
Over the last decade and a half, experimental and clinical studies have focused on the role of brain 
RAS on neuronal and cognitive function, particularly in neurodegenerative conditions such as AD. It 
was recently demonstrated that overactivation of brain cRAS was associated with AD pathogenesis. 
More recently, data from post-mortem brain tissue and in vivo models have indicated that alterations 
within the downstream alternative and regulatory RAS pathways contribute to cRAS overactivation 
and AD pathology. These changes are present in areas of the brain, such as the mid-frontal cortex, that 
are affected in AD and are distinct from those brain regions involved in blood pressure regulation. 
 
1.5.1 The classical RAS of the brain in relation to cognitive function and AD pathology 
 
The cRAS regulates blood pressure but functions independently within the brain and is implicated in 
higher brain functions including cognition and learning and memory. Overaction of cRAS has 





Figure 1.11 Effects of the classical axis of brain RAS. 
Angiotensin II (Ang-II) is the main effector in the classical axis of brain RAS. Ang-II/AT1R coupling 
results in damaging effects to neurons that include vasoconstriction, fibrosis, hypertrophy and 
inflammation. While, angiotensin II (Ang-II) /AT2R interaction counter-regulate the Ang-II/AT1R 
mediated effects. Ang-II has a higher affinity toward AT1R and responsible for the major effects of the 
classical brain RAS c(RAS). ACE-1 – angiotensin II converting enzyme 1; AT1R - angiotensin II type 
1 receptor, AT2R - angiotensin II type 2 receptor.   
 
 
1.5.1.1 Angiotensinogen (AGT) and Angiotensin I (Ang-I) 
 
Activation of the cRAS begins with the synthesis of renin, a protease and a rate-limiting enzyme 
responsible for cleaving the N-terminal portion of AGT to form Ang-I, this conversion can also be 
processed by other enzymes such as elastase, proteinease 3, cathepsin D and E. Although, the AGT 
and Ang-I are biologically inactive and their functions are still generally unknown in the brain 
especially in relation to AD, both act as important precursors for the major active metabolites in RAS, 
	 32 
including Ang-II, Ang (1-7) and Ang (1-9). The decapeptide Ang-I serves as a substrate for ACE-1, 
the main protease in cRAS to yield the biologically active metabolite Ang-II (257). 
 
1.5.1.2 Angiotensin converting enzyme (ACE-1)  
 
ACE-1 (dipeptidyl-dipeptidase) is a membrane-bound zinc metalloprotease (332). In humans, there are 
two isoforms of ACE-1: somatic ACE-1 (sACE-1) and germinal ACE-1 (gACE-1) (333). Somatic 
ACE-1 is a large protein (150-180 KDa) and has two homologous domains, commonly referred to as 
the N-domain and the C-domain. sACE1- is found in various types of endothelial, epithelial and neural 
cells. gACE-1 is a smaller protein (100-110 KDa) that has a single catalytic domain identical to the C-
domain of sACE-1 and is expressed only in developing spermatids and in mature sperm cells (334, 
335). In addition, sACE-1 can be found as a soluble enzyme distributed into many types of 
extracellular fluids including plasma, serum and cerebrospinal fluids (336). For convenience and given 
the high tissue specificity of gACE-1, sACE-1 will henceforth be referred to as ACE-1 for the 
remainder of this thesis and thus will refer to the form of ACE-1 with two catalytic domains.  
 
ACE-1 is abundantly distributed within the human brain where it is expressed widely in dendrite cells, 
is predominantly expressed within neurons and in pyramidal neurons in the cortex (layer V), and 
within the cerebral vasculature (78, 91, 337, 338). In addition to the main role of ACE-1 as an enzyme 
responsible for production of Ang-II, a previous study indicated that ACE-1 was involved in the 
metabolism of neurotensin, a major endogenous substrate of the non-AT1R and non-AT2R binding 
protein (i.e. that was determined to be neurolysin) (339). Several studies also indicated a 
neuroprotective role of neurotensin in learning and memory function (340-342), which had yet to be 
investigated with respect to the pathophysiology of AD. 
 
With respect to two different and independent catalytic domains of ACE-1, which as mentioned are 
called the N-domain and C-domain according to the N- to C- end orientation of ACE-1 when it is 
synthesised (Figure 1.12). Although both domains share greater than 60% overall sequence homology, 
several important biophysical and biochemical similarities and differences have been described. Both 
the N-domain and C-domain contain a zinc binding site (HExxH) that is a functional site and joined by 
a shorter linker sequence. The N-domain and most of the C-domain are normally extracellular but a 
portion of the C-domain is intracellular (C-terminus) (332). Important catalytic differences between 
the catalytic activities of the N-domain and C-domain of ACE-1 have been described. Oba et al. (82) 
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demonstrated that the N-domain of ACE-1 was primarily responsible for Aβ degradation by inhibiting 
the aggregation and cytotoxicity of Aβ in vitro, whereas the C-domain showed less inhibitory effects 
on Aβ accumulation. Another study demonstrated that Aβ42 to Aβ40 converting activity by ACE-1 
was limited to N-domain activity and that Ang-II production was mainly attributed to the C-domain of 
ACE-1 (343). In addition, an in vivo study conducted by Fuchs et al. (344) showed that the C-domain 
of ACE-1 was predominantly involved in Ang-II production. However, not all studies are in agreement 
with these reported distinct roles for each domain, some studies have suggested that both domains 
participate in Aβ degradation (345, 346). Thus, the potential contributory role of the two domains of 
ACE-1 in Aβ pathology remains unresolved.  
 
 
Figure 1.12 Human SACE-1 structure and domain specificity. 
Schematic representation of human SACE-1 domain structure. The two homolgous domains (N-
domain and C-domain) have a catalytic active zinc binding site (HExxH). The N-domain and most of 
C-domain are extracellular. Both domains are linked by a linker sequence (LR). Transmembrane (TM) 
domain joined the C-domain with an intracellular C-terminus (CT) adapted from Harrison and 
Acharya. 2014 (332). There is an important catalytic difference between the N- and C-domains of 
sACE-1 as illustrated in this figure, N-domain is thought to be primarily responsible for amyloid beta 
(Aβ) degradation by inhibiting its aggregation and cytotoxicity (82, 343), whereas the C-domain is 
mostly responsible for the angiotensin II converting activity (343, 344).  
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In vitro ACE-1 has similarly been reported to degrade Aβ (81, 82, 347). ACE-1 was found to cleave 
the neurotoxic Aβ species (Aβ42) to a less neurotoxic species (Aβ40) (83). The physiological role of 
ACE-1 in the metabolism of Aβ in vivo remains unclear. Eckman et al. (348) found no relationship 
between inactivation of brain ACE-1 in mice and Aβ pathology. A later study by Zou et al. (83) found 
that administration of captopril (ACEI) into mice resulted in elevated Aβ deposition. This controversy 
is possibly due to differences between the study designs including age of animals, dosage and duration 
of exposure (which ranged from a single dose to several months of exposure) to ACEIs that suggests 
the need for further investigation in more internally and externally validated animal studies to improve 
clinical translation. Although animal models can be improved to mimic the human clinical conditions, 
the unmodifiable features such as animal-human differences are considered as ongoing issues (349, 
350). 
 
There is also some supportive evidence from genetic association studies in AD patients. A number of 
studies reported strong evidence of a genetic association between ACE1 and AD. The first genetic 
study to describe this association was by Kehoe and colleagues (84), which showed that an insertion 
(I)/ deletion (D) polymorphism within intron 16 of ACE1 associates with increased AD risk. This 
association has replicated in several meta-analyses with data regularly showing that the presence of the 
(I) allele (II and ID genotypes) in individuals was associated with increased the risk for AD, whereas 
homozygosity of the (D) allele was at reduced risk of AD (85, 86, 88, 89). Additional single nucleotide 
polymorphisms (SNPs) have also been shown to be associated with AD risk (351). In a study that set 
out to investigate the relationship between ACE1 variants and the levels of different species of Aβ, 
Miners et al. (90) found that the (II) genotype and other nearby SNPs were associated with increased 
levels of soluble Aβ in AD. More recently, case-control studies supporting the association between 
ACE1 polymorphism and increased risk of AD continue to emerge (155), agreeing with previous meta-
analyses (89). ACE1 DD allele polymorphism was associated with higher serum ACE-1 level 
compared to other genotypes (ID and II) and therefore people with this polymorphism could degrade 
Aβ more effectively than those with II homozygotes (352). Collectively, these data outline another 
layer of complexity implicating ACE-1 in AD in modulating Aβ metabolism in the brain.  
 
Experimental animal and clinical human studies also provide strong supportive evidence that the brain 
RAS is involved in maintaining normal brain function, specifically in learning and memory, and that 
overactivation, or hyperactivity of cRAS axis is involved in the pathogenesis of AD (78, 270, 353). 
Previous work in human brain tissue indicated that the cRAS was overactive in AD. The activity of 
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ACE-1 was significantly increased within the mid-frontal cortex in human post mortem brain tissue 
(78, 354) and the increased level and activity of ACE-1 was demonstrated in the hippocampus, frontal 
and temporal cortex of AD patients (78, 355, 356). It has also been found that ACE-1 activity 
correlated with Aβ senile plaque load (78) and correlated with levels of Aβ deposition in blood vessels 
(311, 357). These observations of upregulated ACE-1 have been suggested to be a response to Aβ 
accumulation. Some animal studies have shown that brain-penetrating ACEIs such as captopril and 
perindopril, or ARBs such as losartan, olmesartan and valsartan, protect against cognitive decline 
(358-362). Not all studies agree, Ferrington et al. (363) did not find any alteration in either 
intraneuronal Aβ or oligomeric Aβ levels in a triple transgenic mouse model of AD after 
administration of ACEI (captopril) and ARBs (eprosartan and valsartan) for two months. The 
discrepant findings to date could indicate variation and inconsistencies in animal models and length of 
exposure times to drugs and require further work.  
 
Yet, these animal data are overall, relatively consistent with the data observed from large 
epidemiological studies where several have indicated that treatment with anti-hypertensive 
medications, including ACEIs and ARBs protect against cognitive decline (364, 365). Data from some 
studies suggest that ARBs were more effective than ACEIs in decreasing the incidence and the rate of 
progression of AD (366-369), although more recently Ding and colleagues (370) found no difference 
afforded between different blood pressure treatment class and AD. The discrepant findings from 
animal and human studies could be related to the utility and validaty of animal models of hypertention 
including representative of discrete form of hypertension, responses to therapy and studies quality 
(371). In addition, the inconsistent observations in both in vivo and in vitro studies, as well as in 
population studies, regarding the role of ACEIs on Aβ metabolism and cognitive decline, and 
potentially on AD risk and progression indicate that there may be a complex interaction between ACE-
1 and Aβ and it may point to the variable affinities of different ACEIs for each ACE-1 domain, in 
addition to other properties such as their ability to cross the BBB. Several experimental studies have 
reported specificities of some commonly used ACEIs on ACE-1 catalytic domains (Table 1.2). Some 
ACEIs were reported to inhibit both ACE-1 domains equally, whilst other ACEIs appeared to be either 
C-domain specific and accordingly thus would reduce Ang-II production, or N-domain specific and 
potentially interfere with Aβ degradation. Thus, considering the ACE-1 domains specificity is 

















Captopril  ++ NONE + (343, 344, 372, 
373)  
 





NONE + NONE (373-375) 
 
Enalapril  ++ NONE + (343, 372, 373) 
 
Ramipril  NONE NONE + (373) 
Perindopril NONE NONE + (343) 
 
∗ RXP407  ++ NONE NONE (372, 373, 376) 
 
∗RXP380  NONE ++ NONE (372, 373, 376) 
 
Experimental compounds are highlighted by ∗.   The degree of affinity is indicated by the number of + while NONE 
indicates no evidence of binding. 
 
Clinical trials are currently underway to test the possible role of ACEIs or ARBs as possible treatments 
against cognitive decline. Examples of these are the RADAR trial of losartan (377) (EuDraCT 
No.2012-003641-15), and the SARTAN-AD study (Identifier NCT02085265) involving both 
telmisartan and perindopril in AD patients with hypertension. In addition, smaller sized studies will 
aim to compare the effects of different ARBs on: CSF levels of RAS components, the HEART study 
(378) (Identifier NCT02471833); executive function in hypertensive patients with mild cognitive 
impairment, the CALIBREX study (Identifier NCT01984164); cardiovascular outcomes in people with 
mild cognitive impairment, the CEDAR study  (Identifier NCT02646982); cognitive performance in 
older adults at high risk of AD, the rrAD study (Identifier NCT02913664). The findings of these 
important clinical trials will provide us with the further critical detail of the potential involvement of 
RAS in the pathogenesis of AD. 
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1.5.1.3 Angiotensin II (Ang-II) 
 
Ang-II is the central active peptide in the ACE-1/Ang-II/AT1R (cRAS) axis and is produced 
predominantly by ACE-1-mediated cleavage of Ang-I. Ang-II can also be produced directly from AGT 
by cathepsin G, tonin, elastase and protease-3 although the abundance of these in the brain is not clear. 
As described, Ang-II exerts its functions through binding to the specific G-protein coupled receptors 
(GPCRs), AT1R and AT2R (379). Ang-II is widely distributed throughout the brain and is detected in 
neurons, present at axon terminals and plasma membranes of dendrites, and astroglia (380, 381). 
Positive immunoreactivity of Ang-II has been reported in areas of the brain responsible for memory 
function and has a reported effect on supressing both long-term potentiation (LTP) and long-term 
depression (LTD) (382, 383).  
 
The current knowledge about cRAS in the brain is largely based upon studies that have investigated 
how Ang-II affects brain functions including learning and memory. The major physiological effects of 
Ang-II are mainly mediated through AT1R and produce neuronal damage and interfere with memory 
acquisition and recall in several in vivo studies. Infusion of Ang-II, the main effector in the classical 
axis of RAS, has been found to interfere with memory acquisition and recall in animal models of 
learning and memory (384, 385). Chronic Ang-II activation decreases synaptic plasticity through 
activation of neuroinflammatory pathway (386). Prolonged administration of Ang-II for three months 
in adult male C57BL/6 mice showed an association with BBB leakage, microglial activation, myelin 
loss and short-term memory impairment (387). In addition, infusion of Ang-II into AD mice model 
(AβPP/PS) resulted in exacerbation of AD pathological changes such as reduced CBF, spatial learning 
and functional dis-connectivity (388). A study conducted by Zhu et al. (238) found that ICV infusion 
of Ang-II into aged rats altered various components of the APP processing pathway (i.e. increased Aβ 
production and altered Aβ42/Aβ40 ratio), while AT1R deletion inhibited production of Aβ and plaque 
formation (389). In addition, ICV infusion of Ang-II increased the levels of phosphorylated tau (390). 
This collection of animal studies suggest that the underlying mechanisms between increased level of 
Ang-II and both cognitive dysfunction and AD could be related to Aβ and tau-related pathology 
including impaired BBB integrity (391) and enhanced neuroinflammatory and oxidative stress (392).  
 
Further support for the involvement of Ang-II in cognition and AD comes from recent human post-
mortem studies. Kehoe et al. (393) found an increase in Ang-II level in frontal cortex of AD patients 
that results from increased level and activity of ACE-1. In addition to preclinical trials and population 
studies that suggested the role of ARBs may reduce the risk and development of AD (367, 394, 395), 
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these studies suggest that the increased level of Ang-II, and the effects of AT1R activation, may be 
central to the pathogenesis of AD.   
 
1.5.1.4 Angiotensin-II receptors 
 
AT1R is composed of 359 amino acids and has an approximate molecular weight around 40-42 kDa. 
AT1R is coupled by guanyl nucleotide binding proteins to phospholipase C, calcium and adenosine 
3',5'-cyclic monophosphate (cAMP) second messenger systems and thus is a GPCR. In humans, the 
AT1R gene (AGTR1) is located on chromosome 3q and there are two subtypes of AT1R known as 
AT1aR and AT1bR in rodents (396). Within the human adult brain, AT1R is expressed more densely 
than AT2R and is located on neurons, astrocytes, oligodendrocytes and microglia of the cortex, 
hippocampus and basal ganglia (397).  
 
ACE-1 upregulation significantly increased production of Ang-II and subsequent activation of AT1R 
and activates several pathways that result in vasoconstriction, apoptosis (cell death) and 
neuroinflammation that collectively exacerbate cognitive impairment (397). In animal studies, 
activation of AT1R was shown to accelerate cell death of cholinergic and non-cholinergic neurons in 
the cortex and hippocampus after ischaemic injury (398) and was involved in the release of pro-
inflammatory cytokines and inflammation that also led to cell death (282). Several ARBs that block 
AT1R activation, such as telmisartan, valsartan, losartan and candesartan, have been shown to improve 
memory impairment and normalize spatial learning and memory in animal studies (291, 399-403). In 
addition, as mentioned, numerous clinical and epidemiological studies have provided clinical evidence 
of the neuroprotective effects of ARBs in reducing the incidence and progression of AD (404-407).  
 
The neurotoxic effects that have been attributed to Ang-II/AT1R binding can be countered by Ang-II-
mediated activation of AT2R, which is also a 7-transmembrane GPCR composed of 363 amino acids 
and weighs approximately 42 kDa sharing 32-34% homology with the AT1R. In humans, the AT2R 
gene (AGTR2) is located on the X chromosome (396). Although, AT1R and AT2R belong to one 
receptor family and have comparable potency and binding efficiency for Ang-II, each type is expressed 
in different areas of the brain and each mediates opposing functions of Ang-II. While AT1R are widely 
distributed in adult brain tissue, AT2R are limited to certain areas, including the thalamus, 
hypothalamus, brainstem nuclei and learning-associated areas (407, 408).  
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In the brain, AT2R activation cause vasodilation, facilitates cognitive function, promotes cell survival 
and has both antioxidant and anti-inflammatory effects (408). Activation of AT2R has been shown to 
attenuate cognitive impairment in several animal studies of brain injury. In a model of cerebral 
ischaemia, activation of AT2R induced neuronal synthesis of VEGF and enhanced survival of cortical 
neurons (409). Direct stimulation of AT2R by administration of an AT2R agonist (compound 21, 
(C21)) enhanced spatial memory and prevented cognitive decline in a model of AD (410). C21 has 
also also been shown to attenuate ischaemic damage in other animal models of ischaemia (411, 412). 
In addition, AT2R deficient mice showed impaired spatial memory and dendritic spine abnormalities 
(385). AT2R knock out animals showed cognitive impairment and reduced hippocampal neurons in 
females (413). Together these studies demonstrated that inhibition of Ang-II/AT1R or activation of 
Ang-II/AT2R axis could be promising targets for improvement of cognitive impairment in AD.  
 
1.5.2 Non-classical regulatory axis of RAS in the brain in AD 
 
We are becoming increasingly aware that downstream brain RAS pathways may have a major impact 
on AD pathogenesis. The non-classical axis or rRAS axis of brain RAS (ACE-2/Ang (1-7)/MasR) has 
regulatory and depressor functions. The protective effect of the non-classical axis may be related to its 
vasodilatory, anti-fibrotic, anti-growth and anti-inflammatory actions (Figure 1.13). Reduction in 
ACE-2/Ang (1-7)/MasR activities have been linked to several neurodegenerative diseases such as 
Multiple sclerosis, Parkinson’s disease and AD (414-416). Reduced level and activity of ACE-2 have 
been reported in human post-mortem studies and are strongly related to disease pathology (417). The 
role of each component of ACE-2/Ang (1-7)/MasR axis in relation to AD pathogenesis will be 




Figure 1.13 Effects of the non-classical axis of brain RAS.  
Angiotensin (1-7) (Ang (1-7)) is the main effector of the non-classical axis of brain RAS. Ang (1-7) 
mainly acts on MasR and results in the neuroprotective effects include vasodilatory, anti-fibrotic, anti-
growth and anti-inflammatory actions. Also, Ang (1-7) binds to another receptor known as MrgD and 
produces similar protective effects. Ang (1-7) can be further converted by decarboxylase into another 
active peptide known as alamandine that interacts with MrgD. Ang (1-7) has a higher affinity toward 
MasR and is responsible for the major effects of the non-classical axis of brain RAS (ACE-2/Ang (1-7) 
/MasR). ACE-2 - Angiotensin converting enzyme 2. MasR - Mas receptor. MrgD - Mas-related G 
protein-coupled receptor D.  
 
 
1.5.2.1 Angiotensin converting enzyme 2 (ACE-2) 
 
ACE-2 is a zinc metallopeptidase and the main enzyme involved in the non-classical rRAS axis (249, 
250). ACE-2 comprises 805 amino acids and shares 42% sequence identity with ACE-1 
metalloprotease, but unlike ACE-1 has only one catalytic domain (250). A major role of ACE-2 is in 
the metabolism of Ang-II forming Ang (1-7). Also, ACE-2 converts Ang-I to Ang (1-9) (251). Like 
ACE-1, ACE-2 is widely distributed in brain tissue, predominantly in neurons and perivascular areas 
involved in the regulation of cardiovascular function and learning and memory, such as the 
hippocampus and cerebral cortex (331, 417-419). In addition, a cell culture study reported that ACE-2 
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is also highly expressed in glial cells and astrocytes (420), although this remains to be confirmed in 
human brain tissue.  
 
Several studies have described the interaction between ACE-2 and AD pathogenesis. Liu S et al., 2014 
found that ACE-2 was involved in metabolism of Aβ where it was able to convert Aβ43 to Aβ42, 
which in turn could be cleaved by ACE-1 to less neurotoxic Aβ40 and Aβ41 species. In addition, they 
found that ACE-2 activity was reduced in the serum of AD patients, suggesting a potentially important 
role of ACE-2 in relation to Aβ neurotoxicity and development of AD. In ACE-2 knockout mice, the 
lack of ACE-2 resulted in cognitive impairment due to enhanced oxidative stress and reduced brain-
derived neurotrophic factor (419). More recently, we found that ACE-2 activity was reduced in human 
post-mortem brain tissue of AD patients and this reduction was associated with increased AD 
pathological hallmarks (total Aβ load and p-tau levels) (417). In addition, the observed reduction in 
ACE-2 activity was inversely correlated with increased ACE-1 activity (417). Together our findings 
indicated the potentially vital role of ACE-2 as a regulator of the brain cRAS and how dysregulation of 
ACE-2 might be a precursor and important factor in the involvement of cRAS in AD pathogenesis. 
Furthermore, activation of ACE-2 by administration of DIZE, an ACE-2 activator in AD animal 
model, in a D-galactose-ovariectomized rat model of AD, resulted in improved learning and memory 
function in the Morris water maze and novel object recognition tests (295). More recently a very 
similar observation was made in a Tg2576 mouse model of Aβ-related cognitive impairment and 
pathology whereby DIZE both prevented the development of Aβ-related cognitive impairment in pre-
symptomatic and restored cognition in mid-age cognitively impaired Tg2576 mice (421). 
 
 
1.5.2.2 Angiotensin 1-7 (Ang (1-7)) 
 
The heptapeptide Ang (1-7) is a bioactive endogenous peptide of the brain RAS. Ang (1-7) has been 
found in different areas of the brain including the cerebellar cortex, hippocampus, hypothalamus, 
substantia nigra, medulla oblongata and amygdala in rat and human brain (422-425). There is more 
than one enzymatic pathway involved in the production of Ang (1-7) in the brain. The dominant 
pathway involved in the conversion of Ang-II into Ang (1-7) directly by the action of ACE-2 (426). 
Also, ACE-2 can produce Ang (1-7) indirectly from converting Ang-I into Ang (1-9) and then ACE-1 
and/or NEP act on Ang (1-9) to form Ang (1-7) (427). Another pathway involved in Ang (1-7) 
production is via Ang-I cleavage by prolyl oligopeptidase, thimet oligopeptidase or NEP although how 
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prominent these are active in the brain, where their relative contributions to the formation of Ang (1-7) 
compared to that via ACE-2 is also still not fully known. It is widely accepted that Ang (1-7) exerts its 
physiological actions through binding to a GPCR namely, MasR (252). Coupling of Ang (1-7) with 
MasR generates several downstream signalling pathways such as stimulation of phospholipase A2, 
increased production of arachidonic acid, release of Ca+ independent activation of NOS, activation of 
phosphatidylinositol 3-kinase/Protein Kinase B (P13K/Akt), Mitogen-activated protein kinase 
(MAPK) and adenosine 3',5'-cyclic monophosphate (cAMP)-dependent protein kinase 
(PKA) (cAMP/PKA) (428). 
 
Although the role of Ang (1-7) has been extensively explored in the cardiovascular and renal system, 
less is known of the neurobiological functions of Ang (1-7). Previous animal studies have focused on 
the role of brain Ang (1-7) as a vasodilator and other vascular related effects. Indeed, brain Ang (1-7) 
plays an important role in maintaining cerebral blood flow. Xie et al. (429) demonstrated that central 
administration of Ang (1-7) in rats with chronic cerebral hypoperfusion restored the cerebral blood 
flow and improved cognitive function. Also, this effect was associated with additional neuroprotective 
actions including increased NO generation, attenuated neuronal loss and suppressed astrocyte 
proliferation in the rat hippocampus. This was further supported by another animal study that showed 
intracerebrovascular infusion of Ang (1-7) in rats promoted brain angiogenesis and increased capillary 
density via a Mas/eNOS dependent pathway (430). Furthermore, other underlying cerebroprotective 
mechanisms of Ang (1-7) have been reported such as increased bradykinin production and higher 
eNOS expression in the brain (328, 431). Collectively, these studies outline a critical role of the active 
RAS metabolite, Ang (1-7), in maintaining homeostasis of brain functions.   
 
In addition to the vascular actions of brain Ang (1-7), a few animal studies have investigated the role 
of this peptide in learning and memory. It has been shown that Ang (1-7), via its action on MasR, 
enhances LTP in the CA1 region of the hippocampus in mice (432). Similarly, Albrecht D. (433) 
showed that Ang (1-7) promoted stable LTP in mice amygdala mediated by cyclooxygenase (COX-2) 
and NO. Moreover, dysregulation of the Ang (1-7)/Mas axis caused memory deficits and affected 
object recognition memory in Mas knockout mice (353). One study examined the role of Ang (1-7) in 
relation to AD pathology, in an animal model of sporadic AD, Jiang et al. (416) found that Ang (1-7) 
levels were reduced in cerebral cortex and hippocampus and inversely correlated with 
hyperphosphorylated tau. In accordance, Uekawa et al. (434) showed that ICV infusion of Ang (1-7) 
alleviates cognitive impairment and improves cerebrovascular reactivity in the AD mouse model.  
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Despite the extensive investigation on the role of Ang (1-7) in previous animal studies, there is very 
little published data on the function of this peptide in humans in relation to AD. The plasma level of 
Ang (1-7) was found to be reduced in AD patients (n= 110) compared to age-matched controls (n= 
128), suggesting that Ang (1-7) could be a potential biomarker for AD (435). In our previous study, we 
found that Ang-II to Ang (1-7) ratio was increased in AD, indicating a reduction in conversion of Ang-
II to Ang (1-7) related to the observed reductions in ACE-2 activity (417).  
 
 
1.5.2.3 Mas receptor (MasR) 
 
The MasR was originally identified as a proto-oncogene due to its ability to transform NIH 3T3 cells 
and induce tumorigenicity in mice. MasR encodes a genetic sequence characteristic of the GPCR 
subfamily and has seven hydrophobic transmembrane domains (436). Recently, the MasR gene has 
been characterised as the most complex gene structure among the GPCR family group (437). In rats, 
the highest MasR expression was found in brain and testis (436). MasR was also found to be expressed 
in different peripheral tissues including heart, kidney, lung, liver, spleen, tongue, skeletal muscle and 
endothelial cells of blood vessels (254). In rat brain, high MasR level was detected within the 
hippocampus, cerebral cortex and in cardiovascular-related areas of the brain such as the hypothalamus 
and medulla (438, 439). The high expression of MasR in the hippocampus reinforces the hypothesis 
that binding of Ang (1-7) to MasR enhances LTP and modulates synaptic plasticity and further 
suggests that alterations to the non-classical axis of RAS may play a role in the cognitive decline in 
AD (432, 433).  
 
MasR knockout mice showed memory deficit and defective novel and spatial object recognition 
memory performance (353). In contrast, MasR activation in the hippocampus and basal ganglia 
promoted cell survival, enhanced synapse formation and improved cognition in rodent and humans 
(425). Accordingly, activation of MasR by Ang (1-7) administration attenuated cognitive decline, 
reduced expression of AD pathological hallmarks (phosphorylated tau, Aβ oligomer and both Aβ40 
and Aβ42 levels) in hippocampus of an AD rat model and co-administration of MasR antagonist 
reversed all of these protective effects (440), suggesting that dysregulation of (ACE-2/Ang (1-
7)/MasR) axis might be highly relevant to cognitive decline in AD. 
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Several lines of evidence suggest an interaction between MasR and the neuroprotective AT2R (441). In 
the mouse heart, Ang (1-7) was found to produce vascular effects by an interaction of the MasR with 
AT1R and AT2R, resulting in the release of prostaglandins and NO (442). More recently, a study 
conducted by Tetzner et al. (443) offered contradictory findings. They posed the possibility for 
interaction between the MasR and other receptors, including AT2R, but excluded AT2R as a receptor 
for Ang (1-7) and identified a second receptor for Ang (1-7) known as Mas-related GPCR, member D 
(MrgD). The coupling of Ang (1-7) with both MasR and MrgD activates intracellular signalling 
pathways involving increased cAMP and phosphokinase A activity. In addition to the complexity of 
the MasR, several studies reported variable selectivity of MasR upon stimulation by angiotensin 
peptides other than Ang (1-7), such as Ang-III and Ang-IV (444, 445). Considering these data, future 
examination and improved understanding of the direct interactions between Ang (1-7)/MasR and the 
intracellular signalling cascade in brain tissue is now of interest and which may also help to inform the 
role of the non-classical axis of RAS in AD pathogenesis.      
 
 
1.5.2.4 Alamandine and MrgD receptor 
 
Alamandine is one of the newly discovered active peptides in the brain RAS. It is an agonist of the 
MrgD receptor and is a heptapeptide that differs by one amino acid from Ang (1-7), where there is an 
alanine instead of aspartate (446, 447). Alamandine is produced from Ang (1-7) by decarboxylase or 
from Ang A, which is generated from the decarboxylation of Ang-II and then subsequent cleavage by 
ACE-2 (Figure 1-12) (448). Due to the sequence homology between Ang (1-7) and alamandine, both 
exert similar protective effects in circulatory and peripheral tissues. Several in vivo studies have 
demonstrated the cardioprotective effects of alamandine. Similar to Ang (1-7), alamandine has 
vasodilatory, anti-inflammatory and anti-hypertrophic actions (449-452). These protective effects 
result from binding of alamandine to the MrgD receptor that is encoded by Mrgprd gene in animals 
and humans (453). Within the brain, MrgD was detected in sensory neurons and has been implicated in 
the perception of neuropathic pain (454). MrgD had also been extensively studied in non-neuronal 
tissue especially cardiovascular tissue where it was found in arterial smooth muscles, endothelial cells 
of blood vessels, and cardiomyocytes (455). MrgD has been found to be expressed within the 
cardiovascular centre of the mouse brain (456). Despite the well know effects of alamandine/MrgD in 
the cardiovascular system, the role of this coupling system in relation to cognitive dysfunction and AD 
pathogenesis is less well studied. 
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1.5.3 Role of the APA/Ang-III/APN/Ang-IV/IRAP pathway in cognitive function and AD 
 
In addition to the main brain RAS pathways described, another downstream regulatory pathway of 
RAS has been identified in the brain involving APA/Ang-III/APN/Ang-IV/IRAP (457). This is another 
rRAS pathway that regulates cerebral blood flow, maintains memory and learning acquisition, and 
enhances synaptic plasticity and has neuroprotective effects in the CNS (458) (Figure 1.14). The role 
of each component of the APA/Ang-III/APN/Ang-IV/IRAP regulatory axis in relation to AD 
pathogenesis will be discussed in the following sections. 
 
 
Figure 1.14 Effects of the regulatory pathway of brain RAS. 
Ang-IV is the main effector of the regulatory pathway of brain RAS. Ang-IV acts on AT4R binding 
sites, including IRAP, to activate neuroprotective signalling resulting in maintaining memory and 
learning, regulating cerebral blood flow, increasing glucose uptake, and enhancing synaptic plasticity 
that together lead to cognitive improvement. The APA/Ang-III/APN/Ang-IV/IRAP enzymatic 
pathway is known as the regulatory pathway of brain RAS. APN -Aminopeptidase A, APN - 
Aminopeptidase N, APB - Aminopeptidase B, AT4R - Angiotensin 4 receptor, IRAP - Insulin-




1.5.3.1 Angiotensin III (Ang-III) 
 
Ang-III is a heptapeptide and a biologically active endogenous peptide in the brain RAS that is derived 
from and exerts similar pressor effects to Ang-II. Ang-III is generated from the cleavage of Ang-II by 
the action of APA but can also result from alternative enzymatic steps, such as APA-mediated 
conversion of angiotensinogen to des-Asp-Angiotensin followed by cleavage by ACE-1 to make Ang-
III (256). Although, some studies found that Ang-III has less affinity than Ang-II toward AT1R and 
AT2R (459), several studies have shown that Ang-III does mediate effects on the regulation of blood 
pressure, fluid homeostasis and vasopressin release (460).  
 
It is well established that Ang-III has significant cardiovascular actions (269). In vivo studies have 
found that Ang-III infusion increases BP, promotes vasoconstriction and stimulates aldosterone 
production (461). In vitro, it stimulates growth, production of proinflammatory mediators, and 
deposition of extracellular matrix proteins (462). Ang-III binds to AT1R, as well as to AT2R. However, 
most of the effects of Ang-III are mediated by AT1R. The role of Ang-III within the brain, in relation 
to AD pathogenesis, is less studied. Recently, our group found increased Ang-III level in human post-
mortem brain tissue of AD patients that correlated strongly with parenchymal Aβ and tau load (393). 
The increase in Ang-III level in AD might reflect hyperactivity of the classical axis of brain RAS 
(ACE-1/Ang-II/AT1R) and reduced activity of the downstream regulatory pathway APA/Ang-
IV/APN/IRAP, which might limit the metabolism of Ang-III in AD.       
 
 
1.5.3.2 Aminopeptidases in the brain RAS 
 
A group of enzymes, that are central to the proteolytic processing of many of the bioactive peptides in 
the brain RAS, are known as aminopeptidases. The two main aminopeptidases implicated in the 
synthesis, metabolism and actions of angiotensins are APA and APN, although APB might also be 
involved (463). All of these enzymes have previously been proposed to be involved in regulation of 
the brain RAS and are implicated in learning and memory (464).  
 
APA is a type II membrane bound monozinc aminopeptidase that is responsible for the hydrolysis of 
Ang-II, the main effector peptides of the brain RAS, to generate Ang-III. APA is also known as 
glutamyl aminopeptidase as its main function involves cleavage of the N-terminal glutamyl residue 
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from Ang-II (465). APA is expressed in many peripheral tissues and within the brain, where it has 
been identified in several brain nuclei sensitive to angiotensins that are involved in regulation of blood 
pressure. APA has been shown to localise to neurons and microglia (393, 466). In the brain RAS, APA 
has been proposed to be involved in two main enzymatic pathways that include the conversion of Ang-
II to Ang-III and also the hydrolysis of the protective peptide Ang (1-7) into less active small peptide 
Ang (2-7) (467).  
 
Previous experimental animal studies have reported increased activity of APA in different 
hypertensive animal models such as the spontaneously hypertensive rat (SHR) and in a salt-dependent 
model of hypertension, the deoxycorticosterone acetate (DOCA)-salt rat (466, 468). One of the novel 
treatment strategies for hypertension is targeting APA activity to reduce production of Ang-III (467), 
suggesting an association between hyperactivity of brain RAS and hypertension. Moreover, a number 
of human studies have investigated the role of APA in relation to AD pathogenesis. APA was able to 
generate the neurotoxic form of Aβ (Aβ42) and contribute directly to AD pathogenesis (469). Other 
studies indicated a reduction in APA activity in plasma and serum of AD patients (258, 464). In human 
post-mortem tissue, APA level and activity was similarly found to be reduced but not significantly so 
in AD (393). These findings suggest that the dysregulation in the upstream pathway of the alternative 
RAS axis may be altered in AD and could contribute to AD pathogenesis.  
  
APN is a type II transmembrane zinc-dependent aminopeptidase that is responsible for the hydrolysis 
of Ang-III to generate the neuroprotective Ang-IV peptide. APN is also known as alanyl 
aminopeptidase since alanine is most efficiently cleaved by APN (467). APN has been found in the 
wall of microvessels in the rat brain and in other brain areas such as the cortex, thalamus, 
hippocampus, substantia nigra, hypothalamus and in neurons of frontal cortex in human brain (393, 
470). In the brain RAS, APN is predominantly responsible for the conversion of Ang-III to Ang-IV 
and also, hydrolyses the small peptide Ang (2-7) into a less active smaller peptide Ang (3-7) (258). To-
date, several studies have shown a reduction of APN activity in association with AD pathogenesis. 
Puertas et al. (258) found that plasma APN activity was reduced in AD patients and associated with 
cognitive decline. In addition, reduced APN activity has been found in AD patients in both serum and 
in mid-frontal cortex of human post-mortem tissue (393, 464). Together these studies indicate that 
dysregulation of APN mediated production of Ang-IV is implicated in cognitive decline in AD.   
 
APB is a type II transmembrane zinc-dependent aminopeptidase that hydrolyse basic amino acid 
(Arginine) from the N-terminal of several peptides. APB is also known as arginine aminopeptidase 
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(467). Similar to APN, APB is also involved in the conversion of Ang-III into Ang-IV. Two studies 
have shown a reduction of APB activity in early stage of AD. Puertas et al. (258) found that plasma 
APB activity was reduced in AD patients and associated with cognitive decline. In addition, reduced 
APB activity has been found in serum of AD patients in the early stage of the disease (464). Both 




1.5.3.3 Angiotensin IV (Ang-IV) 
 
Originally, Ang-IV was thought to be an inactive, small fragment of RAS, however, recent studies 
have shown the hexapeptide to be a bioactive peptide in the brain RAS that plays a role in several 
physiological functions within the brain including facilitation of cognitive processing. Ang-IV is 
produced from Ang-III by the action of APN and APB (471). Within the brain, the Ang-IV binding 
site has been found in neurons in different brain areas including the cortex, hippocampus and basal 
ganglia (246, 472, 473). Accumulating evidence demonstrates that Ang-IV regulates CBF, maintains 
memory and learning acquisition, enhances synaptic plasticity and has neuroprotective effects (458). 
These beneficial effects of Ang-IV are mediated by binding to AT4R. There was a debate for many 
years about the identity of an Ang-IV specific binding site. Albiston et al. (474) discovered that IRAP 
was a specific binding site for Ang-IV. Later in 2008, Wright et al. (473) indicated that Ang-IV also 
binds and activates c-Met, a type 1 tyrosine kinase receptor. It seems that Ang-IV binds to these two 
binding sites independently and mediates different functional effects through inhibiting IRAP activity 
and stimulating the c-Met receptor pathway (475).  
 
Several experimental studies have focused on the effects of Ang-IV and Ang-IV analogues on 
cognitive function, especially in learning and memory. Both Ang-IV and its analogue (Nle1-Ang IV) 
facilitated LTP induction in hippocampal and dentate granule cells both in vitro and in vivo (476-478). 
ICV administration of Ang-IV or Ang-IV analogues have been shown to enhance both spatial working 
memory and object recognition memory. Administration of Ang-IV into the lateral ventricle of normal 
rat (male SDR) enhanced spatial working memory in the plus maze spontaneous alteration task (479). 
Similarly, two studies showed improvement in cognitive performance after treatment with Ang-IV 
alone or combined with an Ang-IV analogue (Nle1-Ang IV or LVV-haemorphin-7) (480, 481). 
Braszko et al. (482) demonstrated that the enhancement of memory after ICV administration of Ang-II 
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in male WR was caused by the shorter peptide, Ang-IV. In addition, Golding and colleagues found 
improvement in object recognition after subcutaneous administration of Ang-IV in the same animal 
model (483). Consistent with all these studies, ICV infusion of Ang-IV rapidly improved novel object 
recognition in a mouse model (male C57BL/6J mice) that was dependent on AT4R expression (484). In 
contrast, two studies found no effects of Ang-IV on the rate of acquisition of cognitive task or on 
object recognition performance after subcutaneous administration of Ang-IV (485, 486).  
 
Ang-IV and a number of its analogues have been found to restore cognitive function and enhance 
spatial working memory in an animal model of Scopolamine-induced memory deficits (487-492). 
More recently, blocking the effects of AT4R with divalinal was found to counter ARBs (losartan) 
effects to rescue spatial learning and memory in a mouse model of AD (493). In addition to the 
neuroprotective effects of Ang-IV, previous results from animal studies support the cerebroprotective 
role of Ang-IV/AT4R in increasing CBF by stimulation of NO production (458, 494, 495). Overall, 
these findings suggest that Ang-IV/AT4R pathway is potentially a promising target for improving 
cognitive decline in AD. 
 
 
1.5.3.4 Insulin regulated aminopeptidase (IRAP) 
 
The AT4R binding site has been identified as IRAP, a type II transmembrane protein that belongs to 
the M1 zinc dependent aminopeptidase family that also contains APA, APN, and APB. IRAP is 
predominantly localised to glucose transporter type 4 (GLUT4) vesicles in insulin-responsive cells, 
which include the pyramidal cell of the hippocampus and cerebral cortex (474, 496, 497). This 
identification was based on observed similarities between human brain AT4R and the known IRAP 
structure, both were found to have high sequence homology and a similar molecular weight of around 
160 kDa. IRAP consists of a 110 amino acid N-terminal hydrophilic intracellular domain that includes 
two dileucine motifs. The hydrophobic transmembrane domain consists of 22 amino acids that 
continue with an 893 amino acid C- terminal extracellular domain associated with its catalytic site 
(459). IRAP also has been known as oxytocinase, cysteine aminopeptidase, and placental leucine 
aminopeptidase (479).  
IRAP has the ability to cleave the N-terminal amino acids from a number of active neuropeptides such 
as, vasopressin, somatostatin, eNOS, met-enkephalin and many others (498, 499). Two groups of 
IRAP inhibitor have been identified that show memory enhancing properties, especially enhancing 
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spatial working memory in animal models: peptide inhibitors (Ang-IV and its analogues, LVV 
haemorphin7) and benzopyran-based inhibitors (HFI-419, HFI-435 and HFI-437) (500-502). Based on 
the physiological actions of IRAP, two potential mechanisms have been proposed to explain the role of 
Ang-IV/IRAP interaction as a memory enhancer in the brain (Figure 1.15). First, Ang-IV 
competitively inhibits the catalytic activity of IRAP toward several neuropeptides such as oxytocine, 
vasopressin, somatostatin, eNOS, met-enkephalin and as a result extends their half-life. Second, Ang-
IV binds to IRAP and inhibits the intracellular GLUT4 vesicular trafficking resulting in sustained 
presence of both IRAP and GLUT4 on the cell surface, thus enhancing memory by increasing neuronal 
glucose uptake (496, 497, 503).  
Contrary to previous animal studies showing the cognitive-enhancing effects of IRAP inhibitors, a 
recent animal study in IRAP knockout mice resulted in significant deficit	 both spatial and object 
recognition memory (504). In accordance, plasma activity of IRAP was found to be significantly 
reduced in AD patients and correlated with worsening MMSE scores (258). Together these studies 
support the hypothesis that IRAP has a vital role in cognitive function, while the implication of Ang-
IV/IRAP pathway in AD pathogenesis is less studied. 
 
1.5.3.5 Angiotensin type 4 receptor (AT4R) subtype (c-Met) 
 
Ang-IV interacts with another AT4R binding site identified as c-MET, a tyrosine kinase receptor (473). 
The c-Met receptor consists of an α-chain (50 kDa) and a β-chain (140 kDa) linked by disulfide bonds. 
Hepatic growth factor (HGF) binds to c-Met resulting in tyrosine phosphorylation leading to the 
activation of a number of biological activities (505). This identification was based on several research 
findings that showed a partial similarity between Ang-IV and HGF in chemical structure and 
physiological function (458). Distribution of the c-MET receptor in the brain was similar with the 
extensive distribution pattern of AT4R in areas responsible for cognitive and motor processing 
including the amygdala, hippocampus, cerebral cortex, substantia nigra, striatum, and thalamus (384, 
472, 492, 506, 507). There is an overlap between many functions mediated by HGF/c-MET and Ang-
IV/AT4R; both coupling systems facilitated memory consolidation, enhanced hippocampal LTP, 
calcium signalling, CBF, synaptic transmission and have been implicated in AD (459, 508). Increased 
HGF level was found in the CSF in AD patients associated with the white matter damage (509). 
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Ang-IV activation of the c-Met receptor induces several signalling pathways (Figure 1.15), Ang-IV 
increases:  
i) intracellular calcium and enhances eNOS production (495);  
ii) calcium entry via different calcium channels and enhances synaptic transmission and LTP 
(478, 510);  
iii) acetylcholine synthesis and release (511);  
iv) dendritic growth in the hippocampus (512).  
 
Together these studies suggest that Ang-IV activation of these intracellular signalling pathways 
facilitates CBF, enhances synaptogenesis and LTP and increases neuroprotection (475). Moreover, 
recent neural imaging indicates that an Ang-IV analogue (Nle1-Ang-IV) stimulates the production of 
new dendritic spines and increases spine head size in hippocampal neurons and reverses learning 
deficits in a scopolamine dementia rat model (491). In summary, Ang-IV seems to mediate its 






Figure 1.15 The possible mechanisms of the neuroprotective effects of Ang-IV. 
Ang-IV mediates several neuroprotective effects through binding to two binding sites independently, 
IRAP and AT4R/c-Met receptor. Ang-IV binds to IRAP and inhibits its aminopeptidase activity 
resulting in increased half-life of several endogenous neuropeptides such as oxytocine, vasopressin, 
somatostatin and eNOS, altogether known to potentiate memory and increase CBF. Also, Ang-IV 
inhibits intracellular GLUT4 vesicular trafficking and increases neuronal glucose uptake. Other effects 
of Ang-IV are mediated trough stimulation of the AT4R/c-Met pathway that stimulates eNOS 
production and increased CBF, increased calcium entry and acetylcholine synthesis and release,  and 
stimulates dendritic growth that altogether lead to enhanced synaptic transmission, LTP, increased 
memory functions and neuroprotection. IRAP - Insulin-regulated aminopeptidase, GLUT4 - Glucose 
transporter type 4, eNOS - endothelial nitric oxide synthase, CBF - cerebral blood flow, AT4R - 
Angiotensin 4 receptor, c-MET - a tyrosin type 1 receptor, LTP - Long-term potentiation. Up pointed 
orange arrows = increase, red circle minus signs = inhibit, green circle plus signs = stimulate.  
     
 
 
1.5.4 Potential therapeutic targets of brain RAS in AD 
 
Improved understanding of the critical roles of brain RAS in neurodegenerative diseases has opened 
new ideas as to potential therapeutic approaches for AD. Although, the development of brain RAS 
targeting drugs that are able to cross the BBB remains challenging, several published data provide 
novel evidence that regulation of brain cRAS and rRAS may provide therapeutic benefit in AD. 
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Currently, the possible RAS pharmacological targets in AD aim to inhibit the overactive cRAS (ACE-
1/Ang-II/AT1R) but novel targets that activate the downstream rRAS (ACE-2/Ang (1-7)/MasR) and 
(APN/Ang-IV/IRAP) might prove to be more efficacious. There are currently eight potential 
targets/approaches (Figure 1.16):  
i. Renin inhibitors:  
 
Renin inhibitors are a class of cRAS targeting anti-hypertensive drugs that inhibit the 
enzymatic activity of renin and prevent formation of Ang-I, the first step toward Ang-II 
production in the RAS. Aliskiren, a highly specific and potent renin inhibitor has been shown 
to exert neuroprotection against Aβ toxicity in cortical neurons of rats (513) and reduce brain 
damage and working memory deficits in a mouse model of chronic cerebral ischaemia (514). 
However, there is limited evidence about the effects of renin inhibitors on cognitive functions 
and AD pathogenesis in human since the drug is relatively new compared to all other RAS 
medications. 
 
ii. ACE-1 inhibitors (ACEIs) 
ACEIs are the most commonly prescribed RAS targeting anti-hypertensive drugs that inhibit 
the enzymatic activity of ACE-1 and prevent the production of Ang-II from Ang-I. A number 
of currently used ACEIs have variable effects on cognitive functions and are associated with 
decreased risk of developing AD (364, 365). However, findings from in vitro and in vivo 
studies regarding the effects of ACEIs on Aβ level are inconsistent and sometimes conflicting. 
Most of the in vitro studies have shown that ACEIs increase both Aβ40 and Aβ42 level and 
inhibit degradation of Aβ42 (79, 81, 343, 347). In contrast, several animal studies have shown 
the beneficial effect of ACEIs, such as perindopril, captopril and enalapril, which are 
associated with decreased Aβ42 level, reduced Aβ plaque and ROS accumulation and 
improved CBF in brain of AD models (361, 515-517). Other studies have showed either no 
effect of ACEIs on Aβ level (518) or increased Aβ level after administration of ramipril in 
mice model of AD (ACE 10/10 mice) (519). Despite the inconsistency of ACEIs effects on Aβ 
level, a large body of evidence from observational and clinical studies support a beneficial 
effect of ACEIs on reducing cognitive decline and slowing the progression of AD in patients 
using ACEIs compared to non-RAS targeting anti-hypertensive drugs (364, 365, 367, 520, 
521).  
	 54 
iii. AT1R blockers (ARBs) 
Ang-II acts on AT1R to exert its neurotoxic effects, thus inhibiting Ang-II by blocking AT1R is 
one of the therapeutic targets of AD. Data from experimental studies have demonstrated the 
beneficial effects of several ARBs such as losartan, valsartan, olmesartan, telmisartan and 
candesartan on both cognitive functions and Aβ pathology in human APP mice (238, 358, 359, 
522-526). Moreover, supportive data from observational and clinical studies has indicated the 
neuroprotective effects of ARBs on cognition and Aβ pathology (366, 367, 377, 527). Some 
recent clinical studies suggest that ARBs are more effective than ACEIs in delaying the onset 
or reducing the rate of cognitive decline in AD (366-369). 
iv. AT2R agonists 
Ang-II also acts on AT2R and mediates beneficial signalling mechanisms opposing those of 
AT1R, and thus activation of AT2R by AT2R agonists could potentially modulate the cognitive 
deficit in AD. Direct activation of AT2R by administration of AT2R agonist (C21) has been 
shown to enhance spatial learning in wild-type mice that were given intracerebral injection of 
Aβ40 (410). AT2R has a higher affinity toward Ang-III, thus stimulation of this receptor 
through targeting Ang-III analogues that are able to penetrate the BBB could be a new 
therapeutic approach for AD (528). 
Together all of these targets aim to inhibit or reduce the deleterious effects of the classical RAS axis 
(ACE-1/Ang-II/AT1R). In contrast, other agents that target the downstream regulatory RAS axis 
include: 
v. ACE-2 activators 
Direct activation of ACE-2 results in reduced effects of Ang-II through conversion of Ang-II 
into the neuroprotective peptide Ang (1-7). Experimental studies have shown that DIZE, a 
trypanocidal drug that can activate ACE-2 (529) has neuroprotective effects against ischaemic 
stroke in rats and improved learning and memory in an AD rat model (295, 326, 441). Mascolo 
and colleagues (530) suggests that direct administration of recombinant human ACE-2 
(rhACE-2) previously investigated in relation to cardiovascular diseases (531), could provide 
therapeutic benefit in AD. However, this targeting strategy still remains less studied in relation 
to cognitive function and AD pathogenesis. 
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vi. MasR agonists 
Ang (1-7) acts on MasR and mediates the cerebroprotective and neuroprotective effects. 
Reduced level of Ang (1-7) was found in both AD patients and a mouse model of sporadic AD 
(416, 435). Direct activation of MasR through ICV administration of Ang (1-7) has been 
shown to improve cognitive performance in an animal model with induced cognitive deficit 
(429, 434). Another non-peptide MasR agonist, AVE 0991, in combination with renin 
inhibitors, showed a beneficial cardiovascular effect of lowering blood pressure in 
hypertensive rats (532). Its potential protective role in relation to cognitive function and AD 
pathogenesis warrants further study.  
Together these pharmacological approaches might potentiate the protective effects of the non-classical 
axis (ACE-2/Ang (1-7) /MasR).  
vii. IRAP inhibitors  
IRAP inhibitors include both the peptide (Ang-IV and Ang-IV analogues) and the non-peptide 
mimetic (HFI-419) that have been shown to promote memory especially enhancing spatial 
working memory in animal models with induced cognitive impairment (500-502). Several 
attempts were made to develop new Ang-IV analogues for the treatment of AD (458), 
however, the short half-life and inability to cross the BBB limited the use of these compounds 
in clinical studies. Developments of Ang-IV analogues that result in more stable smaller 
molecules that are able to cross the BBB (e.g. dihexa) have been shown to facilitate spatial 
memory in scopolamine-induced deficits in Morris water maze (492). 
All of these pharmacological manipulated targets aim to potentiate the neuroprotective effects of the 
brain RAS regulatory axis (APN/Ang-IV/IRAP).  
viii. APA inhibitors  
APA inhibitors inhibit the conversion of Ang-II to Ang-III, which is reported to be increased in AD 
patients and was associated with AD pathology (393). Oral administration of APA inhibitors reduced 
blood pressure (533). Two new drugs targeting APA (EC33 and QGC001) that reduce the blood 
pressure have been shown to cross the BBB (534, 535). In addition, APA was able to generate the 
neurotoxic form of Aβ (Aβ42) and contribute directly to AD pathogenesis (469). Thus, targeting APA 
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activity through APA inhibitors can modulate the toxic effects of Ang-III on blood pressure and APA 
on Aβ metabolism.   
	
	
Figure 1.16 The possible therapeutic targets of brain RAS in AD.  
Eight basic approaches can be considered as new therapeutic targets for AD that aim to inhibit the 
overactive classical axis (ACE-1/Ang-II/AT1R) and/or activate the downregulatory non-classical axes 
(ACE-2/Ang (1-7)/MasR) and (APN/Ang-IV/IRAP). Inhibition of the overactive classical axis (ACE-
1/Ang-II/AT1R) can be achieved by the use of renin inhibitors (Aliskiren), Angiotensin converting 
enzyme-1 inhibitors (ACEIs), AT1R blockers (ARBs) or activators of the the protective AT2R by 
AT2R agonists (compound 21 and Ang-III analogues). Activation of the non-classical axis (ACE-
2/Ang (1-7)/MasR) can result from either the use of ACE-2 activators (rhACE-2 and DIZE) or MasR 
agonists (Ang (1-7), Ang (1-7) analogues AVE 09991). IRAP inhibitors (Ang-IV, Ang-IV analogues 
and HFI-419) are promising targets to activate the regulatory pathway (APN/Ang-IV/IRAP). One of 
the new therapeutic targets within RAS aims to inhibit APA activity by using APA inhibitors (EC33, 
QGC001). rhACE-2 - recombinant human angiotensin converting enzyme 2, DIZE - diminazene 
aceturate. Flat red arrows = inhibition or blocking, Up pointed green arrows = activation (adapted from 






1.6 Hypothesis and aims 
 
Recent studies indicate that an imbalance in brain RAS, due in part to defective rRAS signalling and 
overactive cRAS activity, is associated with disease pathology in human studies. Collective data from 
genetic, in vitro and in vivo, as well as clinical and observational studies support a strong association 
of a dysfunctional brain RAS in the mediation of disease pathology and cognitive decline in human 
and animal studies although there is much to still be understood of the brain RAS in AD. 
 
In this study, I explored the general hypothesis that alterations of both the classical (overactive) and 
non-classical axes of brain RAS (underactive) can influence AD pathogenesis and are related to 
vascular dysfunction.   
 
The main aims were to characterise the expression and distribution of cRAS and rRAS pathways, and 
novel RAS mediators, in AD in relation to disease pathology and markers of vascular dysfunction in 
human post-mortem brain tissue.  
 
The specific aims of the studies in this thesis were: 
 
(i) To determine the relevant contributions of ACE-1 C-domain and N-domain activities to the 
overall increased activity of ACE-1 in AD. 
(ii) To systematically characterise the expression and distribution of major non-classical RAS axis 
pathways (ACE-2/Ang (1-7)/MasR) in AD in relation to AD pathology, 
(iii) To characterise the expression and distribution of the alternative regulatory axis of brain RAS 
(APN/Ang-IV/IRAP) in AD in relation to AD pathological markers.  
(iv) To examine the relationship between alterations of brain RAS markers (Ang (1-7)/MasR), 
(Ang-IV/IRAP) with markers of cerebrovascular dysfunction including brain ischaemia 
(VEGF) and tissue oxygenation (MAG:PLP1 ratio).  
(v) To investigate the level and examine the distribution of the non-AT1R and non-AT2R binding 
protein (neurolysin) in AD in relation to both AD pathological hallmarks and vascular markers, 
and to measure the level of its substrate (neurotensin) in relation to AD pathology. 
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All the details of laboratory equipments, consumable suppliers, constituents of regulary used solutions, 
summary of primary and secondary antibodies, standard proteins and assay kits used in this study are 
listed and presented in chapter 9 (Appendix II).  
 
2.2 Brain tissue acquisition and processing 
 
Human post-mortem brain tissue used in this study was obtained from the Human Tissue Authority-
licensed South West Dementia Brain Bank (SWDBB), University of Bristol, Southmead Hospital, UK 
with local Research Ethics Committee approval (reference 08/H0106/28 + 5).  
 
Brain tissue dissection was performed following a standard procedure that has previously been 
described (78). In summary, for the majority of cases, brain tissue was obtained and processed within 
72 hours of death. The left cerebral hemisphere had been sliced and stored at -80°C for further 
biochemical assessment. The right cerebral hemisphere was fixed in 10% buffered formalin for a 
minimum of three weeks before being sliced coronally into slices of approximately 1 cm thickness and 
embedded into wax blocks. All tissue blocks were used for creating tissue sections using a sledge 
microtome of 7 µm thickness for both pathological assessment and other relevant histological 
investigations. 
 
2.2.1 Cohort selection  
 
Brain tissue used in this study was taken from the mid-frontal cortex (Brodmann area 8/9). AD cases 
(n= 70) were selected with a definite AD diagnosis according to the criteria of the CERAD (189). The 
controls (n= 48) used were selected with no history of dementia and other neuropathological disorders. 
This cohort was selected on the basis that it had also been previously used to study other RAS 
components in relation to AD pathology and from which some data was already available (78). Where 
such data is used in this thesis in various analyses the contributions of any relevant persons for these 
data is made clear. 
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Brain tissue homogenates were made from AD cases (n= 70) that ranged from 47-98 years of age-at-
death (Mean= 77.9, SD= 10.5), which included 44 females and 26 males, and had a post mortem delay 
time ranging from 4 to 99 hours (Mean= 46.7, SD= 25.7). The control group (n= 48) ranged from 43-
95 years of age-at-death (Mean= 78.9, SD= 10.5), included 19 Females and 29 males, and had a PMD 
time that ranged from 3-216 hours (Mean= 47.5, SD= 38). Although some cases had a long PMD time 
and different cause of death that could have an influence on tissue processing, there were no 
significant differences in age-at-death or PMD time between controls and AD cases (p= 0.657; p= 
0.525) respectively. The demographic features of the AD and control cohorts are summarised in Table 
2.1. The details of the study cohorts are described in chapter 9 (Appendix I: Table 9.1 and Table 9.2). 
 






















19 (39.58 %) 
29 (60.42 %) 
 
44 (62.86 %) 
26 (37.14 %) 
PMD (hours) 
Range  
Mean ± SD 
 
3-216 
47. 5 ± 38 
 
4-99 
46.7 ± 25.7 
 
 
The fixed tissue used in this study was from a cohort selected from SWDBB, University of Bristol, 
with local Research Ethics Committee approval. The cohort comprised a total of 7 AD cases, 7 
vascular dementia (VaD) cases and 10 age-matched controls. There were no significant differences in 
age-at-death or PMD time between controls and AD cases (p= 0.349; p= 0.987) respectively. The 
demographic features of the fixed tissue cohort are summarised in Table 2.2. The details of the fixed-
tssue study cohorts are described in chapter 9 (Appendix I: Table 9.3, Table 9.4 and Table 9.5).  
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Table 2.2 Characteristics of fixed tissue cohort. Control, AD and VaD cases include: Age-at-death, 































2 (20 %) 
8 (80 %) 
 
6 (85.71 %) 
1 (14.28 %) 
 
4 (57.14 %) 
3 (42.86 %) 
PMD (hours) 
Range 
Mean ± SD 
 
15-80 
43.8 ± 21.28 
 
9-85 
44 ± 28 
 
22-70 
39.86 ± 20.33 
 
 
2.2.2 Brain tissue homogenisation 
 
Homogenates of mid-frontal cortex (Brodmann area 8/9) made from approximately 200 mg pieces of 
tissue that were prepared in a Precellys 24 homogenizer with 5-10 silica beads (2.3 mm) (Stretton 
Scientific) in either 1% SDS buffer, or 0.5% Triton X-100. The tissue was kept on ice throughout the 
process and homogenised using program comprising 2 rounds of 6000 revolutions-per-minute (rpm) 
for 15 seconds each. The resultant homogenates were then centrifuged at 13,000 x g for 15 minutes at 
4°C using a refrigerated centrifuge (Eppendorf). The supernatants were sub-aliquoted into 100 µl 
volumes and stored at -80°C for later use.  
 
2.3 Total protein measurement 
 
Total protein concentrations of the tissue homogenates were made to allow for adjustments within 
various assays and to help with standardised loading of samples. Total protein was measured using the 
Total Protein Assay Kit (Sigma-Aldrich). The protein assay solution was prepared by mixing one 
volume of protein dye reagent with four volumes of distilled water (dH2O). 5 µl of tissue homogenates 
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were diluted 1:10 in 0.85% NaCl and added in triplicate to wells on a 96 well plate. Then 5 µl of 
0.85% NaCl as blank and protein standard comprising 0.3mg/ml albumin were added in triplicate to 
wells followed by 250 µl of the protein dye reagent. The absorbance of the samples was then read at 
595 nm and the protein concentration was determined using the following formula. The sample values 
determined from the formula were then multiplied by the dilution factor (i.e. 10).  
 
Protein concentration (mg/ml) = Absorbance of sample × Concentration of standard (0.3mg/ml)  
                                                                              Absorbance of standard   
 
 
2.4 Western blotting 
 
Western blotting was used to identify the presence of specific proteins in tissue homogenates and cell 
lysates, as well as help determine the specificity of antibodies. In this technique, specific proteins are 
separated by gel electrophoresis according to molecular weight. The samples are then transferred to a 
nitrocellulose membrane by a blotting approach that relies on capillary action and then the 
nitrocellulose membranes processed to eventually yield a visible band of measurable weight for each 
protein. This was made possible by allowing the membrane to be incubated with specific antibodies to 
allow the detection and visualisation of the target protein band. 
 
2.4.1 Gel electrophoresis  
 
Samples of tissue homogenates or cell lysates were diluted (1:2) in SDS sample buffer (reducing 
buffer) that was prepared prior to use by adding 25 µl of β-mercaptoethanol (Sigma-Aldrich, UK) to 
475 µl SDS reducing buffer under a fume hood. Samples were boiled at 95°C for 5 minutes and then 
allowed to cool at room temperature and spun briefly in a bench top centrifuge. A total volume of 25 
µl per sample and 5 µl of a molecular weight ladder (Precision Plus ProteinTM WesternCTM; Bio-Rad 
Laboratories) was added into respective wells in a 4-20% Tris-HCl pre-cast gels (Mini-PROTEAN® 
TGXTM; Bio-Rad Laboratories). The electrophoresis module (Mini-PROTEAN® 3; Bio-Rad 
Laboratories) was used to separate the proteins using 1x running buffer. After loading the samples into 





The electrophoretic transfer cell (Mini Trans-Blot®; Bio-Rad Laboratories) was used to transfer 
proteins from the gel to a nitrocellulose membrane. The gel and the membrane were placed between 
two filter papers and two filter pads to form a gel sandwich within the gel holder cassette. The cassette 
was placed in the transfer cell tank and filled up with 1x blotting buffer and a small magnetic stirrer 
with an ice pack were used to cool the transfer process. The gel was blotted at 150 V for 1 hour. 
 
 
2.4.3 Protein detection 
 
The membrane was washed briefly in 0.05% TBST and incubated with 10% milk/TBST blocking 
buffer for 1 hour. The membrane was washed in 0.05% TBST (3x 15 minutes) at room temperature on 
a shaker. The membrane was then incubated with primary antibody diluted in 5% milk/TBST antibody 
buffer overnight at 4°C (in the fridge) on a shaker. The membrane was washed in 0.05% TBST (3x 15 
minutes) at room temperature on a shaker. Next, the membrane was incubated with peroxidase-
labelled secondary antibody for 1 hour at room temperature on the shaker. After 3 x 15 minutes 
washing steps with 0.05% TBST, a chemiluminescent HRP substrate (ECL) (Millipore) was added to 
the membrane in a 1:1 ratio (5 ml of reagent 1 and 5 ml of reagent 2) for 5 minutes. Excess substrate 
was removed and the membrane was carefully placed on the centre of the imaging platform which was 
then smoothed out with a roller to remove any bubbles and ensure a uniform imaging. The resultant 
images were captured using ChemiDoc	XRS+	and	Image Lab software, version 0.5 (Bio-Rad). 
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Immunohistochemistry (IHC) is a specific method used to detect and examine the cellular distribution 
of proteins of interest in formalin-fixed brain tissue or frozen tissue. In this thesis the descriptions of 
IHC relate only to formalin fixed tissue. 
 
2.5.1 Slide preparation  
 
Microscope slides (1.0-1.2mm square) (Cell Path) were soaked overnight in 10% decon detergent, then 
washed in 60°C running water for 1 hour. The slides were then rinsed with distilled water and dried in 
an oven at 60°C overnight. After drying overnight, the slides were immersed for 15 seconds in 
different solutions: 2% APES, ethanol and distilled water. The slides were then dried at 40°C for 24 




2.5.2 Tissue preparation  
 
A total of 5 sections (7 µm in thickness) were cut using a sledge microtome (LEICA Biosystems) from 
paraffin-embedded wax blocks of fixed brain tissue of mid-frontal cortex (Brodmann area 8/9). The 
sections were collected on APES-coated slides and dried at 40°C overnight and stored in boxes at 




After overnight incubation at 60°C, the slides were dewaxed 2 X 5 minutes in clearene and dehydrated 
2X 5 minutes in 100% ethanol. Endogenous peroxidase activity was blocked by immersing the slides in 
3% hydrogen peroxide in methanol for 90 minutes. After washing in running tap water for 10 minutes, 
a pre-treatment step was undertaken (sections were immersed in either EDTA or citrate buffer and 
boiled for 10 minutes in a microwave). The sections were then washed in running tap water for 5 
minutes before equilibration in PBS. Non-specific binding was blocked by incubation with normal 
blocking serum (Vectastain®) for 20 minutes. The sections were incubated with a primary antibody 
against MasR, IRAP and neurolysin respectively and incubated overnight (see primary antibody list, 
Table 2.4). A control slide was incubated with PBS only and was included in each experiment. On the 
second day of immunolabelling, sections were rinsed in two changes of PBS for 3 minutes each and 
incubated with Vectastain biotinylated universal secondary antibody for 20 minutes. After another 
wash in two changes PBS for 3 minutes each, sections were incubated with VectaElite Avidin-biotin 
complex (ABC) for 20 minutes, rinsed again and incubated with diaminobenzidine (DAB) for 10 
minutes. The sections were again washed in running water for 10 minutes after incubation with DAB 
and immersed in copper sulphate solution for 4 minutes followed by further washing in running water 
for 5 minutes. The sections were then counterstained with haematoxylin Gill II for 3 seconds, 




Figure 2.2 Immunolabelling sections based on ABC method with VECTASTAIN® Elite ABC kit. 
 
 
2.6 ACE-1 domain specific activity assay  
 
An ACE-1 activity assay was previously developed by Dr. Scott Miners using a fluorescence 
resonance energy transfer (FRET) substrate Abz-FRK(Dnp)p-OH for somatic ACE-1 (78). This FRET 
assay is a sensitive method for quantitative measurement of ACE-1 enzyme activity, using a FRET 
substrate containing o-aminobenzoic acid (Abz) as a fluorescence group (donor) and 2,4-dinitrophenyl 
(Dnp) as the quencher acceptor. ACE-1 enzyme activity is related to the fluorescence generated due to 
the breakdown of the peptide bond between the donor and acceptor pair. This assay measured total 
ACE-1 activity but did not discriminate between domains. In this study, we aimed to measure ACE-1 
N-domain and C-domain activity using selective FRET substrate for N-domain (Abz-SDK(Dnp)-p) 
and for C-domain (Abz-LFK(Dnp)-OH trifluoroacetate salt) (536). 
 
2.6.1 ACE-1 N-domain fluorogenic activity assay  
	
ACE-1 N-domain activity was measured in 1% SDS homogenates using an N-domain-specific 
fluorogenic peptide substrate (Abz-SDK(Dnp)-p (Enzo Life Sciences). The assay was performed in 
black FlouroNUNC 96-well plates. Captopril (10 µl), an ACE-1 inhibitor, at concentration of 10 µM 
was added to all wells to be inhibited and 10 µl of dH2O was added to all paired uninhibited wells. 50 
µl of brain tissue homogenate (27.5 µl in 82.5 µl PBS) and a serial dilution of recombinant human 
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ACE (1000-15.625 ng/ml) (R&D systems) were prepared in a total volume of 50 µl and added in 
duplicate and incubated for 10 minutes at 37°C in either captopril or dH2O. The N-domain-specific 
fluorogenic peptide substrate (Abz-SDK(Dnp)-p was diluted (5:200) in N/C domain assay buffer and 
50 µl of the diluted  substrate was added to each well and incubated in the dark at 37°C. Fluorescence 
was measured with excitation at 320 nm and emission at 405 nm in a fluorescent plate reader a 
FLUOstar OPTIMA (BMG Labtech) at 10, 15, 30 minutes and 1 hour. 
 
2.6.2 ACE-1 C-domain fluorogenic activity assay 
 
ACE-1 C-domain activity was measured in 1% SDS homogenates using a C-domain-selective 
fluorogenic peptide substrate Abz-LFK(Dnp)-OH Trifluroacetate) (Sigma-Aldrich).  The assay was 
performed in black FlouroNUNC 96-well plates. Captopril (10 µl) (ACE-1 inhibitor) at a concentration 
of 10 µM was added to all wells to be inhibited and 10 µl of dH2O was added to all paired uninhibited 
wells. Brain tissue homogenate (27.5 µl in 82.5 µl PBS) and a serial dilution of recombinant human 
ACE (1000-15.625 ng/ml) (R&D systems) respectively were prepared in a total volume of 50 µl and 
added in duplicate and incubated with captopril and dH2O for 10 minutes at 37°C. The C-domain-
specific fluorogenic peptide substrate Abz-LFK(Dnp)-OH Trifluroacetate) was diluted (5:200) in the 
N/C domain assay buffer and 50 µl of the diluted  substrate was added to each well and incubated in 
the dark at 37°C. Fluorescence was measured with excitation at 320 nm and emission at 405 nm in a 
fluorescent plate reader a FLUOstar OPTIMA (BMG Labtech, UK) at 10, 15, 30 minutes and 1 hour. 
 
2.6.3 ACE-1 N-domain immunocapture-based FRET assay 
 
ACE-1 N-domain activity was measured using an immunocapture-based FRET assay. Mouse 
monoclonal anti-human ACE (R&D systems) diluted in PBS (0.5 mg/ml) was coated on a Nunc 
MaxiSorp 96-well plate overnight at room temperature. The plate was washed five times with wash 
buffer (0.05% Tween 20 in PBS) and blocked by addition of PBS:1% bovine serum albumin (BSA) for 
2 hours at room temperature. After another wash step, serial dilutions of recombinant human ACE 
(1000-15.625 ng/ml) (R&D systems) and 100µl of 1% SDS brain tissue homogenates diluted (1:17) in 
PBS were incubated at 26°C with continuous shaking (300 rpm) for 2 hours. After the plate was 
washed a further five times, 40µl assay buffer was added to each well and 10µl of Captopril (10uM) or 
10µl of distilled water was added to inhibited and uninhibited wells respectively and incubated for 10 
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minutes at 37°C. Fluorogenic substrate Abz-SDK(DnP)-P (Enzo Life Sciences) (0.68 mM) diluted in 
N/C domain assay buffer was added and incubated at 37°C in the dark. Fluorescence was measured 
with excitation at 320 nm and emission at 405 nm in a FLUOstar OPTIMA plate reader (BMG 
labtech). Each sample was measured in duplicate and the activity was calculated after subtracting the 
fluorescence in the captopril samples. A serial dilution of ACE-1 was used to minimise variation 
between plates. 
 
2.6.4 ACE-1 C-domain immunocapture-based FRET assay 
	
	
ACE-1 C-domain activity was also measured by immunocapture-based FRET assay. Mouse 
monoclonal anti-human ACE (R&D systems) diluted in PBS (0.5 mg/ml) was coated on Nunc 
MaxiSorp 96-well plate overnight at room temperature. The plate was washed five times with wash 
buffer (0.05% Tween 20 in PBS) and blocked by addition of PBS:1% BSA for 2 hours at room 
temperature. After another wash step, serial dilutions of recombinant human ACE (500-7.8125 ng/ml) 
(R&D systems) and 100µl of 1% SDS brain tissue homogenates diluted (1:5) in PBS were incubated at 
26°C with continuous shaking (300 rpm) for 2 hours. After the plate was washed a further five times, 
40 µl assay buffer was added to each well and 10 µl of Captopril (10 µM) or 10 µl of distilled water 
was added to the inhibited and uninhibited wells respectively and incubated for 10 minutes at 37°C. 
Fluorogenic substrate (Abz-LFK(Dnp)-OH trifluoroacetate salt) (Sigma-Aldrich) (0.14 mM) diluted in 
N/C domain assay buffer was then added to each well and incubated at 37°C in the dark. Fluoroscence 
was measured with excitation at 320 nm and emission at 405 nm in a  FLUOstar OPTIMA plate reader 
(BMG labtech) after 24 hours incubation at 37°C.  
 
2.7 Direct ELISA 
 
Ang-I and Ang (1-7) levels were measured by direct Enzyme linked immunosorbant assay (ELISA) in 
human brain tissue. Both assays were developed in-house by Dr. Scott Miners and Noura AL Mulhim.  
A direct ELISA is a type of ELISA used for detection of specific enzyme labelled antigen-antibody 
complex in biological samples such as brain tissue homogenates to allow accurate quantification of a 









2.7.1 Angiotensin I direct ELISA 
 
Ang-I levels were measured in human brain tissue homogenates prepared in 1% SDS lysis buffer. The 
measurements were performed using an in-house direct ELISA. A two-fold serial dilution of 
recombinant human Ang-I (625-9.76 pg/ml) and human brain tissue homogenates (diluted 1 in 25 in 
PBS) were added into a clear, high-binding capacity 96-well plate (Nunc® MaxisorpTM; Fisher 
Scientific) and incubated for 2 hours at 26°C with shaking. The wells were washed five times with 
wash buffer (0.05% Tween 20 in PBS) and then blocked with 1% BSA in PBS for 1 hour at 26°C with 
shaking. The wells were washed five times with wash buffer and incubated with biotinylated anti-
human Ang-I (1:100 in PBS) (Cloud-Clone Corp) for 2 hours at 26°C with shaking. After another five 
washsteps, 100 µl of Strep-HRP (1:200) in PBS were added to each well and incubated for 20 minutes 
at room temperature in dark. The wells were washed five times and 100 µl of tetramethylbenzidine 
(TMB) substrate (R&D Systems) was added to each well and left in the dark for 20 minutes and the 
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reaction was stopped by adding 50 µl of 2N sulphuric acid (stop solution). The absorbance was read at 
450 nm using a FLUOstar OPTIMA plate reader (BMG labtech). Each sample was measured in 
duplicate. Concentrations were interpolated from standard curve interpolation generated from serial 
dilutions of recombinant human Ang-I. 
 
2.7.2 Angiotensin (1-7) direct ELISA 
 
Ang (1-7) levels were measured in human brain tissue homogenates in 1% SDS lysis buffer. Five-fold 
serial dilutions of recombinant human Ang (1-7) (5000-0.32 pg/ml) and human brain tissue 
homogenates (diluted 1 in 40 in PBS) were used with the biotin-linked polyclonal detection antibody 
to Ang (1-7) (200 µg/ml) diluted 1:100 in PBS. First, 100 µl of recombinant human Ang (1-7) and 
diluted homogenates (1:67) were incubated for 2 hours at 26°C with shaking. After five washing steps, 
the wells were blocked for 1 hour in 1% BSA-PBS (300 µl). Following five washes, 100 µl of biotin-
linked polyclonal antibody to Ang (1-7) was added to each well and incubated for 2 hours at 26°C with 
shaking. The wells were washed and incubated with strep-HRP (1:200) in PBS at room temperature for 
20 minutes in dark. Then, following a further wash step, TMB substrate was added and incubated in 
the dark for 20 minutes. Finally, the reaction was terminated by adding 50 µl of stop solution to each 
well and the absorbance was read at 450 nm using a FLUOstar OPTIMA plate reader (BMG labtech). 
Each sample was measured in duplicate. Concentrations were determined by interpolation of standard 
curve generated from serial dilution of recombinant Ang (1-7). Carry-overs samples in each plate were 




2.8 Sandwich ELISA  
 
A sandwich ELISA is another form of quantitative and highly sensitive technique used for the 
detection and quantification of a specific antigen in a biological sample using two specific antibodies. 
A microplate is first coated with a ‘capture’ antibody specific for a protein (antigen) of interest. Any 
remaining binding sites are blocked using a suitable blocking buffer e.g. BSA. In commercial kits, 
plates are normally supplied pre-coated and blocked. Standards and samples are then added into the 
wells and any antigen presented binds to the capture antibody. After removing any unbound substances 
and washing, a specific ‘detection’ antibody (raised against a different epitope on the same target 
protein) is then added into the wells. An enzyme-linked secondary antibody is then used to bind the 
detection antibody which is followed by the addition of a substrate to allow detection of the secondary 
antibody. The amount of colour change detected is in proportion of the amount of bound target antigen 
in the samples (Figure 2.3). 
 
2.8.1 MasR sandwich ELISA 
	
	
MasR protein levels were measured using a commercially available quantitative sandwich ELISA 
(MyBiosource). The assay was performed following the manufacturer’s protocol. 50 µl of undiluted 
brain tissue homogenates, 50 µl of serial diluted standards (1000-31.2 pg/ml) and 50 µl of sample 
diluent as a blank were added to the respective wells. 100 µl of HRP-conjugated reagent was added to 
each well then incubated for 1 hour at 37°C. After 4 washes step using proprietary wash buffer, 50 µl 
of chromogen A and chromogen solution B was added to each well and incubated for 15 minutes at 
37°C. The reaction was stopped by adding 50 µl of stop solution. Absorbance was measured at 450 nm 
using a FLUOstar OPTIMA plate reader (BMG labtech). Each sample was measured in duplicate. 
Concentrations of MasR were interpolated from standard curve generated from serial diluted 
standards. Carry-overs samples in each plate were used to measure and adjust for plate-to plate 
variation.  
 
2.8.2 Angiotensin IV sandwich ELISA 
	
	
Commercial sandwich ELISA kits were used for measuring Ang-IV level in brain tissue homogenates 
according to the manufacturer’s protocol (MyBioSource). All reagents were allowed to reach a room 
temperature (18 -25°C). 50 µl of each of the following was added to wells: sample diluent as blank, 
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serial dilution of standards (1000-31.2 pg/ml) and undiluted 1% SDS brain tissue homogenates. HRP-
conjugated reagent (100 µl) was added to each well then incubated for 1 hour at 37°C. Following 4 
washing steps, 50 µl of chromogen A and chromogen B solution (1:1) was added to each well and 
incubated for 15 minutes at 37°C in the dark. A 50 µl of stop solution was added to each well to stop 
the reaction. Absorbance was measured at 450 nm using a FLUOstar OPTIMA plate reader (BMG 
labtech). Each sample was measured in duplicate. Concentrations were determined by interpolation of 
standard curve generated by dilution of recombinant Ang-IV. Carry-overs samples in each plate were 
used to measure and adjust for plate-to plate variation. 
 
 
2.8.3 IRAP sandwich ELISA  
 
 
IRAP levels were measured using a commercial sandwich ELISA kit able to quantified IRAP in 
human tissue homogenates and other biological fluids (Cloud-Clone Corp.). This kit is supplied with a 
microplate pre-coated with an antibody specific to IRAP. The assay was performed following the 
manufacturer’s protocol. All reagents were allowed to reach room temperature before use. Serial 
diluted standards (10-0.156 ng/ml), standard diluent as a blank and brain tissue homogenates diluted 
(1:10) in PBS (all 100 µl) were incubated for 1 hour at 37°C. After aspiration, 100 µl of detection 
reagent A was added to each well and incubated for 1 hour at 37°C. Following three washes, 100 µl of 
detection reagent B was added to each well and incubated for 30 minutes at 37°C. After five washes, 
90 µl of Tetramethylbenzidine (TMB) substrate solution was added to each well and incubated for 20 
minutes at 37°C in the dark. Absorbance was measured at 450 nm using a FLUOstar OPTIMA plate 
reader (BMG labtech) after adding 50 µl of stop solution to each well. Each sample was measured in 
duplicate. Concentrations were interpolated from standard curve interpolation generated from serial 
diluted standards. Carry-overs samples in each plate were used to measure and adjust for plate-to plate 
variation. 
 
2.8.4 Neurotensin sandwich ELISA 
 
The level of neurotensin was measured in 1% SDS brain tissue homogenates using a commercially 
available quantitative sandwich ELISA kit (CUSABIO). Following the manufacturer’s protocol, all 
reagents were allowed to reach a room temperature before use. Human neurotensin standard (1000-
15.6 pg/ml), standard diluent as a blank and tissue homogenates diluted (1:10) in sample diluent (all 
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100 µl) were incubated for 2 hours at 37°C. After aspiration, 100 µl of biotin-labelled detection 
antibody was added to each well and incubated for 1 hour at 37°C. Following three wash steps, HRP-
avidin (100 µl) was added to each well and incubated for 1 hour at 37°C. Washes were repeated five 
times before adding 90 µl of TMB substrate to each well and incubated for 30 minutes at room 
temperature in the dark. 50 µl of stop solution was added to each well to stop the reaction. Absorbance 
was measured at 450 nm using a FLUOstar OPTIMA plate reader (BMG labtech). Each sample was 
measured in duplicate. Concentrations were determined by interpolation of standard curve generated 
from serially diluted standards. Carry-overs samples in each plate were used to measure plate-to plate 
variation.  
 
2.8.5 Human Vascular Endothelial Growth Factor (VEGF) sandwich ELISA  
 
A commercially available DuoSet ELISA kit (R&D systems) was used to measure VEGF level in 1% 
SDS brain tissue homogenates. The assay was performed following the manufacture’s protocol. A 96-
well microplate was coated with mouse anti-human VEGF capture antibody diluted 1:120 to the 
working concentration (1.00 µg/ml) and incubated overnight at room temperature. After 4 washes, the 
plate was blocked with 300 µl/well of blocking buffer (1% BSA in PBS) and incubated for 1 hour at 
26°C with agitation. Following 4 washing cycles with washing buffer, a 100 µl of two-fold serial 
dilutions of human VEGF standard (2000-31.3 pg/ml), brain tissue homogenates diluted in 1% BSA in 
PBS (1:10) and PBS:BSA blanks were added to respective wells and incubated for 2 hours at 26°C 
with agitation. After 4 further washes, 100 µl of biotinylated human VEGF detection antibody (100 
ng/ml) diluted (1:60) was added to each well and incubated for 2 hours at 26°C with agitation. 100 µl 
of Strep-HRP diluted (1:40) was added to each well and incubated in the dark at room temperature for 
20 minutes. After the last wash step, 100 µl of Substrate A and B in a 1:1 ratio was added to each well 
and incubated in dark for 20 minutes. Absorbance was measured at 450 nm using a FLUOstar 
OPTIMA plate reader (BMG labtech) after adding 50 µl of stop solution to each well. Each sample 
was measured in duplicate. Concentrations were interpolated from standard curves generated from 





2.8.6 Human Proteolipid Protein 1 (PLP1) sandwich ELISA 
 
PLP1 level was measured in 1% SDS brain tissue homogenates using a commercially available  
sandwich ELISA kit (Cloud-clone Corp.). The assay was performed according to the manufacturer’s 
protocol. All reagents were brought at room temperature before use. Recombinant PLP (10-0.156 
ng/ml), diluted samples (1:50) in PBS and a PBS blank (all 100 µl) were added to microplate pre-
coated with an antibody specific to PLP1 and incubated for 1 hour at 37°C. Following five wash steps, 
a 100 µl of detection reagent A was added to each well and incubated for 1 hour at 37°C. After another 
five wash steps, a 100 µl of detection reagent B was added to each well and incubated for 30 minutes 
at 37°C. After further wash steps, 90 µl of TMB substrate was added to each well and incubated for 10 
minutes at 37°C in the dark. The reaction was stop by adding 50 µl of stop solution and the absorbance 
was measured at 450 nm using a FLUOstar OPTIMA plate reader (BMG labtech). Each sample was 
measured in duplicate. Concentrations were determined by interpolation of standard curve generated 
from serially diluted standards. Carry-over samples on each plate were used to measure and adjust for 
plate-to plate variation.       
 
2.8.7 Neurolysin competitive ELISA  
 
Neurolysin concentration was measured in 1% SDS human post-mortem brain tissue homogenates 
using a competitive ELISA kit (MyBioscource) (see Figure 2.3 for general description of a competitive 
ELISA). The assay was performed following the manufacturer’s protocol. Recombinant neurolysin 
(10-0 ng/ml), diluted samples (1:10) in PBS, and a PBS blank, were incubated with NLN-HRP 
conjugate in a pre-coated plate for 1 hour at 37 °C.  Following 5 wash steps, 50 µl of chromogen A and 
chromogen solution B (1:1) was added to each well and incubated for 15 minutes at 37°C. A 50 µl of 
stop solution was added to each well to stop the reaction. Absorbance was measured at 450 nm using a 
FLUOstar OPTIMA plate reader (BMG labtech). Each sample was measured in duplicate. 
Concentrations were interpolated from standard curve generated from serial diluted standards. Carry-





2.10 IRAP activity assay  
 
IRAP enzyme activity was determined in brain tissue homogenates prepared in 0.5% Triton X-100 
buffer using a substrate, L-Leucine-p-nitroanilide (L-Leu-pNA) (Sigma-Aldrich) as previously 
described (464). 50 µl of brain tissue homogenates diluted (1:20) in Tris assay buffer (0.05 M Tris, 
0.14 M NaCl, pH 7.4) were incubated with 200 µl of L-Leu-pNA (1mM) diluted (1:16) in assay buffer 
at 37°C in 96-well plates. Absorbance was measured at 405 nm after 1 hour, 90 minutes and overnight.  
 
 
2.11 Cell culture  
 
Cell culture is the technique of growing live cells within a controlled and sterile environment. Cells 
can be derived directly from source tissue (primary cells) or originated from continuous immortalised 
cell lines. In this section, general methods used to grow and maintain healthy cell cultures and 
preparing cell lysate are discussed in detail. All work was conducted in a class II laminar flow hood 
(Holten) to maintain a sterilised air flow. The hood was switched on for 15 minutes before use and UV 
light was used to sterilise the surface for 15 minutes before and after use. Prior to work, pipette tips, 
tubes, reagents and the hood surface were sprayed with 70% ethanol solution. 
 
2.11.1 Cell line 
 
SH-SY5Y neuroblastoma cells (European Collection of Authenticated Cell Cultures (ECACC) were 
used in this experiment.  The culture medium to maintain SH-SY5Y cells was Dulbecco’s modified 
Eagle's medium (DMEM) consisting of amino acids, salts (calcium chloride, potassium chloride, 
magnesium sulphate, sodium chloride, and monosodium phosphate), glucose, vitamins (folic acid, 
nicotinamide, riboflavin, B12), iron and phenol red) (Sigma-Aldrich) and supplemented with 15% 
foetal bovine serum (Sigma-Aldrich) and 2 mM L- Glutamine (Sigma-Aldrich).  
 
2.11.2 Growing cells and maintaining healthy cell cultures 
 
Culture medium, PBS and other solutions were warmed in water bath to 37°C for 30 minutes prior to 
use.	 T75cm3 flasks (Greiner Bio-One: T75; surface area of 75 cm2) were used to grow cells after 
adding 10 ml of growth medium. Vial of cells were carefully removed from storage and warmed in a 
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water bath to 37°C for 1 minute. 1 ml of cells was transferred into the flask and gently agitated from 
side to side, then placed in incubator under conditions set to a temperature 37°C and 5% CO2 
overnight. The treating freezing medium, which contains Dimethyl Sulfoxide (DMSO), was replaced 
the next day with fresh 10 ml DMEM. Every two days the growth medium was replaced until cells 
reached 90% confluent then cells were either used for experimentation or passaged. 
 
2.11.3 Cell Passaging  
 
Cells were passaged when approximately 90% confluent. Old growth medium was aspirated and the 
flask was washed with 10 ml pre-warmed PBS. After removal of PBS, 3 ml Trypsin with EDTA 
(Sigma-Aldrich) was added to detach cells from the flask surface following 5 minutes. incubation at 
37°C. 7 ml of fresh pre-warmed complete growth medium (to neutralise trypsin) was added to the 
flask. The cell suspension was transferred into 15 ml centrifuge tube and centrifuged for 3 minutes at 
1000 x g. The cell medium was aspirated with a glass pipette and the pelleted cells were mixed with 
1.0 ml of fresh complete growth medium. 200 µl of cell suspension was added into new labelled flasks 
prepared with 10 ml of fresh growth medium. Flasks then placed into the incubator and media changed 
every tow days.  
 
2.11.4 Preparation of cell lysates 
 
Following the experiment (details described later in chapter 9). Medium from each flask was 
transferred into 10 ml centrifuged tube and stored at -80°C. Cells were washed with 10 ml sterile PBS 
and following aspiration of PBS, 3 ml of accutase (Sigma-Aldrich) was added and the flask was 
incubated for 5 minutes to detach the cells. 7 ml of PBS was then added into each flask and the 
solution was transferred to a 10 ml tube and spun for 3 minutes at 1000 x g. The supernatant was 
carefully aspirated and the cell pellet was collected and lysed using 70 µl of cell lysis buffer (CelLytic 
M reagent (Sigma-Aldrich). Cell lysates were left at incubator (26°C) with shaking for 1 hour (as per 
manufacturer’s instruction) before the tube was stored at -80 °C. Total protein concentrations of the 
cell lysates were measured using the Total Protein Assay Kit (Sigma-Aldrich) (previously described in 





2.12 Statistical analysis 
 
Statistical tests were performed using either SPSS (version 21) or GraphPad Prism version 7. Normal 
distribution of all data sets was tested with the Shapiro-Wilk normality test and presented in chapter 9 
(Appendix III). If the data sets were normally distributed, an unpaired samples t-test was used to 
compare one variable between control and AD groups. For correlation between two variables, a 
Pearson’s correlation coefficient was used. One-way ANOVA with Dunnett’s post-hoc was used to 
compare differences between three groups.  
 
When the data sets were not normally distributed, non-parametric tests were used to identify 
differences between two groups (control vs. AD) using the Mann-Whitney U test. For correlations 
using non-parametric data, the Spearman’s correlation coefficient was used. A non-parametric 
equivalent of an analysis of variance (ANOVA), the Kruskal-Wallis test with Dunn’s post-hoc test was 
used to determine if there is an overall significant difference between three groups. Log transformation 
or square-root transformation was performed to attempt to reach normal distribution. Parametric tests 
were performed on the transformed data and presented in chapter 9 (Appendix VI). For all data sets, 
the Robust regression and Outlier removal (ROUT) method was used to detect outliers in all datasets 
and in case of outliers, the data was re-analysed after outliers were removed and presented in chapter 9 




Chapter 3. The classical axis of RAS in Alzheimer’s disease - 
investigating the divergent role of ACE-1 in AD 
 
3.1 Abstract  
 
 
The cRAS (ACE-1/Ang-II/AT1R) within the brain is overactive in AD and ACE-1, the central enzyme 
involved in the production of Ang-II, is increased in AD (78, 393). Despite a central role in the 
production of Ang-II, the role of ACE-1 remains unclear since it has also been shown to cleave Aβ42 
in to less harmful shorter Aβ fragments that are less toxic and more easily cleared (83). ACE-1 consists 
of two homologous N- and C-domains, which show different substrate specificities. The N-domain is 
mainly involved in Aβ degradation whereas the C-domain is largely responsible for Ang-II production. 
This apparent divergent role of ACE-1 in the pathogenesis of AD may be explained by the domain-
specific actions of ACE-1 in AD. 
 
Human post-mortem brain tissue was obtained from the SWDBB, University of Bristol, with local 
Research Ethics Committee approval. We studied mid-frontal cortex (Brodmann area 8/9) from AD 
cases (n= 70) and age-matched controls (n= 48) that were matched closely for age-at-death and PMD. 
ACE-1 N-domain and C-domain activities were measured using specific fluorogenic substrates and 
immunocapture-based enzyme activity assays. Ang-I level was measured using a direct ELISA method 
for all cases. Previous measurement of ACE-1 activity (total), Ang-II, parenchymal Aβ and tau load, 
and ELISA-measurements of insoluble Aβ40 and Aβ42 concentrations were previously measured and 
available for further analysis.  
 
ACE-1 C-domain activity was significantly elevated in AD and ACE-1 N-domain activity was 
significantly reduced in AD compared to age-matched controls. Ang-I level was reduced and the ratio 
of Ang-II:Ang-I was increased in AD - as would be expected with overactivation of ACE-1. Together, 
these novel data indicate a disease-related alteration of domain-specific activity of ACE-1 in AD that 
potentially favours Ang-II production and limits Aβ42 clearance. These data provide further 
mechanistic insight into the role of ACE-1 in AD and suggest that selective inhibitors of ACE-1 C-
domain could prove to be a more effective treatment strategy for AD compared to non-domain specific 





The RAS is implicated in the pathogenesis of AD (56, 537). Overactivation of cRAS within the brain, 
in regions associated with disease pathology and cognition, is associated with the pathogenesis of AD. 
ACE-1 is the rate-limiting enzyme in the production of Ang-II, which, via activation of AT1R, is 
thought to be primarily responsible for most AD-related pathology. Previous human post-mortem 
studies have shown that elevated ACE-1 activity and increased Ang-II level in AD are associated with 
increased Aβ and Tau levels (reviewed in (538)). Infusion of Ang-II in aged SDR elevated the 
formation of Aβ (238) and mediated phosphorylation of tau (390) indicating the direct involvement of 
cRAS in disease pathology in addition to vaso-modulatory influences.	
Previous evidence ranging from genetic, cell-culture based, animal, epidemiological, and human post-
mortem studies have supported an association between ACE-1 activity and disease progression in AD 
(78, 84, 347, 354, 367, 539, 540). Moreover, epidemiological population-based studies and clinical-
based studies have provided evidence that ACEIs or ARBs delay the progression of cognitive decline 
and reduce the incidence of AD (367, 369, 406, 541). In addition, several animal studies show that 
brain-penetrating ACEIs such as captopril and perindopril or AT1R blockers, such as losartan, 
olmesartan and valsartan protect against cognitive decline and AD-related disease pathology (359-
362). Some of these animal studies have, however, highlighted potential differences between the 
effectiveness ACEIs and ARBs (358, 522) whilst others e.g. Ferrington et al. (363) did not find any 
alteration in either intraneuronal Aβ or oligomeric Aβ levels in a triple transgenic mouse model of AD 
after administration of ACEI (Captopril) and ARBs (eprosartan and valsartan). The discrepant findings 
to date may simply relate to variation in the drug treatment periods and modes of administration and 
differences in the animal models used and it is noteworthy that on balance the vast majority of studies 
agree to the potential protective effect of these drugs against AD. Clarification may yet emerge from 
ongoing exploratory clinical trials in humans testing various rRAS inhibitor drugs in AD and AD-
related clinical populations (reviewed in (538)). In summary, most of the data support a role of ACE-1 
in cRAS overactivation in support of the detrimental effects of Ang-II overproduction in the 
pathogenesis of AD. 
The ACE1 was first reported to be a genetic risk factor for AD by Kehoe et al. (84). The study reported 
that an insertion (I)/ deletion (D) polymorphism of an Alu repeat sequence within intron 16 of ACE1 
was associated with AD risk. Furthermore, this association has been demonstrated by several 
subsequent genetic studies that indicate that inheritance of the (I) allele increased the risk for AD, 
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whereas homozygosity of the (D) allele was protective (85, 86, 88, 89). This genetic relationship has 
continued to be published over a period of almost two decades (155). Furthermore, there is a gene 
dose-dependent partial association between ACE1 genotypes and ACE-1 activity, such that possession 
of an I/I genotype is associated with the lowest peripheral plasma ACE-1 activity, homozygotes for 
DD with the highest levels and heterozygotes having intermediate levels (352). This was initially 
puzzling with respect to how an ACE1 II genotype i.e. lower ACE-1 activity, was associated with 
increased AD risk. However, our previous studies in brain tissue indicate that brain ACE-1 activity 
does not simply match serum changes. In this study, Miners and colleagues (90) found that (II) 
genotype and other nearby SNPs on ACE1 were associated with increased levels of soluble Aβ in AD. 
This data indicates that ACE-1 may be involved in Aβ clearance, which is supported, by in vitro 
studies and data from animal models of AD. Hu and colleagues (81) reported that ACE-1 was able to 
degrade Aβ in vitro. Several other in vitro and in vivo studies also supported these findings (82, 347). 
Zou and colleagues (83) found that ACE-1 was able to convert the long neurotoxic species of Aβ 
(Aβ42) to a short and less neurotoxic species (Aβ40) and that administration of captopril (ACEI) into 
mice resulted in elevated Aβ deposition. These findings placed a different perspective on the how risk 
variants in ACE1, which ordinarily might be associated with lower levels of ACE-1, are associated 
with AD. These findings also posed a suggestion that the inheritance of ACE1 I alleles may be 
associated with an individual’s reduced capacity to degrade Aβ throughout life which may contribute 
to or exacerbate the development of AD.  
As previously described, ACE-1 within the brain comprises N- and C- catalytic domains that have 
different substrate specificities (332). The N-domain favours cleavage of Aβ at Asp5His6, as well as 
having endopeptidase activity that promotes the conversion of Aβ42 to Aβ40, whilst the C-domain is 
reported to preferentially convert Ang-I to Ang-II. However, not all studies supported the reported dual 
properties of the N- and C- domains and some have suggested that both domains participate to similar 
extents in Aβ degradation (345, 346). Until now, this has remained an unresolved controversy 
concerning the involvement of ACE-1 in AD, where it may also have a bearing on the sometimes 
conflicting findings as to the involvement of different ACEIs in conferring protection (360, 361, 364, 
542, 543) or increased risk (368, 544) in the incidence and progression of AD.  
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3.3 Study aims and hypothesis 
	
	
In this chapter, I have explored the hypothesis that there is domain-specific variation in ACE-1 
activity in AD such that N-domain activity (favouring Aβ-degradation) is decreased and C-domain 
activity (favouring Ang-II production) is increased in AD compared to age-matched controls and that 
changes in ACE-1 domain activity will be related to markers of disease pathology in AD.  
 
The aims of the study were: 
 
(i) To measure ACE-1 N-domain and C-domain activities in post-mortem brain tissue 
homogenates from mid-frontal cortex of human AD and control brains and explore the 
relationship between ACE-1 domain specific activities and AD pathological hallmarks (Aβ 
and tau). 
(ii)  To measure Ang-I level and through access to existing data on Ang-II, examine whether the 
Ang-II:Ang-I ratio is a proxy indicator of ACE-1 activity and to determine whether changes in 
Ang-I level, or the Ang-II:Ang-I ratio, were associated with AD pathological hallmarks (Aβ 





3.4.1 Study cohort 
 
Human post-mortem brain tissue homogenates from mid-frontal cortex (Brodmann area 8/9) were used 
for measurements of ACE-1 N-domain activity, C-domain activity and Ang-I level. The study cohort 
included controls (n= 48) and AD cases (n= 70). Demographic features of study cohort are described 
in chapter 2 (Table 2.1) for full details (Appendix I: Table 9.1 and Table 9.2). 
 
3.4.2 ACE-1 N-domain fluorogenic activity assay 
 
 
Measurements of ACE-1 N-domain activity in brain homogenates from mid-frontal cortex were 
described in the general methods (section 2.6.1). In this experiment, brain homogenates were prepared 
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in 0.5% Trition X-100 buffer, as described in the methods (section 2.2.2). The N-domain specific 
fluorogenic substrate (Abz-SDK(Dnp)-p (Enzo Life Sciences) was optimised before use in this 
experiment (see results section (3.5.1)). Samples were measured in triplicate and four carry-overs 
samples were repeated in each plate.  
 
 
3.4.3 ACE-1 C-domain fluorogenic activity assay 
 
 
The ACE-1 C-domain activity was measured in brain homogenates prepared as previously described in 
the general methods (section 2.2.2). Brain homogenates used in this experiment were homogenised in 
0.5% Trition X-100 buffer. Different dilutions of C-domain specific fluorogenic substrate (Abz-
LFK(Dnp)-OH Trifluroacetate) (Sigma-Aldrich) were tested prior to use in this assay (see results 
section (3.5.2)). ACE-1 C-domain activity was measured using the method described in the methods 
(section 2.6.2). Samples were measured in triplicate and four carry-overs samples were repeated across 
all plates.  
 
 
3.4.4 ACE-1 N-domain immunocapture-based FRET assay 
 
 
An immunocapture-based FRET assay, in which ACE-1 was isolated prior to addition on the FRET 
substrate (to improve specificity), was developed to measure ACE-1 N-domain activity using the N-
domain specific fluorogenic substrate (Abz-SDK(Dnp)-p (Enzo Life Sciences). The details of the 
assay were described in the general methods (section 2.6.3). The N-domain activity was measured in 
brain tissue homogenates from mid-frontal cortex homogenised in 1% SDS lysis buffer. The 
homogenisation process was described in the methods (section 2.2.2). The assay conditions, such as 
optimising the concentration of N-domain specific fluorogenic substrate (Abz-SDK(Dnp)-p (Enzo Life 
Sciences) and the effect of time on reaction were tested prior to use in this assay (Appendix II: Figure 




3.4.5 ACE-1 C-domain immunocapture-based FRET assay 
 
 
An ACE-1 C-domain immunocapture enzyme activity assay, in which specificity was improved by 
capturing ACE-1 prior to the addition of the FRET substrate, was developed measure C-domain 
activity. The general method using an immunocapture-based FRET assay is described in detail in 
method (section 2.6.4). Brain homogenates used in this experiment were from mid-frontal cortex and 
homogenised in 1% SDS lysis buffer described previously in the methods (section 2.2.2). The assay 
conditions e.g. substrate concentration and incubation times were optimised (Appendix II: Figure 9.6) 
prior to use. ACE-1 C-domain activity was measured in triplicate and four carry-overs samples were 
repeated across all plates.  
 
 
3.4.6 Angiotensin I direct ELISA  
 
 
The concentration of Ang-I was measured in each sample in brain homogenates from mid-frontal 
cortex prepared in 1% SDS as previously described in the general methods (section 2.2.2). Ang-I level 
was measured using a direct ELISA method. A general description of the method has been described 
in method (section 2.7.1). Ang-I measurement was adjusted for total protein level to account for any 
variation in total protein between samples. The method used for total protein measurement is described 
in the methods (section 2.3). Samples were measured in duplicate and four carry-overs samples were 
repeated across all plates. 
 
3.4.7 Statistical analysis 
 
 
The distributions of all datasets were initially analysed by the Shapiro-Wilk normality test. A p value, 
p < 0.05 indicated that the data sets were not normally distributed. The ACE-1 N-domain activity 
assay, ACE-1 C-domain activity assay and Ang-I direct ELISA data did not follow a normal 
distribution (even after log transformation for ACE-1 C-domain activity assay) (Appendix III: Table 
9.21) and therefore comparisons of the data (ACE-1 N-domain activity, ACE-1 C-domain activity and 
Ang-I level) between controls and AD cases were tested with a non-parametric test, Mann-Whitney 
test. Comparison of the data between Braak tangle stage groups (Braak stage 0-II, Braak stage III-IV, 
Braak stage V-VI) was performed with a non-parametric Kruskal-Wallis test and Dunn’s post-hoc test 
	 83 
was used to determine if there was an overall significant difference between the three groups. 
Correlations of ACE-1 N-domain activity and ACE-1 C-domain activity data with total Aβ load, tau 
load, insoluble Aβ40, insoluble Aβ42, confounding factors (age-at-death, PMD) were assessed by the 
Spearman’s correlation coefficient. Association of ACE-1 N-domain activity and ACE-1 C-domain 
activity with gender and APOE genotype were explored using a Mann-Whitney test. The relationship 
between Ang-I level, total Aβ load, tau load, confounding factors (age-at-death, PMD) and ACE-1 
activity were assessed using the Spearman’s correlation coefficient. Associations of Ang-I level with 
gender and APOE genotype were explored using a Mann-Whitney test. Also, comparison of Ang-
II:Ang-I ratio between controls and AD cases was analysed using a non-parametric Mann-Whitney 
test. Log transformed data for ACE-1 N-domain activity and Ang-I level is presented in chapter 9 
(Appendix VI: Section 9.6.1). For all tests applied, a p-value < 0.05 was considered statistically 
significant.  
 
For all datasets, the ROUT method was applied to detect outliers. In datasets where outliers were 





3.5.1 Optimisation of ACE-1 N-domain activity 
 
Preliminary experiments were performed to optimise the ACE-1 N-domain enzyme activity assay 
using the domain-selective substrate (Abz-SDK(Dnp)-p in human brain tissue homogenates (Appendix 
II: Figure 9.1). The concentration of the FRET substrate, inhibitor and the effect of time on substrate 
cleavage were characterised (Appendix II: Figure 9.2). The variation between measurements was 
determined by calculating the coefficient of variation (CV%) (Appendix IV: Table 9.22). Optimal 
conditions identified from these preliminary experiments were substrate concentration at (10 µM) 
inhibitor at (10 µM) and time at (2 hours) at 37°C (that are used in subsequent experiments). Activity 




3.5.1.1 Comparisons of ACE-1 N-domain FRET activity between control and AD 
 
ACE-1 N-domain activity in the mid-frontal cortex was compared between AD cases and age-matched 
controls. The median for ACE-1 N-domain activity in the AD group (13728 (r.f.u)) was numerically 
lower than in controls (15229 (r.f.u)) after 2 hours. However, a Mann-Whitney test showed that this 






Figure 3.1 ACE-I N-domain activity in AD cases compared to controls. 
Bar chart showing ACE-1 N-domain activity in AD (n= 70) compared to age-matched controls (n= 48) 
in the mid-frontal cortex measured using an ACE-1 N-domain fluorogenic activity assay. Mann-
Whiney test showed no significant difference between groups (p= 0.981). Bars show the median and 
95% confidence intervals. 
 
 
3.5.1.2 ACE-1 N-domain FRET activity in relation to disease severity 
 
ACE-1 N-domain activity was not found to change in relation to Braak tangle stage pathology (0-II, 
III-IV and V-VI) (p = 0.783) (Figure 3.2). The median values according to Braak stages were: 0-II = 
15267 (r.f.u), III-IV = 15233 (r.f.u) and V-VI = 13707 (r.f.u). Although there appeared to be a 









































Figure 3.2 ACE-1 N-domain activity in relation to Braak tangle stage.  
Bar chart showing relationship between ACE-1 N-domain activity and Braak tangle stage. No 
significant differences (p= 0.783) were found by Kruskal-Wallis test for ACE-1 N-domain activity 
between Braak tangle stages 0-II (n= 36), III-IV (n= 20), V-VI (n= 61). The bars indicate the median 




3.5.2 Optimisation of ACE-1 C-domain activity 
 
	
Preliminary experiments were first performed to optimise the use of the C-domain substrate (Abz 
(LFK(DnP)-OH Trifluroacetate) in human brain tissue homogenates. First, the optimal concentration 
of the FRET substrate was determined and the effect of incubation time on the reaction was 
characterised (Appendix II: Figure 9.3). Range of captopril concentrations was also tested (Appendix 
II: Figure 9.4). The variation between duplicate measurements was determined by calculating the intra-
assay CV% (Appendix IV: Table 9.23). The resultant optimal conditions included using a substrate 
concentration at (10 µM), a concentration of inhibitor at (10 µM) and an assay time at (2 hours) at 












































3.5.2.1 ACE-1 C-domain FRET activity in control and AD 
 
In mid-frontal cortex, ACE-1 C-domain activity measured by FRET activity assay was compared 
between AD cases (n=70) and controls (n=48). The median for ACE-1 C-domain activity was 
numerically higher in AD cases (7088 r.f.u) compared to controls (5938 r.f.u). However, a Mann-
Whitney test showed that there was no statistical significant difference in enzyme activity between 
groups (p= 0.132) (Figure 3.3). 
 
 
Figure 3.3 ACE-1 C-domain activity in control and AD cases. 
Bar chart showing ACE-1 C-domain enzyme activity in AD (n= 70) compared to age-matched controls 
(n= 48) in the mid-frontal cortex measured using an ACE-1 C-domain fluorogenic activity assay. 
Mann-Whitney test showed no significant difference between groups (p= 0.132). Bars show the 
median and 95% confidence intervals. 
 
 
3.5.2.2 ACE-1 C-domain FRET activity in relation to disease severity 
	
ACE-1 C-domain activity was also examined in relation to Braak tangle stage (Braak stage 0-II, Braak 
stage III-IV, Braak stage V-VI) that equate to moderate/early and severe/end stage AD). A Kruskal-











































Figure 3.4 ACE-1 C-domain activity in relation to Braak tangle stage.  
ACE-1 C-domain activity did not vary significantly between Braak tangle stage groups (Braak stages 
0-II (n= 36), III-IV (n= 20), V-VI (n= 61)) according to Kruskal-Wallis test (p= 0.466). The bars 




3.5.3 Optimisation of ACE-1 N-domain immunocapture-based activity 
 
 
An assay to measure ACE-1 N-domain activity using an immunocapture-based FRET activity 
approach was developed. These assays benefit from using an ‘immunocapture step’ to pull-down and 
capture ACE-1 from biological samples prior to the addition of the FRET substrate and therefore 
reduce the risk of non-specific proteolytic cleavage of the substrate. Previous studies found that 
immunocapture-based fluorometric assays for the measurement of Aβ degrading enzymes (IDE and 
NEP) allowed sensitive and specific measurement of enzyme activity (77, 78). As before the optimal 
reaction conditions for the assay were first identified and a substrate concentration (0.68 mM) inhibitor 
(10 µM) and time (24 h) were used in subsequent experiments (Appendix II: Figure 9.5). Activity was 
expressed as r.f.u. Variation between measurements was determined by calculating the intra-assay 
CV% (Example in Appendix VI: Table 9.24). 
 
3.5.3.1 ACE-1 N-domain immunocapture-based activity in controls and AD  
	
The ACE-1 N-domain activity in mid-frontal cortex measured by immunocapture-based FRET activity 








































to aged-mated controls (n= 48) by 49%. The Mann-Whitney test revealed that the median for ACE-1 
N-domain activity in AD cases (6708 (r.f.u)) was significantly lower in AD (p= 0.024) compared to 
activity in controls (13248 (r.f.u)) (Figure 3.5). 
	
	
Figure 3.5 Reduction in ACE-1 immunocapture N-domain activity in Alzheimer’s disease. 
Bar chart showing ACE-1 N-domain enzyme activity measured by immunocapture-based FRET 
activity assay in AD (n= 70) compared to age-matched controls (n= 48) in the mid-frontal cortex. A 
Mann-Whiney test showed a significant difference between groups (p= 0.024). Bars show the median 




3.5.3.2 ACE-1 N-domain immunocapture-based activity in relation to disease severity 
 
The relationship between ACE-1 N-domain activity and Braak tangle stages (0-II, III-IV, V-VI) was 
explored. ACE-1 N-domain activity was numerically lower in cases with end-stage AD i.e. Braak 
stage V-VI group compared to controls and early-mid stage AD (III-IV), however, Kruskal-Wallis test 
did not detect a statistical difference between the medians across all Braak stages, Kruskal-Wallis test 
(p= 0.126). The medians for the various Braak stages was: 0-II= 13282 (r.f.u), III-IV= 11655.1 (r.f.u), 




















































Figure 3.6 ACE-1 N-domain immunocapture-based activity in relation to disease severity. 
No significant difference was found for ACE-1 N-domain activity measured by immunocapture-based 
activity assay between Braak tangle stage groups (0-II (n= 36), III-IV (n= 20), V-VI (n= 61)), Kruskal-




3.5.4 Optimisation of ACE-1 C-domain immunocapture-based activity 
 
We next developed, optimised and measured C-domain activity using a more specific immunocapture-
based FRET activity assay. Optimal conditions for the immunocapture C-domain activity assay were 
observed with substrate concentration (0.14 mM) inhibitor (10 µM) and time (24 hours) (Appendix II: 
Figure 9.6). Activity was expressed as r.f.u. All samples were measured in duplicate and ran alongside 
one sample in the presence of the inhibitor. The variation between measurements of samples was 



















































3.5.4.1 Comparison of ACE-1 C-domain immunocapture-based activity between controls and AD 
patients 
 
In mid-frontal cortex, ACE-1 C-domain activity measured by immunocapture-based FRET activity 
assay was found to be significantly higher in AD cases (n= 70) compared to age-matched controls (n= 
48). The median for ACE-1 C-domain activity was increased by ~30% in AD = 30656 (r.f.u) compared 
to controls = 23515 (r.f.u).  A Mann-Whitney test detected a significant difference between the 
medians (p = 0.011) (Figure 3.7).    
	
	
Figure 3.7 Immunocapture-based ACE-1 C-domain activity in control and AD cases.  
Bar chart showing ACE-1 C-domain activity in mid-frontal cortex, measured by immunocapture-based 
FRET activity assay, in AD (n= 70) and age-matched controls (n= 48). Mann-Whitney test revealed 
that ACE-1 C-domain activity was significantly higher in the AD group compared to age-matched 


















































3.5.4.2 ACE-1 C-domain immunocapture-based activity in relation to disease severity 
 
ACE-1 C-domain activity measured by an immunocapture-based FRET activity assay was assessed in 
relation to Brake tangle stage (0-II (n= 36), III-IV (n= 20), V-VI (n= 61)). Kruskal-Wallis test found 
no significant difference of the medians between all Braak stage groups (p= 0.104) (Figure 3.8). The 




Figure 3.8 ACE-1 C-domain immunocapture-based activity in relation to Braak tangle stage. 
No significant difference was found for ACE-1 C-domain activity between (Braak tangle stages 0-II 
(n= 36), III-IV (n= 20), V-VI (n= 61)) using a Kruskal-Wallis test (p= 0.104). The bars indicate the 
median and 95% confidence intervals. 
 
 
3.5.4.3 Relationships between ACE-1 N- and C-domain immunocapture-based activity and AD 
pathological hallmarks 
 
Given the significant differences between the ACE-1 N- and C-domains in AD cases and controls it 
was next important to examine the relationship between domain-specific activity and variables 
associated with AD pathology. The relationship between immunocapture-based ACE-1 N- and C-
domain activity and previously measured guanidine Aβ (measured by ELISA) and tau load 















































previously measured by ELISA, were assessed. Insoluble Aβ levels measured by sandwich ELISA 
were available for controls (n= 28) and AD cases (n= 61)) (545) and Tau load was previously 
measured for all cases as part of routine pathological assessment of AD cases within the SWDBB by 
field fraction analysis and was available (for controls (n= 29) and AD cases (n= 89)). Both insoluble 
Aβ42 and insoluble Aβ40 were also previously measured by sandwich ELISA, for a subset of the cases 
studied (insoluble Aβ42 measures were available for controls (n= 20) and AD cases (n= 33)), as well 
as insoluble Aβ40 data for controls (n= 20) and AD cases (n= 34) (314).  
Spearman’s correlation coefficient test showed no significant correlations between ACE-1 N-domain 










Figure 3.9 Relationships between ACE-1 N-domain activity and AD pathological hallmarks (total 
insoluble Aβ load, tau load, insoluble Aβ42 and insoluble Aβ40). 
A. Scatterplots showing no correlation between ACE-1 N-domain activity and total insoluble Aβ load 
(measured by enzyme-linked immunosorbent assay), Spearman’s correlation coefficient test (r= 0.014, 
p = 0.898). B. No significant correlation found between ACE-1 N-domain activity and tau load 
(measured by field fraction analysis), Spearman’s correlation coefficient test (r= -0.143, p= 0.158). C-
D. Scatterplots showing no correlation between ACE-1 N-domain activity and both insoluble Aβ42 
and insoluble Aβ40 (measured by enzyme-linked immunosorbent assay), for insoluble Aβ42 
Spearman’s correlation coefficient test (r= -0.102, p= 0.465) and for insoluble Aβ40 Spearman’s 
correlation coefficient test (r= -0.096, p= 0.489). The solid inner line indicates the best-fit linear 




ACE-1 C-domain activity was positively correlated with total insoluble Aβ load and Spearman’s 
correlation coefficient test detected a significant relationship (r= 0.251, p= 0.017) indicate that 
increased ACE-1 C-domain activity in AD is associated with increased level of insoluble Aβ (Figure 
3.10 A). In contrast, there was no significant correlation between ACE-1 C-domain activity and tau 
load (r= 0.181, p= 0.073) (Figure 3.10 B). Spearman’s correlation coefficient test revealed a significant 
























































































positive correlation between ACE-1 C-domain activity and insoluble Aβ42 levels (r= 0.318, p= 0.020) 
(Figure 3.10 C) but no significant correlation was found for insoluble Aβ40 levels (r= 0.233, p= 0.089) 
(Figure 3.10 D). 
	
	
Figure 3.10 Correlations between ACE-1 immunocapture C-domain activity and AD pathological 
hallmarks (total insoluble Aβ load, tau load, insoluble Aβ42 and insoluble Aβ40).  
A. Scatterplot showing a positive relationship between ACE-1 C-domain activity and total insoluble 
Aβ load (measured by enzyme-linked immunosorbent assay), Spearman’s correlation coefficient test 
(r= 0.251, p= 0.017). B. Scatterplot showing no correlation between ACE-1 C-domain activity and tau 
load (measured by field fraction analysis), Spearman’s correlation coefficient test (r= 0.181, p= 0.073). 
C. Scatterplot showing no correlation between ACE-1 C-domain activity and insoluble Aβ40 
(measured by enzyme-linked immunosorbent assay), Spearman’s correlation coefficient test (r= 0.233, 
p= 0.089). D. Scatterplot showing positive correlation between ACE-1 C-domain activity and 
insoluble Aβ42 (measured by enzyme-linked immunosorbent assay), Spearman’s correlation 
coefficient test (r= 0.318, p = 0.020). The solid inner line indicates the best-fit linear regression and the 
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3.5.4.4 Relationships between ACE-1 N- and C-domain immunocapture-based activity and possible 
confounding factors  
 
Age and APOE genotype (APOE ε4 allele) are the major risk factors of AD and females have a higher 
risk for AD than males (131). PMD has been shown to affect the protein measurement (546). All these 
possible confounders could affect protein measurements and/or enzyme activity. The relationship 
between ACE-1 N- and C-domain activity, measured by immunocapture-based activity assay, and 
potential confounding factors including age-at-death, PMD and gender were explored. Spearman’s test 
showed no correlations between ACE-1 N-domain activity with age-at-death or PMD. Also, there was 
no significant difference of ACE-1 N-domain activity between females and males (Appendix V: Table 
9.37). There was no difference in ACE-1 N-domain activity depending on the presence or absence of 
APOE ε4 allele (Appendix V: Table 9.38). Spearman’s test also showed no correlation between ACE-1 
C-domain activity with age-at-death or PMD, or between females and males (Appendix V: Table 
9.37). Also, there was no significant difference of ACE-1 C-domain activity depending on the 
presence or absence of APOE ε4 allele (Appendix V: Table 9.38). 
 
	
3.5.5 Measurement of Angiotensin I level in AD 
 
Given that Ang-I is a pre-cursor to Ang-II, mediated by the action of ACE-1 activity, it was helpful to 
explore the levels of Ang-I relative to Ang-II that could also serve to provide information regarding 
ACE-1 activity. Ang-I level in the mid-frontal cortex was measured using a direct ELISA on post- 
mortem brain homogenates from the cohort described. The variation of this assay was determined by 
calculating the intra-assay CV% (Example in Appendix IV: Table 9.26). Both unadjusted Ang-I 
measurements and protein-adjusted measurements were used for comparisons between control and 
AD. Relationships between Ang-I level and disease severity (Braak tangle stage), AD pathological 
hallmarks (Aβ load, Tau load) and possible confounding factors (age-at-death, PMD, gender and 





3.5.5.1 Comparisons of Ang-I level between controls and AD cases 
 
Ang-I level was significantly reduced in the AD group compared to age-matched controls (p= 0.006) 
(Figure 3.11). The median for Ang-I level was lower in the AD group (median= 1546 (pg/ml)) 
compared to the control group (median= 1736 (pg/ml)). When Ang-I level was adjusted for total 
protein concentration, a significant reduction of Ang-I level was also observed in the AD group 
compared to age-matched controls (p= 0.013). The Mann-Whitney test allowed comparison of the 
median Ang-I level of the AD group (median= 4601 (pg/mg total protein)) in comparison to the control 
group (median= 4762 (pg/mg total protein)) (data shown in Appendix IX:  Figure 9.47).  
 
 
Figure 3.11 Angiotensin-I level (Ang-I) was reduced in mid-frontal cortex in Alzheimer’s disease 
(AD).  
Ang-I level was reduced in AD (n= 70) compared with age-matched control (n= 48) in mid-frontal 
cortex measured using an in-house Ang-I direct ELISA. Mann-Whitney test revealed that Ang-I level 

























3.5.5.2 Ang-I level in relation to disease severity 
 
Ang-I level was assessed in relation to Braak tangle stage (0-II, III-IV, V-VI). Kruskal-Wallis test 
revealed a significant difference in the median between all groups (p= 0.008). Post-hoc analysis 
(Dunn’s Test) revealed a significant reduction of Ang-I level in Braak stage (V-VI) compared to Braak 




Figure 3.12 Ang-I level in relation to Braak tangle stage.  
Ang-I level differed with disease severity measured by Braak tangle stage groups (0-II (n= 36), III-IV 
(n= 20), V-VI (n= 61)) when analysed with a Kruskal-Wallis test (p= 0.008). Ang-I level was 
significantly lower in cases with Braak stage (V-VI) compared with cases in Braak stage (0-II) (post-




3.5.5.3 Correlation between Ang-I level and AD pathological hallmarks  
 
Ang-I level unadjusted to protein concentration was inversely correlated with both insoluble Aβ and 
tau load, Spearman’s correlation coefficient test found a strong inverse significant correlation between 
Ang-I level and insoluble Aβ (r= -0.389, p= 0.0001) (Figure 3.13 A) and between tau load (r= -0.347, 
p= 0.0004) (Figure 3.13 B). Correlations between protein adjusted data and AD pathological hallmarks 
























Figure 3.13 Inverse correlation between Angiotensin-I level and AD pathological hallmarks (Aβ 
load and tau load).  
A. Scatterplot showing an inverse relationship between Ang-I level and total insoluble Aβ load 
(measured by enzyme-linked immunosorbent assay), Spearman’s correlation coefficient test (r = -0.389, 
p= 0.0001). B. Scatterplot showing that Ang-I level was inversely correlated with tau load (measured by 
field fraction analysis), Spearman’s correlation coefficient test (r= -0.347, p= 0.0004). The solid inner 
line indicates the best-fit linear regression and the outer lines the 95% confidence intervals. Blue dots = 




3.5.5.4 Relationship between Ang-I level and ACE-1 activity 
 
Ang-I is a major substrate for ACE-1. The relationship between Ang-I level and ACE-1 activity was 
assessed. Previous measurements of ACE-1 activity by FRET activity assay were available for controls 
(n= 43) and AD cases (n= 66) (78). Spearman’s correlation coefficient test detected a weak but 
nonetheless significant inverse correlation between Ang-I level unadjusted to total protein 
concentration and ACE-1 activity (r= -0.189, p= 0.048) (Figure 3.14). Correlations between protein 
adjusted data and ACE-1 activity presented in chapter 9 (Appendix IX: Figure 9.49).  
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Figure 3.14 Relationship between Ang-I level and ACE-1 activity.  
Scatterplot showing an inverse correlation between Ang-I level unadjusted to protein concentration 
and ACE-1 activity measured by FRET activity assay in mid-frontal cortex. Spearman’s correlation 
coefficient test  (r= -0.189, p= 0.048). The solid inner line indicates the best-fit linear regression and 
the outer lines the 95% confidence intervals. Blue dots= controls, red dots= AD cases. 
 
 
3.5.5.5 Investigating the Ang-II:Ang-I ratio in AD  
 
The Ang-II:Ang-I ratio is potentially a useful proxy marker of ACE-1 activity. The previous 
measurements of Ang-II level measured by sandwich ELISA were available for controls (n= 43) and 
AD cases (n= 70) and were showed to be significantly increased in AD (393). The median for Ang-
II:Ang-I ratio was significantly increased in AD (median = 0.0131) compared to controls (median = 
0.0086) indicating an increase in Ang-II relative to reduced Ang-I, which would be predicted in the 
presence of higher ACE-1 activity. Mann-Whitney test detected a significant p value (p= 0.0003) 
(Figure 3.15).  
 
 
































Figure 3.15 The ratio of Ang-II to Ang-I is increased in AD compared with age-matched controls.  
Increased Ang-II:Ang-I ratio in AD (n= 70) compared to controls (n= 43) in mid-frontal cortex. 
Differences between groups were compared using Mann-Whitney test (p= 0.0003). The bars indicate 




3.5.5.6 Relationship between Ang-II:Ang-I ratio and ACE-1 activity 
 
The Ang-II:Ang-I ratio is a potential proxy marker of ACE-1 activity. The relationship between Ang-
II:Ang-I ratio and ACE-1 activity was assessed. ACE-1 activity was measured previously by FRET 
activity assay in controls (n= 43) and AD cases (n= 66) (78). Spearman’s correlation coefficient test 
detected a significant positive correlation between the Ang-II:Ang-I ratio and ACE-1 activity (r= -




























Figure 3.16 Relationship between Ang-II:Ang-I ratio and ACE-1 activity.  
Scatterplot showing a positive correlation between the Ang-II:Ang-I ratio and ACE-1 activity 
measured by FRET activity assay in mid-frontal cortex. Spearman’s correlation coefficient test (r= 
0.229, p= 0.016). The solid inner line indicates the best-fit linear regression and the outer lines the 




3.5.5.7 Relationship between Ang-I and APOE genotype 
 
Ang-I level was analysed in relation to APOE ε4 allele for both unadjusted and protein–adjusted data. 
Mann-Whitney test revealed that Ang-I level unadjusted to total protein was reduced in cases with one 
or two APOE ε4 allele. The median for Ang-I level in cases with absence of APOE ε4 allele, median 
=1734 (pg/ml) was higher compared to cases with presence of one or two APOE ε4 allele, median = 
1533 (pg/ml), (p= 0.02). There was no difference in protein-adjusted Ang-I level depending on the 
presence or absence of APOE ε4 allele (Appendix V: Table 9.38). 

































Figure 3.17 Ang-I level in relation to APOE genotype. 
Ang-I level was significantly lower in cases with one or two APOE ε4 allele (1) compared with cases 
with absence of APOE ε4 allele (0). Differences between groups were compared using Mann-Whitney 
test (p= 0.02). The bars indicate the median and 95% confidence intervals.  
 
 
3.5.5.8 Relationships between Ang-I level and confounding factors 
 
The potential relationships between Ang-I level and protein-adjusted Ang-I level data with 
confounding factors of age-at-death, gender and PMD were investigated. There was no correlation 
between both unadjusted and protein-adjusted levels of Ang-I with age-at-death or PMD. Similarly, 
there was no significant difference in Ang-I level between males and females for either comparison of 
Ang-I levels (Appendix V: Table 9.37).  
 
 
3.6 Discussion  
 
This chapter involved an in-depth study of ACE-1 in relation to AD and explored the association 
between ACE-1 activity and pathological hallmarks of AD. The first question we sought to determine 
was whether changes in ACE-1 N-domain and C-domain activities were apparent in AD compared to 
controls and then we assessed the relationship between these domain-specific activities and AD 
pathological hallmarks. Secondly, we determined whether Ang-I level, as the precursor to Ang-II and a 



















were altered in AD in relation to pathological hallmarks of AD. The latter provided an alternative 
means to explore ACE-1 activity and allow the determination of whether these measurements were 
potentially useful proxy markers of ACE-1 activity. The data highlighted divergent changes in ACE-1 
domain activity that suggest that in AD there are disease-specific alterations in ACE-1 domain activity 
that potentially favour increased Ang-II production and interfere with Aβ degradation. The data also 
indicate that Ang-I level was reduced and the Ang-II:Ang-I ratio was increased in AD and may be a 
useful proxy marker of ACE-1 activity. 
 
ACE-1 is the central and rate-limiting enzyme in the classical RAS pathway. It is responsible for the 
generation of Ang-II and total ACE-1 activity is elevated in AD in relation to parenchymal Aβ level 
(78). ACE-1 also cleaves and degrades Aβ42, facilitating its removal from the brain. This apparent 
divergent role of ACE-1 in AD underpins the complex relationship between ACE-1 and cRAS 
activation in AD. Here, we show that ACE-1 C-domain activity, largely responsible for converting 
Ang-I to Ang-II (547), is elevated in AD. Overactivation of C-domain activity would support an idea 
that elevated Ang-II mediated AT1R signalling contributes to AD progression in accordance with the 
angiotensin hypothesis of AD (393). We also found that ACE-1 C-domain activity positively 
correlated with insoluble total Aβ and insoluble Aβ42 level but not with Aβ40 level or tau load. Ang-II 
mediated AT1R activation, which has been shown to cause increased Aβ expression in adult SDR by 
stimulating amyloidogenic processing of APP metabolism (238) may be responsible for the positive 
correlations with Aβ. No significant association was found between ACE-1 C-domain activity in mid-
frontal cortex and Braak tangle stage, age-at-death, PMD, gender or APOE genotype. 
 
ACE-1 has been shown to degrade Aβ peptides in various pre-clinical investigations. Cleavage 
products of Aβ are less toxic and more easily cleared. Several in vitro studies found that ACE-1 was 
involved in the degradation of Aβ peptides (81-83, 345, 346) and in some animal studies, ACE-1 
inhibitor administration is associated with elevated Aβ-related pathology (519, 548). The N-domain 
has been reported to favour Aβ degradation (82, 343, 549). We report novel evidence in post-mortem 
brain tissue of reduced N-domain activity that was associated with AD. We hypothesised that reduced 
N-domain activity could contribute to elevated Aβ in AD, however surprisingly and contrary to 
expectations, we did not find any significant correlations with N-domain ACE-1 activity and guanidine 
extracted Aβ load, Aβ42 or Aβ40 levels or tau load. A recent study proposed that N-domain activity 
enhanced the risk of AD by generating a toxic endogenous Aβ isoform (isoAβ(6-x) that is extremely 
susceptible to oligomerisation (550). Perhaps reduced N-domain activity is a protective compensatory 
response to elevated Aβ pathology but a more comprehensive assessment of Aβ species in relation to 
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ACE-1 activity is required. ACE-1 N-domain activity did not vary with age-at-death, PMD, gender or 
APOE genotype.  
 
We report for the first time that there is imbalance in the activity of the two catalytic domains of ACE-
1 in AD. Together, these data provide a potential explanation into seemingly paradoxical roles in 
ACE-1 in AD. This could be explained by common differences between N-domain and C-domain in 
substrate specificiteis, physiological properties (glycolysation level) and structural characteristics 
(551). Both glycolysation and peptide binding target the C-terminal in N-domain that is thought to 
affect glycolsation and its vital role in folding, localisation and enzyme activity as well (552). Reduced 
N-domain potentially impedes Aβ metabolism whereas increased ACE-1 C-domain activity could 
contribute to overproduction of Ang-II, for which we recently reported is elevated in AD. This 
possible relationship and the domain-specific changes may also provide an explanation for some of the 
inconsistences observed in previous studies linking ACE-1 and AD risk or progression. A number of 
animal and epidemiological studies have shown beneficial effects of ACEIs on cognition and reduce 
the risk of AD (361, 364, 365, 367, 542), whereas other studies have shown that ACEIs were 
associated with increased risk of AD or have no effect on AD risk (218, 363, 368, 370). The domain-
selectivity of ACEIs, which remains unknown for most types of ACEI, may therefore have dramatic 
effects on disease progression in AD depending of its domain-specificity. 
 
We also found that domain-specific immunocapture-based activity assays were more sensitive at 
detecting changes in AD compared to the equivalent FRET-based assays. We found that although 
ACE-1 N- and C-domain activity, when measured by FRET activity assay, showed trends towards 
lower N-domain activity in AD and higher C-domain activity in AD, these trends were not statistically 
significant in AD cases compared to controls. In contrast, ACE-1 N-domain activity, when measured 
by the more sensitive immunocapture-based FRET activity assay, was significantly lower in AD cases 
by ≈ 50% compared to controls. Similarly, the immunocapture-based C-domain activity assay revealed 
a significant increase in C-domain activity in AD cases by more than 25%. The reason for these 
differences is likely to be due to the improved specificity of the immunocapture assays and the longer 
incubation time, which is likely to have improved the sensitivity of the assay. These data highlight the 
possible need to further investigate and perform a more comprehensive analysis to try and better 
understand the potential causes and effects of ACE-1 domain specific changes in AD.  
 
Finally, we measured Ang-I level and calculated the ratio of Ang-II:Ang:I in mid-frontal cortex to 
provide an additional way to help inform and support the ACE-1 activity findings. I found that Ang-1 
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level was reduced and the Ang-II:Ang:I ratio was increased in AD. This is the first study to show that 
Ang-I levels are reduced in AD, and that the reduction in Ang-I was related to disease severity 
according to Braak tangle stage such that it was more pronounced in more severe AD. Interestingly, a 
reduction in Ang-I level (that would occur through overactivity of ACE-1 that has been previously 
shown (78, 354)) was inversely correlated with increased levels of two AD pathological hallmarks 
(guanidine Aβ and tau load). That the ratio of Ang-II:Ang-I was significantly increased in AD cases 
compared to controls, is also consistent with increased activity of ACE-1. This analysis was possible 
through the availability of Ang-II data that were previously measured in the mid-frontal cortex and 
were found to be increased in AD (393). Both the reduction in Ang-I levels and the observed inverse 
correlation between Ang-I level and ACE-1 activity thus support the previous findings of increased 
ACE-1 level and activity in AD (78, 354). It also suggests that the Ang-II:Ang-I ratio can be used as a 
proxy marker for ACE-1. Moreover, the reduction of Ang-I level was associated with the presence of 
one or two APOE ε4 alleles and implies an association between RAS and APOE as suggested by 
another earlier study (417).  
 
In conclusion, the data presented in this chapter provides further support and novel insights into the 
role of the brain cRAS in AD. For the first time, we provide evidence of divergent catalytic activity of 
ACE-1 catalytic domains in AD, which may begin to explain some of the conflicting findings in 
previous studies that have used various and perhaps different domain-binding ACEIs across diverse 
models of AD (343, 345, 346, 547). The potential impact of ACEI on disease pathogenesis, depending 
on domain-binding, may also provide a means to better explore the specificities of clinically used 
ACEIs for the ACE-1 catalytic domains in future studies (343, 344, 373-376). We report that, in 
addition, Ang-I is reduced and the ratio of Ang-II:Ang-I is increased in AD, which is consistent with 
increased ACE-1 activity and which also provides support for the utility of the Ang-II:Ang-I ratio as 
an alternative measure to estimate ACE-1 activity. These findings pose some questions as to the 
potential value of better discrimination of existing ACEIs as selective C-domain ACEIs that would 
preferentially target Ang-II production (whilst leaving Aβ-degradation unimpaired) and which could 
then be used exclusively to manage hypertension either in people at risk or in the early stages of AD, 










The cRAS (ACE-1/Ang-II/AT1R) exerts damaging effects and hyperactivity of this axis locally within 
the brain contributes to the pathogenesis of AD. Alternative ‘downstream’ RAS pathways have 
recently been discovered that counter-regulate the damaging effects of cRAS signalling, whilst also 
regulating synaptic function and boosting learning and memory. Yet, the expression of these rRAS 
pathways remains poorly characterised within the brain and their possible association with AD 
pathogenesis remains unclear. We previously showed that ACE-2 activity was reduced in AD in 
association with disease pathology (Aβ/Tau) and overactivity of ACE-1 (417). In this chapter, I have 
further characterised the ACE-2/Ang (1-7)/MasR pathway in AD. I have characterised the distribution 
and expression of angiotensin (1-7), MasR and the lesser known MrgD receptor involved in the 
alternative rRAS signalling pathway in relation to disease pathology in a well-characterised cohort of 
post-mortem brains.  
  
Human post-mortem brain tissue was obtained from the SWDBB, University of Bristol, with local 
Research Ethics Committee approval. We studied mid-frontal cortex (Brodmann area 8/9) from AD 
cases (n= 70) and age-matched controls (n= 48) that were matched closely for age-at-death and PMD. 
The level of Ang (1-7) was measured in the mid-frontal cortex by an in-house direct ELISA. The 
expression and distribution of MasR was determined by ELISA and IHC. The expression of MrgD was 
determined by western blotting. Pre-existing data on Braak tangle stage, total insoluble Aβ, insoluble 
Aβ40 and Aβ42 and tau load was also available for analysis. We also calculated the ratio of Ang-
II:Ang (1-7) to determine if it was a useful potential proxy marker for ACE-2 activity. 
 
In this chapter we show that MasR was expressed primarily in neurons and that the level of Ang (1-7) 
and MasR were unaltered in AD and were not associated with AD pathological hallmarks. MrgD was 
also found to be expressed in human post-mortem brain tissue with no obvious difference between 
controls and AD cases.  We also report that the Ang-II:Ang (1-7) ratio was significantly increased in 
AD compared to controls, consistent with recent findings of reduced ACE-2 activity (and thus reduced 
conversion of Ang-II to Ang (1-7)) in AD. 
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Together, these studies provide novel evidence that components of the alternative rRAS pathways i.e. 
Ang (1-7) and MasR are unchanged in AD, despite our findings of increased Ang-II:Ang (1-7) ratio, 





The non-classical rRAS is composed of and relies heavily on the function and activity of ACE-2, the 
rate-limiting enzyme in the conversion of Ang-II to Ang (1-7), the primary agonist of MasR (ACE-
1/Ang (1-7)/MasR). This rRAS pathway counter-regulates the disease-associated actions that are 
generally attributed to the cRAS axis (254). Ang (1-7) activation of MasR activates signalling 
pathways associated with several protective actions such as vasodilation, anti-inflammatory, anti-
proliferative and anti-fibrotic effects (455). Ang (1-7) activation of the MasR is associated with LTP 
and boosts memory and cognition in mouse models of AD (432-434). 
 
There is evidence that the rRAS (ACE-2/Ang (1-7)/MasR) pathway is dysregulated in AD. Our 
previous study showed a reduction in ACE-2 activity in AD human post-mortem brain tissue in the 
mid-frontal cortex, which was inversely associated with Aβ and tau pathology (417). The reduction of 
ACE-2 activity was also inversely correlated with ACE-1 activity, and the ratio of ACE-1 to ACE-2 
(proxy markers of the activity of cRAS and rRAS respectively) was increased, suggesting an 
imbalance in brain RAS (favouring excess cRAS activity) in AD. Notably, serum ACE-2 activity was 
found to be reduced in AD patients compared to controls (79). Cognitive impairment and disease 
pathology, associated with increased oxidative stress and decreased brain-derived neurotrophic factor 
(BDNF) in the hippocampus, due to cRAS activation, has also been reported in ACE-2 knock-out mice 
(419), whilst activation of the ACE-2/Ang (1-7)/MasR axis has previously been shown to boost 
learning and memory in an AD rat model (295). Interestingly, ACE-2 has been shown to convert the 
neurotoxic form of Aβ (Aβ43) into (Aβ42), which in turn is cleaved by ACE-1 to less toxic Aβ species 
(Aβ40 and Aβ41) (79).  
 
The beneficial effects of Ang (1-7) against disease-pathology and cognitive dysfunction has been 
reported to be mediated via activation of a GPCR, namely MasR (252). Activation of MasR by the 
binding of Ang (1-7) stimulates several downstream signalling pathways that counter-regulate cRAS 
disease-associated signalling including: stimulation of phospholipase A2, increased arachidonic acid, 
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release of Ca+ independent activation of NOS, activation of PI3K/Akt, MAPK and cAMP/PKA (428). 
ICV administration of Ang (1-7) into rats has been shown to restore cerebral blood flow and improve 
cognitive function through increased NO generation (429), promotion of brain angiogenesis and 
increased capillary density via a Mas/eNOS dependent pathway (328, 430, 431). In accordance, 
cerebroprotective mechanisms of ICV infusion of Ang (1-7) are due to reduced levels of oxidative 
stress and pro-inflammatory cytokines in the ischaemic area (292). Collectively, these studies outline a 
critical role of the active RAS metabolite (Ang (1-7)) in maintaining the physiological homeostasis of 
cerebrovascular function. 
 
It has been shown that Ang (1-7) is implicated in learning and memory via its action on MasR. MasR 
was originally identified as a proto-oncogene and it encodes a genetic sequence characteristic of the 
GPCR subfamily and has seven hydrophobic transmembrane domains (436). High expression of MasR 
has been detected in rat brain within the hippocampus, cerebral cortex and also in cardiovascular 
function related areas in the brain such as hypothalamus and medulla (438, 439). Ang (1-7) also 
enhances LTP in the CA1 region of the hippocampus and amygdala in mice (432, 433). Moreover, 
dysregulation of Ang (1-7)/MasR axis has been found to cause memory deficit and affect the object 
recognition memory in MasR knockout mice (353). MasR activation in hippocampus and basal ganglia 
promoted cell survival, enhanced synapse formation and improved cognition in rodent and humans 
(425). In accordance, activation of MasR by Ang (1-7) administration attenuated cognitive decline and 
reduced expression of AD pathological hallmarks (phosphorylated tau, Aβ oligomer and both Aβ40 
and Aβ42 levels) in the hippocampus of an AD rat model. Co-administration of a MasR antagonist 
reversed the protective effects (440). These findings suggested that dysregulation of (ACE-2/Ang (1-
7)/MasR) axis might contribute to cognitive decline and disease pathology seen in AD. Activity of the 
main enzyme in the protective axis, ACE-2 was reduced in human post-mortem brain tissue of AD 
patients and this reduction was associated with increased AD pathological hallmarks (total Aβ load and 
p-tau levels) (417). Activation of ACE-2 by administration of DIZE, an ACE-2 activator in AD animal 
model, resulted in both prevented development of cognitive deficit and improved learning and memory 
function (295, 421).  Jiang et al. (416) found that Ang (1-7) levels were reduced in AD and inversely 
correlated with hyperphosphorylated tau. Recently, Uekawa et al. (434) showed that ICV infusion of 
Ang (1-7) alleviated cognitive impairment and improved cerebrovascular reactivity (i.e. CBF) in an 
AD mouse model. In addition, a recent study has shown the beneficial effects of an Ang (1-7) 
analogue on cognitive function (553).  
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Together, these data indicate an important role of the ACE-2/Ang (1-7)/MasR pathway in AD, but the 
characterisation of this pathway in human brain tissue remains poorly described. In humans, plasma 
levels of Ang (1-7) were significantly reduced in AD patients compared to controls. The study by 
Jiang et al. (435) suggested that Ang (1-7) may be considered as a potential biomarker in AD 
diagnosis. However, cerebral Ang (1-7) levels in AD patients have not been investigated. Finally, 
MrgD is a member of the GPCR family group and has been reported to be expressed in neurons (554). 
Tetzner and colleagues (443) recently identified MrgD as a second receptor for Ang (1-7) although 
much is still unknown about this receptor. The coupling of Ang (1-7) with both MasR and MrgD has 
been shown to activate intracellular signalling pathways that induce increased cAMP and 
phosphokinase A activity. However, the role of both of these receptors in relation to AD-associated 
pathology and cognitive dysfunction is less studied.  
 
In this chapter, we have characterised the rRAS pathway (downstream of ACE-2) and have measured 
the expression of Ang (1-7) and the expression and distribution of both the MasR and MrgD receptors 




4.3 Study aims and hypothesis 
 
The aims of the study described in this chapter were: 
 
(i) To determine if the level of Ang (1-7) and/or the ratio of Ang-II/Ang (1-7) in mid-frontal 
cortex is altered in AD in relation to disease pathology 
(ii) To characterise the expression and distribution of MasR and MrgD receptors in the mid-
frontal cortex in AD in relation to markers of disease pathology 
 
We wished to test the hypothesis that the downstream components of the rRAS pathway beyond ACE-
2 i.e. Ang (1-7), MasR and MrgD expression was altered in mid-frontal cortex of AD brains compared 









4.4.1 Study cohort 
 
Human post-mortem brain tissue homogenates from mid-frontal cortex (Brodmann area 8/9) were used 
for measurements of Ang (1-7) level and MasR level. The study cohort included a total of controls (n= 
48) and AD cases (n= 70). Demographic features of study cohort are described in the methods section 
(see Table 2.1) for full details (Appendix I: Table 9.1 and Table 9.2). Previous measurements of total 
insoluble Aβ by sandwich ELISA were available for controls (n= 28) and AD cases (n= 61) (545). Tau 
load was previously measured for all cases as part of routine assessment of AD cases within the 
SWDBB by field fraction analysis and was available for controls (n= 29) and AD cases (n= 89). Both 
insoluble Aβ40 and insoluble Aβ42 were previously measured by sandwich ELISA and were available 
for controls (n= 20) and AD cases (n= 33) for insoluble Aβ42, and for controls (n= 20) and AD cases 
(n= 34) for insoluble Aβ40 (314). The previous measurements of Ang-II level measured by sandwich 
ELISA were available for controls (n= 43) and AD cases (n= 70). All these previous measurements of 
AD pathological hallmarks and RAS marker were used for analysis in this chapter. 
 
 
4.4.2 Angiotensin (1-7) direct ELISA 
 
The level of Ang (1-7) was measured in brain homogenates from mid-frontal cortex using an in-house 
direct ELISA as described in detail in the general methods (section 2.7.2). Brain homogenates were 
prepared in 1% SDS lysis buffer as described in the methods (section 2.2.2). Recombinant Ang (1-7) 
(serially diluted to produce a 1000-15.62 pg/ml standard curve) and tissue samples diluted 1:40 in PBS 
were incubated in a clear high-binding capacity NUNC maxisorp plate (Fisher Scientific) for 2 hours 
at room temperature with shaking. After washing in PBS/0.05% Tween-20 five times, wells were 
blocked for 1 hour using PBS:1% BSA (Sigma Aldrich). Following a further wash step, a biotinylated 
detection antibody against Ang (1-7) (100 µl) (Cloud-Clone) (diluted 1:100 in PBS) was incubated for 
2 hours at 26°C with shaking. After five washes, the wells were incubated with strep:HRP (R&D 
System) (1:200) in PBS with 0.01% Tween-20 at room temperature for 20 minutes in dark. Following 
a further wash step, TMB substrate (R&D systems) was added and incubated in the dark for 20 
minutes. 50 µl of Sulfuric acid (stop solution) (Sigma-Aldrich) was added to each well and the 
absorbance at 450nM was read using a FLUOstar OPTIMA plate reader (BMG labtech). The assay 
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showed minimal cross reactivity with a number of closely related angiotensin peptides, namely Ang-I, 
Ang-II, Ang-III and Ang-IV (Figure 4.1).  
 
 
Figure 4.1 Cross reactivity test of the Ang (1-7) direct ELISA using biotin-linked polyclonal 
antibody to Ang (1-7) (Cloud-Clone Corp) with serial dilutions of closely-related recombinant 
human angiotensins (Ang (1-7), Ang-II, Ang-III, Ang-IV and Ang-I).  




Ang (1-7) measurements were adjusted for total protein level determined using a method described in 
chapter 2 (section 2.3). Ang (1-7) level was measured in duplicate and four carry-over samples were 
used and repeated in each plate assayed. The variation between Ang (1-7) measurements was 
determined by calculating the intra-assay CV% (Appendix IV: Table 9.27).  
 
4.4.3 Angiotensin (1-7) sandwich ELISA  
 
The level of Ang (1-7) in brain homogenates from the mid-frontal cortex was also measured in a 
subset of control (n= 19) and AD cases (n= 19) using a quantitative commercially available sandwich 
ELISA (Human Angiotensin 1-7 (ANG1-7) ELISA kit) (MyBioSource), according to the 
manufacturer’s instructions. A detailed method is described in the chapter 2 (section 2.8.1). Brain 
homogenate samples were added in duplicate and averaged and the variation of this assay was 
determined by calculating the intra-assay CV% (Example in Appendix IV: Table 9.28). 
 
 























4.4.4 Expression of MasR in human brain tissue 
 
4.4.4.1 Western blot for MasR expression 
 
The standard protocol for western blotting is described in detail in chapter 2 (section 2.4). Details of 
the primary and secondary antibodies used are listed in chapter 9 (Appendix II: Table 9.13) and (Table 
9.14) respectively. In summary for detection of MasR in brain homogenate samples, the membrane 
was blocked in 10% milk/TBST buffer for 1 hour. After it had been washed with 0.05% TBST (3x 15 
minutes) at room temperature on a shaker, the membrane was then incubated with anti-MAS1 antibody 
diluted 1:800 in 5% milk/TBST antibody buffer overnight at 4°C (in the fridge) on a rotating platform. 
Following a wash step with 0.05% TBST (3x 15 minutes) at room temperature on the rotating 
platform, the membrane was incubated with the secondary antibody (peroxidase conjugated anti-
rabbit) diluted 1: 5000 in 5% milk/TTBS for 1 hour. After 3x 15 minutes wash steps with 0.05% 
TBST, a chemiluminescent HRP substrate (ECL) (Millipore) was added to the membrane in a 1:1 ratio 
(5 ml of reagent 1 and 5 ml of reagent 2) for 5 minutes. Images were acquired using Image Lab 
(ChemiDoc XRS+, Bio-RAD) and Image Lab software, version 5.0 (Bio-RAD).  
 
4.4.4.2 Immunohistochemistry for MasR 
 
The specificity of the anti-MAS1 antibody (ab66030) was further tested by immunohistochemistry to 
examine the distribution of the MasR in formalin-fixed brain tissue. The standard protocol used for 
immunohistochemical staining is described in detail in chapter 2 (section 2.5). Immunohistochemical 
staining of MasR was initially optimised by comparing standardised antigen retrieval pre-treatment 
steps with either EDTA or citrate buffer and optimising the dilution of the primary antibody (1:100, 
1:500, 1:1000). The best assay conditions for MasR staining were achieved when slides were pre-
treated with EDTA and boiled in the microwave for 10 minutes. After washing with running tap water 
for 5 minutes, slides were incubated with blocking serum for 20 minutes then incubated with the 
primary antibody (anti-MAS1 antibody (ab66030)) diluted 1:100 in PBS (10 µg/ml) at 4°C overnight. 
After rinsing the sections in two changes of PBS for 3 minutes each, sections were incubated with 
Vectastain biotinylated universal secondary antibody for 20 minutes followed by another wash with 
PBS and then the VectaElite ABC complex for 20 minutes and rinsed again. Sections were then 
incubated with DAB for 10 minutes then washed in running water for 10 minutes and immersed in 
copper sulphate solution for 4 minutes followed by washing in running water for 5 minutes. The 
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sections were then counterstained with haematoxylin Gill II for 3 seconds, dehydrated, cleared and 
mounted.  
  
4.4.5 MasR sandwich ELISA 
 
The level of MasR in brain homogenates from the mid-frontal cortex was measured using a 
quantitative commercially available sandwich ELISA (Human Mas Proto-Oncogen (MAS1) ELISA 
kit) (MyBioSource), according to the manufacturer’s instructions. A detailed method is described in 
chapter 2 (section 2.8.2). Brain homogenate samples were added in duplicate and averaged and 
measurements of four carry-overs samples were repeated across all plates. MasR measurements were 
adjusted to total protein level for each brain homogenate sample. The variation of this assay was 
determined by calculating the intra-assay CV% (Example in Appendix IV: Table 9.29). Both 
unadjusted MasR measurements and protein-adjusted measurements were used for comparisons 
between control and AD. Relationships between MasR level and disease severity (Braak tangle stage), 
AD pathological hallmarks (total insoluble Aβ, insoluble Aβ40, insoluble Aβ42 and tau load) were 
also examined.  
 
 
4.4.6 Expression of MrgD in brain tissue 
 
4.4.5.1 Western blotting for MrgD  
 
A standard protocol for western blotting was used and is described in detail in chapter 2 (section 2.4). 
Details of the primary and secondary antibodies used are described in chapter 9 (Appendix II: Table 
9.13) and (Table 9.14) respectively. In summary, for detection of MrgD in brain homogenate samples, 
the membrane was blocked in 10% milk/TBST buffer for 1 hour. Following a wash step with 0.05% 
TBST (3x 15 minutes) at room temperature on a shaker, the membrane was then incubated with 
MRGPRD antibody (NBP1-91964) diluted 1:500 in 5% milk/TBST antibody buffer overnight at 4°C 
(in the fridge) on a rotating platform. After it had been washed with 0.05% TBST (3x 15 minutes) at 
room temperature on a shaker, the membrane was incubated with a secondary antibody (peroxidase 
conjugated anti-rabbit) diluted 1:5000 in 5% milk/TBST for 1 h. After 3x 15 minutes wash steps with 
0.05% TBST, a chemiluminescent HRP substrate (ECL) (Millipore) was added to the membrane in a 
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1:1 ratio (5 ml of reagent 1 and 5 ml of reagent 2) for 5 minutes. The images were then acquired using 
Image Lab (ChemiDoc XRS+, Bio-RAD) and Image Lab software, version 5.0 (Bio-RAD). 
 
4.4.6 Statistical analysis 
 
All datasets were initially analysed by the Shapiro-Wilk normality test to determine whether they were 
normally distributed. A significant p value p< 0.05 was used to indicate if the data were not normally 
distributed. Ang (1-7) direct ELISA were normally distributed whilst MasR sandwich ELISA data 
were not normally distributed. 
 
Comparison of Ang (1-7) level between controls and AD cases was tested using an Unpaired samples 
t-test. Protein–adjusted data was not normally distributed and therefore a non-parametric test, Mann-
Whitney test was used. Correlations of Ang (1-7) data with total insoluble Aβ and tau load were 
assessed by the Pearson’s correlation coefficient for unadjusted data and Spearman’s correlation 
coefficient for protein-adjusted data. Comparison of Ang-II:Ang (1-7) ratio between controls and AD 
cases was analysed using a parametric test, unpaired samples t-test. 
 
Both MasR and protein-adjusted MasR data were not normally distributed. A non–parametric Mann-
Whitney test was therefore performed to compare AD cases and controls for both datasets. 
Comparison of MasR and protein-adjusted MasR data between Braak tangle stage groups (Braak stage 
0-II, Braak stage III-IV, Braak stage V-VI) was assessed using a non-parametric Kruskal-Wallis test. 
MasR and MasR protein-adjusted level correlations with total insoluble Aβ, tau load, insoluble Aβ40 
and insoluble Aβ42 were assessed by the Spearman’s correlation coefficient.  
 
Log transformation for unadjusted and protein-adjusted MasR data was performed to attempt to reach 
normal distribution (Appendix VI: Section 9.6.2). Unpaired sample t-tests were used for log 
transformed unadjusted and protein-adjusted data to compare between AD cases and controls. A one-
Way ANOVA test was performed to compare log transformed MasR data between Braak tangle stage 
groups. Correlations between log-transformed MasR data and total insoluble Aβ, tau load, insoluble 
Aβ40 and insoluble Aβ42 were assessed by Pearson’s correlation coefficient. For all tests applied, a P-
value < 0.05 was considered statistically significant.  
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For all datasets, the ROUT method was used to detect outliers, in datasets where outliers were 





4.5.1 Comparison of Angiotensin (1-7) level in controls and AD   
 
In the mid-frontal cortex, Ang (1-7) level measured by direct ELISA, was not significantly different in 
AD cases compared to age-matched controls. The mean and standard error of mean (SEM) for controls 
was (31668 ± 1014) and for AD cases (32572  ± 892.4) (Figure 4.2 A). The Ang (1-7) measurements 
were then adjusted to total protein level where Mann-Whitney test similarly revealed no significant 
difference between AD cases (median = 121204 pg/mg) and controls (median = 111555 pg/mg) 
(Figure 4.2 B).  
 
Figure 4.2 Comparison of Angiotensin (1-7) level between controls and AD cases.  
A. Bar chart showing unchanged Ang (1-7) level in AD (n= 70) compared with age-matched control 
(n= 48) in mid-frontal cortex measured using an in-house Ang (1-7) direct ELISA. Unpaired samples t-
test revealed no significant difference between AD and controls (p= 0.514). The bars indicate the mean 
± SEM. B. Bar chart showing protein-adjusted Ang (1-7) level did not differ between AD group 
compared to age-matched group, Mann-Whitney test (p= 0.222). The bars indicate the median and 






















































Similar to the results of Ang (1-7) direct ELISA, Ang (1-7) measured by sandwich ELISA was not 
significantly different in AD cases (n= 19) compared to age-matched controls (n= 19). The median 
total Ang (1-7) level was: controls = 22.92 (pg/ml) and AD = 25.06 (pg/ml). Mann-Whitney test 
showed no statistical significance between groups (p= 0.220) (Figure 4.3 A). The median for Ang (1-7) 
protein-adjusted data in AD cases (125.5 (pg/mg total protein)) did not differ from controls (131.9 
(pg/mg total protein)). Mann-Whitney test similarly revealed no statistical significance between groups 
(p= 0.402) (Figure 4.3 B). Ang (1-7) level measured by direct ELISA was not correlated with data 
measured by sandwich ELISA in the subsets of AD cases (n= 19) and age-matched controls (n= 19) 
(Pearson’s correlation coefficient r= 0.194, p= 0.243). 
 
  
Figure 4.3 Comparison of Angiotensin (1-7) level between controls and AD cases using a 
commercial sandwich ELISA.  
A. Bar chart showing unchanged Ang (1-7) level in AD (n= 19) compared with age-matched control 
(n= 19) in mid-frontal cortex measured using an Ang (1-7) sandwich ELISA. Mann-Whitney test 
revealed no significant difference between AD and controls (p= 0.220). The bars indicate the median 
and 95% confidence intervals. B. Bar chart showing protein-adjusted Ang (1-7) level did not differ 
between AD group compared to age-matched group, Mann-Whitney test (p= 0.402). The bars indicate 
the median and 95% confidence intervals. 
 
 
4.5.1.1 Relationship between Ang (1-7) and Aβ and Tau load 
 
The relationship between Ang (1-7) level (measured by direct ELISA) and levels of insoluble Aβ load 
and Tau load in mid-frontal cortex were assessed. Both total Ang (1-7) and protein-adjusted 
measurements showed no correlation with either insoluble Aβ load (Pearson’s correlation coefficient 



















































and B). No significant correlations were found between both unadjusted Ang (1-7) and protein-
adjusted measurements with tau load (Pearson’s correlation coefficient r= 0.095, p= 0.358; Spearman’s 
correlation coefficient r= 0.165, p= 0.113) respectively (Figure 4.4 C and D). 
 
 
Figure 4.4 Relationships between Ang (1-7) level and Aβ and tau load.  
A. Scatterplot showing no correlation between Ang (1-7) level and guanidine Aβ load (measured by 
enzyme-linked immunosorbent assay), Pearson’s correlation coefficient (r= 0.096, p= 0.381). B. 
Scatterplot showing no significant correlation between Ang (1-7) protein-adjusted level and guanidine 
Aβ load, Spearman’s correlation coefficient (r= 0.114, p= 0.306). C. Scatterplot showing no 
correlation between Ang (1-7) level and tau load (measured by field fraction analysis), Pearson’s 
correlation coefficient (r= 0.095, p= 0.358). D. Scatterplot showing no significant correlation between 
Ang (1-7) protein-adjusted level and tau load, Spearman’s correlation coefficient (r= 0.165, p= 0.113). 
The solid inner line indicates the best-fit linear regression and the outer lines the 95% confidence 





































































































4.5.1.2 The Ang-II:Ang (1-7) ratio is increased in AD 
 
We next calculated the Ang-II:Ang (1-7) ratio, which is potentially a proxy indicator of ACE-2 
activity. The previous measurements of Ang-II level were available for controls (n= 42) and AD cases 
(n= 68). The mean ± SEM for Ang-II:Ang (1-7) ratio was significantly increased in AD compared to 
controls, unpaired samples t-test (p= 0.004) (Figure 4.5). An increased ratio of Ang-II:Ang (1-7) in AD 




Figure 4.5 The ratio of Ang-II:Ang (1-7) in AD compared with age-matched controls.  
Bar chart showing increased Ang-II:Ang (1-7) ratio in AD (n= 68) compared to controls (n= 42) in the 
mid-frontal cortex. Differences between groups were compared using Unpaired samples t-test at **P= 
0.004. The bars indicate the mean ± SEM. 
 
 
4.5.2 Expression of MasR in human brain tissue 
 
To detect and examine the distribution of MasR in the mid-frontal cortex, the specificity of MasR 
antibody was first tested by western blot and then by immunohistochemical staining. Four AD cases 
and controls were used for this experiment. Details of the chosen samples are described in chapter 9 
























4.5.2.1 Validation of MasR antibody specificity 
 
A representative image of the MasR western blot is shown (Figure 4.6). The antibody detected a band 
at approximately 37 kDa, which is the expected molecular weight (MW) for the MasR protein (440). 
An additional lower band was detected at 20 kDa – the identity of this band is unknown but could 
possibly be a protein degradation product. There was no obvious difference in the levels of expression 
of MasR in AD and controls (see Figure 4.6) although this was a small sample set (n= 4). 
Densitometry was performed but no significant difference in band volume (p= 0.221) was observed 
between AD and controls.  
 
	  
Figure 4.6 MasR expression in human post-mortem brain tissue homogenates detected by 
Western blot. 
MasR expression in human brain tissue was studied by Western blotting: left side represents 
expression of MasR in human brain tissue from non-diseased controls (lines 1-4). Right side shows 
MasR expression in AD cases (lines 6-9). Lane 5 includes MW markers. The membrane was blotted 
with polyclonal rabbit antibody to MAS1 (ab66030). The reported size of MasR is predicted to be 





4.5.2.2 Immunolabelling of MasR in human brain tissue   
 
MasR labelling was mainly localised to neurons in control, AD and VaD cases. In a control case, 
positive MasR staining was predominantly observed in parenchymal neurons (Figure 4.7 A and B). In 
a vascular case, positive labelling was also seen around some blood vessels (Figure 4.7 C-F).  
 
Figure 4.7 Immunolabelling of MasR in the mid-frontal cortex.  
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A-B. MasR labelling in brain sections from a non-diseased control case was mainly detected in 
parenchymal neurons (indicated by arrows). C-F. immunohistochemical staining of MasR in brain 
sections from a vascular case indicates that MasR was mostly present in neurons but with some 
additional staining of blood vessels evident (indicated by arrows). Images were taken by Professor Seth 
Love. (Image taken at 10x magnification for C, at 20x magnification for A and D, at 40x magnification 
for B, E and F). 
 
4.5.3 Measurement of MasR level in AD  
 
4.5.3.1 Comparison between control group and AD group  
 
The level of MasR and MasR adjusted for total protein did not significantly differ between AD cases 
(n= 70) and controls (n= 48) (Figure 4.8 A and B). These data were not normally distributed. The 
median total MasR level was: controls= 51.39 (pg/ml) and AD= 57.56 (pg/ml). Mann-Whitney test 
showed no statistical significance between groups (p= 0.359). The median for MasR protein-adjusted 
data in AD cases (347 (pg/mg total protein)) did not differ from controls (327.9 (pg/mg total protein)). 






Figure 4.8 MasR level in mid-frontal cortex in Alzheimer’s disease (AD).  
A. Bar chart showing MasR concentration was unchanged in AD (n= 70) compared with age-matched 
control (n= 48) in mid-frontal cortex measured using a MasR sandwich ELISA, Mann-Whitney test 
(p= 0.359). The bars indicate the median and 95% confidence intervals. B. Bar chart showing protein-
adjusted MasR level did not differ in the AD group compared to age-matched group, Mann-Whitney 

















































4.5.3.2 Relationship between MasR and Braak tangle stage pathology 
 
Both MasR level and MasR protein-adjusted level were assessed in relation to Braak tangle stage 
(Braak stage 0-II (n= 36), Braak stage III-IV (n= 20), Braak stage V-VI (n= 61)). Kruskal-Wallis test 
indicated that there was no significant difference in MasR medians between all Braak stage groups (p= 
0.309) (Figure 4.9 A). The median of Braak stage 0-II = 55.305 (pg/ml), Braak stage III-IV= 47.265 
(pg/ml) Braak stage V-VI= 60.61 (pg/ml). Similarly, no significant difference was observed between 
the MasR protein-adjusted medians in relation to Braak tangle stage (p= 0.794). The corresponding 
medians in this case were for Braak stage 0-II= 325.177 (pg/mg total protein), Braak stage III-IV= 
281.641 (pg/mg total protein) Braak stage V-VI= 338.564 (pg/mg total protein) (Figure 4.9 B).  
 
 
Figure 4.9 MasR level in relation to Braak tangle stage. 
A. Bar chart showing no significant difference in MasR level measured by sandwich ELISA assay in 
relation to Braak tangle stage groups (Braak stage 0-II (n= 36), Braak stage III-IV (n= 20), Braak stage 
V-VI (n= 61)), Kruskal-Wallis test (p= 0.309. The bars indicate the median and 95% confidence 
intervals. B. Bar chart showing no difference between MasR protein-adjusted level and Braak tangle 
stage groups: (Braak stage 0-II (n= 36), Braak stage III-IV (n= 20), Braak stage V-VI (n= 61)), 




4.5.3.3 Relationship between MasR and AD pathology hallmarks 
 
The association between total MasR and protein-adjusted MasR measurements with AD pathology 





















































level and total insoluble Aβ when Spearman’s correlation coefficient test was applied (r= 0.008, p= 
0.939). Protein-adjusted MasR level was also not correlated with total insoluble Aβ (r= 0.019, p= 
0.855) using Spearman’s correlation coefficient (Figure 4.10 A and B).  
 
Similarly, no correlation was seen between total MasR level and tau load when Spearman’s correlation 
coefficient test applied (r= 0.105, p= 0.296). Spearman’s correlation coefficient test also showed a 
non-significant correlation between protein-adjusted MasR measurements and tau load (r= 0.079, p= 





Figure 4.10 Relationship between MasR level and total insoluble Aβ and tau load.  
A. Scatterplot showing no correlation between total MasR level and total insoluble Aβ (measured by 
enzyme-linked immunosorbent assay), Spearman’s correlation coefficient (r= -0.008, p= 0.939). B. 
Scatterplot showing no significant correlation between protein-adjusted MasR level and total insoluble 
Aβ, Spearman’s correlation coefficient (r= 0.019, p= 0.855). C-D. Scatterplot showing no significant 
correlation between both total MasR level and MasR protein-adjusted level and tau load (measured by 
field fraction analysis), Spearman’s correlation coefficient (r= 0.105, p= 0.296), Spearman’s 
A B
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correlation coefficient (r= 0.079, p= 0.433). The solid inner line indicates the best-fit linear regression 




MasR was not associated with different isoforms of Aβ, Spearman’s correlation coefficient test 
showed no significant correlations between total MasR level and both insoluble Aβ40 (r= -0.011, p= 
0.936) and Aβ42 (r= -0.024, p= 0.861) (Figure 4.11 A and C). MasR protein-adjusted level was not 
correlated with either insoluble Aβ40 (r= -0.164, p= 0.229) or Aβ42 (r= -0.163, p= 0.238) in mid-





Figure 4.11 Relationship between MasR level and insoluble Aβ40 and insoluble Aβ42.  
A and C. Scatterplots showing no correlation between total MasR level and both insoluble Aβ40 and 
insoluble Aβ42 (measured by enzyme-linked immunosorbent assay), Spearman’s correlation 
coefficient (r= -0.011, p= 0.936), (r= -0.024, p= 0.861). B and D. Scatterplot showing no significant 
correlation between MasR protein-adjusted level and both insoluble Aβ40 and insoluble Aβ42, 
A B
C D





























































































Spearman’s correlation coefficient (r= -0.164, p= 0.229) and (r= -0.163, p= 0.238) respectively. The 
solid inner line indicates the best-fit linear regression and the outer lines the 95% confidence intervals. 
Blue dots = controls, red dots = AD cases. 
 
 
4.5.4 Expression of MrgD in human brain tissue 
 
To detect the expression of MrgD in human post-mortem brain tissue, the specificity of MrgD 
antibody, (NB1-91964) was tested by western blot. Four AD cases and four non-diseased controls 
were chosen randomly for this experiment. Details of the chosen samples are described in chapter 9 
(Appendix I: Table 9.7).   
 
4.5.4.1 Validation of MrgD antibody specificity using western blot 
 
A representative image is shown of the western blot with the MrgD antibody (Figure 4.12). A 
prominent single band at approximately 37 kDa is observed, consistent with expected MW of MrgD 
(555). The identity of some very faint lower bands detected at a MW 25 kDa is unknown but is 
potentially representative of a degradation product of MrgD or non-specific binding. Very faint higher 
MW bands at ~ 150 kDa are also observed; the identity of these bands is also unknown. There was no 





Figure 4.12 Detection of MrgD in mid-frontal cortex in human post-mortem brain tissue 
homogenates using Western blot. 
MrgD expression in human brain tissue was studied by Western blotting: left side represents 
expression of MrgD in human brain tissue of controls (lines 1-4). Right side shows MrgD expression 
in AD cases (lines 6-9). Lanes (5 and 10) include MW markers. The membrane was blotted with 
polyclonal rabbit antibody to MRGD (NBP1-91964). The reported molecular weight of MrgD was 





In this study, the downstream rRAS (ACE-2/Ang (1-7)/MasR) pathway that has recently been shown 
to be dysregulated in AD was further investigated. The brain rRAS pathway has been shown to 
counter-regulate the cRAS in various disease-associated scenarios. ACE-2 activity has been reported 
to be reduced in AD in relation to increased amyloid and tau load (417). Here we measured the levels 
of Ang (1-7) and explored the distribution of MasR in AD in relation to disease pathology.  We found 
that the ratio of Ang:II:Ang (1-7) is increased in AD in keeping with our previous study showing that 
ACE-2 activity, the rate limiting enzyme in the ACE-2/Ang (1-7)/MasR pathway, is reduced in AD. 
Surprisingly, however, the level of Ang (1-7) was unaltered in AD as was MasR expression, which 
was predominantly expressed by pyramidal neurons within the neocortex. As opposed to ACE-2 
activity, neither Ang (1-7) or MasR expression was related to amyloid or tau pathology. These data 
suggest that changes in rRAS downstream of ACE-2 remain unaltered in AD.  
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Our findings in human post-mortem brain tissue contrast with previous studies in animal models of 
AD that found reduced Ang (1-7) level in SAMP8 mice (an animal model of overproduction of APP) 
and P301S mice -	an animal model of pure tauopathy. Ang (1-7) level was inversely correlated with 
tau hyperphosphorylation (416). This inconsistency may simply be due to the differences in species 
(animal vs. human). These animal models in previous studies have more aggressive Aβ pathology and 
tauopathy, which is associated with more extensive oxidative stress and brain damage, compared to 
brain changes in the human brain of an AD patient (556). Some of the differences may also relate to 
regional differences. The hippocampus was studied in mice, whereas here we studied the mid-frontal 
cortex. An important next step would be to validate my initial findings in other regions such as the 
entorhinal cortex and hippocampus. Some of the discrepancies could also simply be a reflection of 
different methods used to measure Ang (1-7): we measured Ang (1-7) using in-house direct ELISA 
while the previous study used commercially ELISA kits (S-1330; Bachem Inc.). Although we have 
also measured Ang (1-7) in a subset of cases, control (n= 19) and AD cases (n= 19) using a 
commercially available ELISA (Human angiotensin (1-7) ELISA kit) (MyBiosource) and found no 
difference in AD. It will be important to validate our data using another approach such as western 
blotting or another sandwich ELISA.  
 
It is also important to consider that there are alternative pathways that might give rise to the generation 
of Ang (1-7) in brain tissue e.g. from conversion of Ang (1-9) into Ang (1-7) by the action of ACE-1. 
Since the activity of ACE-1 has been found to be increased in AD (78), the production of Ang (1-7) 
from this pathway may compensate for the reduced production of Ang (1-7) from the ACE-2 mediated 
action on Ang-II. This would also suggest the potentially important role of Ang (1-9) as a reservoir to 
potentially help offset dysregulation of the rRAS in AD and thus requires further study. Despite the 
unchanged Ang (1-7) level in AD, the ratio of Ang-II to Ang (1-7) was increased in AD. This is 
consistent with observed reports of reduced ACE-2 activity and in turn reduced ACE-2 mediated 
production of Ang (1-7) (417). Although these data support recent studies that ACE-2 is dysregulated 
in AD, that levels of Ang (1-7) and MasR (downstream of ACE-2) are unaltered in AD may suggest 
the involvement of additional mechanisms that have yet to be identified and explored in AD. 
Furthermore, additional validation studies would be helpful in confirming or refuting these unexpected 
findings across different regions in human post-mortem brain tissue.  
 
Immunohistochemical staining sought to determine the expression of MasR in human brain tissue. 
Immunolabelling of MasR showed positive staining in parenchymal neurons in the human mid-frontal 
cortex. This result is in keeping with the IHC findings of Becker et al. (438) who previously detected 
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MasR in neurons within the rat brain and previous studies that also detected MasR in neurons (253, 
326, 557, 558). The immunostaining showed no obvious difference in the expression of MasR between 
AD, VaD and age-matched controls, however, the nature of this very small pilot study prevented any 
meaningful statistical analysis. MasR staining of some blood vessels was observed in vascular cases, 
which supports a previous study showing positive MasR immunolabelling in small and large cerebral 
vessels (327) and others report positive staining of MasR in microglia (327), a finding that we did not 
replicate on initial inspection. 
 
Whilst there has been an observed reduction of ACE-2 activity in the mid-frontal cortex of AD cases 
(417), there are no previous studies that have measured MasR level in AD patients. Previous studies in 
animal models of stroke have been inconsistent: Lu et al. (331) found increased expression of MasR 
and cerebral Ang (1-7) level in an ischaemic rat model with overactivation of ACE-2 activity. 
Similarly, MasR was observed in an area surrounding ischaemia in rodents (559). These results are in 
contrast to earlier findings that indicated a decline in MasR with advanced age (397) and down-
regulation of (Ang (1-7)/MasR) axis in an ischaemic model (560). These apparent discrepancies could 
be attributed to the rat ischaemic model used in these studies and the type of ischaemia induced (e.g. 
acute vs. chronic). The combined and unknown potential confounding effects of cerebrovascular 
damage on MasR expression in AD cases is similarly not known in this study and has the potential to 
mask any pure AD-related changes.  
 
This study was limited by the characterisation of expression of rRAS markers in one brain area (mid-
frontal cortex) while investigating other brain regions (temporal and hippocampus) will be interesting. 
Another limitation of this study was the measurement of Ang (1-7) was through one limited 
methodological approaches (direct and sandwich ELISA). However, this peptide has a short half-life 
and arguably needs to be detected by more sensitive methods. While we did not find any significant 
difference of PMD in our cohort, degradation of Ang (1-7) in brain tissue might be affected by PMD. 
It is also conceivable that a larger cohort sample size might have allowed detection of any alterations 
in Ang (1-7) or MasR, however the similarities in the existing levels, both unadjusted and adjusted 
suggests this might be unlikely. Further research should be undertaken to characterise the expression 
of these rRAS markers Ang (1-7) and MasR (and the other less known MrgD receptor) in different 
brain regions and by more than one method such as IHC for MrgD and RT-PCR for both receptors. 
Some additional work to investigate other RAS metabolites such as Ang (1-9) might also be timely, as 
it provides another means to the production of Ang (1-7) and possibly has a bearing on the scale and 
overall consequences of dysregulation of this rRAS pathway in AD. More investigation on the 
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expression of MrgD and its agonist (Alamandine) in human post-mortem brain tissue will be 
informative about the role of this peptide in AD pathogenesis 
  
In conclusion, this chapter provides some evidence in support of previous findings of reduced ACE-2, 
the rate-limiting enzyme in the non-classical axis of brain rRAS in AD. However, the levels of 
downstream mediators within this pathway, including Ang (1-7) and MasR, are unchanged in AD and 
not related to disease pathology. It is unclear if changes in other alternative downstream rRAS 
pathways are associated with AD pathology.  
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Chapter 5. Alternative regulatory pathway of brain RAS (APA/Ang-





Hyperactivity of the brain cRAS is associated with AD pathogenesis. In addition to a common ACE-2 
mediated rRAS pathway, there are also additional alternative downstream pathways in RAS that have 
been identified in the brain, including the APA/Ang-III/APN/Ang-IV/IRAP axis, which is immediately 
downstream of Ang-II and is believed to regulate cerebral blood flow and has been implicated in 
memory and learning acquisition and synaptic plasticity. It has previously been shown that the 
upstream pathway of the alternative brain RAS axis (APA/Ang-III/APN) is dysregulated in AD in 
association with disease pathology. However, the involvement of the further downstream elements of 
this alternative regulatory RAS pathway (i.e. Ang-IV/IRAP) in relation to AD pathogenesis remains 
unclear. In this chapter, we investigated the expression and distribution of Ang-IV and the Ang-IV 
binding receptor, IRAP, in AD in a well-characterised cohort of post-mortem brains.  
 
Human post-mortem brain tissue was obtained from the SWDBB, University of Bristol, with local 
Research Ethics Committee approval. We studied mid-frontal cortex (Brodmann area 8/9) from AD 
cases (n= 70) and age-matched controls (n= 48) that were matched closely for age-at-death and PMD. 
The level of Ang-IV was measured by sandwich ELISA. The expression and distribution of IRAP was 
determined by sandwich ELISA and IHC. The enzyme activity of IRAP was also measured using an 
in-house developed catalytic activity assay. Pre-existing data on Braak tangle stage and pathological 
hallmarks (total insoluble Aβ, insoluble Aβ40 and Aβ42 and tau load) was also available for analysis. 
 
The levels of both Ang-IV and IRAP remained unchanged in AD whereas IRAP enzyme activity was 
significantly reduced in AD (p= 0.003). IRAP activity, which is arguably the most biological 
meaningful measure for this part of the pathway, was inversely correlated with total insoluble Aβ and 
tau load.  
 
In conclusion, my studies extend previous work on downstream alternative regulatory pathways of 
brain RAS in AD and show that they extend further through to the Ang-IV/IRAP (AT4R) elements of 




The brain RAS has a vital role in the pathophysiology of hypertension but is also involved in cognitive 
function and has been implicated in several neurodegenerative disorders of the CNS (255). As 
previously mentioned, the overall balance of this peptidergic system is reliant on the function of two 
main opposing axes: the cRAS (ACE-1/Ang-II/AT1R) and the rRAS (ACE-2/Ang (1-7)/MasR) (56, 
253). However, an additional regulatory pathway also exists that is downstream of where both cRAS 
and rRAS interact, which is the production or degradation of Ang-II. This pathway has been identified 
in the brain comprising the APA/Ang-III/ APN/Ang-IV/IRAP axis (457) (Figure 1.14). In short it is an 
additional or alternative mechanism to ACE-2 mediated regulation of Ang-II levels and through a 
series of sequential enzymatic steps can generate additional downstream Ang-II metabolites. There is 
already some evidence that dysregulation of the upper part of this axis (APA/Ang-III/ APN) is 
associated with AD pathology. Elevated Ang-III in AD was found in relation to increased APA 
activity and reduced APN activity and was strongly related to both Aβ and tau load (to a greater extent 
than had previously been found for Ang-II) (393).  
 
The APA/Ang-III/APN/Ang-IV/IRAP, rRAS pathway controls cerebral blood flow, modulates 
memory and learning acquisition. It also enhances synaptic plasticity and has neuroprotective effects in 
the CNS (458). These protective effects have largely been attributed to the active peptide, Ang-IV 
(270), which is produced from Ang-III by the action of APN. Ang-III is itself generated from Ang-II 
by APA and/or DAP cleavage (427). Thus, both APA and DAP perform a similar function to ACE-2 
in serving to lower Ang-II levels but produce different metabolites that in turn serve as different 
substrates for different receptors. Originally, Ang-IV was considered be an inactive small fragment of 
RAS, however, recent studies have shown that this hexapeptide regulates several physiological 
functions within the brain (528). What has given rise to some confusion and debate in the field is the 
discussion in relation to the identity of the Ang-IV specific binding site and effector receptor of Ang-
IV. Some groups have described this as the AT4R receptor whilst others have suggested it to be the 
insulin- regulated aminopeptidase (IRAP) (474, 496, 561). Some of the studies designed to define and 
characterise the AT4R binding site in the human brain showed that it was highly distributed in the 
cerebral cortex, hippocampus and claustrum (472) but also the similarities with those seen for IRAP 
led to the proposal that IRAP was AT4R (474). Yet, there still remains some controversy and debate 
because more recently, Ang-IV was also found to bind and activate c-Met - a type 1 tyrosine kinase 
receptor (499), the function of which in the brain still remains largely unknown.  
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Several previous studies have focused on the effect of Ang-IV on cognitive function, especially in 
learning and memory. Brazko et al. (482) demonstrated that enhanced memory following ICV 
administration of Ang-II was caused by the shorter (Ang-IV) peptide. ICV administration of Ang-IV 
into the lateral ventricle in non-diseased rats was also found to enhance spatial working memory in the 
plus maze spontaneous alteration task (479). In addition, ICV infusion of Ang-IV rapidly improved 
novel object recognition in a C57BL/6J mouse model that was dependent on AT4R expression (484). 
More recently, activation of Ang-IV/AT4R was found to restore Aβ-related cognitive deficit and 
cerebrovascular deficits in transgenic C57BL/6 mice overexpressing the human APP, carrying the 
Swedish and Indiana mutations (APP mice, J20 line) (493). A cerebroprotective role of Ang-IV/AT4R 
was shown to be associated with increased CBF through stimulation of NO production (458, 494, 495). 
Overall, these findings suggested that an Ang-IV/AT4R pathway was a potential target for improving 
cognitive decline and cerebrovascular deficits in AD. 
 
As mentioned, several studies identified IRAP as a specific binding site for Ang-IV and likely 
candidate for the AT4R (474, 496, 561). IRAP is a type II transmembrane protein and belongs to the 
M1 aminopeptidase family that includes two other homologous aminopeptidases including APA and 
APN (458). Localisation of both IRAP mRNA and IRAP protein were found in areas similar to the 
distribution of Ang-IV (AT4R) binding site in mouse brain (474). The highest distribution of IRAP was 
found in brain areas associated with cognitive functions such as prefrontal cortex, entorhinal cortex, 
hippocampus and amygdala (496). Notably IRAP was also found to co-localise with GLUT4, in the 
same vesicles in the pyramidal neurons of the hippocampus and was found to facilitate glucose intake 
in active neurons (497).  
 
Ang-IV has been reported to improve cognition by acting on two different receptors, IRAP and the c-
Met receptor. First, Ang-IV acts as an IRAP inhibitor by binding to and inactivating IRAP. Ang-IV-
mediated inhibition of IRAP catalytic activity, in turn prevents the degradation and prolongs the half-
life of neuropeptides that have also been implicated in learning and memory such as oxytocin, 
vasopressin, met-enkephalin and Ang-III that are normally cleaved by IRAP (498, 500). Second, Ang-
IV acts on the c-Met receptor and activates several signaling pathways that positively modulate 
synaptic plasticity and facilitate memory acquisition. These include: 
i) Ang-IV increases intracellular calcium and enhances NO synthase (495);  
ii) Ang-IV increases calcium entry via different calcium channels and enhances synaptic 
transmission and LTP (478, 510);  
iii) Ang-IV increases acetylcholine synthesis and release (511);  
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iv) Ang-IV stimulates dendritic growth in the hippocampus (512).  
  
Several animal studies have shown the beneficial effects of IRAP inhibitors (Ang-IV and LVV 
haemorphin-7) on cognitive function, especially spatial working memory (479, 500). In addition, other 
small molecule IRAP inhibitors (benzopyran compounds) have been developed to enhance learning 
and memory by increasing hippocampal dendritic spine density via a GLUT4 mediated mechanism in 
animal models (498, 502, 562-565). In a recent animal study, regional-specific IRAP knockout in the 
postnatal forebrain in mice resulted in a decline in spatial and object recognition memory (504).  
 
In related research, plasma activity of IRAP was studied and found to be significantly reduced in AD 
patients compared to controls and there was some evidence that the IRAP activity correlated with the 
MMSE result (258). These studies support the hypothesis that IRAP has a vital role in cognitive 
function but seem to contradict earlier findings. More recently, we showed that dysregulation of the 
upper part of this IRAP regulatory pathway was associated with Aβ and tau pathology (393). However, 
there is little data on the role of the Ang-IV/IRAP pathway in AD pathogenesis, whilst understanding 
of the behaviour of each of the components of the APA/Ang-III/APN/Ang-IV/IRAP pathway in AD 
remains poorly characterised, particularly in human post-mortem tissue in AD. 
 
 
5.3 Study aims and hypothesis 
 
The aims of the study described in this chapter were: 
 
 
(i)  To measure the level of Ang-IV and calculate the ratio of Ang-III:Ang-IV in mid-frontal 
cortex in AD in relation to disease pathology  
(ii)  To characterise the expression and distribution of IRAP in AD in relation to markers of 
disease pathology 
(iii)  To measure the catalytic activity of IRAP in AD and examine the relationship between IRAP 
activity and AD pathological hallmarks 
 
We wished to test the hypothesis that the lower downstream components of the alternative regulatory 
axis of brain RAS (Ang-IV/IRAP) are altered in mid-frontal cortex in AD and are associated with 
pathological markers of AD. 
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5.4 Methods  
 
5.4.1 Study cohort 
 
Human post-mortem brain tissue homogenates from mid-frontal cortex (Brodmann area 8/9) were used 
in this study and included a total of controls (n= 48) and AD cases (n= 70) for measurements of Ang-
IV level, IRAP level and IRAP activity. Demographic features of study cohort are described in the 
methods section (Table 2.1) or for full details (Appendix I: Table 9.1 and Table 9.2).  
 
Previous measurements of total insoluble Aβ by sandwich ELISA were available for controls (n= 28) 
and AD cases (n= 61) (545). Tau load was previously measured for all cases as part of routine 
assessment of AD cases within the SWDBB by field fraction analysis and was available for controls 
(n= 29) and AD cases (n= 89). Both insoluble Aβ40 and insoluble Aβ42 were previously measured by 
sandwich ELISA and were available for controls (n= 20) and AD cases (n= 33) for insoluble Aβ42, for 
controls (n= 20) and AD cases (n= 34) for insoluble Aβ40 (314). Ang-III level was previously 
measured by direct ELISA in mid-frontal cortex and available for controls (n= 31) and AD (n= 62) 
(393). All these previous measurements of AD pathological hallmarks and Ang-III level were included 
for analysis in this chapter. 
 
 
5.4.2 Ang-IV sandwich ELISA 
 
The level of Ang-IV in brain homogenates (1% SDS) from the mid-frontal cortex was measured using 
a quantitative commercially available sandwich ELISA (Human Angiotensin 4 (ANG4) ELISA kit) 
(MyBioSource) according to the manufacturer’s protocol (described in detail in chapter 2 section 
2.8.3). Ang-IV was measured in duplicate for each case. Carry-over samples were repeated across all 
plates to facilitate adjustment for plate-to-plate variation. Ang-IV measurements were adjusted to total 
protein level for each brain homogenate sample where indicated. The variation of this assay was 





5.4.3 Expression of IRAP in human brain tissue 
 
5.4.3.1 Western blot detection of IRAP in human post-mortem samples 
 
The standard protocol for western blotting used in this study is as described in detail in chapter 2 
(section 2.4). Details of the primary and secondary antibodies used are described in chapter 9 
(Appendix II: Table 9.13) and (Table 9.14) respectively. In summary, for detection of IRAP in brain 
homogenate samples, the membrane was blocked in 10% milk/TBST buffer for 1 hour. After it had 
been washed with 0.05% TBST (3x 15 minutes) at room temperature on a shaker, the membrane was 
incubated with anti-LNPEP (an alias for IRAP) antibody (aa 1-50, IHC-plus) diluted 1:2000 in 5% 
milk/TBST antibody buffer overnight at 4°C (in the fridge) on a shaker. Following a wash step with 
0.05% TBST (3x 15 minutes) at room temperature on a shaker, the membrane was incubated with 
secondary antibody (peroxidase conjugated anti-rabbit) diluted 1:5000 in 5% milk/TBST for 1 hour. 
After 3x 15 minutes wash steps with 0.05% TBST, A chemiluminescent HRP substrate (ECL) 
(Millipore) was added to the membrane in a 1:1 ratio (5 ml of reagent 1 and 5 ml of reagent 2) for 5 
minutes. The images then were acquired using (ChemiDoc XRS+, Bio-RAD) and Image Lab software, 
version 5.0 (Bio-RAD). 	
 
 
5.4.3.2 Immunohistochemistry of IRAP in formalin-fixed paraffin-embedded tissue sections 
 
The anti-LNPEP antibody ((aa 1-50) IHC-plus (LS-B12918)) was further tested by 
immunohistochemistry to detect and examine the distribution of IRAP in formalin-fixed brain tissue. A 
standard immunohistochemical staining protocol was used as described in detail in the chapter 2 
(section 2.5). The immunohistochemical staining procedure was initially optimised by comparing 
antigen retrieval pre-treatment steps with either EDTA or citrate buffer and testing a range of dilutions 
of the primary antibody (1:100, 1:200, 1:500). The best assay conditions for IRAP staining were 
achieved when slides were pre-treated with citrate buffer and boiled in microwave for 10 minutes. 
After washing with running water for 5 min, slides were incubated with blocking serum for 20 minutes 
then incubated with the primary antibody (Anti-LNPEP antibody (aa 1-50) IHC-plus (LS-B12918)) 
diluted 1:200 in PBS (5 µg/ml) overnight. After rinsing the sections in two changes of PBS for 3 
minutes each, the sections were incubated with Vectastain biotinylated universal secondary antibody 
for 20 minutes followed by another wash with PBS and then VectaElite ABC complex for 20 minutes, 
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rinsed again and incubated with DAB for 10 minutes, then washed in running water for 10 minutes and 
immersed in copper sulphate solution for 4 minutes, followed by washing in running water for 5 
minutes. The sections were then counterstained with haematoxylin Gill II for 3 seconds, dehydrated, 
cleared and mounted.   
 
5.4.4 IRAP sandwich ELISA 
 
The level of IRAP in brain homogenates from the mid-frontal cortex was measured using a 
quantitative commercially available sandwich ELISA (Human Leucyl/Cystinyl aminopeptidase 
(LNPEP) ELISA Kit) (Cloud-Clone Corp.), according to the method described previously in chapter 2 
(section 2.8.4). Unlike the anti-LNPEP (aa 1-50) IHC-plus (LS-B12918) used in IHC, the immunogen 
characteristic of anti-LNPEP in this kit was unspecified. Optimisation stepts to select appropriate 
homogenate dilutions are described in chapter 9 (Appendix II: Section 9.2.3.1). Brain homogenate 
samples were assayed in duplicate and four carry-over samples were repeated across all plates. The 
variation of this assay was determined by calculating the intra-assay CV% (Example in Appendix IV: 
Table 9.31).   
 
5.4.5 IRAP activity assay 
 
IRAP activity was measured in brain homogenates from mid-frontal cortex prepared as previously 
described (chapter 2, section 2.2.2). Brain homogenates used in this experiment were homogenised in 
0.5% Triton X-100 buffer. This homogenisation method is also described in chapter 2 (section 2.10). 
All samples were measured in duplicate, whilst four carry-over samples were repeated in each plate. 
The variation between measurements was determined by calculating the intra-assay coefficient of 
variation (CV%) (Appendix IV: Table 9.32). 
 
Preliminary experiments were performed to optimise the use of IRAP substrate L-Leucine-p-
nitroanilide (L-Leu-pNA) (Sigma-Aldrich) in human brain tissue homogenates. The optimal 
concentration of the colorimetric substrate was first determined by testing 10-fold serial dilutions of 
the substrate ranging from (25- 25×10-6 mg/ml) on brain homogenates diluted 1:40 in assay buffer 
(0.05 M Tris, 0.14 M NaCl, pH 7.4) (Appendix II: Figure 9.8 A). Next, the optimal substrate dilution 
was tested by adding serial dilutions of the substrate ranging from (125-1.95 mg/ml) on brain 
homogenates diluted 1:40 in assay buffer (0.05 M Tris, 0.14 M NaCl, pH 7.4) (Appendix II: Figure 9.8 
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B). The optimal substrate concentration was chosen and tested on two different homogenate dilutions 
(1:10 and 1:20). Also, the effect of incubation length (1 hour, 2 hours and overnight) was determined. 
(Appendix II: Figure 9.9). Optimal conditions were achieved when the substrate L-Leu-pNA stock 
(1mM) was diluted (1:16), the homogenate was diluted (1:20) and the reaction proceeded overnight at 
4°C. These conditions were used in all subsequent experiments. Enzyme activity was expressed as 
relative absorbance units (OD).  
 
5.4.6 Statistical analysis 
 
The Shapiro-Wilk normality test was applied to test the normal distribution of all datasets. A 
significant p value, p < 0.05 was used to indicate if the individual data sets were not normally 
distributed. Ang-IV and protein-adjusted Ang-IV data were not normally distributed. Both log 
transformed and square-root transformed data did not pass the normality test and therefore a non–
parametric Mann-Whitney test, was used for both Ang-IV and protein-adjusted Ang-IV data when 
comparing between AD cases and controls. Comparison of the total Ang-IV level and Ang-IV protein-
adjusted data between Braak tangle stage groups (Braak stage 0-II, Braak stage III-IV, Braak stage V-
VI) was performed with the non-parametric Kruskal-Wallis test. Correlations between total Ang-IV 
level and protein-adjusted Ang-IV with total insoluble Aβ, tau load, insoluble Aβ40 and insoluble 
Aβ42 were assessed using Spearman’s correlation coefficient analysis. The Ang-III-Ang-IV ratio data 
were not normally distributed and comparison of the Ang-III-Ang-IV ratio in controls and AD was 
tested using a non-parametric test, Mann-Whitney test.  
 
IRAP level and protein-adjusted IRAP data were similarly not normally distributed. A non–parametric 
test, Mann-Whitney test, was performed to compare both IRAP and protein-adjusted IRAP between 
AD cases and controls. Comparison of the IRAP level and protein-adjusted IRAP data between Braak 
tangle stage groups (Braak stage 0-II, Braak stage III-IV, Braak stage V-VI) was performed using a 
non-parametric Kruskal-Wallis test. Correlations between IRAP level and protein-adjusted data with 
total insoluble Aβ, tau load, insoluble Aβ40 and insoluble Aβ42 were assessed using the Spearman’s 
correlation coefficient. Log transformation for unadjusted and protein-adjusted data was performed to 
attempt to reach normal distribution. In this case, the transformed data was normally distributed and 
unpaired samples t-test was used for log transformed unadjusted and protein-adjusted data to compare 
between AD cases and controls. The transformed data is presented separately in chapter 9 (Appendix 
VI: Section 9.6.3.1). 
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IRAP activity data was not normally distributed. A non–parametric test, Mann-Whitney test was 
performed to compare between AD cases and controls. Comparison of the IRAP activity data between 
Braak tangle stage groups (Braak stage 0-II, Braak stage III-IV, Braak stage V-VI) was performed 
using a non-parametric Kruskal-Wallis test. Correlations between IRAP activity with total insoluble 
Aβ, tau load, insoluble Aβ40 and insoluble Aβ42 were assessed using the Spearman’s correlation 
coefficient. Square-rooted transformation for IRAP activity data was shown to normalise the data. 
Unpaired samples t-test was used for transformed IRAP activity data to compare between AD cases 
and controls. A One-Way ANOVA test was performed to compare transformed IRAP activity data 
between Braak tangle stage groups. Correlations between transformed IRAP activity data and total 
insoluble Aβ, tau load, insoluble Aβ40 and insoluble Aβ42 were assessed by the Pearson’s correlation 
coefficient. Analysis of the transformed data is presented in chapter 9 (Appendix VI: Section 9.6.3.2). 





5.5.1 Comparison of Ang-IV level in controls and AD 
 
Ang-IV and protein-adjusted Ang-IV levels were unchanged between AD cases (n= 70) and controls 
(n= 48) (Figure 5.1 A and B). The median for Ang-IV level was lower in controls (21.71 pg/ml) than 
AD (26.55 pg/ml) but the Mann-Whitney test showed no statistical significance between groups (p= 
0.501). The median for Ang-IV protein-adjusted data did not differ between AD cases (130.5 pg/mg 
total protein) compared to controls (150.6 pg/mg total protein). A Mann-Whitney test showed no 




Figure 5.1 Angiotensin-IV level in mid-frontal cortex in Alzheimer’s disease (AD).  
A. Bar chart showing Ang-IV level is unchanged in AD (n= 70) compared with age-matched control 
(n= 48) in mid-frontal cortex measured using an Ang-IV sandwich ELISA, Mann-Whitney test (p= 
0.501). The bars indicate the median and 95% confidence intervals. B. Bar chart showing protein-
adjusted Ang-IV level did not differ in the AD group (n= 70) compared to age-matched group (n= 48), 
Mann-Whitney test (p= 0.744). The bars indicate the median and 95% confidence intervals.  
 
 
5.5.1.2 Ang-IV level in relation to disease severity  
 
The total Ang-IV level and Ang-IV protein-adjusted level were assessed in relation to Braak tangle 
stage (Braak stage 0-II (n= 36), Braak stage III-IV (n= 20), Braak stage V-VI (n= 61)). Kruskal-Wallis 
test indicated no significant difference of the total Ang-IV medians between Braak stage groups (p= 
0.499) (Figure 5.2 A). The median of Braak stage 0-II= 29.176(pg/ml), Braak stage III-IV= 20.064 
(pg/ml) Braak stage V-VI= 26.933(pg/ml). The medians of Ang-IV protein-adjusted level were 
unchanged between Braak stages. The median of Braak stage 0-II= 163.235 (pg/mg total protein), 
Braak stage III-IV= 130.487 (pg/mg total protein) Braak stage V-VI= 135.459 (pg/mg total protein) 



















































Figure 5.2 Angiotensin-IV level in relation to Braak tangle stage. 
A. Bar chart showing no significant difference for total Ang-IV level measured by sandwich ELISA 
between Braak tangle stage groups (Braak stage 0-II (n= 36), Braak stage III-IV (n= 20), Braak stage 
V-VI (n= 61)), Kruskal-Wallis test (p= 0.499). The bars indicate the median and 95% confidence 
intervals. B. Bar chart showing Ang-IV protein-adjusted level was unchanged between Braak tangle 
stages groups (Braak stage 0-II (n= 36), Braak stage III-IV (n= 20), Braak stage V-VI (n= 61)), 
Kruskal-Wallis test (p= 0.577). The bars indicate the median and 95% confidence intervals.  
 
5.5.1.3 Relationship between Ang-IV level and AD pathology hallmarks 
 
No significant correlation was found between total Ang-IV level and total insoluble Aβ (Spearman’s 
correlation coefficient r= 0.034, p= 0.746) and between Ang-IV protein-adjusted level and total 
insoluble Aβ (Spearman’s correlation coefficient r= 0.065, p= 0.536) (Figure 5.3 A and B). Similarly, 
no correlation was seen between both total Ang-IV level and tau load (Spearman’s correlation 
coefficient r= 0.087, p= 0.388) and between Ang-IV protein-adjusted level and tau load (Spearman’s 

























































Figure 5.3 Relationships between Angiotensin-IV level and total insoluble Aβ and tau load.  
A and B. Scatterplots showing no correlation between total Ang-IV level and Ang-IV protein-adjusted 
level and total insoluble Aβ (measured by enzyme-linked immunosorbent assay), Spearman’s 
correlation coefficient (r= 0.034, p= 0.746) and (r= 0.065, p= 0.536).  C and D. Scatterplots showing 
no significant correlation between total Ang-IV and Ang-IV protein-adjusted level and tau load 
(measured by field fraction analysis), Spearman’s correlation coefficient (r= 0.087, p= 0.388) and (r= 
0.085, p= 0.399). The solid inner line indicates the best-fit linear regression and the outer lines the 
95% confidence intervals. Blue dots= controls, red dots= AD cases. 
 
 
No significant correlations were observed between total Ang-IV level and both insoluble Aβ40 
(Spearman’s correlation coefficient r= -0.110, p= 0.419) and Aβ42 (Spearman’s correlation coefficient 
r= -0.189, p= 0.167) (Figure 5.4 A and C). Ang-IV protein-adjusted level was not correlated with 
either insoluble Aβ40 (Spearman’s correlation coefficient r= -0.197, p= 0.146) and Aβ42 (Spearman’s 
correlation coefficient r= -0.203, p= 0.136) (Figure 5.4 B and D). 
 
 


























































































Figure 5.4 Relationship between Angiotensin-IV level and insoluble Aβ40 and insoluble Aβ42.  
A and C. Scatterplots showing no correlation between total Ang-IV level and both insoluble Aβ40 
(measured by enzyme-linked immunosorbent assay), Spearman’s correlation coefficient (r= -0.110, p= 
0.419), and insoluble Aβ42, Spearman’s correlation coefficient (r= -0.189, p = 0.167). B and D. 
Scatterplots showing no significant correlation between Ang-IV protein-adjusted level and both 
insoluble Aβ40, Spearman’s correlation coefficient (r= -0.197, p= 0.146) and insoluble Aβ42, 
Spearman’s correlation coefficient (r= -0.203, p= 0.136). The solid inner line indicates the best-fit 




5.5.1.7 The Ang-III:Ang-IV ratio is unchanged in AD 
 
The Ang-III:Ang-IV ratio can be viewed as a possible proxy marker for APN enzyme activity 
(responsible for the production of Ang-IV from Ang-III) in the Ang-III/APN/Ang-IV/IRAP pathway. 
Ang-III level was previously measured by direct ELISA in mid-frontal cortex of controls (n= 31) and 
AD (n= 62) and was shown to be significantly increased in AD (393). The median for Ang-III:Ang-IV 
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ratio was numerically slightly higher in AD cases (= 549.4) compared to the median of controls (= 
370.5), suggestive of reduced APN enzyme activity, however, a Mann-Whitney test showed no 




Figure 5.5 The ratio of Angiotensin-III:Angiotensin-IV in mid-frontal cortex in Alzheimer’s 
disease (AD).  
Bar chart showing the Ang-III:Ang-IV ratio in AD (n= 62) compared to age-matched controls (n= 31) 
in the mid-frontal cortex. Mann-Whitney test showed no significant difference between groups (p= 

























5.5.2 Expression of IRAP in human brain tissue  
 
The specificity of the IRAP antibody (anti-LNPEP antibody (aa 1-50) IHC-plus (LS-B12918)), used 
for immunohistochemical staining to examine the distribution of IRAP in mid-frontal cortex, was first 
tested by western blot. This polyclonal antibody is raised against specific region between residue 1 to 
50 of human LNPEP using the portion of GeneID: 4012. Randomly chosen samples from four AD and 
four control homogenates were used for this experiment. Details of the chosen samples are described 
in chapter 9 (Appendix I: Table 9.6). The western blot shown below in (Figure 5.6) shows distinct 
bands at the expected MW150 kDa. There was no obvious difference in the expression of IRAP in AD 
and controls. Volumetric analysis, using Image Lab software, version 5.0 (Bio-RAD) revealed that the 




Figure 5.6 Insulin-regulated aminopeptidase (IRAP) expression determined by western blot in 
human post-mortem brain tissue homogenates. 
IRAP expression in human brain tissue in controls (lanes 2-5) and AD cases (lanes 7-10). Lanes (1 and 
6) include MW markers. The membrane was blotted with polyclonal rabbit antibody to IRAP (Anti-






5.5.2.2 Immunolabelling of IRAP in human brain tissue  
 
IRAP labelling was predominantly neuronal in all studied sections of control, AD and VaD cases. 
Positive IRAP staining was mainly observed in pyramidal neurons with strong staining of dendrites 
(See Figure 5.7 B from an indicative AD case). There was no obvious observed difference in the level 
of IRAP staining between controls and VaD/AD cases, although we did not perform quantitative 
analysis because the number of sections studied was small and intended for a qualitative examination 




Figure 5.7 Immunolabelling of IRAP in the mid-frontal cortex. 
IRAP labelling in brain sections from a control case (A), AD case (B) and vascular case (C) showed 
IRAP was mainly expressed in parenchymal neurons. In B. IRAP was present mainly in pyramidal 
neurons and dentrites (indicated by the arrow) (Images taken at 10x magnification). 
 
 
5.5.3 Measurement of IRAP level by ELISA in controls and AD  
 
IRAP level was not significantly different between AD cases (n= 70) and controls (n= 48) (Figure 5.8 
A). The median for IRAP level was - controls= 12.26 (ng/ml) and AD= 11.46 (ng/ml). The data was 
not normally distributed so a Mann-Whitney test was performed but showed no statistical significance 
between groups (p= 0.997).  The IRAP protein-adjusted level was similarly unchanged in AD cases 
compared to controls. Again, these data were not normally distributed. The median for IRAP protein-
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adjusted level was - controls= 20.09 (ng/ml) and AD= 23.33 (ng/ml). Mann-Whitney test showed no 
statistical significance between groups (p= 0.405) (Figure 5.8 B).  
 
 
Figure 5.8 Measurement of IRAP level between controls and AD cases.  
A. Bar chart showing IRAP level was unchanged in AD (n= 70) compared with age-matched control 
(n= 48) in mid-frontal cortex measured using an IRAP sandwich ELISA, Mann-Whitney test (p= 
0.997). The bars indicate the median and 95% confidence intervals. B. Bar chart showing protein-
adjusted IRAP level did not differ in AD group compared to age-matched group, Mann-Whitney test 
(p= 0.405). The bars indicate the median and 95% confidence intervals. 
 
 
5.5.3.2 IRAP level in relation to disease severity 
 
Both IRAP level unadjusted to protein concentration and protein-adjusted level were assessed in 
relation to Braak tangle stage (0-II (n= 36), III-IV (n= 20), V-VI (n= 61)). As for IRAP level, both 
datasets were not normally distributed. A Kruskal-Wallis test found no significant difference of the 
unadjusted IRAP medians between Braak stage groups (p= 0.885) (Figure 5.9 A). The median IRAP 
level in Braak stage 0-II= 11.757 (ng/ml), Braak stage III-IV= 12.524 (ng/ml) and Braak stage V-VI= 
11.537 (ng/ml). The medians of IRAP protein-adjusted level were similarly unchanged between all 
Braak stages (p= 0.675). The median for Braak stage 0-II= 18.377 (ng/mg total protein), Braak stage 



















































Figure 5.9 IRAP level in relation to Braak tangle stage. 
A. Bar chart showing no significant difference for unadjusted IRAP level measured by sandwich 
ELISA assay and between Braak tangle staged groups (Braak stage 0-II (n= 36), Braak stage III-IV 
(n= 20), Braak stage V-VI (n= 61)), Kruskal-Wallis test (p= 0.885). The bars indicate the median and 
95% confidence intervals. B. Bar chart showing IRAP protein-adjusted level was unchanged between 
Braak tangle staged groups (Braak stage 0-II (n= 36), Braak stage III-IV (n= 20), Braak stage V-VI 
(n= 61)), Kruskal-Wallis test (p= 0.675). The bars indicate the median and 95% confidence intervals.  
 
 
5.5.3.3 Relationship between IRAP level and Aβ and Tau level   
 
No significant correlation was found between unadjusted IRAP level and total insoluble Aβ 
(Spearman’s correlation coefficient r= -0.087, p= 0.412) (Figure 5.10 A). IRAP protein-adjusted level 
similarly did not correlate with total insoluble Aβ in mid-frontal cortex, (Spearman’s correlation 
coefficient r= -0.081, p= 0.445) (Figure 5.10 B). Similarly there was no correlation between 
unadjusted IRAP level (Spearman’s correlation coefficient r= 0.023, p= 0.831) (Figure 5.10 C) or 
IRAP protein-adjusted level (Spearman’s correlation coefficient r= 0.127, p= 0.207) (Figure 5.10 D) 





















































Figure 5.10 Relationships between IRAP level and total insoluble Aβ and tau load.  
A and C. Scatterplots showing no correlation between unadjusted IRAP level and both total insoluble 
Aβ (measured by enzyme-linked immunosorbent assay), Spearman’s correlation coefficient (r= -0.087, 
p= 0.412) and tau load (measured by field fraction analysis), Spearman’s correlation coefficient (r= 
0.023, p= 0.831). B and D. No significant correlation was found between IRAP protein-adjusted level 
and both total insoluble Aβ, Spearman’s correlation coefficient (r= -0.081, p= 0.445) and tau load 
Spearman’s correlation coefficient (r= 0.127, p= 0.207). The solid inner line indicates the best-fit 




Next we examined IRAP levels and Aβ40 and Aβ42. First, there were no significant correlations 
observed between unadjusted IRAP level and both insoluble Aβ40 (r= -0.055, p= 0.685) and Aβ42 
(Spearman’s correlation coefficient r= 0.069, p= 0.616) (Figure 5.11 A and C). Similarly, IRAP 
protein-adjusted level also did not correlate with either insoluble Aβ40 (r=0.186, p= 0.169) or Aβ42 
(r= 0.206, p= 0.131) in mid-frontal cortex using Spearman’s correlation coefficient test (Figure 5.11 B 
and D). 
 





























































































Figure 5.11 Relationship between IRAP level and insoluble Aβ40 and insoluble Aβ42.  
A and C. Scatterplots showing no correlation between IRAP level and both insoluble Aβ40 (measured 
by enzyme-linked immunosorbent assay), Spearman’s correlation coefficient (r= 0.055, p= 0.685), and 
insoluble Aβ42 (r= 0.069, p= 0.616). B and D. No significant correlation was found between IRAP 
protein-adjusted level and both insoluble Aβ40, Spearman’s correlation coefficient (r= 0.186, p= 
0.169) and insoluble Aβ42, Spearman’s correlation coefficient (r= 0.206, p= 0.131). The solid inner 
line indicates the best-fit linear regression and the outer lines the 95% confidence intervals. Blue dots 
= controls, red dots = AD cases. 
 
 
5.5.4 Comparison of IRAP activity in controls and AD 
 
In mid-frontal cortex, IRAP enzyme activity was measured in AD (n= 70) and age-matched controls 
(n= 48). IRAP activity was found to be significantly reduced in AD cases compared to controls by 
28.5%. A Mann-Whitney test revealed that the median OD for IRAP activity in AD cases (= 0.5623  
(relative absorbance units (Abs))) was significantly lower than in controls (= 0.7863 (Abs)) (p= 0.003) 
(Figure 5.12 A).  
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Figure 5.12 Reduction in IRAP enzyme activity in Alzheimer’s disease. 
Bar chart showing reduced IRAP enzyme activity in AD (n= 70) compared to age-matched controls 
(n= 48) in mid-frontal cortex measured using an in-house IRAP activity assay. Mann-Whitney test 




5.5.4.1 IRAP enzyme activity in relation to disease severity 
 
IRAP enzyme activity was also assessed in relation to Braak tangle stage (0-II (n= 36), III-IV (n= 20), 
V-VI (n= 61)). Kruskal-Wallis test revealed a significant difference of the median between all groups 
(p= 0.008). Furthermore, a significant reduction of IRAP activity was observed in end-stage severe AD 
cases (Braak stages (V-VI)) compared to controls Braak stages (0-II) (p= 0.034) and earlier (less 



























Figure 5.13 IRAP activity in relation to Braak tangle stage. 
Bar chart showing a significant difference in IRAP activity between all groups (Braak stage 0-II (n= 
36), Braak stage III-IV (n= 20), Braak stage V-VI (n= 61)) when analysed with Kruskal-Wallis test (p= 
0.008). IRAP activity was found to be significantly lower in cases with higher Braak stage (V-VI) 
compared with cases in Braak stage (0-II) (post-hoc Dunn’s multiple comparisons test, p= 0.034) and 
Braak stage (III-IV) (post-hoc Dunn’s multiple comparisons test, p= 0.024) and. The bars indicate the 
median and 95% confidence intervals.  
 
 
5.5.4.2 Relationship between IRAP enzyme activity and Aβ and Tau  
 
Spearman’s correlation coefficient test revealed a significant inverse correlation between IRAP 
enzyme activity with both total insoluble Aβ (r= -0.311, p= 0.003) (Figure 5.14 A) and tau load in 
mid-frontal cortex (r= -0.297, p= 0.003) (Figure 5.14 B). Spearman’s correlation coefficient similarly 
revealed a significant inverse correlation between IRAP activity and insoluble Aβ40 (r= -0.312, p= 
0.019) (Figure 5.14 C) but no significant correlation between IRAP activity and insoluble Aβ42 (r= -


























Figure 5.14 Relationships between IRAP enzyme activity and total insoluble Aβ, tau load, 
insoluble Aβ40 and insoluble Aβ42.  
A. Scatterplot showing a significant inverse correlation between IRAP activity and total insoluble Aβ 
(measured by enzyme-linked immunosorbent assay), Spearman’s correlation coefficient (r= -0.311, p= 
0.003). B. Scatterplot showing a significant inverse correlation between IRAP activity and tau load 
(measured by field fraction analysis), Spearman’s correlation coefficient (r= -0.297, p= 0.003). C. 
Scatterplot showing a significant inverse correlation between IRAP activity and insoluble Aβ40 
(measured by enzyme-linked immunosorbent assay), Spearman’s correlation coefficient (r= -0.312, p= 
0.019). D. Scatterplot showing no correlation between IRAP activity and insoluble Aβ42 (measured by 
enzyme-linked immunosorbent assay), Spearman’s correlation coefficient (r= -0.164, p= 0.229). The 
solid inner line indicates the best-fit linear regression and the outer lines the 95% confidence intervals. 


















































































5.5.4.3 Relationships between IRAP enzyme activity and confounding factors 
 
Given the association between IRAP activity and variables associated with AD, we also explored and 
tested for relationships with confounding factors including age-at-death, gender, PMD and APOE 
genotype. On investigation no correlation between IRAP enzyme activity (either untransformed or 
square-root transformed) with age-at-death, PMD or gender (Appendix V: Table 9.37) was found. 
There was no difference in IRAP activity depending on the presence or absence of APOE ε4 allele 
(Appendix V: Table 9.38). 
 
 
5.6 Discussion  
 
This chapter explored changes in the main components of the downstream alternative pathway of brain 
rRAS (APA/Ang-III/APN/Ang-IV/IRAP) in relation to AD pathogenesis. In this chapter, we found 
that Ang-IV and IRAP protein expression within the mid-frontal cortex, the latter being predominantly 
expressed in pyramidal neurons, were unchanged in AD. In contrast, IRAP enzyme activity, arguably 
the most biologically relevant indicator, was reduced in AD in association with disease severity and 
Aβ and tau load. These data suggest that dysregulated IRAP activity in AD could contribute to disease 
pathogenesis.     
 
Dysregulation of the upstream pathway of the alternative RAS axis (APA/Ang-III/APN/Ang-IV/IRAP) 
has previously been reported and is associated with AD pathogenesis. A previous study showed that 
increased Ang-III was strongly related to Aβ load and tau load, much more so than Ang-II. 
Furthermore, increased Ang-III level in AD was associated with increased APA activity (responsible 
for conversion of Ang-II to Ang-III) and reduced APN activity (responsible for conversion of Ang-III 
to Ang-IV). These data viewed together indicate that dysregulation within this major regulatory rRAS 
pathway was strongly associated with disease pathology in AD (393). I wanted to extend these 
findings with further investigations to characterise the expression of the components further 
downstream of Ang-III i.e. Ang-IV and IRAP, which both remained poorly characterised in human 
brain tissue in AD at the time of undertaking this work.  
 
Despite observed changes in Ang-III and APA and APN (393) we did not find a change in Ang-IV 
expression in AD. This is the first study, to our knowledge, to characterise Ang-IV expression in 
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human post-mortem brain tissue from AD patients and compared with aged-matched controls. As 
such, and to provide greater confidence in my findings, it will be necessary to repeat these studies in 
different, preferably larger, indpendent studies. 
 
Immunohistochemical staining was performed to qualitatively assess the expression and distribution of 
IRAP in the brain tissue of AD patients and controls. Immunolabelling revealed positive staining of 
pyramidal neurons and dendrites in the mid-frontal cortex. This is consistent with previous studies that 
reported IRAP expression was mainly restricted to neurons in the cortex, hippocampus and basal 
ganglia (425, 472). A few studies in rodent brain, however, reported positive IRAP staining within 
astrocytes (504, 566). Although I did not specifically perform co-labeling to identify astrocytes, based 
on morphology, we did not observe obvious positive staining of IRAP in non-neuronal cells. IRAP 
immunostaining did not appear to be different between control, AD and VaD cases. This was in 
agreement with the ELISA measurements of IRAP in a larger dataset that also found no change in the 
IRAP level in AD.  
 
In contrast, IRAP enzyme activity was reduced in AD associated with disease severity and inversely 
correlated with Aβ load, tau load and insoluble Aβ40 level. These novel and interesting observations 
could indicate that IRAP – the terminal effector receptor of the rRAS pathway may contribute to 
disease pathology in AD. These findings are in keeping with a previous study that reported a reduction 
of IRAP activity in the plasma of AD patients (258). In contrast, a study of Gard et al. (464) reported 
no difference in serum IRAP activity in patients with early stage AD. These apparent differences in 
IRAP activity in AD might reflect differences in the tissue studied (e.g. brain versus serum versus 
plasma) or stage of disease, or possibly differences in the methodological approach (fluorogeneic or 
colorometric) used to measure IRAP activity. Together, these studies indicate possible disruption of 
IRAP activity within the CNS and periphery in AD that need to be evaluated and confirmed in larger 
independent studies. 
 
A reduction of IRAP activity in our study is incongruent with previous studies in animal models that 
have found protective effects of IRAP inhibitors against cognitive decline (474, 479, 484, 493). These 
studies suggest that loss of IRAP activity is likely to be protective in AD possibly suggestive that loss 
of IRAP is a compensatory response as AD progresses. Yet, not all studies support these earlier 
findings. In a recent animal study, IRAP knockout in the postnatal forebrain in mice resulted in a 
decline in spatial and object recognition memory (504). In accordance, plasma activity of IRAP has 
also been found to be significantly reduced in AD patients and correlated with the MMSE result (258). 
	 155 
In AD, reduction in IRAP activity (and reduced formation of Ang-IV) may minimise the effect of the 
intrinsic negative feedback mechanism of IRAP on Ang-III and thus result in maintenance of higher 
Ang-III levels that contribute to AD pathogenesis. 
 
The colocalisation of IRAP and GLUT4 in glucose storage vesicles in the hippocampus could explain 
the cognitive enhancing role of IRAP by increasing neuronal glucose entry through inhibition of 
intracellular trafficking of GLUT4 and maintaining the presence of GLUT4 on the plasma membrane 
(497). Reduction in IRAP activity in AD could feasibly minimise the inhibition on the intracellular 
trafficking of GLUT4 and result in decrease GLUT4 translocation at the plasma membrane which in 
turn could decrease neuronal glucose entry and impair cognition. Neuronal glucose entry is a 
requirement for cognitive enhancement by hippocampal Ang-IV (567). An in vivo study found that 
intrahippocampal administration of Aβ42 in rats impaired spatial working memory through reduced 
plasma membrane translocation of GLUT4 (568). Together these findings strongly support a key role 
of IRAP/GLUT4 on cognitive function that requires further study. 
  
Possible weaknesses of the current study include the potential unknown effect of a PMD on the level 
of endogenous Ang-IV and IRAP. Ang-IV, for example, has a short half-life in serum/plasma (528), 
yet, as for other peptides, such as Ang-II and endothelin-1, we were able to measure it in brain tissue 
(393, 569). Although we found no evidence that Ang-IV and IRAP levels were related to PMD it 
would be important to confirm the stability of the peptide and receptor in brain tissue by performing 
post-mortem simulated studies (354). Another possible limitation of our study was that measurement 
of these RAS markers was restricted to one brain tissue region (mid-frontal cortex). It would be of 
interest to explore the distribution of Ang-IV/IRAP in the temporal cortex and hippocampus of AD 
patients, especially since studies in rodents indicate that IRAP, and Ang-IV, are highly enriched within 
the hippocampus.  As well as AD, it would be interesting to know if this rRAS pathway, and especially 
IRAP activity, was dysregulated in other types of dementia.  
 
Future studies should focus on confirming that Ang-IV level remains unchanged in AD by other 
methodologies and in different brain regions in independent cohorts. In addition, it would be 
informative to measure the level of other less-abundant angiotensin metabolites such as Angiotensin 3-
7 in AD, which has also been shown to have high affinity for IRAP and has been implicated in 
learning and memory (570, 571). It would also be interesting to determine whether dysregulation in 
IRAP is restricted to enzyme activity in AD by measuring IRAP mRNA level that might be expected 
to be similarly unchanged as was found for IRAP levels. The measurement of IRAP activity by using 
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other substrates (e.g. fluorometric substrate) to provide supportive trends of change would also be 
worthwhile. The apparent divergence between unchanged IRAP level and reduced IRAP activity in our 
study might also be related to post-translational modification of IRAP that warrants future study. S-
acylation, a type of post-translational modification of protein, has been shown to regulate IRAP and to 
a lesser degree affect intracellular trafficking of GLUT4 in rat brain (572). Further studies could also 
explore alternative rRAS pathways and receptors e.g. HGF/c-MET receptor in human post-mortem 
tissue in AD, since Ang-IV facilitates memory by activation of c-MET receptor via several signalling 
pathways (495, 510, 512).  
 
In conclusion, my findings provide novel evidence of reduced catalytic activity of IRAP in AD 
associated with pathological hallmarks of disease pathogenesis that warrant further study.  
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Chapter 6. Alternative regulatory RAS pathways in relation to markers 





Overactivity of the brain cRAS is associated with neurogenic hypertension and neurodegenerative 
disorders including AD and is associated with an imbalance in the brain RAS as a result of cRAS 
overactivity and underactivity of rRAS pathways. Brain rRAS pathways are composed of two main 
axes: the non-classical axis (ACE-2/Ang (1-7)/MasR) and the alternative (APN/Ang-IV/IRAP) 
pathway. These pathways counter-regulate cRAS signalling and dysregulation of the rRAS has been 
implicated in neurodegenerative and cerebrovascular disorders. Despite the obvious importance of 
rRAS in potentially reducing disease pathology, and the direct involvement and potential contribution 
of rRAS pathways in learning and memory, there is very little information about the dysregulation of 
these two protective arms of brain RAS in relation to disease pathology (Aβ and Tau) and similarly in 
relation to markers of hypoperfusion and ischaemia in AD. Previous chapters discussed the exploration 
of the relationship between rRAS pathways and classical neuropathological hallmarks of AD. In this 
chapter, I investigate the relationship between the major angiotensins and related receptors in brain 
rRAS pathways in AD in relation with markers of cerebral hypoperfusion and ischaemia: VEGF that is 
increased in relation to ischaemia, and MAG:PLP1 ratio that is reduced in poorly perfused tissue and is 
reduced in AD.  
 
Human post-mortem brain tissue was obtained from the SWDBB, University of Bristol, with local 
Research Ethics Committee approval. We studied mid-frontal cortex (Brodmann area 8/9) from AD 
cases (n= 35) and age-matched controls (n= 17) that were matched closely for age-at-death and PMD. 
The level of VEGF was determined by sandwich ELISA. Pre-existing data on MAG level was 
available and PLP1 level was measured by sandwich ELISA allowing the MAG:PLP1 ratio to be 
calculated for all cases. Existing brain RAS markers (Ang (1-7), MasR, Ang-IV and IRAP level and 
activity) were available for analysis.  
 
  
We found that MasR reduction in AD correlated with two independent markers of reduced 
oxygenation of brain tissue i.e. MasR was negatively associated with VEGF and positively associated 
with the ratio of MAG:PLP1. In contrast, no correlations were found between Ang (1-7) level and both 
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VEGF and MAG:PLP1 ratio. Both Ang-IV and IRAP level negatively correlated with VEGF but no 
correlation was observed with the MAG:PLP1 ratio. No correlations were found between IRAP 
activity and both VEGF and MAG:PLP1 ratio. Together, these findings indicate that rRAS 
dysregulation in AD is associated with markers of vascular dysfunction. 
 
 
  6.2 Introduction 
 
 
The brain rRAS pathways (ACE-2/Ang (1-7)/MasR and APN/Ang-IV/IRAP) are the major counter-
regulatory pathways of the cRAS axis and mediate both depressor and neuroprotective actions in the 
brain (455). The cRAS and rRAS pathways are inter-dependent and loss of rRAS activity is often 
associated with cRAS overactivation. Loss of rRAS signalling has been implicated in oxidative stress 
(573), cerebral ischaemia (330, 430, 574), and inflammation (575-577) associated with CNS injury, 
including cognitive impairment and dementia (419, 429, 433). The brain rRAS pathway (APN/Ang-
IV/IRAP) has also notably been shown to regulate CBF, maintain memory, learning acquisition and 
enhance synaptic plasticity and has neuroprotective effects in the CNS (reviewed by (458)).  
 
Brain ischaemia, as a result of reduced cerebral blood flow (i.e. cerebral hypoperfusion), is the 
defining pathological process that underlies vascular dementia. There is now also overwhelming 
evidence that cerebral hypoperfusion and ischaemia also contributes to disease pathogenesis in AD and 
is evident even in the early stages of AD. The extent of cerebral hypoperfusion is now recognized as a 
sensitive predictor of cognitive decline (118, 305-307). Moreover, cerebral ischaemia associated with 
cerebral hypoperfusion and cognitive decline aggravates Aβ-related pathology (308-310). 
Overactivation of the classical RAS axis (ACE-1/Ang-II/AT1R), resulting in overproduction of the 
potent vasoconstrictor peptide Ang-II, is thought to contribute toward cerebral hypoperfusion and 
ischaemic injury in AD (559, 578), while activity within rRAS (ACE-2/Ang (1-7)/MasR), which is 
protective (579), is reduced in AD.  
 
We have previously shown that activity within the (ACE-2/Ang (1-7)/MasR) pathway, specifically a 
50% loss of ACE-2 activity, is strongly associated with the Aβ and Tau parenchymal load in post-
mortem brain tissue in AD (417). However, despite the role of RAS in the regulation of cerebral blood 
flow and the likely involvement of cRAS in mid-life hypertension (a modifiable risk factor for AD), 
the association between dysregulation of the two alternative rRAS pathways with markers of perfusion 
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and ischaemia in AD remains relatively unexplored. In this chapter, I have examined the relationship 
between alterations of (Ang (1-7)/MasR) and (Ang-IV/IRAP) with markers of brain ischaemia (VEGF) 
and reduced brain tissue oxygenation i.e. cerebral hypoperfusion (MAG:PLP1 ratio).  
 
Our group has previously developed two novel independent markers of cerebral perfusion in post-
mortem human brain tissue. The ratio of two myelin proteins, MAG and PLP1 has been shown to a 
useful marker of tissue oxygenation and is reduced under conditions of cerebral hypoperfusion. MAG 
is expressed distally at the adaxonal loop of the myelin sheath i.e. furthest away from the 
oligodendrocyte cell body and is the first part of the cell to degenerate under conditions of 
hypoperfusion. In contrast, PLP1 is widely distributed throughout the myelin sheath and is more 
resistant to ischaemia and hypoperfusion, illustrated in (Figure 6.1). The utility of MAG:PLP1 as a 
post-mortem marker of tissue perfusion prior to death has been developed and validated across 
multiple independent cohorts (45). A reduction in the MAG:PLP1 ratio has been shown not only in 
VaD but also in mid-frontal and medial parietal cortex (precuneus) in human post-mortem brain tissue 
in AD (312-315). VEGF is a protein that is induced under hypoxic conditions and is an ischaemic-
sensitive marker. The level of brain VEGF has previously been shown to be elevated in the mid-frontal 
cortex in AD and was inversely related to a reduction in MAG:PLP1 (314). The increase in VEGF in 
AD has also been shown to be positively correlated with insoluble Aβ42 level and the Aβ42:Aβ40 
ratio. Collectively these studies demonstrate the now accepted direct relationship between ischaemia 





Figure 6.1 Schematic illustration of the distribution of both MAG (Pink dots) and PLP1 (Green 
dots) in the myelin sheath (Taken from Love S and Miners JS, 2016) (45).  
Expression of myelin proteins, MAG and PLP1, is an energy dependent process. Reduced cerebral 
perfusion of the oligodendrocyte (blue) results is more significant loss of MAG (expressed distally from 
the oligodendrocyte) compared to PLP, which is expressed throughout the myelin sheath and is more 
resistant to reduced perfusion. 
 
6.3 Study aims and hypothesis 
 
The aims of the work described in this chapter were: 
 
(i) To examine the relationship between Ang (1-7) and MasR expression with the markers of 
ischaemia (VEGF) and cerebral hypoperfusion (MAG:PLP1 ratio) 
(ii) To examine the relationship between Ang-IV and IRAP level and activity with markers of 
ischaemia (VEGF) and cerebral hypoperfusion (MAG:PLP1 ratio) 
(iii) To pilot the effect of ischaemia on expression of MasR in neuronal SH-SY5Y cells cultured 
under hypoxic conditions i.e. 2% oxygen for 24 hours to model chronic low-level perfusion in 
AD. Presented in chapter 9 (Appendix X). 
 
 
The aims were designed to test the hypothesis that the dysregulation and loss of activity within the 
rRAS pathways (Ang (1-7), MasR, Ang-IV and IRAP level and activity) are associated with cerebral 







6.4.1 Study cohort 
 
Human post-mortem brain tissue homogenates were prepared from mid-frontal cortex (Brodmann area 
8/9) in aged-matched controls (n= 17) and AD cases (n= 35). The demographic features of this study 
cohort are described in detail (Appendix I: Table 9.8 and Table 9.9). Previous measurements of MAG 
(312) and RAS markers (Ang (1-7), MasR, Ang-IV and IRAP) were available for analysis. 
 
 
6.4.2 Human vascular endothelial growth factor (VEGF) sandwich ELISA  
 
The level of VEGF was measured in 1% SDS brain homogenates from the mid-frontal cortex using the 
quantitative commercially available DuoSet ELISA kit (R&D systems) according to the 
manufacturer’s protocol described previously in the general methods (section 2.8.5). Measurements 
were made in duplicate and four carry-over samples were repeated on each plate to adjust for plate-to-
plate variation. The variation of this assay was determined by calculating the intra-assay CV% 
(Example in Appendix IV: Table 9.33). 
 
 
6.4.3 Human proteolipid protein 1 (PLP1) sandwich ELISA  
 
PLP1 level was measured in 1% SDS brain tissue homogenates using a commercially available 
sandwich ELISA kit (Cloud-clone Corp.). The assay was performed according to the manufacturer’s 
protocol described previously in the methods (section 2.8.6). Each sample was measured in duplicate 
and the mean was presented. Concentrations were determined by interpolation from the standard 
curve. Carry-over samples were repeated across all plates to adjust for any plate-to plate variation. The 







6.4.4 Statistical analysis 
 
The distributions of all datasets in this chapter were analysed by the Shapiro-Wilk normality test. A 
significant p value, p< 0.05 indicated that the data sets were not normally distributed. The data from 
Ang (1-7) direct ELISA was normally distributed while data from MasR, Ang-IV and IRAP sandwich 
ELISA did not follow a normal distribution. 
 
Correlations of both total Ang (1-7) and Ang (1-7) protein-adjusted data with VEGF level and 
MAG:PLP1 ratio were assessed by the Pearson’s correlation coefficient test. MasR unadjusted and 
protein-adjusted data were not normally distributed and therefore correlations between total MasR 
level and MasR protein-adjusted data with VEGF level and MAG:PLP1 ratio were assessed using 
Spearman’s correlation coefficient. Log transformation for unadjusted and protein-adjusted MasR data 
was performed to attempt to reach normal distribution (Appendix VI: Section 9.6.4). Correlations 
between log-transformed MasR data and VEGF level and MAG:PLP1 ratio were assessed by the 
Pearson’s correlation coefficient test.  
 
Ang-IV protein concentration and protein-adjusted Ang-IV data were both not normally distributed. 
Log transformation and square-root transformation did not ‘normalise’ the distribution of the datasets 
and therefore both total Ang-IV level and Ang-IV protein-adjusted level correlations with VEGF level 
and MAG:PLP1 ratio were assessed by the Spearman’s correlation coefficient. Both IRAP level and 
protein-adjusted data were not normally distributed. IRAP unadjusted to protein concentration and 
protein-adjusted data correlations with VEGF level and MAG:PLP1 ratio were assessed by the 
Spearman’s correlation coefficient. Log transformation of unadjusted and protein-adjusted data was 
performed to attempt to reach normal distribution (Appendix VI: Section 9.6.4). Correlations between 
log-transformed IRAP data and VEGF level and MAG:PLP1 ratio were assessed by the Pearson’s 
correlation coefficient test. Correlations between IRAP activity data and VEGF and MAG:PLP1 ratio 
were assessed by the Pearson’s correlation coefficient test. For all tests applied, a P-value < 0.05 was 
considered statistically significant.  
 
For all data sets, the ROUT method was used to detect outliers, where outliers existed and were 






6.5.1 Relationship between Ang (1-7) and MasR expression and markers of ischaemia in AD 
 
 
Ang (1-7) and protein-adjusted Ang (1-7) level showed no evidence of a correlation with VEGF level 






Figure 6.2 Relationship between Ang (1-7) level and VEGF level. 
A. Scatterplot showing no correlation between Ang (1-7) level and VEGF level (measured by 
sandwich enzyme-linked immunosorbent assay), Pearson’s correlation coefficient test (r= -0.269, p= 
0.061). B. Scatterplot showing no significant correlation between Ang (1-7) protein-adjusted level and 
VEGF level, Pearson’s correlation coefficient test (r= -0.223, p= 0.124). The solid inner line indicates 
the best-fit linear regression and the outer lines the 95% confidence intervals. Blue dots = controls, red 




The relationship between total MasR level and MasR protein-adjusted data with VEGF level in mid-
frontal cortex was similarly assessed. Again, no evidence of correlation was seen between total MasR 
levels and VEGF level when Spearman’s Pearson’s correlation coefficient test was applied (r= -0.046, 
p= 0.750) (Figure 6.3 A). However, MasR protein-adjusted level was inversely correlated with VEGF 
level in mid-frontal cortex, (r= -0.424, p= 0.002) using Spearman’s Pearson’s correlation coefficient 
test (Figure 6.3 B). Simillary, MasR protein-adjusted level was inversely correlated with VEGF level 
after removal of outliers (Appendix VII, Figure 9.35). 






















































Figure 6.3 Relationship between MasR level and VEGF level. 
A. Scatterplot showing no correlation between total unadjusted MasR level and VEGF level (measured 
by sandwich enzyme-linked immunosorbent assay), Spearman’s correlation coefficient (r= -0.046, p= 
0.750). B. Scatterplot showing a moderate inverse correlation between MasR protein-adjusted level 
and VEGF level, Spearman’s correlation coefficient (r= -0.424, p= 0.002). The solid inner line 
indicates the best-fit linear regression and the outer lines the 95% confidence intervals. Blue dots = 




6.5.2 Relationship between Ang (1-7) and MasR and markers of brain tissue oxygenation in AD 
 
 
The relationship between unadjusted Ang (1-7) and protein adjusted Ang (1-7) level with the 
MAG:PLP1 ratio was also assessed in the mid-frontal cortex. There was no evidence of correlation 
with the MAG:PLP1 ratio (Pearson’s correlation coefficient, r= -0.039, p= 0.786; r= -0.244, p= 0.091) 






















































Figure 6.4 Relationship between Ang (1-7) level and the MAG:PLP1 ratio. 
A. Scatterplot showing no correlation between Ang (1-7) level and MAG:PLP1 ratio, Pearson’s  
correlation coefficient test (r= -0.039, p= 0.786). B. Scatterplot showing no significant correlation 
between Ang (1-7) protein-adjusted level and MAG:PLP1 ratio, Pearson’s correlation coefficient test 
(r= -0.244, p= 0.091). The solid inner line indicates the best-fit linear regression and the outer lines the 




Similarly, the association between both total unadjusted MasR level and protein-adjusted MasR 
measurement and the MAG:PLP1 ratio was examined. No significant correlation was found between 
total MasR level and MAG:PLP1 ratio (Spearman’s correlation coefficient, r= -0.056, p= 0.696) 
(Figure 6.5 A). MasR protein-adjusted level was also not correlated with MAG:PLP1 ratio in mid-

























































Figure 6.5 Relationship between MasR level and brain MAG:PLP1 ratio. 
A. Scatterplot showing no correlation between total MasR level and MAG:PLP1, Spearman’s  
correlation coefficient test (r= -0.056, p= 0.696). B. Scatterplot showing no significant correlation 
between MasR protein-adjusted level and MAG:PLP1 ratio, Spearman’s  correlation coefficient test 
(r= 0.066, p= 0.644). The solid inner line indicates the best-fit linear regression and the outer lines the 




 6.5.3 Relationship between Ang-IV and IRAP with marker of brain ischaemia in AD 
 
 
Total unadjusted Ang-IV level did not significantly correlate with VEGF level (Spearman’s correlation 
coefficient, r= -0.013, p= 0.931) (Figure 6.6 A). In contrast, Ang-IV protein-adjusted level was 
inversely correlated with VEGF level (Spearman’s correlation coefficient, r= -0.337, p= 0.019) (Figure 
































































































Figure 6.6 Relationship between Ang-IV level and VEGF level. 
A. Scatterplot showing no correlation between total Ang-IV level and VEGF level (measured by 
sandwich enzyme-linked immunosorbent assay), Spearman’s correlation coefficient test (r= -0.013, p= 
0.931). B. Scatterplot showing a significant inverse correlation between Ang-IV protein-adjusted level 
and VEGF level, Spearman’s correlation coefficient test (r= - 0.337, p= 0.019). The solid inner line 
indicates the best-fit linear regression and the outer lines the 95% confidence intervals. Blue dots = 





The relationship between total unadjusted IRAP level and protein-adjusted IRAP with VEGF level in 
mid-frontal cortex were similarly assessed.  In the case of total unadjusted IRAP level an inverse 
correlation was seen with VEGF level (Spearman’s correlation coefficient, r= -0.398, p= 0.004) 
(Figure 6.7 A). When protein-adjusted IRAP levels were similarly compared to VEGF level, a similar 
significant inverse correlation was observed (Spearman’s correlation coefficient, r= -0.398, p= 0.015) 















































Figure 6.7 Relationship between IRAP level and VEGF level. 
A. Scatterplot showing a moderately strong inverse correlation between total IRAP level and VEGF 
level (measured by sandwich enzyme-linked immunosorbent assay), Spearman’s correlation 
coefficient test (r= -0.398, p= 0.004). B. Scatterplot showing a significant inverse correlation between 
IRAP protein-adjusted level and VEGF level, Spearman’s correlation coefficient test (r= -0.398, p= 
0.015). The solid inner line indicates the best-fit linear regression and the outer lines the 95% 
confidence intervals. Blue dots= controls, red dots= AD cases. 
 
 
The relationship between IRAP activity and VEGF level was assessed. No significant correlation was 
found between IRAP activity and VEGF level in mid-frontal cortex (Pearson’s correlation coefficient, 
r= -0.131, p= 0.363) (Figure 6.8).  
 
 
Figure 6.8 Relationship between IRAP activity and VEGF level. 
A. Scatterplot showing no correlation between IRAP activity and VEGF level (measured by sandwich 
enzyme-linked immunosorbent assay), Pearson’s correlation coefficient test (r= -0.131, p= 0.363). The 
solid inner line indicates the best-fit linear regression and the outer lines the 95% confidence intervals. 
Blue dots= controls, red dots= AD cases. 
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6.5.4 Relationship between Ang-IV and IRAP with markers of brain tissue oxygenation  
 
 
Following the investigations with VEGF, similar investigations were undertaken with MAG:PLP1 
ratio.  No significant correlation was found between total unadjusted Ang-IV level and MAG:PLP1 
ratio (Spearman’s correlation coefficient, r= 0.017, p= 0.907) and between protein-adjusted Ang-IV 




Figure 6.9 Relationship between Ang-IV level and the MAG:PLP1 ratio. 
A. Scatterplot showing no correlation between total Ang-IV level and MAG:PLP1 ratio, Spearman’s  
correlation coefficient test (r= 0.017, p= 0.907). B. Scatterplot showing no significant correlation 
between Ang-IV protein-adjusted level and MAG:PLP1 ratio, Spearman’s correlation coefficient test 
(r= 0.151, p= 0.301). The solid inner line indicates the best-fit linear regression and the outer lines the 




Investigation of total unadjusted IRAP level showed no evidence of a correlation with the MAG:PLP1 
ratio in mid-frontal cortex (Spearman’s correlation coefficient, r= 0.154, p= 0.279) (Figure 6.10 A). 
Similarly IRAP protein-adjusted level did not correlate with MAG:PLP1 ratio (Spearman’s correlation 
coefficient, r= -0.029, p= 0.839) (Figure 6.10 B).  
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Figure 6.10 Relationship between IRAP level and brain tissue oxygenation marker (MAG:PLP1 
ratio). 
A. Scatterplot showing no correlation between total IRAP level and MAG:PLP1, Spearman’s  
correlation coefficient test (r= 0.154, p= 0.279). B. Scatterplot showing no significant correlation 
between IRAP protein-adjusted level and MAG:PLP1 ratio, Spearman’s correlation coefficient test (r= 
-0.029, p= 0.839). The solid inner line indicates the best-fit linear regression and the outer lines the 




Similarly, no significant correlation was found between IRAP activity and MAG:PLP1 ratio in mid-




































































































Figure 6.11 Relationship between IRAP activity and brain tissue oxygenation marker 
(MAG:PLP1 ratio). 
A. Scatterplot showing no correlation between total IRAP activity and MAG:PLP1, Pearson’s 
correlation coefficient test (r= 0.229, p= 0.105). The solid inner line indicates the best-fit linear 




6.6 Discussion  
 
 
In this chapter, I explored the relationship between brain rRAS pathways and markers of cerebral 
ischaemia and hypoperfusion. We report for the first time that MasR expression, when adjusted to total 
protein level, was inversely correlated with VEGF, a marker of brain ischaemia. However, there was 
no correlation with a marker of brain tissue oxygenation, namely MAG:PLP1. In contrast, Ang (1-7) 
was not found to be associated with markers of ischaemia and or hypoperfusion. In relation to the 
components of another rRAS pathway, Ang-IV and IRAP levels, both were inversely correlated with 
VEGF but not with MAG:PLP1. While, IRAP activity was not found to be associated with both VEGF 
and MAG:PLP1 ratio. These data suggest that dysregulation of brain rRAS pathways is associated, to 
some extent with vascular dysfunction in AD, reinforcing the hypothesis that there is an interaction 
between RAS, cerebrovascular disease and neurodegenerative disease. 
 
As mentioned, reduction of ACE-2 activity, the rate-limiting enzyme in the brain rRAS axis (ACE-
2/Ang (1-7)/MasR) has been associated with AD pathogenesis (417) and contributes to the 
pathogenesis of cerebral ischaemia (441, 580). Here I have investigated the relationship between 




















expression of the downstream elements of the pathway i.e. Ang (1-7) and MasR), in relation to 
markers of brain ischaemia and cerebral hypoperfusion in AD. Whilst I did not find a relationship 
between Ang (1-7) and MasR expression with Aβ or tau in a larger cohort presented previously in 
chapter 4, I did find an interesting relationship showing that reduced MasR expression in mid-frontal 
cortex was inversely associated with cerebral ischaemia. This was indicated by a negative correlation 
with VEGF levels that increase under conditions of cerebral ischaemia in AD. We did not, however, 
observe a similar relationship with an independent marker of cerebral hypoperfusion (MAG:PLP1 
ratio).  
 
Cerebral ischaemia has been shown to reduce Ang (1-7) and MasR expression whilst inducing Ang-
II/AT1R signalling in a rat model of stroke (560). Directly supporting this, Ang (1-7) administration 
and subsequent induction of the ACE-2/Ang (1-7)/MasR pathway protected against cerebral ischaemia 
in animal models of stroke (326, 329, 330). Indeed, administration of a MasR agonist (Ang (1-7)) in an 
animal model of stroke showed a reduction in infarct volume and improved CBF (327, 430, 573). In a 
rat model of focal cerebral ischaemia, Ang (1-7) contributed to the neuroprotection that was observed 
from the administration of the ACE-inhibitor captopril in ischaemic stroke (581).  
 
These findings highlight the vital protective role that rRAS signalling provides in ischaemia. In 
contrast, Lu et al. (331) showed that components of the ACE-2/Ang (1-7)/MasR pathway are 
upregulated after acute ischaemic stroke in rat, which could represent a compensatory physiological 
response to acute ischaemia. Contrary to expectations, we did not find a significant correlation 
between Ang (1-7) level with either VEGF levels or MAG:PLP1. My results are likely to be related to 
unchanged level of Ang (1-7) in the AD group compared to significant reductions of Ang (1-7) 
observed in both human plasma and brain tissue in an animal model of sporadic AD (senescence-
accelerated mouse prone 8 (SAMP8) mice) (416, 435). The different findings may also be due to 
differences in the method used to measure Ang (1-7) (direct ELISA used in my study vs. sandwich 
ELISA kit used in previous studies), the species of study sample (human vs. animal) or (plasma vs. 
brain tissue), or the potential effect of PMD on Ang (1-7) degradation, however, I did not find any 
significant difference of PMD in our cohort (chapter 2: Section 2.2.1).  
 
Dysregulation of the downstream components of the alternative RAS axis (APA/Ang-III/APN/Ang-
IV/IRAP) have previously been studied in AD in relation to disease pathology: Ang-III was increased 
in AD and strongly associated with both Aβ and Tau pathology (393). The lower downstream pathway 
elements of brain rRAS pathway (Ang-IV/IRAP) have also been reported to regulate cerebral blood 
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flow and have been implicated in cerebral ischaemia (495). Other research has shown that boosting 
this pathway was also associated with improved cognition and mediated the cerebrovascular and 
cognitive effects of treatment with the ARB (Losartan) (362, 493, 582). In this study, we wanted to 
investigate whether these downstream components of rRAS pathway (i.e. Ang-IV and IRAP) were 
related to markers of ischaemia and hypoperfusion in AD, which has not received much attention.  
 
Ang-IV and IRAP protein levels were found to be unchanged in the AD cohort (presented in chapter 5) 
and these markers did not correlate with Aβ or tau. However and interestingly, both Ang-IV and IRAP 
were negatively correlated with VEGF level, but no associations were found with MAG:PLP1 - a 
marker of cerebral hypoperfusion for both Ang-IV and IRAP level and activity. In contrast, IRAP 
activity was not found to be associated with markers of ischaemia. Activation of the Ang-IV/AT4R 
axis has previously been shown to be cerebroprotective against ischaemia in animal models of stroke 
(494, 583-585). In contrast, there is also counter evidence of cerebrovascular protection seen in IRAP 
knockout mice where reduced cerebral infarcts volume was observed (586). This rather contradictory 
result may be due to difference in the study subject (rat vs. mice). There are still many unknown roles 
of this brain rRAS pathway in relation to cerebral ischaemia and further studies in this area will be 
very valuable. 
 
One of the limitations in this study, which could have affected the evaluation of the relationship 
between brain rRAS markers and ischaemic and hypoperfusion markers was the small sample size of 
previously available VEGF and MAG:PLP1 ratio measurements. Caution must also be applied to the 
interpretation of the results as some of the significant correlations might be caused by the potential 
impact of outliers (Appendix VII: Section 9.7.3). Another limitation of our study was that the effect of 
ischaemia in cell culture was focused on expression of MasR only and due to some limitations at the 
end of my study I was unable to complete this pilot investigation. Further characterisation of the effect 
of ischaemia on expression of IRAP in neuronal SH-SY5Y cells would provide more insight about the 
relationship between brain rRAS (APN/Ang-IV/IRAP) and cerebral ischaemia. Little is known 
regarding the role of rRAS pathway in vascular dementia that will be important to explore in future 
studies. Exploring the relationship between brain rRAS and other neuronal markers such as neuron-
specific enolase (NSE) and markers of glial injury would be interesting to investigate, to confirm the 
relationship between brain rRAS pathways and damage associated with cerebral ischaemia. 
 
In conclusion, this study provides preliminary evidence in human post-mortem tissue that 
dysregulation in rRAS axis, specifically MasR and IRAP, are related to markers of vascular 
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dysfunction in AD. Together, these findings suggest that dysregulation of downstream rRAS pathways 
are more closely associated with vascular dysfunction than established Aβ and Tau-related pathology. 
Larger independent studies are required to validate our preliminary observations in humans and studies 





























The RAS has traditionally been viewed to elicit its biological effects via activation of more widely 
known GPCRs (AT1R, AT2R, MasR) and IRAP. However, another element of the RAS complexity has 
been shown through the reported existence of a non-AT1R and non-AT2R binding protein, which has 
been reported to occur in the human and rat brain. This binding site was subsequently identified as the 
zinc metalloendopeptidase - neurolysin. Furthermore, dysregulation of neurolysin has been implicated 
in the pathophysiology of cardiovascular and cerebrovascular disorders including stroke. However, its 
contribution to neurodegenerative diseases including AD remains unknown. Another consideration of 
a possible role of neurolysin in AD is the neuropeptide neurotensin, which is metabolised by ACE-1 
but is also a major endogenous substrate of neurolysin. Changes in neurotensin level have been 
associated with dysregulation of blood pressure, the pathophysiology of stroke and some 
neurodegenerative diseases (Parkinson's disease and AD). In this study, I have undertaken the first 
investigation of the expression and distribution of neurolysin and neurotensin in AD in a well-
characterised cohort of post-mortem brains.  
 
 
Human post-mortem brain tissue was obtained from the SWDBB, University of Bristol, with local 
Research Ethics Committee approval. We studied mid-frontal cortex (Brodmann area 8/9) from AD 
cases (n= 70) and the age-matched controls (n= 48) that were matched closely for age-at-death and 
PMD. The expression and distribution of neurolysin was assessed using a competitive ELISA and 
IHC. The level of neurotensin was measured by sandwich ELISA. Pre-existing data on Braak tangle 
stage, pathological hallmarks (total insoluble Aβ, insoluble Aβ40 and Aβ42 and tau load), brain RAS 
markers (Ang-II, Ang-III and Ang-II:Ang (1-7) ratio),  and markers of brain tissue oxygenation and 
ischemia (MAG:PLP1 ratio and VEGF) were available for analysis. 
 
 
I found that the level of neurolysin was significantly reduced in AD, compared to controls, and the 
reduction was in association with increased levels of brain RAS markers (Ang-II, Ang-II:Ang (1-7) 
ratio, and Ang-III). Similarly, neurolysin levels were also inversely associated with the level of VEGF 
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(a marker of brain ischaemia). In contrast the level of expression of neurotensin remained unchanged 
in AD and was not associated with any other RAS markers or markers of ischaemia. 
Together, these studies have produced a novel finding that the level of neurolysin was dysregulated in 
post-mortem AD brain tissue in association with RAS markers and with a marker of ischaemia, 
suggesting some association with vascular dysfunction in AD. These studies highlight additional 
components of RAS that are potentially involved in the pathogenesis of AD and in doing so broaden 






The main components of RAS have been well-characterised in renal, cardiac and neurological diseases 
(255, 267, 269). However, as discussed, the role and function of major angiotensin receptors, due in 
part to a lack of specific antibodies for some of the main receptors, remains unclear, especially within 
the brain. An additional level of complexity was identified in the RAS when a novel non-AT1R and 
non-AT2R binding protein was discovered in rat brain. The same group also identified that there was a 
similar binding site in human brain tissue (587). This binding protein was reported to have different 
properties from the more established angiotensin receptors (AT1R, AT2R, MasR and AT4R) that had 
already been identified (588). For example, this new molecule was found to have a higher molecular 
mass than most of the established GPCRs. Additionally, the new protein did not appear to undergo 
post-translational N-glycosylation, nor did it seem to be coupled to a G-protein. Most importantly 
perhaps was the finding that it acts independently of the main cRAS receptors, as it was not stimulated 
or inhibited by selective AT1R and AT2R agonists and antagonists respectively (275, 588). This non-
AT1R and non-AT2R receptor was later identified as a zinc metalloendopeptidase and was found to 
correspond to the previously characterised neurolysin, which is a monomeric protein containing 704 
amino acids with an approximate MW of 78 kDa (589, 590). Known endogenous substrates for 
neurolysin include neurotensin, Ang-I and Ang-II, bradykinin, substance P, hemopressin and 
somatostatin (591, 592). Neurolysin has since become considered an important component of brain 
RAS function and has been reported to be involved in the pathophysiology of cardiovascular and 
cerebrovascular diseases (275, 590, 593). The expression of neurolysin in human post-mortem tissue in 
AD remained uncharacterised at the time this work was first undertaken. 
 
	 177 
Neurolysin has been reported to be widely distributed in rodent and mammalian tissues and is 
expressed centrally within the brain and peripheral tissues including the testis (587, 588, 594). At a 
subcellular level, neurolysin has been localised to the plasma membrane but is also present in the 
cytosol and mitochondria (595, 596). Within the brain, neurolysin has been reported to be expressed in 
both neurons and glia (595-597).  
 
Neurolysin has also been reported to have numerous roles in RAS. It has been reported to generate 
(Ang (1-7)) from Ang-I and degrades Ang-II and Ang-III into more inactive peptides Ang (1-4) and 
Ang (5-8). Neurolysin has also been reported to act as a novel clearance Ang-II/Ang-III receptor that 
works to internalise Ang-II and Ang-III and thus counter-regulate the function of AT1R (275, 593, 598, 
599). Together these studies indicate a significant potentially protective role of neurolysin in the 
regulation of the brain cRAS, which could acts as a neuroprotective enzyme by generating Ang (1-7) 
and inactivating Ang-II. The proposed neuroprotective roles that neurolysin might provide are 
summarized in Figure 7.1.  
 
 
Figure 7.1 Schematic of suggested neuroprotective roles of neurolysin in the brain RAS.  
Neurolysin can convert Ang-I into the neuroprotective Ang (1-7), which via stimulation of the MasR 
counter-regulates the disease-associated effects of cRAS signalling. Neurolysin has also been shown to 
degrade Ang-II and Ang-III into small inactive peptides (Ang (1-4) and Ang (5-8)), which are less 
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neurotoxic and more easily cleared. Neurolysin also binds to and facilitates the clearance of Ang-II and 
Ang-III and limits the access of Ang-II and Ang-III to AT1R. 
 
 
Previous studies have highlighted the involvement of neurolysin in the pathophysiology of 
cerebrovascular diseases associated with overactive RAS such as stroke (593, 600). In a mouse model 
of stroke, neurolysin activity was upregulated in the frontoparietal cortex 7 days post-stroke (593). A 
similar increase in neurolysin expression in mouse brain was previously associated with neuronal cell 
death (601) and these studies suggest that neurolysin plays a role in the pathophysiology of stroke. In 
SHR, an animal model of hypertension, neurolysin was significantly reduced in the brainstem’s 
cardiovascular regulatory centres (rostral ventrolateral medulla (RVLM), caudal ventrolateral medulla 
(CVLM), as well as dorsomedial medulla (DMM)), compared to normotensive Wistar–Kyoto rats. 
This finding suggested a possible role of neurolysin in the regulation of blood pressure through its 
regulation of the main angiotensins (Ang-II and Ang-III) (275). Neurolysin has also been shown to be 
involved in metabolism of Aβ. In a recent in vitro study, human mitochondrial neurolysin degraded Aβ 
peptide (Aβ40), cleaving the hydrophobic fragment of the peptide (Aβ35-40) (602). Despite these 
potentially neuroprotective functions of neurolysin, together these studies indicate a complex and 
poorly understood role in the pathophysiological of stroke. Little is known regarding its function in 
AD. 
 
The 13 amino acid neuropeptide neurotensin, is also worthy of consideration as an endogenous active 
substrate of neurolysin within the brain and which has been shown to play a vital role in brain 
functions including learning and memory (603, 604). A previous study revealed that ACE-1 was 
involved in the metabolism of neurotensin (339), and thus would be consistent of memory related 
deficits resulting from increased levels of ACE-1 activity that have also been reported in the AD brain 
(354). Immunohistochemical studies have also identified high levels of expression of neurotensin in 
several brain regions including the prefrontal areas, amygdala and hypothalamus (605-607). This 
tridecapeptide is also densely distributed in the entorhinal cortex in the hippocampus (608) indicative 
perhaps of a central role in learning and memory.  
 
Neurotensin has been reported to bind to three different receptors, in addition to neurolysin including: 
neurotensin type-1 receptor (NTSR1), neurotensin type-2 receptor (NTSR2) and neurotensin type-3 
receptor (NTSR3). Both NTSR1 and NTSR2 are GPCRs while NTSR3 is a trans-membrane single 
domain like sortilin/gp95 family receptor (595, 609). NTSR1 is widely distributed in neurons while 
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NTSR2 has been found in glia (610, 611). This overall pattern of distribution is thought to suggest a 
predominant role of NTSR1 on cognitive function compared to NTSR2.  
 
Some studies have suggested a neuroprotective role of neurotensin in AD. Reduction in neurotensin 
level and its receptors have been found in several brain regions of AD patients such as the 
suprachiasmatic nucleus, amygdala, entorhinal area, dentate gyrus and temporal gyrus (606, 612-615). 
Neurotensin was also found to increase the neuronal excitability and improve spatial learning and 
memory (340), as well as block neurotoxicity of the sortilin-induced precursor form of nerve growth 
factor (proNGF) (616). In addition, the density of amyloid plaques in the occipital cortex was 
negatively associated with neurotensin sensitive neurons in the suprachiasmatic nucleus in AD patients 
(615). Findings from experimental animal studies are controversial. Neurotensin administration was 
found to increase spatial learning and memory, improve cognitive function and play an inhibitory role 
in memory related to fear (340-342). Whilst another study found that an NTSR1 agonist did not 
improve cognitive function in Long Evan rats, an animal model of neuropsychiatric disorders (341). 
Further studies are needed to clarify the role of neurotensin on cognitive function and the possible 
implication of this neuropeptide in the pathophysiology of AD remains unexplored. 
 
 
7.3 Study aims and hypothesis 
 
The aims of the investigations described in this chapter were: 
 
(i) To characterise the expression and distribution of neurolysin in post-mortem AD brain tissue 
and examine the relationship with markers of brain RAS, vascular dysfunction and disease 
pathology in AD 
(ii) To measure neurotensin level in mid-frontal cortex in AD and explore the relationship with 
markers of disease pathology  
 
I wished to test the hypothesis that the expression of both neurolysin and neurotensin were altered 







7.4.1 Study cohort 
 
Human post-mortem brain tissue homogenates from mid-frontal cortex (Brodmann area 8/9) were used 
in this study and neurolysin and neurotensin levels were measured in age-matched controls (n= 48) and 
AD cases (n= 70). Demographic features of the study cohort are described in the methods section 
(Table 2.1) for full details (Appendix I: Table 9.1 and Table 9.2). Previous measurements of insoluble 
Aβ, measured by sandwich ELISA, were available for controls (n= 28) and AD cases (n= 61) (545). 
Tau load was previously measured by field fraction analysis and was available for controls (n= 29) and 
AD cases (n= 89) (analysis performed by routine histological assessment of tau load in cases from the 
SWDBB). Both insoluble Aβ40 and insoluble Aβ42 were previously measured by sandwich ELISA 
and were available for controls (n= 20) and AD cases (n= 33) for insoluble Aβ42, and for controls (n= 
20) and AD cases (n= 34) for insoluble Aβ40 (314). Previous measurement of Ang-II level, measured 
by sandwich ELISA, were available for controls (n= 43) and AD cases (n= 70) (393). Ang-III level 
was also previously measured by direct ELISA in mid-frontal cortex and available for controls (n= 31) 
and AD (n= 62) (393). The Ang-II:Ang (1-7) ratio was also calculated and available for controls (n= 
42) and AD (n= 68) (417). Previous measurements of VEGF level and MAG:PLP1 ratio were 
measured by sandwich ELISA and were available for controls (n= 17) and AD cases (n= 35) (314).  
 
 
7.4.2 Expression of neurolysin in human brain tissue 
 
7.4.2.1 Western blotting for neurolysin 
 
A standard protocol for western blotting used is described in detail in chapter 2 (section 2.4). Details of 
the primary and secondary antibodies used are described in chapter 9 (Appendix II: Table 9.13) and 
(Table 9.14) respectively. In summary, for detection of neurolysin in brain homogenate samples, the 
membrane was blocked in 10% milk/TBST buffer for 1 hour. After it had been washed with 0.05% 
TBST (3x 15 minutes) at room temperature on a shaker, the membrane was then incubated with a 
mouse anti-human neurolysin antibody (1D6) (NBP2-01693) diluted 1:500 in 5% milk/TBST antibody 
buffer overnight at 4°C (in the fridge) on a shaker. Following a wash step with 0.05% TBST (3x 15 
minutes) at room temperature on shaker, the membrane was incubated with a secondary antibody 
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(peroxidase conjugated anti-mouse) diluted 1:5000 in 5% milk/TBST for 1 hour. After 3x 15 minutes 
wash steps with 0.05% TBS with tween-20 (TBST), a chemiluminescent HRP substrate (ECL) 
(Millipore) was added to the membrane in a 1:1 ratio (5 ml of reagent 1 and 5 ml of reagent 2) for 5 
minutes. The images then were acquired using (ChemiDoc XRS+, Bio-RAD) and Image Lab software, 





The neurolysin antibody (1D6) (NBP2-01693) was used by IHC to detect and examine the distribution 
of neurolysin in formalin-fixed brain tissue. The standard protocol used for immunohistochemical 
staining is described in detail in the method (section 2.5). The immunohistochemical protocol was 
initially optimised by comparing the antigen retrieval pre-treatment step using either EDTA or citrate 
buffer and optimising the dilution of the primary antibody (1:150, 1:300, 1:500). The optimal assay 
conditions for neurolysin staining were achieved with microwave- EDTA pre-treatment and an 
antibody dilution at 1:150 in PBS. After washing with running tap water for 5 minutes, slides were 
incubated with blocking serum for 20 minutes then incubated with the primary antibody diluted 1:150 
in PBS (5 µg/ml) overnight. After rinsing the sections in two changes of PBS for 3 minutes each, 
sections were incubated with Vectastain biotinylated universal secondary antibody for 20 minutes 
followed by another wash with PBS and then the VectaElite ABC complex for 20 minutes. The 
sections were rinsed again and incubated with DAB for 10 minutes then washed in running water for 
10 minutes and immersed in copper sulphate solution for 4 minutes followed by washing in running 
water for 5 minutes. The sections were then counterstained with haematoxylin Gill II for 3 seconds, 
dehydrated, cleared and mounted.   
  
 
7.4.3 Neurolysin competitive ELISA 
 
The level of neurolysin in brain homogenates from the mid-frontal cortex, prepared in 1% SDS, was 
measured using a quantitative commercially available competitive ELISA (Human Neurolysin, (NLN) 
ELISA kit) (MyBioSource)) according to the manufacturers protocol, which is described in detail in 
chapter 2 (section 2.9). Different homogenate dilutions (1:2, 1:4, 1:10 and 1:20) were initially tested to 
identify the dilution of homogenate that fell within the linear part of the standard curve (Appendix II: 
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Table 9.19) and a dilution of 1 in 10 was chosen for further studies. Neurolysin level was initially 
determined in two controls and two AD cases to confirm that the chosen dilution was within the range 
of standard curve (Appendix II: Figure 9.10 and Table 9.19). Neurolysin was then measured in the 
entire cohort in duplicate and averaged for all cases. Measurements from four carry-over samples were 
repeated across all plates to help measure and minimise plate-to-plate variation. Neurolysin 
measurements were adjusted to total protein level for each brain homogenates sample. The variation of 
this assay was determined by calculating the intra-assay CV% (Example in Appendix IV: Table 9.35). 
Both unadjusted neurolysin measurements and protein-adjusted measurements were used for 
comparisons between control and AD.  
 
7.4.4 Neurotensin sandwich ELISA 
 
The level of neurotensin in brain homogenates from the mid-frontal cortex, prepared in 1% SDS, was 
measured using a commercially available sandwich ELISA (Human Neurotensin (NT) ELISA kit) 
(CUSABIO) according to the manufacturer’s protocol described in detail in the general methods 
(section 2.8.5). Different homogenate dilutions (1:2, 1:4, 1:10 and 1:20) were initially tested and a 1:10 
dilution fell within the linear range of the standard curve and was chosen for further experiments 
(Appendix II: Table 9.20). Neurotensin level were calculated in two controls and two AD cases to 
confirm whether the selected dilution was appropriate and fell within the range of the standard curve 
(Appendix II: Figure 9.11 and Table 9.20). Neurotensin level was then measured across the entire 
cohort in duplicate and averaged and measurements from four carry-overs samples were repeated 
across all plates. Neurotensin measurements were adjusted to total protein level for each brain 
homogenates sample. The variation of this assay was determined by calculating the intra-assay CV% 
(Example in Appendix IV: Table 9.36). Both unadjusted neurolysin measurements and protein-
adjusted measurements were used for comparisons between control and AD.  
 
 
7.4.5 Statistical analysis 
 
The Shapiro-Wilk normality test was applied to test the normal distribution of all datasets in this 
chapter. A significant p value, p < 0.05 indicated that the data sets were not normally distributed. 
Neurolysin concentration and protein-adjusted levels were not normally distributed. Both log 
transformation and square root transformation of the data did not pass the normality test and therefore 
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a non–parametric, Mann-Whitney test, was used to assess whether total and protein-adjusted levels 
varied between AD cases and controls, male and females and in the presence or absence of the APOE 
ε4 allele. Comparison of both neurolysin and protein-adjusted data between Braak tangle stage groups 
(Braak stage 0-II, Braak stage III-IV, Braak stage V-VI) was made using a non-parametric Kruskal-
Wallis test. Correlations between both neurolysin unadjusted data and protein-adjusted data with total 
insoluble Aβ, tau load, insoluble Aβ40, insoluble Aβ42, Ang-II, Ang-III, Ang-II:Ang (1-7) ratio, 
MAG:PLP1 ratio, VEGF, age and PMD were assessed by the Spearman’s correlation coefficient. 
 
Neurotensin data was normally distributed. Comparison of neurotensin level between controls and AD 
cases were tested with a parametric, Unpaired samples t-test. Comparison of the neurotensin 
unadjusted data between Braak tangle stage groups (Braak stage 0-II, Braak stage III-IV, Braak stage 
V-VI) was made by use of a parametric One-Way ANOVA test. Protein–adjusted data was not 
normally distributed and the comparison was tested with a non-parametric test, Mann-Whitney test. 
Both log transformation and square root transformation of the data did not pass the normality test and 
therefore non–parametric tests were applied for protein-adjusted data. A non-parametric Kruskal-
Wallis test was performed to compare neurotensin protein-adjusted between Braak tangle stage groups. 
Correlations of neurotensin unadjusted data with total insoluble Aβ, tau load, insoluble Aβ40 and 
insoluble Aβ42 were assessed by the Pearson’s correlation coefficient and Spearman’s correlation 
coefficient was used for protein-adjusted data. For all datasets, the ROUT method was used to detect 
outliers and the data was re-analysed following the removal of potential outliers and is presented in 





7.5.1 Expression of neurolysin in human brain tissue 
 
The specificity of the neurolysin antibody used for immunohistochemical staining to detect and 
examine the distribution of neurolysin in mid-frontal cortex was first tested by western blot. Four AD 
and four controls homogenates were used for this experiment and chosen randomly. Details of the 
chosen samples are described in chapter 9 (Appendix I: Table 9.7).   
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7.5.1.1 Validation of neurolysin antibody  
 
A representative image of the western blot is shown below in (Figure 7.2). It shows a predominant 
band at the anticipated estimated MW of 75-79 kDa using the neurolysin antibody ((1D6, Catalogue 
number NBP2-01693)). There was no obvious difference in the expression of neurolysin in AD and 
controls, although this is a small sample set (n= 4). Densitometry was performed but no significant 
difference in band volume was observed between AD and controls (p= 0.351).  The identity of the very 
faint lower band detected at approximately 37 kDa is unknown but could potentially be a protein 
degradation product.   
 
 
Figure 7.2 Western blot of neurolysin expression in human post-mortem brain tissue. 
Neurolysin expression in human brain tissue was studied by Western blotting: left side represents 
expression of neurolysin in human brain tissue from AD cases (lines 1-4). Right side shows neurolysin 
expression in controls (lines 6-9). Lanes (5 and 10) include MW markers. The membrane was blotted 
with monoclonal mouse antibody to neurolysin (Neurolysin Antibody (1D6) (NBP2-01693)). The 
reported size of neurolysin was between 75-79 kDa. The smaller bands at MW 37 kDa are unknown 




7.5.1.2 Immunolabelling of neurolysin in human brain tissue 
 
Neurolysin predominantly labelled neurons in a control, AD and VaD case in the mid-frontal cortex. 
No obvious difference in the level of neurolysin immuno-positive staining was observed between 
controls, AD and VaD cases; although the staining was not quantified since the staining was intended 
to be principally qualitative (Figure 7.3 A-C).  
 
Figure 7.3 Immunolabelling of neurolysin in mid-frontal cortex. 
Neurolysin labelling in the mid-frontal cortex of control (A), AD case (B) and VaD case (C) showed 
neurolysin was mainly present in neurons. (Image taken at 10x magnification for A and at 40x 




7.5.2 Measurement of neurolysin level in AD 
 
7.5.2.1 Reduction of neurolysin level in AD 
 
Neurolysin protein level, measured by ELISA, was significantly reduced in the AD group compared to 
age-matched controls (p= 0.004) (Figure 7.4 A). The median for total neurolysin level was lower in the 
AD group (median= 7.368 (ng/ml)) compared to control group (median= 8.164 (ng/ml)). When 
neurolysin level was adjusted to total protein concentration to account for any variations in sample 
concentration, a significant reduction of neurolysin level was still evident in the AD group compared 
to age-matched controls (p= 0.008). A Mann-Whitney test compared the median of AD group 
(median= 20.4 (ng/mg total protein)) to control group (median= 23.66 (ng/mg total protein)) (Figure 





Figure 7.4 Neurolysin level, measured by ELISA, in Alzheimer’s disease compared to age-
matched controls.  
A. Bar chart showing total neurolysin level was significantly reduced in AD (n= 70) compared with 
age-matched control (n= 48) in mid-frontal cortex measured using a neurolysin competitive ELISA. 
Mann-Whitney test revealed that total neurolysin level was lower in AD (p= 0.004) compared to 
controls. B. Neurolysin protein-adjusted measurement was significantly reduced in AD cases (n= 70) 
compared to age-matched controls (n= 48). Difference between groups was compared using Mann-
Whitney test at P= 0.008. The bars indicate the median and 95% confidence intervals. 
 
 
7.5.2.2 Neurolysin level in relation to disease severity 
 
Neurolysin level and protein-adjusted neurolysin level was assessed in relation to Braak tangle stages 
(0-II, III-IV, V-VI). A Kruskal-Wallis test revealed a significant difference of the median between all 
groups for neurolysin level (p= 0.005): the median level of Braak stage 0-II= 8.273 (ng/ml), Braak 
stage III-IV= 7.145 (ng/ml), and Braak stage V-VI= 7.447 (ng/ml). A significant reduction of 
neurolysin level was observed in Braak stage (III-IV) compared to Braak stage (0-II) (p= 0.035) and 
between cases in Braak stage (V-VI) and Braak stage (0-II) (p= 0.004) using Dunn’s multiple 
comparisons test (Figure 7.5 A). For neurolysin protein-adjusted data, no significant variation of the 
median between all groups was observed (p= 0.059). The median of Braak stage 0-II= 24.183 (ng/ml), 




























































Figure 7.5 Neurolysin level in relation to Braak tangle stage pathology.  
A. Bar chart showing significant variation in neurolysin level between Braak groups (Braak stage 0-II 
(n= 36), Braak stage III-IV (n= 20), Braak stage V-VI (n= 61)) when analysed with Kruskal-Wallis test 
(p= 0.005). Neurolysin level was significantly lower in Braak stage (III-IV) compared with cases in 
Braak stage (0-II) (p= 0.035) and between cases in Braak stage (V-VI) and Braak stage (0-II) (p= 
0.004) (post-hoc Dunn’s multiple comparisons test). The bars indicate the median and 95% confidence 
intervals. B. No significant difference was found for neurolysin protein-adjusted measurement between 
Braak tangle stage groups (Braak stage 0-II (n= 36), Braak stage III-IV (n= 20), Braak stage V-VI (n= 
61)), Kruskal-Wallis test (p= 0.059). The bars indicate the median and 95% confidence intervals. 
 
 
7.5.2.3 Neurolysin level in relation to AD pathological hallmarks 
 
Correlations between neurolysin level and insoluble total Aβ, tau load, and insoluble Aβ40 and Aβ42 
level were also examined. Unadjusted neurolysin data was not correlated with either total insoluble Aβ 
or tau load using (Spearman’s correlation coefficient r= -0.108, p= 0.311) and (Spearman’s correlation 
coefficient r= -0.077, p= 0.446) respectively (Figure 7.6 A and C). Spearman’s correlation coefficient 
test showed no significant correlations between protein-adjusted neurolysin data and either total 




























































Figure 7.6 Relationship between neurolysin level and total insoluble Aβ and tau load.  
A and C. Scatterplots showing no correlation between neurolysin level and both total insoluble Aβ 
(measured by enzyme-linked immunosorbent assay), Spearman’s correlation coefficient (r= -0.108, p= 
0.311) and tau load (measured by field fraction analysis), Spearman’s correlation coefficient (r= 0.077, 
p= 0.446). B and D. Scatterplots showing no significant correlation between neurolysin protein-
adjusted level and both total insoluble Aβ, Spearman’s correlation coefficient (r= -0.077, p= 0.474) 
and tau load, Spearman’s correlation coefficient (r= 0.029, p= 0.774). The solid inner line indicates the 
best-fit linear regression and the outer lines the 95% confidence intervals. Blue dots = controls, red 
dots = AD cases. 
 
 
Neurolysin level did not correlate with either insoluble Aβ40 and insoluble Aβ42 (Spearman’s 
correlation coefficient r= -0.095, p= 0.484) and (Spearman’s correlation coefficient r= -0.207, p= 
0.130) respectively (Figure 7.7 A and C). Similarly, neurolysin protein-adjusted data did not correlate 
with either insoluble Aβ40 and insoluble Aβ42 (Spearman’s correlation coefficient r= -0.081, p= 
0.555) and (Spearman’s correlation coefficient r= -0.014, p= 0.917) respectively (Figure 7.7 B and D). 
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Figure 7.7 Relationships between neurolysin level and insoluble Aβ40 and insoluble Aβ42.  
A and C. Scatterplots showing no correlation between neurolysin level and both insoluble Aβ40 
(measured by enzyme-linked immunosorbent assay), Spearman’s correlation coefficient (r=-0.095, p= 
0.484), and insoluble Aβ42 (r= -0.207, p= 0.130). B and D. No significant correlation found between 
neurolysin protein-adjusted level and both insoluble Aβ40, Spearman’s correlation coefficient (r= -
0.081, p= 0.555) and insoluble Aβ42, Spearman’s correlation coefficient (r= -0.014, p= 0.917). The 
solid inner line indicates the best-fit linear regression and the outer lines the 95% confidence intervals. 
Blue dots= controls, red dots= AD cases. 
 
 
7.5.2.4 Relationship between neurolysin level and age-at-death, gender and PMD 
 
In additional analyses, total and protein-adjusted neurolysin level did not correlate with either age-at- 
death or PMD. Neurolysin level did not vary between male and female, however, neurolysin protein-




































































































7.5.2.5 Relationship between neurolysin level and APOE genotype 
 
APOE genotype (APOE ε4 allele) is one of the major risk factors of AD. The relationship between 
neurolysin and APOE genotype was explored. Neurolysin level was significantly reduced in AD cases 
or individuals with one or two APOE ε4 alleles. The median for unadjusted neurolysin level in APOE 
ε4 negative cases= 8.037 (ng/ml) compared to APOE ε4 positive cases= 7.449 (ng/ml), (p= 0.045) 
(Figure 7.8 A). There was no difference in protein-adjusted neurolysin level in relation to the presence 
or absence of APOE ε4 allele (p= 0.219) (Figure 7.8 B).  
 
 
Figure 7.8 Relationship between neurolysin level and APOE genotype 
A. Bar chart showing reduced neurolysin level in the presence of one or two APOE ε4 alleles (1) 
compared to cases with the absence of an APOE ε4 allele (0). Differences between groups were 
compared using Mann-Whitney test (p= 0.045). The bars indicate the median and 95% confidence 
intervals. B. Bar chart showing no significant difference in neurolysin protein-adjusted measurement in 
association with the presence or absence of APOE ε4 allele (p= 0.219). The bars indicate the median 
and 95% confidence intervals. 
 
7.5.2.6 Neurolysin level in relation to brain RAS markers 
 
The relationship between Ang-II level and neurolysin level was also assessed. Total unadjusted 
neurolysin level and protein-adjusted neurolysin level both correlated inversely with Ang-II level 
















































Similar investigations with Ang-III showed that unadjusted neurolysin was also correlated inversely 
with Ang-III level (Spearman’s correlation coefficient r= -0.224, p= 0.030) but no significant 
correlation was found between protein-adjusted neurolysin data and Ang-III level (Spearman’s 
correlation coefficient r= -0.005, p= 0.595) (Figure 7.9 C and D).  
 
 
Figure 7.9 Relationship between neurolysin level and Angiotensin-II and Angiotensin-III.  
A. Scatterplot showing a significant inverse correlation between neurolysin level and Ang-II level 
(measured by enzyme-linked immunosorbent assay), Spearman’s correlation coefficient (r= -0.238, p= 
0.012). B. Scatterplot showing a significant inverse correlation between neurolysin protein-adjusted 
level and Ang-II level, Spearman’s correlation coefficient (r= -0.258, p= 0.006). C. Scatterplot 
showing a significant inverse correlation between neurolysin level and Ang-III level (measured by 
enzyme-linked immunosorbent assay), Spearman’s correlation coefficient (r= -0.224, p= 0.030). D. 
Scatterplot showing no correlation between neurolysin protein-adjusted level and Ang-III level, 
Spearman’s correlation coefficient (r= -0.055, p= 0.595). The solid inner line indicates the best-fit 







































































































Both unadjusted neurolysin and protein-adjusted neurolysin level were also significantly inverse 
correlated with the Ang-II:Ang (1-7) ratio (Spearman’s correlation coefficient r= -0.192, p= 0.043) and 
(Spearman’s correlation coefficient t r= -0.276, p= 0.003) respectively (Figure 7.10 A and B). 
 
 
Figure 7.10 Relationship between neurolysin level and the ratio of Ang-II:Ang (1-7).  
A. Scatterplot showing a significant inverse correlation between neurolysin level and the Ang-II:Ang 
(1-7) ratio, Spearman’s correlation coefficient (r= -0.129, p= 0.043). B. Scatterplot showing a 
significant inverse correlation between neurolysin protein-adjusted level and Ang-II:Ang (1-7) ratio, 
Spearman’s correlation coefficient (r= -0.276, p= 0.003). The solid inner line indicates the best-fit 




7.5.2.7 Neurolysin level in relation to markers of ischaemia and brain tissue oxygenation  
 
Neurolysin level was dysregulated in relation to cerebral ischaemia (593). VEGF level is increased and 
the MAG:PLP1 ratio reduced in AD (314). I explored the relationship between neurolysin and markers 
of ischaemia and tissue oxygenation in AD. A significant inverse correlation was observed between 
protein-adjusted neurolysin level and VEGF level (Spearman’s correlation coefficient r= -0.345, p= 
0.015) (Figure 7.10 B). No significant correlation was found between unadjusted neurolysin and 
VEGF level (Spearman’s correlation coefficient r= 0.129, p= 0.369) (Figure 7.11 A). In contrast, both 
unadjusted neurolysin and protein-adjusted neurolysin data were not associated with MAG:PLP1 ratio 
(Spearman’s correlation coefficient r= 0.045, p= 0.753; Spearman’s correlation coefficient r= 0.145, 
p= 0.315) respectively. 
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Figure 7.11 Relationship between neurolysin level and ischemic marker (VEGF) 
A. Scatterplot showing no significant correlation between neurolysin level and VEGF level (measured 
by enzyme-linked immunosorbent assay), Spearman’s correlation coefficient (r= 0.129, p=0.369). B. 
Scatterplot showing a significant inverse correlation between neurolysin protein-adjusted level and 
VEGF level, Spearman’s correlation coefficient (r= -0.342, p= 0.015). The solid inner line indicates 
the best-fit linear regression and the outer lines the 95% confidence intervals. Blue dots= controls, red 
dots= AD cases. 
 
 
7.5.3 Neurotensin level in AD 
 
7.5.3.1 Comparison of neurotensin level in controls and AD  
 
Neurotensin level and protein-adjusted neurotensin levels were not statistically different between AD 
cases (n= 70) and controls (n= 48) (Figure 7.12 A and B). The mean ± SEM for unadjusted neurotensin 
level was: controls= 746.9 ± 19.2pg/ml and AD= 751 ± 16.47pg/ml. Unpaired samples t-test showed 
no statistical significance between groups (p= 0.875). The median for neurotensin protein-adjusted 
data in AD cases was slightly numerically lower in AD (= 2096 (pg/mg total protein)) than in controls 
(= 2245 (pg/mg total protein)), however, a Mann-Whitney test showed no statistical significant 
difference between the groups (p= 0.259). 
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Figure 7.12 Measurement of neurotensin level in Alzheimer’s disease compared to age-matched 
controls.  
Neurotensin level was measured by sandwich ELISA in AD (n= 70) and age-matched controls (n= 48) 
in mid-frontal cortex measured using a neurotensin sandwich ELISA. A. Bar chart showing neurotensin 
level was unchanged in AD, unpaired samples t-test (p= 0.875). The bars indicate the mean ± SEM. B. 
Bar chart showing protein-adjusted neurotensin level did not differ in AD, Mann-Whitney test (p= 
0.259). The bars indicate the median and 95% confidence intervals.  
 
 
7.5.3.2 Neurotensin level in relation to disease severity 
 
The neurotensin level in mid-frontal cortex was assessed in relation to Braak tangle stages (0-II (n= 
36), III-IV (n= 20), V-VI (n= 61)). One-Way ANOVA test indicated no significant difference was 
present when the mean neurotensin levels were compared between Braak stage groups (p= 0.528) 
(Figure 7.13 A). The mean of Braak stage 0-II= 749.245 (pg/ml), Braak stage III-IV= 719.254 (pg/ml) 
Braak stage V-VI= 759.076 (pg/ml). For neurotensin protein-adjusted level, Kruskal-Wallis test 
indicated no significant difference of the medians between Braak stage groups (p= 0.683) (Figure 7.13 
B). The median of Braak stage 0-II= 2157.280 (pg/mg total protein), Braak stage III-IV= 2093.885 


























































Figure 7.13 Neurotensin level in relation to Braak tangle stage. 
A. Bar chart showing no significant difference in neurotensin level measured by sandwich ELISA 
between Braak tangle stage groups (Braak stage 0-II (n= 36), Braak stage III-IV (n= 20), Braak stage 
V-VI (n= 61)), One-Way ANOVA test (p = 0.528). The bars indicate the mean ± SEM. B. Bar chart 
showing no significant difference in neurotensin protein-adjusted measurement between Braak tangle 
stage groups (Braak stage 0-II (n= 36), Braak stage III-IV (n= 20), Braak stage V-VI (n= 61)), 
Kruskal-Wallis test (p= 0.683). The bars indicate the median and 95% confidence intervals. 
 
 
7.5.3.3 Neurotensin level in relation to traditional pathological hallmarks 
 
No significant correlation was found between neurotensin level and total insoluble Aβ (Pearson’s 
correlation coefficient r= 0.023, p= 0.831) (Figure 7.14 A) or tau load in mid-frontal cortex (Pearson’s 
correlation coefficient r= 0.067, p= 0.510) (Figure 7.14 C). Spearman’s correlation coefficient test 
showed no significant correlation between neurotensin protein-adjusted level and both total insoluble 
Aβ (Spearman’s correlation coefficient r= 0.003, p= 0.977) and tau load (Spearman’s correlation 






























































Figure 7.14 Relationship between neurotensin level and total insoluble Aβ and tau load.  
A and C. Scatterplots showing no correlation between neurotensin level and total insoluble Aβ 
(measured by enzyme-linked immunosorbent assay), Pearson’s correlation coefficient (r= 0.023, p= 
0.831) and tau load (measured by field fraction analysis), Pearson’s correlation coefficient (r= 0.067, 
p= 0.510). B and D. Scatterplots showing no significant correlation between neurotensin protein-
adjusted level and total insoluble Aβ, Spearman’s correlation coefficient (r= 0.003, p= 0.977) and tau 
load Spearman’s correlation coefficient (r= 0.154, p= 0.125). The solid inner line indicates the best-fit 




Neurotensin level did not correlate with insoluble Aβ40 (Pearson’s correlation coefficient= 0.056, p= 
0.682) or Aβ42 (r= 0.036, p= 0.791) (Figure 7.15 A and C). Protein-adjusted neurotensin level was not 
correlated with either insoluble Aβ40 (r= -0.030, p= 0.825) or Aβ42 (r= 0.074, p= 0.589) using 

































































































Figure 7.15 Relationship between neurotensin level and insoluble Aβ40 and insoluble Aβ42.  
A and C. Scatterplots showing no correlation between neurotensin level and insoluble Aβ40 (measured 
by enzyme-linked immunosorbent assay), Pearson’s correlation coefficient (r= 0.056, p= 0.62), and 
insoluble Aβ42 (r= 0.036, p= 0.791). B and D. Scatterplots showing no significant correlation between 
neurotensin protein-adjusted level and insoluble Aβ40, Spearman’s correlation coefficient (r= -0.030, 
p= 0.824) or insoluble Aβ42, Spearman’s correlation coefficient (r=0.074, p= 0.589). The solid inner 
line indicates the best-fit linear regression and the outer lines the 95% confidence intervals. Blue dots 





































































































This chapter explored the expression and distribution of the non-AT1R and non-AT2R RAS binding 
site (neurolysin) and its substrate (neurotensin) in relation to AD pathogenesis. I report for the first 
time that neurolysin expression in the mid-frontal cortex was reduced in AD in association with 
disease severity, brain RAS markers, APOE ε4 and a marker of ischaemic damage (VEGF). In 
contrast, neurotensin level in the mid-frontal cortex was unchanged in AD and was not associated with 
disease pathology. These data suggest that dysregulation of neurolysin may play an important role in 
modulating brain RAS and vascular dysfunction in AD and has been largely overlooked to-date. 
 
The role of neurolysin as a metalloendopeptidase that is involved in the degradation of numerous 
bioactive peptides makes it interesting in relation to AD. That it has been identified as a novel non-
AT1R/AT2R binding site in brain RAS and cleaves both Ang-II and Ang-III (275, 590, 593, 598) is 
also interesting in relation to the angiotensin hypothesis of AD (538). Dysregulation of neurolysin has 
been previously associated with the pathophysiology of stroke and hypertension, both of which are risk 
factors for AD, yet few studies have explored its potential role in AD pathogenesis (275, 593, 617).  
 
This is the first study, to the best of my knowledge, of neurolysin expression in human post-mortem 
brain tissue in AD. My novel findings indicated that neurolysin level was significantly reduced in the 
mid-frontal cortex in post-mortem brain tissue in AD in association with markers of disease severity. 
This reduction was inversely correlated with Ang-II, Ang-III levels and the Ang-II:Ang (1-7) ratio in 
AD. These observations are in keeping with previous studies that reported a neuroprotective role of 
neurolysin in the degradation of both Ang-II and Ang-III into inactive metabolites (275, 593) but also 
consistent as a possible contributory factor for the excess levels of Ang-II and Ang-III that have been 
reported in AD (393, 417). Thus, these findings suggest that reduction of neurolysin could be an 
important contributor to the overactivation of the cRAS in AD.  
 
Despite observed lower levels of neurolysin in AD and a relationship with some of the key markers of 
cRAS, I did not find any significant correlations between neurolysin level and total insoluble Aβ, tau 
load, insoluble Aβ40 and insoluble Aβ42. These findings are unexpected given recent data indicating a 
role of neurolysin in degradation of Aβ (602). Neurolysin level did not significantly change with age 
and PMD but was significantly reduced in female and in AD cases or individuals with one or two 
APOE ε4 alleles. Neurolysin level was inversely correlated with VEGF level, a marker of brain 
ischaemia that is elevated in AD (314). Yet, these findings of reduced neurolysin in association with 
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VEGF in AD, might appear at odds with a previous study that found neurolysin was up-regulated in 
stroke (593, 601). These differences might be explained by the duration or scale of the cerebral 
ischaemia that is evident in both diseases, where up-regulation of neurolysin expression observed after 
stroke corresponded to acute ischaemia, possibly as a compensatory mechanism, whilst in AD there is 
a lower and more chronic level of ischaemia. Yet, together these data indicate a consistent role of 
neurolysin in different degenerative disorders of the brain and point to a possibly important role in 
vascular dysfunction in AD that requires further characterisation in future studies. 
 
Immunohistochemical staining was also performed to explore the expression and distribution of 
neurolysin. This revealed positive neuronal staining in the mid-frontal cortex. This supports previous 
findings that also reported similar neurolysin expression patterns in neurons within the brain (595-
597). Immunohistochemical studies in rodent brains have also reported positive neurolysin staining 
within glia (596), however, I did not observe obvious positive staining of neurolysin in non-neuronal 
cells. Neurolysin immunostaining was similar between controls, AD and VaD brain tissue sections 
examined, although quantification of neuronal labelling was not possible and the study was performed 
in a small sample set in contrast to the ELISA measurements of neurolysin in a larger cohort.  
	
	
Neurotensin is a neuroendocrine peptide that metabolised by neurolysin. Previous studies with a small 
sample size have reported reduced neurotensin protein and mRNA levels, as well as reduced levels of 
two of its receptors (NTSR1 and NTSR2) in post-mortem brain tissue of AD patients (614, 618). 
Contrary to expectation, we did not find a significant difference in neurotensin level, measured by 
ELISA, between AD cases and age-matched controls in the mid-frontal cortex. The discrepant findings 
may be explained by regional differences and/or different methodological approaches, as previous 
studies have examined neurotensin expression in the amygdala by IHC (606) or neurotensin level has 
been measured by real time-RT-PCR in the temporal cortex (614). In these studies, a modest reduction 
in neurotensin mRNA was observed compared to more obvious loss of expression of NTSR1 and 
NTSR2 in AD. Reduced NTSR was also reported in post-mortem hippocampal tissue, using 
autoradiography the authors detected a 57% reduction in entorhinal region (612). However, the small 
sample size of this study (8 AD cases compared to 9 controls) warrants caution in interpreting these 
results. To the best of our knowledge this is the first study to have measured neurotensin level by 
quantitative ELISA in the mid-frontal cortex of AD patients in a large cohort. The discrepant findings 
for neurotensin level in AD prompts a need for further investigations in independent cohorts, using a 
	 200 
combination of different methodological approaches, to confirm or refute the involvement of 
neurotensin in AD pathogenesis.       
 
 
This study has several limitations: we only measured neurotensin expression in AD by one 
methodological approach (ELISA) and this was restricted to one brain area (mid-frontal cortex) in AD. 
Other studies indicate that neurotensin is highly distributed in the hippocampus so this should be an 
area of interest in future studies. It will also be of interest to explore the distribution of neurotensin in 
different brain areas and by other methods such as reverse transcription-polymerase chain reaction 
(RT-PCR) and immunohistochemical studies. It would be interesting to determine if neurotensin 
expression varied in other types of dementia especially vascular dementia. In addition, further 
characterisation of the NTSR in human post-mortem brain tissue would also provide further 
information about this pathway in AD.  
 
In conclusion, my findings provide novel evidence of reduced neurolysin level and its association with 
brain RAS markers and vascular dysfunction in AD. Further studies are now required to characterise 






Chapter 8. General discussion and Conclusions 
 
 
The now increasingly recognised association between overactivity within the cRAS and AD has 
framed a rapid growth in research to better understand the mechanisms behind this interaction and the 
scope for translational and intervention opportunities not only for AD but also increasingly in a 
number of related, overlapping neurodegenerative conditions.  
 
Studies in animal models have indicated that ICV infusion of Ang-II accelerated both Aβ and Tau 
deposition, which was associated with cognitive decline. Notably, cRAS-blockers that are available for 
the treatment of hypertension, a risk factor for AD, rescued these deficits to varying degrees or reduced 
the extent of pathology and rate of progression observed. The translational potential and importance of 
these pre-clinical findings are consistent with the reported findings of several clinical and 
epidemiological studies that indicate that ACEIs and ARBs reduce the incidence and delay the 
progression of AD. The real test will come from the results of various clinical trials that are underway 
in AD patients or related populations of mild cognitive impairment to determine if cRAS-targeting 
medication may be of therapeutic benefit in AD patients (538).  
 
Despite our increased understanding of RAS in AD there are still many gaps in our knowledge. Herein 
I have presented data that explores the divergent role of ACE-1 activity in AD. I have explored the 
apparent contradictory role of ACE-1 to generate Ang-II (disease-promoting) but also potentially 
cleave and degrade Aβ42 (disease-protective) in AD. I have also investigated further the expression 
and behaviour of two major rRAS pathways in AD (ACE-2/Ang (1-7)/MasR) and the alternative 
(APA/Ang-III/APN/Ang-IV/IRAP) in relation to AD. These more recently identified pathways are 
thought to counter-regulate the potentially harmful effects of cRAS and are also notably directly 
implicated in learning and memory. Lastly, I have undertaken exploratory studies on a number of new 
and less well characterised RAS pathways. These include the non-AT1R and non-AT2R binding 
receptor and associated enzyme (Neurolysin) within RAS in relation to AD. I have also undertaken 
some exploratory studies to try and further our understanding of the specificity of commercial 
antibodies for the AT1R and AT2R receptors (presented in Appendix XI). In summary, this thesis 
presents data that continues to indicate and support previously findings that both cRAS and rRAS 
pathways are dysfunctional in AD and provides further insights into the complex relationship between 
the RAS and AD pathogenesis.  With these new findings the following research questions can be 
posed and explored further. 
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8.1 Could divergent ACE-1 C-domain and N-domain activities provide a new 
therapeutic target for AD?  
 
 
The role of ACE-1 has been extensively investigated in AD. Several reports have demonstrated an 
association between increased ACE-1 and AD pathogenesis (78, 90, 155, 311, 354, 357). The role of 
ACE-1 in AD is certainly complex. On the one hand, ACE-1 is responsible for the generation of Ang-
II and is associated with several aspects of disease pathogenesis. ACE-1 activity is elevated in AD in 
human post-mortem studies in relation to parenchymal Aβ load (78, 311, 354, 357). ACEIs improve 
cognitive function and disease pathology in animal models of AD (360, 361, 515, 619) and slow the 
progression and reduce the incidence of AD in human epidemiological studies (364, 365, 367-370, 
520, 542). In contrast, ACE-1 has also been shown to cleave and degrade Aβ42 in vitro (81-83, 347, 
549, 550) – ACE-1 mediated degradation of Aβ generates cleavage products that are potentially less 
neurotoxic and therefore potentially more easily cleared. There is also an established literature in 
which in vitro and in vivo studies have shown that the use of ACEIs increases both Aβ40 and Aβ42 
level and inhibits the degradation of Aβ42 (79, 81, 343, 347, 518, 519). Previous genetic evidence has 
linked lower serum/CSF ACE-1 level with increased AD risk indicated by an association with ACE 
genotype and accumulation of Aβ in the brain (86, 620, 621). We propose that the inconsistencies in 
some previous findings reflect the variable affinities of different ACEIs for each ACE-1 domain 
(which are responsible for Ang-II generation and Aβ cleavage respectively).  
 
Herein, I have shown for the first time a disease-related change in ACE-1 catalytic domain activity in 
AD. Previous studies have highlighted the domain-specificity of ACE-1: the C-domain is largely 
responsible for converting Ang-I to Ang-II (547) whereas the N-domain is involved in Aβ degradation 
(82, 343, 549). I have now found that in AD, ACE-1 C-domain activity, largely responsible for Ang-II 
production (343, 344, 547) was increased and was positively correlated with insoluble total Aβ and 
insoluble Aβ42 level, whilst N-domain activity, potentially contributing to Aβ cleavage and clearance, 
was reduced in AD. These novel data provide further insight and a possible explanation for the 
apparent divergent role of ACE-1 in AD where the combined effect of the domain-specific alterations 
would favour Ang-II mediated disease progression but also result in impeded Aβ clearance (via 
reduced N-domain activity) (550). This imbalance in the activity of the two ACE-1 catalytic domains 
might therefore resolve the conflicting findings in previous studies regarding the role of ACE-1 
domains in AD e.g. both ACE-1 catalytic domains involved in Aβ cleavage (345, 346). 
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My findings may also provide for the first time, a possible mechanistic explanation for the apparent 
discrepant findings in previous pharmaco-epidemiological studies comparing different ACEIs and AD 
risk and progression i.e. where some have been found to reduce risk of AD (364, 365), where 
following adjustment for prescribing bias that they have no protective effect, or that ACEIs might even 
be more harmful (368, 544). My findings point to potentially far-reaching implications in clinical 
populations since different ACEIs have been reported to have higher affinities and domain selectivity 
e.g. clinically prescribed lisinopril, or experimental drugs like RXP380 and proline-rich oligopeptides 
(PRO8)) have C-domain specificity (343, 344, 372, 373, 376, 622). Any selective C-domain inhibitors 
will likely inhibit Ang-II production while preserving Aβ metabolism i.e. since N-domain activity 
should not be unaltered. These findings warrant further experimental investigations to characterise the 
domain-specificity of the ACEIs currently prescribed for the treatment of hypertension with respect to 
their inhibitory effects on the activity of the two ACE-1 domains. I suggest that selective C-domain 
ACEIs may have greater therapeutic benefit for AD. 
    
 
 8.2 Are the rRAS pathways altered in AD in relation to vascular dysfunction? 
 
The cRAS pathway and its associated elevated activity is well-established in AD. However, attention 
has more recently begun to be focussed on the brain rRAS pathways. The rRAS pathways are 
responsible for the metabolism of Ang-II. These metabolites, that were originally thought to be 
inactive, have now been shown to have important biological functions. The two main axes of rRAS: 
the non-classical axis (ACE-2/Ang (1-7)/MasR) and the alternative (APA/Ang-III/APN/Ang-IV/IRAP) 
pathway counter-regulate cRAS signalling. Importantly, dysregulation of the rRAS has been 
implicated in several neurodegenerative and cerebrovascular disorders (330, 419, 429, 430, 433, 458, 
574). Interestingly, these pathways are highly expressed within the hippocampus and basal forebrain 
and have been shown to be directly involved in learning and memory. The role of these pathways in 
AD is now becoming an area of increased interest and investigation. In recent studies, we found that 
the activity of ACE-2 (an enzyme involved in the generation of Ang  (1-7) from Ang-II) was reduced 
in AD, concomitantly with increased ACE-1, and was strongly related to disease pathology. Notably, 
restoration of ACE-2 activity, or Ang (1-7) infusion, has been shown to be protective against cognitive 
decline and disease pathology in mouse models of AD (295, 434, 440). Yet, the expression and 
behaviour of these rRAS pathways remains poorly characterised in the human brain and its possible 
association with AD pathology and vascular dysfunction remains unclear. The intention of the work 
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described in chapters 4, 5 and 7 was to further investigate the major components of the rRAS pathways 
(Ang (1-7), MasR, Ang-IV, IRAP level and activity) in relation to AD pathogenesis and vascular 
dysfunction in post-mortem human brain tissue.  
 
 
In these studies, I found that the ratio of Ang-II:Ang (1-7) was increased in AD in keeping with our 
previous study showing reduced ACE-2 activity in AD (417). Despite the observed reduction of ACE-
2 activity in AD, I present new data showing that the levels of Ang (1-7) were unaltered in AD as was 
MasR expression in the same cases. MasR was predominantly expressed by pyramidal neurons within 
the neocortex, although neither Ang (1-7) nor MasR expression was related to amyloid or tau 
pathology. The implications of these findings are somewhat difficult to interpret as to-date there are 
only a few studies that have investigated the Ang (1-7)/MasR pathways in AD. These were two studies 
with different study samples, one using animal brain tissue and the other reporting on human plasma 
and both used different methods to those I employed here. In the first study, Ang (1-7) levels were 
reduced in an animal model of sporadic AD in two different brain regions (hippocampus and cerebral 
cortex) and inversely correlated with tau hyperphosporylation. Despite the reduction of Ang (1-7) and 
similar to our finding, this study reported no significant reduction of MasR expression in AD (416). 
The same group conducted another study in human plasma and reported that plasma Ang (1-7) levels 
were reduced in AD patients and positively correlated with cognitive decline. However, in this study 
no reduction of ACE-2 activity was observed (435). These findings, along with my own findings are 
somewhat puzzling as one might expect to see changes in levels of Ang (1-7) with respect to reduced 
ACE-2 activity. Similarly, one might expect to see any changes in Ang (1-7) reflected by some 
changes in MasR given their relationship with respect to signalling.  
 
Some of the apparent inconsistence across studies may simply reflect differences in study subjects 
(animal vs. human), the methods used to measure Ang (1-7)(different ELISA, in-house direct vs. 
commercially ELISA kit), different methods to measure MasR (western blot vs. ELISA) and ACE-2, 
and regional difference (hippocampus vs. mid-frontal cortex). Aspects of PMD or sample processing 
of blood plasma and timelines for the preparation of animal tissue might also contribute however this 
is largely speculative. Another possible explanation is that ACE-1 is involved in the formation of Ang 
(1-9) forming alternate processing pathways involved in rRAS signalling. These angiotensin peptides 
and alternative processing pathways remain almost completely uncharacterised in human brain tissue 
at present. It will be important to confirm in future studies whether Ang (1-7) and MasR are related to 
AD, as well achieve a better understanding of both ACE-1 and ACE-2 in the dynamics of this 
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relationship. My studies here suggest that although ACE-2 activity is reduced in AD that some of the 
downstream pathways remain unaltered although, as mentioned, alternative uncharacterised rRAS 
pathways may be involved.  
 
 
In this thesis I also investigated the main components of the downstream alternative pathway of brain 
RAS (APA/Ang-III/APN/Ang-IV/IRAP) in relation to AD pathogenesis and vascular dysfunction. 
Previous findings indicated that the upstream components of this rRAS pathway (e.g. Ang-III) are 
dysregulated and associated with AD pathogenesis (393). Based on this previous evidence and other 
experimental animal studies that showed beneficial effects of Ang-IV treatment on Aβ related 
cognitive decline (479, 482, 484, 493), I expected to see a reduction of the downstream rRAS pathway 
in AD. Contrary to expectations, I found that Ang-IV and IRAP protein expression within the mid-
frontal cortex, the latter being predominantly expressed in pyramidal neurons, were unchanged in AD. 
IRAP enzyme activity, arguably the more biologically relevant measure, was reduced in AD in 
association with disease severity and Aβ and tau load. These findings are in keeping with a previous 
study that reported a reduction of IRAP activity in the plasma of AD patients (258). Yet, these findings 
seem incongruent with previous studies in animal models that have reported the protective effects of 
IRAP inhibitors (i.e. that would lower IRAP activity) against cognitive decline (474, 479, 484, 493). 
Considering the complex structure and function of IRAP and its complex role in AD and in relation to 
other RAS markers (459), these novel preliminary findings require further investigation in the context 
of AD. It is possible that the observed reduction in IRAP activity in AD in this study corresponds to a 
compensatory response to disease pathology. Yet, Ang-IV and IRAP protein levels were unchanged in 
AD. The reason for the discrepancy between protein and enzyme activity is unclear; future studies 
should perhaps try to characterise the expression and distribution of the RNA transcript to clarify this 
surprising observation or the extent to which the activity of the enzyme might be influenced by post-
translational modifications that are also modulated by the disease process. Thus, levels of IRAP 
protein might continue to be maintained, or even slightly elevated to try and compensate for the lack of 
activity that the disease might be directly influencing. 
 
I also explored the relationship between brain rRAS pathways and markers of cerebral ischaemia 
(VEGF) and hypoperfusion (MAG:PLP1). In this smaller cohort, I found for the first time that MasR 
expression adjusted to total protein level was inversely correlated with VEGF, a marker of brain 
ischaemia. Similarly, I found that Ang-IV and IRAP protein levels, which were unchanged in AD, 
were both inversely correlated with VEGF. In contrast, the expression of MasR, Ang-IV and IRAP did 
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not correlate with MAG:PLP1 ratio, a novel marker of brain tissue oxygenation in post-mortem brain 
tissue, which reflects changes in brain perfusion several months prior to death (312-315). These data 
suggest that the downstream brain rRAS pathways are associated with cerebral ischaemia in AD, 
reinforcing the interaction between rRAS and cerebrovascular dysfunction in AD. Larger independent 
studies are now required to further investigate and validate these preliminary observations and should 
be focussed on addressing causality and the direction of the observed relationships. In summary, my 
data supports previous studies suggesting that downstream rRAS pathways are potentially 
dysfunctional in AD in relation to vascular changes, rather than classical markers of disease pathology, 
namely Aβ and Tau.   
 
 
8.3 Is non-AT1R and non-AT2R binding protein expression in AD related to 
markers of disease pathology and vascular dysfunction in AD?  
 
 
The cRAS elicits its biological effects through activation of the GPCRs (AT1R and AT2R) (255, 267, 
269). A novel non-AT1R and non-AT2R binding protein was discovered in human and rat brain and 
was identified as a zinc metalloendopeptidase known as neurolysin (587, 588). Dysregulation of 
neurolysin has been reported to be associated with the pathophysiology of stroke and hypertension 
with little evidence of its role in AD pathogenesis (275, 593, 617). My novel findings indicate that 
neurolysin level is significantly reduced in the mid-frontal cortex in post-mortem brain tissue in AD in 
association with disease severity (Braak tangle stage). This reduction in neurolysin was inversely 
correlated with Ang-II, Ang-III levels and the Ang-II:Ang (1-7) ratio in AD. These interesting 
observations are in agreement with previous studies that have reported a neuroprotective role of 
neurolysin in the degradation of both Ang-II and Ang-III into inactive metabolites (275, 593). The 
possible role of neurolysin in Ang-II and Ang-III metabolism, which works by internalising and 
facilitating the degradations of these angiotensins, thus limiting their access to AT1R, is interesting. 
Thus the observed reduction of neurolysin in AD is another level of evidence in support of the 
angiotensin hypothesis of AD.  
 
I also investigated whether the reduction of neurolysin was related to markers of ischaemia e.g. VEGF 
and hypoperfusion e.g. MAG:PLP1 in AD. Interestingly, the reduced level of neurolysin was inversely 
correlated with VEGF level, a marker of brain ischaemia (that is elevated in AD brain), but not with 
MAG:PLP1 in these tissue samples (314). These findings contrast with those in a previous study 
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reporting that neurolysin was up-regulated in early phase (after 7 days) post-acute stroke in mouse 
brain (593, 601). The duration of cerebral ischaemia (acute vs. chronic) and study subject (animal vs. 
human) could explain the inconsistences with previous studies.  
 
In summary, my novel findings suggest that a reduction of neurolysin could contribute to the 
overactivation of cRAS reported in AD (because the levels of Ang-II and Ang-III signaling are less 
well controlled), and similarly are associated with vascular dysfunction, both of which now require 
further characterisation in future studies. 
 
 
8.4 Study Limitations  
 
In this study, I have attempted to map the distribution and expression of human RAS in AD. These 
studies have been performed in relatively large cohorts that were previously characterised in terms of 
disease pathology (Aβ and Tau) and disease severity. I have identified a number of novel findings in 
relation to RAS changes in AD: domain specific alterations in ACE-1, reduction in IRAP enzyme 
activity and lower neurolysin activity in AD in relation to increased Ang-II and Ang-III. In contrast, I 
did not detect any change in angiotensin level (Ang-IV and Ang (1-7)) and failed to detect any change 
in the expression of MasR and IRAP protein level in AD. Preservation of brain proteins is an important 
factor that could affect the stability of the endogenous protein level (546, 623). Both Ang (1-7) and 
Ang-IV for example ordinarily have a short half-life in serum/plasma that could be affected by long 
PMD in post-mortem brain tissue (528). Other peptides, such as Ang-II and another vasoconstrictor 
ET-1, are measurable and stable in post-mortem brain tissue (393, 569). Although I found no evidence 
that the measured proteins were altered by PMD and my tissue sample groups were matched in relation 
to PMD, it will be important to confirm the stability of selected angiotensin peptides in brain tissue by 
performing, as for other study, an experimental simulation of PMD on samples for up to 72 hours, at 
room temperature or 4°C. (354). Post-mortem stability may also account for the observation that MasR 
protein levels were unaltered in AD although this would need to be confirmed in larger independent 
studies using more than one experimental approach. 
 
Another limitation of these studies in general is that characterisation of the RAS markers were 
restricted to one brain area (mid-frontal cortex). Investigating other brain regions that are affected in 
AD, such as the temporal cortex and hippocampus, will be interesting especially since studies in 
rodents have indicated that expression of rRAS, for instance, are highly enriched within the 
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hippocampus (246). Again, a general limitation throughout is the reliance on RAS marker 
measurements that were limited to one methodological approach such as ELISA only. It will be 
important to explore the expression and distribution of these proteins by other methods such as RT-
PCR, RNAscope and immunohistochemical studies and to validate our original findings in larger 
independent cohorts. Another limitation in this study, which could have affected the evaluation of the 
relationship between brain RAS markers and AD pathological hallmarks, and that of ischaemic and 
hypoperfusion markers, was the small sample size used, which was determined partly by the numbers 
of tissue samples with previously collected data on VEGF and MAG:PLP1.  
 
 
8.5 Future work 
 
My novel findings of divergent catalytic activity of ACE-1 C-domain and N-domain in AD warrant 
further experimental investigation to explain the underlying mechanisms of this imbalance in AD.  
Some related research questions on this could include the following: 
i. What are the disease-related changes and mechanisms that alter domain-specific ACE-1 
activity in AD?  
ii. Are domain-specific changes related to post-translational modifications?  
iii. Does disease-modified ACE-1 have a higher specificity for Ang-I than in controls? 
iv. Is ACE-1 mediated Aβ cleavage impaired in AD in vivo?  
v. Do certain ACEIs alter levels of ACE-mediated degradation of Aβ and thus pose as potential 
risk factors for AD?  
vi. Are more selective C-domain targeting ACEIs a new therapeutic option for AD? 
 
Other findings of note relate to reduced neurolysin levels that warrant further study. Questions arising 
include: 
i. What is the combined effect of reduced neurolysin and ACE-2 on Ang-II and Ang-III levels, 
compared with ACE-1 activity? 
ii. Are there any licensed pharmacological compounds that might activate neurolysin, which 
might have a net detrimental effect in AD? 
 
Other general questions worth exploring include further study on other RAS metabolites, currently not 
studied, which could influence the activity of rRAS pathways. These include Ang (1-9) and 
	 209 
Angiotensin (3-7). Ang (1-9) is a pre-cursor in the production of Ang (1-7) and might be implicated in 
the rRAS pathway in AD. Angiotensin 3-7 also has a high affinity for IRAP and has been implicated in 
learning and memory.  
 
Similarly, further investigations would be beneficial into the expression of less well known RAS 
receptors, such as MrgD and its agonist (Alamandine), AT4R/ HGF/c-MET subtype receptor in human 
post-mortem brain tissue. These are necessary and will provide new data to broaden our understanding 
of the role of these rRAS components in AD pathogenesis. Further expanded investigations of IRAP 
activity would also be worthwhile as well as exploring the impact of AD-associated IRAP changes on 
glucose metabolism considering the normal intimate relationship between IRAP and GLUT4 
trafficking (497).  
 
I also undertook some initial pilot studies of the possible use of SH-SY5Y cells as a tool to allow more 
experimental investigations of the RAS, particularly allowing investigation of the effects of ischaemia 
and potentially other exposures (e.g. Aβ) on numerous RAS components that could also allow 
subsequent testing or screening of potential pharmacological interventions. Similarly, the scope to 
explore the effects of ischaemia will allow the important study of the role of RAS in VaD, which could 
then be further validated in human tissue and subsequent in vivo studies.  
 
 
8.6 Final conclusions  
 
 
In this thesis, I have uncovered novel domain-specific changes in ACE-1 in AD that could account for 
the discrepant findings within the AD field in relation to more widely studied ACEIs and has the 
potential to pave the way to discovering ACEIs that might exacerbate AD pathology and also the 
identification of domain-specific ACE-1 inhibitors for AD treatment i.e. inhibit Ang-II production 
whilst allowing unhindered Aβ degradation.  I have also been the first to explore and report a reduction 
in the non-AT1R and non-AT2R binding protein (neurolysin) in relation to Aβ, tau and ischaemia in 
AD that has a regulating role in both the cRAS and rRAS pathways but which now requires further 
study in AD. I also report changes of some components within the rRAS pathways (e.g. Ang-II:Ang 
(1-7) ratio and IRAP activity) that have recently been shown to be dysregulated in relation to AD 
pathogenesis (Figure 8.1) and some RAS changes (IRAP and Ang-IV level) that are associated with 
ischaemic markers. More detailed studies may indicate whether the newly identified brain RAS 
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components in the rRAS pathways contribute to AD and are associated with vascular dysfunction that 
could offer new therapeutic targets in AD.  
 
I propose a summary of the role of changes to RAS in AD that I have identified in this thesis and 
present in the following schematic (Figure 8.1). With these newly found changes in mind I also 
provide a further summary update of reported changes in RAS to-date that incorporate my new 
findings and that clearly show the extent to which RAS changes continue to be found in relation to AD 
(Figure 8.2). 
 
Figure 8.1 Levels and activities of RAS components in the AD brain compared to controls 
identified in this thesis.  
Up pointed green arrow indicates a significant increase of the RAS component in AD compared to 
age-matched controls in the mid-frontal cortex. Down pointed red arrows indicates a significant 
decrease in either protein level or activity. Horizontal black arrows indicate unchanged of the protein 
level in AD compared to controls.  
ACE-1 - Angiotensin converting enzyme 1, ACE-2 - Angiotensin converting enzyme 2, APA -
Aminopeptidase A, APN - Aminopeptidase N, APB - Aminopeptidase B, ASAP - Aspartyl 







Figure 8.2 Summary update of reported changes in RAS components in the AD brain compared 
to controls. 
Up pointed green arrow indicates significant increase of the RAS component in AD compared to age-
matched controls in the mid-frontal cortex. Down pointed red arrows indicated significant decrease in 
either protein level or activity. Horizontal black arrows indicate unchanged of the protein level in AD 
compared to controls identified in this thesis. Up pointed and down pointed blue arrows indicated 
significant increase or decrease of other brain RAS components in AD identified previously (Miners et 
al., 2008; Kehoe et al., 2016; Kehoe et al., 2017).  
ACE-1 - Angiotensin converting enzyme 1, ACE-2 - Angiotensin converting enzyme 2, APA -
Aminopeptidase A, APN - Aminopeptidase N, APB - Aminopeptidase B, ASAP - Aspartyl 




Chapter 9. Appendices 
 
9.1 Appendix I: Study cohorts 
 
9.1.1 Control cohort 
 
Table 9.1 Demographic and neuropathological characteristics for the control cohort cases used 















1 62 M 4 0 ID 3.4 
16 95 F 46 II ID 2.3 
36 78 F 24 II ID  
48 83 M 80 III ID 3.3 
50 71 M 25 I DD 3.3 
57 82 F 35 III II  
66 64 M 12 II ID 3.4 
69 64 M 16 0 DD 3.3 
72 72 M 42 I ID 3.3 
73 80 M 106 II DD 3.3 
74 90 M 45 II DD 2.3 
75 83 M 86 II ID  
79 81 F 103 II DD 3.3 
81 64 M 23 II DD 3.3 
84 77 M 55 I ID 3.3 
95 73 M 36 II ID 3.3 
98 88 F 62 II II 3.3 
103 76 F 106 II ID 3.3 
106 88 F 72 0 DD 3.3 
110 93 F 18 II ID 3.3 
112 80 F 92 0 DD 3.3 
120 88 F 28 II DD 3.3 
122 82 M 30 II II 3.3 
127 84 M 48 III II 3.3 
128 90 M 48 II DD 3.3 
130 75 M 48 II ID 3.3 
141 89 F 15 I ID 3.3 
147 73 M 33 II ID 2.3 
150 69 M 66 II DD 3.3 
206 73 F 59 III DD 3.3 
254 90 M 40 II DD 3.3 
259 89 M 91 II DD 3.4 
269 83 F 24 II ID 3.3 
295 82 M 3 II DD 3.3 
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328 43 F 12 . DD  
333 84 F 17 I ID 2.3 
336 82 F 37 II ID 4.4 
338 53 M 7 III ID 3.3 
355 78 M 48 I II 3.3 
390 82 M 56 II II 3.3 
402 76 M 23 II ID 3.3 
412 82 F 96 III ID 3.4 
461 77 M 10 III DD 2.3 
467 75 M 6 III .  
597 93 F 53 III ID 2.4 
678 84 F 216 II DD 3.4 
714 73 M 35 III DD 3.3 







   
 
9.1.2 AD cohort  
 
















190 89 F 71 V ID 3.3 
196 78 F 77 VI DD 4.4 
205 78 F 9 V ID 3.4 
212 81 F 80 III ID 3.4 
213 81 F 42 VI ID 3.4 
219 77 F 43 IV ID 3.4 
223 71 F 67 V ID 4.4 
224 96 F 53 IV ID 2.3 
228 87 F 72 V ID 3.4 
241 87 F 67 V II 2.4 
242 79 F 70 III ID 3.3 
243 88 F 79 VI DD 3.3 
263 91 F 70 V DD 2.4 
278 78 F 35 VI ID 3.3 
284 82 F 24 VI DD 3.4 
287 85 M 58 IV DD 3.4 
289 91 M 43 III ID 3.3 
290 89 F 82 V DD 3.3 
302 70 F 25 VI ID 3.4 
326 69 M 48 V DD 4.4 
330 74 M 50 V DD 3.4 
341 95 M 48 III ID 3.3 
370 74 F 12 VI ID 3.4 
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378 89 F 4 VI ID 3.4 
400 79 M 28 VI ID 3.4 
405 85 M 66 VI DD 3.4 
424 90 F 21 IV ID 4.4 
426 57 F 24 V ID 3.4 
435 54 F 24 VI II 3.3 
451 84 F 20 V ID 3.4 
470 79 F 72 V DD  
488 74 F 53 V II 4.4 
495 80 M 49 V DD 3.4 
498 83 F 5 V II 3.3 
499 74 F 35 V ID 3.3 
508 80 M 5 V II 3.4 
512 77 F 26 VI DD 3.4 
538 63 M 43 VI ID 3.3 
541 60 F 68 VI II 3.3 
558 64 M 9 VI ID 3.4 
561 74 M 24 V ID 3.4 
562 85 F 49 V II 3.4 
567 68 F 87 VI II 3.4 
568 78 F 21 VI ID 4.4 
572 79 M 84 V ID 3.4 
573 89 F 39 V DD 4.4 
577 77 F 14 VI ID 3.4 
579 84 M 64 V ID 3.4 
580 65 M 90 VI II 3.3 
584 85 F 85 VI II 3.4 
586 80 F 71 VI II 3.3 
592 65 F 22 VI II 3.3 
601 68 M 61 VI II 3.3 
665 88 F 75 V ID 3.4 
670 83 F 85 VI ID 4.4 
681 47 F 54 VI ID  
683 83 M 48 V DD 3.3 
685 74 M 48 V ID 2.3 
687 60 F 5 VI   
691 83 M 99 IV DD 3.4 
697 87 M 36 VI DD 4.4 
713 62 M 25 VI II 3.4 
715 78 M 50 VI II 3.4 
717 85 M 50 VI DD 3.3 
718 98 M 21 V II 3.4 
725 69 M 12 V ID 3.4 
726 61 M 38 V DD 3.4 
731 88 F 88 V ID 3.3 
737 67 F 24 VI ID 4.4 
745 84 F 21 VI  3.3 








9.1.3 Fixed-tissue control cases 
 
Table 9.3 Demographic and neuropathological characteristics of fixed control brain samples 
used in immunohistochemistry study 
 





48 83 M 80 III 
50 71 M 25 I 
72 72 M 42 I 
84 77 M 55 I 
106 88 F 72 0 
122 82 M 30 II 
130 75 M 48 II 
141 89 F 15 I 
355 78 M 48 I 










9.1.4 Fixed-tissue AD cases 
 
Table 9.4 Demographic and neuropathological characteristics of fixed AD brain samples used in 
immunohistochemistry study 
 





205 78 F 9 V 
213 81 F 42 VI 
223 71 F 67 V 
426 57 F 24 V 
451 84 F 20 V 
584 85 F 85 VI 












9.1.5 Fixed-tissue VaD cases 
 
Table 9.5 Demographic and neuropathological characteristics of fixed VaD brain samples used 
in immunohistochemistry study 
  





27 81 M 66 0 
32 84 F 20 II 
78 80 F 70 II 
170 90 F 31 I 
324 84 M 30 II 
347 76 M 40 III 











9.1.6 AD cases and controls used for MasR and IRAP western blotting 
 
Table 9.6 Demographic characteristics and total protein level of samples used in MasR and 











48 83 M 80 5.03 
50 71 M 25 4.19 
72 72 M 42 3.24 
79 81 F 103 4.66 
223 71 F 67 8.4 
212 81 F 80 5.65 
196 78 F 77 3.09 






9.1.7 AD cases and controls used for MrgD and neurolysin western blotting 
 
 
Table 9.7 Demographic characteristics and total protein level of samples used in MrgD and 











336 82 F 37 2.61 
106 88 F 72 6.82 
333 84 F 17 3.47 
120 88 F 28 5.38 
219 77 F 43 3.72 
426 57 F 24 3.83 
243 88 F 79 2.72 
242 79 F 70 5.39 
 
 
9.1.8 Control cohort used in chapter 6 
 
Table 9.8 Demographic and neuropathological characteristics of frozen control cohort cases used 















16 95 F 46 II ID 2.3 
50 71 M 25 I DD 3.3 
72 72 M 42 I ID 3.3 
74 90 M 45 II DD 2.3 
84 77 M 55 I ID 3.3 
98 88 F 62 II II 3.3 
141 89 F 15 I ID 3.3 
147 73 M 33 II ID 2.3 
150 69 M 66 II DD 3.3 
206 73 F 59 III DD 3.3 
269 83 F 24 II ID 3.3 
295 82 M 3 II DD 3.3 
336 82 F 37 II ID 4.4 
355 78 M 48 I II 3.3 
402 76 M 23 II ID 3.3 
714 73 M 35 III DD 3.3 











9.1.9 AD cohort used in chapter 6 
 
Table 9.9 Demographic and neuropathological characteristics of frozen AD cohort cases used in 















190 89 F 71 V ID 3.3 
205 78 F 9 V ID 3.4 
213 81 F 42 VI ID 3.4 
219 77 F 43 IV ID 3.4 
223 71 F 67 V ID 4.4 
224 96 F 53 IV ID 2.3 
228 87 F 72 V ID 3.4 
241 87 F 67 V II 2.4 
242 79 F 70 III ID 3.3 
278 78 F 35 VI ID 3.3 
289 91 M 43 III ID 3.3 
341 95 M 48 III ID 3.3 
370 74 F 12 VI ID 3.4 
400 79 M 28 VI ID 3.4 
405 85 M 66 VI DD 3.4 
451 84 F 20 V ID 3.4 
488 74 F 53 V II 4.4 
498 83 F 5 V II 3.3 
508 80 M 5 V II 3.4 
512 77 F 26 VI DD 3.4 
541 60 F 68 VI II 3.3 
577 77 F 14 VI ID 3.4 
579 84 M 64 V ID 3.4 
592 65 F 22 VI II 3.3 
601 68 M 61 VI II 3.3 
683 83 M 48 V DD 3.3 
685 74 M 48 V ID 2.3 
687 60 F 5 VI   
697 87 M 36 VI DD 4.4 
713 62 M 25 VI II 3.4 
715 78 M 50 VI II 3.4 
725 69 M 12 V ID 3.4 
726 61 M 38 V DD 3.4 
737 67 F 24 VI ID 4.4 













9.2 Appendix II: Materials and methods 
 
9.2.1 Materials 
9.2.1.1 Commercial supplies of equipment  
	
Table 9.10 Details of laboratory equipment used in this study 
 




Balance  European Instruments 
ChemiDoc XRS+ Bio-Rad Laboratories 
Bench top centrifuge MSE Scientific Instruments 
Class II laminar flow hood Holten 
CO2 incubator (maintained at 37°C and 5% 
CO2) 
Thermo Electron Corp. 
Confocal microscope Nikon 
FLUOstar OPTIMA microplate reader                                              BMG Labtech 
Fume hood Surgipath Europe 
Gilson Pipettes Gilson 
Magnetic stirrer and stir bars VWR Jencons 
Mini Trans-Blot®, electrophoretic transfer cell Bio-Rad Laboratories 
Mini-PROTEAN® 3, electrophoresis module Bio-Rad Laboratories 
Oven (37°C) LTE Scientific 
Oven (60°C)                                                                                                       Philip Harris 
pH meter Hanna Instruments 
Plate Incubator/Shaker Thermo Scientific 
Plate shaker Janke & Kunkel Gmbh 
Precellys 24 automated homogeniser                                                                Stretton Scientific 
Refrigerated centrifuge Eppendorf 
Sledge Microtome                                                                                             LEICA Biosystems




9.2.1.2 Commercial consumables  
 
Table 9.11 Details of consumable suppliers used in this study 
 




3-amin-propyl-triethoxy-saline (APES) Sigma-Aldrich 
Accutase Sigma-Aldrich 
Acetonitrile Fisher Scientific 
Aprotinin Sigma-Aldrich 
Β-mercaptoethanol Sigma-Aldrich 
Blotting paper Fisher Scientific 
Bovine serum albumin (BSA) Fisher Scientific 
Bromophenol blue Sigma-Aldrich 
Captopril Biomol 
Cell LyticTM M reagent Sigma-Aldrich 
Clearene Surgipath 
Clear 96 well plates R&D Systems 
Colorometric substrate L-Leucine-p-nitroanilide 
(L-Leu-pNA) 
Sigma-Aldrich 
Cover slips Surgipath 
Decon detergent Decon Laboratories Inc 
Diaminobenzidine (DAB) substrate Kit Vector Laboratories 
Dimethyl Sulfoxide (DMSO) Sigma-Aldrich 
Dulbecco’s modified Eagle medium (DMEM) Sigma-Aldrich 
ECL (Enhanced chemiluminescence) western 
blotting detection reagents 
Millipore 
Eppendorf tubes (0.5 ml, 1.5 ml, 2 ml) Greiner Bio-One 
Ethylenediamine tetraacetic acid (EDTA) Sigma-Aldrich 
Flasks, cell culture with filter cap (75 cm2) Greiner Bio-One 
Fluorogenic substrate (Abz-LFK(DnP)-OH 
Trifluroacetate) 
Sigma-Aldrich 
Fluorogenic substrate (Abz-SDK(DnP)-P Enzo Life Sciences 
Foetal bovine serum (FBS) Sigma-Aldrich 
Glycerol Sigma-Aldrich 
Glycine Fisher Scientific 
Haemotoxylin (Gill II) Surgipath 
Horse serum (blocking serum) Vector Laboratories 
HRP-conjugated streptavidin (Strep-HRP)                                                                           R&D Systems
Hydrogen peroxide (H2O2) Fisher Scientific 
L-Glutamine Sigma-Aldrich 
MarvelTM skimmed milk powder Premier Foods 
Methanol Fisher Scientific 
Microplates: 96-well, black, Nunc® MaxisorpTM Fisher Scientific 
Microscope slides (3” x 1.5”) Cell Path 
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Mini-PROTEAN® TGX TM 4-20% pre-cast gels Bio-Rad Laboratories 
Nitrocellulose transfer membrane (0.45 µm) Fisher Scientific 
Pasteur Pipettes, plastic (3 ml)  Greiner Bio-One 
PAP pen Vector Laboratories 
Phenylmethylsulphonyl fluoride (PMSF) Sigma-Aldrich 
Phosphate buffered saline (PBS)                                           Fisher Scientific 
Pipettes, glass, single wrap (1ml, 5ml, 10 ml, 
25ml, 50 ml)  
Greiner Bio-One 
Pipette tips (10µl, 200µl, 1000µl) Greiner Bio-One 
Plate sealers                                                                                                       R&D Systems 
Precision Plus ProteinTM WesternCTM standards Bio-Rad Laboratories 
Protease inhibitor cocktail Sigma-Aldrich 
Sodium Chloride (NaCl)                                                                                                Fisher Scientific
Sodium dihydrogen orthophosphate 1-hydrate Fisher Scientific 
Sodium dodecyl sulphate (SDS) Sigma-Aldrich 
Sodium hydrogen orthophosphate 12-hydrate Fisher Scientific 
Substrate Reagent (A/B)                                                                                   R&D Systems
Sulfuric Acid (stop Solution) Sigma-Aldrich 
Tris-HCl Sigma-Aldrich 
Triton X-100 Fisher Scientific 
Trypsin-EDTA Sigma-Aldrich 
Tween®-20 (polysorbate-20) Sigma-Aldrich 
VECTASTAIN® ABC kit Vector Laboratories 
Zinc Chloride                                                                                                    Sigma-Aldrich





9.2.1.3 Constituents of commonly used solutions  
 
Table 9.12 Constituents of regularly used solutions 
 
Solutions Constituents Method 
 
1% Bovine serum albumen 
(BSA)  
1% BSA in PBS ELISA 
10x Blotting buffer 0.25 M Tris base, 1.92 M 
Glycine, 1L distilled water 
(dH2O) 
Western blot 
1x Blotting buffer 200 ml Methanol, 100 ml 10x 
Blotting buffer, 700 ml dH2O 
Western blot 
10x Running buffer 0.25 M Tris base, 1.92 M Glycine 
1% (w/v) SDS, dH2O 
Western blot 
1x Running buffer 50ml 10x running buffer, 450 ml 
dH2O 
Western blot 
1% SDS Lysis buffer  10 mM Tris base (pH 6.0) ,0.1 Brain tissue 
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mM NaCl 
1 µM PMSF 
1 µg/ml Aprotinin 
homogenisation 
0.5% Triton X-100 20mM Tris (pH 7.4), 10% sucrose 
(w/v), 10 mM PMSF 
1 µg/ml Aprotinin 
Brain tissue 
homogenisation 
Antibody buffer 5% Marvel in TBST Western blot 
Avidin-biotin complex (ABC) Vectastain Universal Elite kit – 2 
drops Reagent A, 2 drops Reagent 
B in 5 ml PBS.  
IHC 
Blocking serum Vectastain Universal Elite kit – 1 
drop horse serum in 5ml PBS 
IHC 
DAB 2 drops H2O2, 4 drops DAB 
solution, 2 drops buffer in 5 ml 
dH2O 
IHC 
Citrate buffer 9 mM tri-sodium citrate, pH 6.0 IHC 
Copper sulphate 0.16M Copper (II) sulphate 5-
hydrate, 0.12M sodium chloride 
IHC 
EDTA 1 mM EDTA pH 8 IHC 
N/C domain assay buffer 0.1 M Tris-HCL pH 7.0 , 0.05 M 
NaCl, 10 µM ZnCl2 
ACE-1 N/C domain 
activity assay 
 Phosphate buffered saline 
(PBS) 
90 g sodium chloride, 126.8 g 
sodium dihydrogen 
orthophosphate 1-hydrate, 2.9 g 
sodium hydrogen orthophosphate 
12-hydrate, 10 l dH2O, pH 7.1  
Various 
SDS reducing buffer 0.5 M Tris-HCL (pH 6.8), 0.25% 
Glycerol, 
10% (w/v) SDS 




Vectastain Universal Elite kit – 2 
drops horse serum and 2 drops 
secondary antibody in 5 ml PBS 
IHC 
Stop solution 2 N (1 M) Sulphuric acid ELISA 
Tris-buffered saline containing 
Tween®-20 (TBST)  
10% 10x TBS, 0.05% Tween-20 Western blot 
Tris-buffered saline 10x (TBS) 0.2 M Tris base, 5 M NaCl Western blot 
Tris assay buffer 0.05 M Tris, 0.14 M NaCl, pH 7.4 IRAP activity assay 
Wash buffer 0.05% Tween 20 in PBS Various 
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9.2.1.4 Primary antibodies 
  
Summary of the primary antibodies used in this study are outlined in Table 9.13 
 





























antibody (aa 1-50) 
IHC-plus 
























Polyclonal Rabbit Kindly provided 










Polyclonal Rabbit Kindly provided 











































II Type 2 receptor 
antibody  




9.2.1.5 Secondary antibodies  
 
Table 9.14 Summary of secondary antibodies  
 
Secondary antibody Suppliers Code 
Anti-Rabbit IgG Vector Laboratories WB-1000 
Anti-Mouse IgG Vector Laboratories WB-2000 
Vectastain biotinylated universal 
secondary antibody 
Vector Laboratories PK-6200 
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9.2.1.6 Standard proteins 
 
Table 9.15 Summary of standard proteins 
 
Protein Suppliers Code 
Angiotensin I (Ang-I) Enzo Life Sciences ALX-151-037-M005 
Angiotensin 1-7 (Ang (1-7)) Enzo Life Sciences ALX-151-041-M005 




Amyloid beta 42 (Aβ 42) rPeptide A-1002-1 
Recombinant human ACE-1 
/CD143 somatic form 
R&D Systems 929-ZN-010 
 
 
9.2.1.7 Assay kits 
 
Table 9.16 Commercial suppliers of assay kits used in this study 
 
Assay Kits Suppliers  
(Code) 
DAB substrate Kit Vector Laboratories  
(SK-4100) 
Human Angiotensin II Receptor 2 (AGTR2) 
ELISA kit 
 
Cloud-Clone Corp.  
(SEA973Hu) 
Human Angiotensin 1-7 (ANG1-7) ELISA Kit MyBioSource  
(MBS084052) 
Human Angiotensin 4 (ANG4) ELISA Kit MyBioSource  
(MBS028441) 
Human Leucyl/Cystinyl aminopeptidase 
(LNPEP) ELISA Kit 
 
Cloud-Clone Corp.  
(SEH723Hu)  
Human Mas Proto-Oncogene (MAS1) ELISA 
Kit    
                                           
MyBioSource  
(MBS9327239) 





Human Neurotensin (NT) ELISA Kit CUSABIO 
(CSB-E09144h) 
Human proteolipid protein 1 (PLP1) ELISA Kit 
 
Cloud-Clone Corp.  
(SEA417Hu) 
Human VEGF DuoSet ELISA kits R&D systems  
	 226 
(DY293B-05) 
Total protein Kit Sigma-Aldrich  
(TP0100) 




9.2.2 Optimisation steps of experiments from Chapter 3: 
 
9.2.2.1 Optimisation steps of ACE-1 N-domain FRET activity assay 
 
The optimal concentration of the N-domain selective substrate (Abz-SDK(Dnp)-p in human brain 
tissue homogenates was determined by testing different dilution ranges (10-0.625 µM). Optimal 







Figure 9.1. Test of Different dilutions of N-domain specific fluorogenic substrate Abz-
SDK(Dnp)-P (Enzo Life Sciences).  
Standard curves of recombinant human ACE-1 activity as measured using a range of concentrations of 




The effect of incubation time on the reaction was characterised (Figure 9.2 A). A range of captopril 
concentrations was also tested to determine the dose-related changes to the inhibition of substrate 













































Figure 9.2. Standard curves of recombinant human ACE-1 activity as measured using a rang of 
FRET (Abz-SDK(Dnp)-P) substrate Measurements are based on substrate cleavage after 
incubation for 1 hour at 37°C. A. Effect of time on reaction. B. Captopril inhibition of fluorogenic 




9.2.2.2 Optimisation of ACE-1 C-domain FRET activity assay 
 
As for the N-domain assay, the concentration of C-domain selective substrate (Abz (LFK(DnP)-OH 
Trifluroacetate) in human brain tissue homogenates was characterised. The resultant optimal 





Figure 9.3. Test of Different dilutions of C-domain specific fluorogenic substrate (Abz-
LFK(Dnp)-OH Trifluroacetate) (Sigma-Aldrich). 
Standard curves of recombinant human ACE-1 activity as measured using a rang of FRET 
(Abz(LFK(DnP)-OH Trifluroacetate)  substrate Measurements are based on substrate cleavage after 
incubation for 1 hour at 37°C. 
 



















































































































































The optimal concentration of inhibitor and the effect of time on substrate cleavage were characterised 




Figure 9.4. Standard curves of recombinant human ACE-1 activity as measured using a rang of 
FRET (Abz(LFK(DnP)-OH Trifluroacetate)  substrate Measurements are based on substrate 
cleavage after incubation for 1 hour at 37°C. A. Effect of time on reaction. B. Captopril inhibition 




9.2.2.3 Optimisation of ACE-1 N-domain immunocapture-based activity assay 
 
The effect of time on reaction and the inhibitor concentration were determined in optimising the 
immunocapture-based FRET activity assay. The reaction was measured after 1 hour, 20 and 24 hours 




Figure 9.5.  Standard curves of recombinant human ACE-1 activity as measured using of FRET 
substrate (Abz-SDK(Dnp)-P) at concentration (0.68 mM). Measurements are based on substrate 
cleavage after incubation for 1 hour, 20 and 24 hours at 37°C. A. Effect of time on reaction. B. 




































































































































































































9.2.2.4 Optimisation of ACE-1 C-domain immunocapture-based activity assay  
 
The effect of 2 and 24 hours incubation on the reaction of C-domain selective substrate 
(Abz(LFK(DnP)-OH Trifluroacetate) cleavage was measured. The inhibitor effect on the reaction at 





Figure 9.6. Standard curves of recombinant human ACE-1 activity as measured using of FRET 
substrate (Abz(LFK(DnP)-OH Trifluroacetate) at concentration (0.14 mM). Measurements are 
based on substrate cleavage after incubation for 2 hours and 24 hours at 37°C. A. Effect of 2 
hours incubation on reaction and Captopril inhibition of (Abz-SDK(Dnp)-P) fluorogenic peptide 
substrate cleavage. B. Effect of 24 hours incubation on reaction and Captopril inhibition of (Abz-




9.2.3 Optimisation steps of experiments from Chapter 5: 
 
9.2.3.1 Optimisation steps of IRAP sandwich ELISA 
 
Preliminary experiments were first performed to optimise the homogenate concentration to use for the 
IRAP sandwich ELISA. First, I tested different dilutions of homogenate (2-fold serial dilution of 1:10) 
(Table 9.17). Then I compared two dilutions 1:10 and 1:20 by measuring two samples of control and 
two AD cases. There was no difference in the concentration of IRAP level measured in homogenate 
diluted 1:10 and 1:20 (Table 9.18).  
 
Table 9.17 Results from first optimisation step of IRAP sandwich ELISA 
 
A B










































2 h + Captopril (10 µM)










































24 h + Captopril (10 µM)
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dilution of 1:10 








































































Table 9.18 Results from second optimisation step of IRAP sandwich ELISA  
 



























































Figure 9.7. Standard (StD) curve of recombinant human IRAP as measured using (Human 




9.2.3.2 Optimisation steps of IRAP activity assay  
 
 
Preliminary experiments were performed to optimise the use of IRAP substrate L-Leucine-p-
nitroanilide (L-Leu-pNA) (Sigma-Aldrich) in human brain tissue homogenates. The optimal 
concentration of the colorimetric substrate was first determined by testing 10-fold serial dilutions and 



























Figure 9.8. Test of different dilutions of colorimetric IRAP substrate L-Leucine-p-nitroanilide 
(L-Leu-pNA) (Sigma-Aldrich). 
A. Standard curves of IRAP activity as measured using 10-fold serial dilutions of the substrate ranging 
from (25-0.000025 mg/ml). Measurements are based on substrate cleavage after incubation for 1 hour 
at 37°C. B. Standard curves of IRAP activity as measured using 2-fold serial dilutions of the substrate 
ranging from (125-1.95 mg/ml). Measurements are based on substrate cleavage after incubation for 1 
hour at 37°C. 
 
 
The effect of incubation length on the reaction (1 hour, 2 hours and overnight) was determined on two 





Figure 9.9.  Testing the effect of time on colorimetric IRAP substrate L-Leucine-p-nitroanilide 
(L-Leu-pNA) (Sigma-Aldrich) cleavage.  
A. The effect of time on reaction measured on homogenate diluted (1:10). B. The effect of time on 
reaction measured on homogenate diluted (1:20). Measurements are based on substrate cleavage after 
incubation for 1 hour (blue), 2 hours (red) and 24 h (green) at 4°C.  
 






































































 9.2.4 Optimisation steps of experiments from Chapter 7: 
 
9.2.4.1 Optimisation steps of neurolysin competitive ELISA 
 
The optimal concentration of brain homogenate was determined before using the neurolysin 
competitive ELISA. First, I tested different dilutions of homogenate (1:2, 1:4, 1:10 and 1:20) (Table 
9.19). Homogenate diluted 1:10 was chosen for further studies. 
 
 
Table 9.19 Results from optimisation steps of neurolysin competitive ELISA 
 












































Figure 9.10. Standard (StD) curve of recombinant human neurolysin as measured using (NLN, 
competitive ELISA kit, MyBioSource). 
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9.2.4.2 Optimisation steps of neurotensin sandwich ELISA 
 
Different homogenate dilutions (1:2, 1:4, 1:10 and 1:20) were initially tested and a 1:10 dilution fell 




Table 9.20 Results from optimisation steps of neurotensin sandwich ELISA 
 









































Figure 9.11. Standard (StD) curve of recombinant human neurotensin as measured using 




















9.3 Appendix III: Shapiro-Wilk normality test  
 
All datasets were analysed by Shapiro-Wilk test to determine the distribution of the data. P-value  
<0.05 were considered not normally distributed.  
 
Table 9.21 Shapiro-Wilk normality tests 
 
Data Sets Shapiro-Wilk normality test 
           p-value                 Normally distributed? 
Chapter 3 
ACE-1 N-domain FRET activity  <0.0001 No 
ACE-1 C-domain FRET activity <0.0001 No 
ACE-1 N-domain immunocapture-based 
activity 
<0.0001 No 
ACE-1 C-domain immunocapture-based 
activity 
<0.0001 No 
Total Ang-I level 0.001 No 
Ang-I protein-adjusted level <0.0001 No 
Chapter 4 
Total Ang (1-7) level 0.405 Yes 
Ang (1-7) protein-adjusted level <0.0001 No 
Total MasR level <0.0001 No 
MasR protein-adjusted level <0.0001 No 
Chapter 5 
Total Ang-IV level <0.0001 No 
Ang-IV protein-adjusted level <0.0001 No 
Total IRAP level <0.0001 No 
IRAP protein-adjusted level <0.0001 No 
IRAP activity 0.008 No 
Chapter 6 
(Ang (1-7), MasR, Ang-IV, IRAP) 
Small cohort (control, n= 17) and (AD, n= 35) 
Total Ang (1-7) level 0.733 Yes 
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Ang (1-7) protein-adjusted level 0.211 Yes 
Total MasR level <0.0001 No 
MasR protein-adjusted level <0.0001 No 
Total Ang-IV level <0.0001 No 
Ang-IV protein-adjusted level <0.0001 No 
Total IRAP level 0.003 No 
IRAP protein-adjusted level 0.003 No 
IRAP activity 0.050 Yes 
Chapter 7 
Total neurolysin level 0.0002 No 
Neurolysin protein-adjusted level <0.0001 No 
Total neurotensin level 0.054 Yes 





9.4 Appendix IV: Intra-assay coefficient of variation (CV%) of measured proteins 
 
9.4.1 Results and data analyses from chapter 3:  
 
9.4.1.1 ACE-1 N-domain FRET activity data 
 
Table 9.22 Intra-assay CV% of ACE-1 N-domain FRET activity assay from a 96 well plate. 
CV% was calculated using the following formula: CV%= (Standard deviation (SD)/Mean) *100 
 
ACE-1 N-domain FRET activity 
 
Sample Reading 1 Reading 2 Mean SD CV% 
6 24682 24935 24808.5 178.89 0.72 
16 22359 23013 22686 462.447 2.04 
36 25371 25459 25415 62.22 0.24 
48 5233 5290 5261.5 40.30 0.77 
66 15513 15642 15577.5 91.22 0.58 
74 18609 18473 18541 96.16 0.51 
147 20578 20854 20716 195.16 0.94 
190 21693 21957 21825 186.68 0.85 
205 11922 12969 12445.5 740.34 5.95 
213 20005 19909 19957 67.88 0.34 
242 17964 17929 17946.5 24.75 0.14 
269 15643 15609 15626 24.04 0.15 
284 25089 24879 24984 148.49 0.59 
321 17492 17216 17354 195.16 1.12 
424 16496 17630 17063 801.86 4.69 
426 10520 10661 10590.5 99.70 0.94 
435 11012 10865 10938.5 103.94 0.95 
451 15492 15097 15294.5 279.30 1.83 
470 17403 17683 17543 197.99 1.13 
721 16303 16391 16347 62.22 0.38 




9.4.1.2 ACE-1 C-domain FRET activity data 
 
Table 9.23 Intra-assay CV% of ACE-1 C-domain FRET activity assay from a 96 well plate. 
CV% was calculated using the following formula: CV%= (Standard deviation (SD)/Mean) *100 
 
ACE-1 C-domain FRET activity 
 
Sample Reading 1 Reading 2 Mean SD CV% 
6 20400 22150 21275 1237.44 5.82 
16 29147 28840 28993.5 217.08 0.75 
36 22213 21336 21774.5 620.13 2.85 
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48 16189 16548 16368.5 253.85 1.55 
66 11991 12530 12260.5 381.13 3.11 
74 14211 16454 15332.5 1586.04 10.34 
147 16699 19112 17905.5 1706.25 9.53 
190 22477 24588 23532.5 1492.70 6.34 
205 17419 22320 19869.5 3465.53 17.44 
213 21000 23867 22433.5 2027.27 9.03 
242 21214 23148 22181 1367.54 6.17 
269 15501 16774 16137.5 900.15 5.58 
284 29662 30589 30125.5 655.49 2.17 
321 18368 22072 20220 2619.12 12.95 
424 24008 23962 23985 32.53 0.13 
426 15625 15721 15673 67.88 0.43 
435 15919 10196 13057.5 4046.77 30.99 
451 23565 25796 24680.5 1577.55 6.39 
470 20673 23029 21851 1665.94 7.62 
721 10914 11610 11262 492.15 4.37 
Mean     7.18 
 
 
9.4.1.3 ACE-1 N-domain immunocapture-based activity data 
 
Table 9.24 Example of intra-assay CV% of ACE-1 N-domain immunocapture-based activity 
assay from a 96 well plate. CV% was calculated using the following formula: CV%= (Standard 
deviation (SD)/Mean) *100 
 
ACE-1 N-domain immunocapture-based activity 
 
Sample Reading 1 Reading 2 Mean SD CV% 
66 14283 13947 14115 453.69 3.21 
69 14073 14965 14519 889.28 6.12 
461 14428 16109 15268.5 1991.88 13.04 
467 16439 19232 17835.5 1828.50 10.25 
597 15747 19212 17479.5 3729.61 21.33 
678 24757 19158 21957.5 4893.26 22.28 
219 14669 14269 14469 563.19 3.89 
223 14646 15593 15119.5 635.64 4.20 
601 14067 14952 14509.5 571.85 3.94 
665 15828 16184 16006 1175.17 7.342 
725 16329 18426 17377.5 877.881 5.051 
670 17662 17191 17426.5 1854.36 10.64 
681 20072 21026 20549 2099.05 10.21 
683 24760 23073 23916.5 2148.93 8.98 
592 19664 23206 21435 4392.19 20.49 
687 14370 14137 14253.5 437.34 3.07 
685 14216 15094 14655 514.82 3.51 
691 14784 15427 15105.5 1628.46 10.78 
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697 13084 17020 15052 1638.86 10.89 
713 15654 15558 15606 306.57 1.96 
715 16200 16041 16120.5 1036.38 6.43 
717 17651 18113 17882 939.88 5.26 
718 15932 17126 16529 844.28 5.10 




9.4.1.4 ACE-1 C-domain immunocapture-based activity data 
 
Table 9.25 Example of intra-assay CV% of ACE-1 C-domain immunocapture-based activity 
assay from a 96 well plate. CV% was calculated using the following formula: CV%= (Standard 
deviation (SD)/Mean) *100 
 
ACE-1 C-domain immunocapture-based activity 
 
Sample Reading 1 Reading 2 Mean SD CV% 
72 11568 12293 11930.5 512.65 4.29 
73 12275 12123 12199 107.48 0.88 
74 11843 12527 12185 483.66 3.97 
75 11974 12821 12397.5 598.92 4.83 
79 12900 13107 13003.5 146.37 1.12 
81 12450 13097 12773.5 457.49 3.58 
84 12769 13389 13079 438.41 3.35 
95 12367 13396 12881.5 727.61 5.65 
98 10563 10991 10777 302.64 2.81 
103 12045 10898 11471.5 811.05 7.07 
106 12498 12112 12305 272.94 2.22 
110 12388 12244 12316 101.82 0.83 
223 12914 12491 12702.5 299.11 2.35 
224 12837 12714 12775.5 86.97 0.68 
228 13598 13977 13787.5 267.99 1.94 
241 12948 13620 13284 475.17 3.58 
242 9964 9576 9770 274.36 2.81 
243 10389 9691 10040 493.56 4.92 
263 10510 10067 10288.5 313.25 3.04 
278 11327 10819 11073 359.21 3.24 
284 12098 12154 12126 39.59 0.33 
287 12609 13276 12942.5 471.64 3.64 
289 13184 12915 13049.5 190.21 1.46 
290 13411 14039 13725 444.06 3.23 





9.4.1.5 Ang-I level data  
 
Table 9.26  Example of intra-assay CV% of absorbance values for Ang-I direct ELISA from a 96 
well plate. CV% was calculated using the following formula: CV%= (Standard deviation 
(SD)/Mean) *100 
 
Ang-I direct ELISA 
 
Sample Reading 1 Reading 2 Mean SD CV% 
1 0.292 0.298 0.295 0.004 1.44 
16 0.326 0.321 0.3235 0.003 1.09 
36 0.31 0.31 0.31 0 0 
48 0.334 0.342 0.338 0.005 1.67 
50 0.346 0.342 0.344 0.002 0.82 
57 0.314 0.302 0.308 0.008 2.75 
66 0.339 0.339 0.339 0 0 
69 0.305 0.301 0.303 0.003 0.93 
72 0.295 0.335 0.315 0.028 8.98 
73 0.369 0.395 0.382 0.018 4.81 
74 0.345 0.338 0.3415 0.005 1.45 
75 0.311 0.308 0.3095 0.002 0.68 
79 0.319 0.33 0.3245 0.008 2.39 
81 0.349 0.345 0.347 0.002 0.81 
95 0.275 0.315 0.295 0.028 9.59 
98 0.317 0.303 0.31 0.009 3.19 
106 0.31 0.339 0.3245 0.020 6.31 
110 0.311 0.315 0.313 0.003 0.90 
112 0.335 0.361 0.348 0.018 5.28 
120 0.328 0.346 0.337 0.013 3.78 
122 0.325 0.328 0.3265 0.002 0.65 
127 0.297 0.348 0.3225 0.036 11.18 
219 0.327 0.335 0.331 0.005 1.71 
220 0.34 0.343 0.3415 0.002 0.62 













241 0.31 0.299 0.3045 0.008 2.55 
242 0.34 0.347 0.3435 0.005 1.44 
254 0.348 0.345 0.3465 0.002 0.61 
256 0.323 0.325 0.324 0.001 0.43 
257 0.296 0.292 0.294 0.003 0.96 
259 0.307 0.336 0.3215 0.021 6.38 
263 0.31 0.31 0.31 0 0 
269 0.318 0.311 0.3145 0.005 1.57 
277 0.277 0.288 0.2825 0.008 2.75 
278 0.305 0.336 0.3205 0.022 6.84 
284 0.315 0.346 0.3305 0.022 6.63 
Mean     2.84 
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9.4.2 Results and data analyses from chapter 4:  
 
9.4.2.1 Ang (1-7) direct ELISA data 
 
 
Table 9.27 Intra-assay CV% of Ang (1-7) direct ELISA from a 96 well plate. CV% was 
calculated using the following formula: CV%= (Standard deviation (SD)/Mean) *100 
 
Ang (1-7) direct ELISA 
 
Sample Reading 1 Reading 2 Mean SD CV% 
1 0.248 0.252 0.25 0.003 1.131 
36 0.233 0.387 0.31 0.109 35.127 
50 0.237 0.243 0.24 0.004 1.768 
57 0.358 0.225 0.291 0.094 32.263 
69 0.217 0.233 0.225 0.011 5.028 
72 0.257 0.262 0.259 0.003 1.362 
73 0.594 0.212 0.403 0.270 67.026 
75 0.254 0.258 0.256 0.003 1.105 
79 0.229 0.228 0.229 0.001 0.309 
81 0.254 0.279 0.267 0.018 6.633 
84 0.237 0.246 0.242 0.006 2.635 
95 0.278 0.25 0.264 0.019 7.499 
98 0.233 0.213 0.223 0.014 6.342 
103 0.222 0.236 0.229 0.009 4.323 
106 0.217 0.22 0.218 0.002 0.971 
110 0.248 0.253 0.250 0.004 1.411 
112 0.279 0.261 0.27 0.012 4.714 
196 0.24 0.259 0.249 0.013 5.385 
205 0.208 0.246 0.227 0.027 11.837 
212 0.154 0.171 0.163 0.012 7.397 
223 0.255 0.232 0.243 0.016 6.679 
224 0.263 0.251 0.257 0.008 3.302 
228 0.182 0.194 0.188 0.008 4.513 
241 0.284 0.278 0.281 0.004 1.509 
243 0.267 0.259 0.263 0.006 2.151 
256 0.266 0.28 0.273 0.009 3.626 
257 0.276 0.25 0.263 0.018 6.990 
263 0.272 0.287 0.279 0.011 3.795 
277 0.243 0.251 0.247 0.006 2.290 
278 0.224 0.252 0.238 0.019 8.318 
287 0.221 0.299 0.26 0.055 21.213 
289 0.218 0.222 0.22 0.003 1.286 






9.4.2.2 Ang (1-7) sandwich ELISA data 
 
 
Table 9.28 Intra-assay CV% of Ang (1-7) sandwich ELISA from a 96 well plate. CV% was 
calculated using the following formula: CV%= (Standard deviation (SD)/Mean) *100 
 
Ang (1-7) sandwich ELISA 
 
Sample Reading 1 Reading 2 Mean SD CV% 
66 0.391 0.369 0.38 0.015 4.094 
69 0.361 0.389 0.375 0.019 5.279 
72 0.317 0.306 0.311 0.008 2.497 
73 0.273 0.273 0.273 0 0 
74 0.411 0.388 0.399 0.016 4.071 
75 0.375 0.361 0.368 0.009 2.691 
79 0.348 0.333 0.340 0.011 3.115 
81 0.389 0.401 0.395 0.008 2.148 
84 0.319 0.334 0.326 0.011 3.248 
95 0.397 0.419 0.408 0.015 3.813 
98 0.301 0.309 0.305 0.005 1.855 
103 0.399 0.428 0.413 0.020 4.959 
106 0.425 0.458 0.441 0.023 5.285 
110 0.369 0.392 0.380 0.016 4.274 
120 0.386 0.394 0.39 0.006 1.450 
122 0.415 0.472 0.443 0.040 9.088 
127 0.433 0.448 0.440 0.011 2.408 
128 0.583 0.602 0.592 0.013 2.267 
130 0.388 0.449 0.418 0.043 10.307 
190 0.382 0.426 0.404 0.031 7.701 
196 0.443 0.434 0.438 0.006 1.451 
205 0.41 0.476 0.443 0.047 10.535 
212 0.325 0.344 0.334 0.013 4.016 
213 0.347 0.361 0.354 0.009 2.796 
219 0.415 0.393 0.404 0.015 3.850 
223 0.398 0.388 0.393 0.007 1.799 
224 0.39 0.358 0.374 0.022 6.050 
228 0.349 0.39 0.369 0.029 7.846 
241 0.462 0.45 0.456 0.008 1.861 
243 0.38 0.446 0.413 0.047 11.300 
263 0.358 0.374 0.366 0.011 3.091 
278 0.361 0.566 0.463 0.145 31.274 
284 0.518 0.829 0.673 0.219 32.651 
287 0.455 0.677 0.566 0.157 27.734 
290 0.48 0.436 0.458 0.031 6.793 
341 0.345 0.396 0.370 0.036 9.733 
370 0.405 0.434 0.419 0.020 4.888 
378 0.367 0.377 0.372 0.007 1.901 
Mean     6.582	
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9.4.2.3 MasR sandwich ELISA data 
 
Table 9.29 Intra-assay CV% of MasR sandwich ELISA from a 96 well plate. CV% was 
calculated using the following formula: CV%= (Standard deviation (SD)/Mean) *100 
 
MasR sandwich ELISA 
Sample Reading 1 Reading 2 Mean SD CV% 
66 0.279 0.277 0.278 0.001 0.509 
69 0.259 0.232 0.245 0.019 7.778 
72 0.198 0.197 0.197 0.001 0.358 
74 0.288 0.288 0.288 0 0 
75 0.22 0.226 0.223 0.004 1.902 
79 0.203 0.219 0.211 0.011 5.362 
84 0.185 0.219 0.202 0.024 11.902 
95 0.289 0.263 0.276 0.018 6.661 
98 0.235 0.256 0.245 0.015 6.048 
103 0.274 0.307 0.290 0.023 8.032 
106 0.318 0.333 0.325 0.011 3.258 
110 0.209 0.255 0.232 0.032 14.020 
112 0.202 0.24 0.221 0.027 12.158 
120 0.254 0.308 0.281 0.038 13.588 
122 0.375 0.302 0.338 0.051 15.249 
127 0.274 0.274 0.274 0 0 
128 0.393 0.389 0.391 0.002 0.723 
130 0.312 0.331 0.321 0.013 4.179 
220 0.304 0.295 0.299 0.006 2.125 
223 0.241 0.252 0.246 0.008 3.155 
224 0.234 0.227 0.230 0.005 2.147 
228 0.321 0.209 0.265 0.079 29.885 
241 0.338 0.283 0.310 0.039 12.525 
242 0.305 0.371 0.338 0.046 13.807 
256 0.397 0.348 0.372 0.035 9.301 
257 0.268 0.319 0.293 0.036 12.287 
263 0.269 0.238 0.253 0.022 8.647 
277 0.252 0.281 0.266 0.020 7.694 
278 0.273 0.356 0.314 0.059 18.661 
284 0.438 0.478 0.458 0.028 6.176 
287 0.272 0.293 0.282 0.014 5.256 
288 0.226 0.231 0.228 0.003 1.547 
289 0.34 0.367 0.353 0.019 5.401 
290 0.358 0.336 0.347 0.015 4.483 
291 0.251 0.283 0.267 0.023 8.475 
302 0.299 0.414 0.356 0.081 22.809 
319 0.321 0.339 0.33 0.013 3.856 
1 0.285 0.284 0.284 0.001 0.248 
213 0.219 0.282 0.250 0.044 17.783 
216 0.257 0.297 0.277 0.028 10.211 
Mean     7.955 
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9.4.3 Results and data analyses from chapter 5:  
 
9.4.3.1 Ang-IV sandwich ELISA data 
 
Table 9.30 Intra-assay CV% of Ang-IV sandwich ELISA from a 96 well plate. CV% was 
calculated using the following formula: CV%= (Standard deviation (SD)/Mean) *100 
 
Ang-IV sandwich ELISA 
 
Sample Reading 1 Reading 2 Mean SD CV% 
1 0.255 0.279 0.267 0.017 6.356 
16 0.403 0.341 0.372 0.044 11.785 
36 0.438 0.385 0.411 0.037 9.107 
50 0.202 0.245 0.223 0.030 13.604 
328 0.184 0.184 0.184 0 0 
333 0.268 0.262 0.265 0.004 1.601 
336 0.21 0.213 0.211 0.002 1.002 
338 0.263 0.27 0.266 0.005 1.857 
355 0.325 0.421 0.373 0.068 18.199 
390 0.289 0.278 0.283 0.008 2.744 
412 0.24 0.246 0.243 0.004 1.746 
461 0.247 0.325 0.286 0.055 19.285 
597 0.213 0.223 0.218 0.007 3.244 
678 0.448 0.435 0.441 0.009 2.082 
326 0.214 0.217 0.215 0.002 0.984 
330 0.291 0.273 0.282 0.012 4.513 
573 0.378 0.385 0.381 0.005 1.297 
577 0.209 0.215 0.212 0.004 2.001 
579 0.282 0.263 0.272 0.013 4.930 
580 0.262 0.275 0.268 0.009 3.424 
584 0.403 0.491 0.447 0.062 13.921 
586 0.222 0.222 0.222 0 0 
592 0.221 0.288 0.254 0.047 18.615 
601 0.251 0.271 0.261 0.014 5.418 
665 0.267 0.271 0.269 0.003 1.051 
670 0.237 0.233 0.235 0.003 1.203 
681 0.302 0.294 0.298 0.006 1.898 
683 0.305 0.282 0.293 0.016 5.541 
685 0.233 0.248 0.240 0.011 4.410 
687 0.28 0.289 0.284 0.006 2.237 
691 0.291 0.298 0.294 0.005 1.680 
697 0.31 0.323 0.316 0.009 2.904 
Mean     5.062 
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9.4.3.2 IRAP sandwich ELISA data 
 
Table 9.31 Intra-assay CV% of IRAP sandwich ELISA from a 96 well plate. CV% was 
calculated using the following formula: CV%= (Standard deviation (SD)/Mean) *100 
 
IRAP sandwich ELISA 
Sample Reading 1 Reading 2 Mean SD CV% 
1 0.583 0.488 0.535 0.067 12.544 
16 0.711 0.681 0.696 0.021 3.047 
36 0.582 0.602 0.592 0.014 2.389 
48 0.716 0.609 0.662 0.075 11.420 
50 0.727 0.711 0.719 0.011 1.573 
57 0.566 0.55 0.558 0.011 2.027 
66 0.71 0.661 0.685 0.034 5.054 
69 0.628 0.736 0.682 0.076 11.197 
150 0.742 0.749 0.745 0.005 0.663 
206 0.699 0.716 0.707 0.012 1.699 
254 0.677 0.685 0.681 0.005 0.831 
259 0.553 0.567 0.56 0.009 1.767 
269 0.681 0.644 0.662 0.026 3.949 
295 0.748 0.703 0.725 0.031 4.385 
328 0.682 0.718 0.7 0.025 3.636 
333 0.657 0.612 0.6345 0.032 5.015 
336 0.683 0.493 0.588 0.134 22.848 
338 0.554 0.477 0.515 0.054 10.562 
72 0.738 0.648 0.693 0.063 9.183 
84 0.746 0.671 0.708 0.053 7.485 
190 0.911 0.725 0.818 0.131 16.078 
196 0.621 0.606 0.613 0.011 1.728 
205 0.753 0.813 0.783 0.042 5.418 
212 0.964 0.948 0.956 0.011 1.183 
213 0.531 0.472 0.501 0.041 8.318 
219 0.612 0.538 0.575 0.052 9.100 
302 0.658 0.618 0.638 0.028 4.433 
405 0.509 0.483 0.496 0.018 3.706 
424 0.534 0.576 0.555 0.029 5.351 
426 0.621 0.561 0.591 0.042 7.178 
435 0.71 0.637 0.673 0.052 7.664 
451 0.605 0.586 0.595 0.013 2.256 
470 0.687 0.722 0.704 0.025 3.513 
478 0.692 0.614 0.653 0.055 8.446 
488 1.049 1.141 1.095 0.065 5.941 
495 0.531 0.478 0.504 0.037 7.428 
498 0.666 0.661 0.663 0.003 0.533 
499 0.627 0.603 0.615 0.016 2.759 
223 0.711 0.65 0.680 0.043 6.338 
224 0.599 0.593 0.596 0.004 0.711 
Mean     5.734 
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9.4.3.3 IRAP activity data 
 
Table 9.32 Intra-assay CV% of IRAP activity assay from a 96 well plate. CV% was calculated 







IRAP activity assay 
 
Sample Reading 1 Reading 2 Mean SD CV% 
50 1.087 1.174 1.130 0.061 5.441 
57 0.833 0.896 0.864 0.044 5.153 
69 0.816 0.878 0.847 0.043 5.175 
72 0.873 0.937 0.905 0.045 5.001 
73 1.111 1.205 1.158 0.066 5.739 
74 1.079 1.58 1.329 0.354 26.646 
75 2.14 1.003 1.571 0.804 51.160 
79 0.665 0.656 0.660 0.006 0.963 
81 0.827 0.87 0.848 0.030 3.583 
84 0.81 0.831 0.820 0.015 1.809 
190 0.9 0.913 0.906 0.009 1.014 
196 0.709 0.742 0.725 0.023 3.216 
212 1.368 1.474 1.421 0.075 5.275 
219 0.935 1.017 0.976 0.058 5.941 
223 0.919 0.937 0.928 0.013 1.371 
224 0.993 1.076 1.034 0.058 5.673 
228 0.93 1.66 1.295 0.516 39.860 
241 1.735 1.813 1.774 0.055 3.109 
243 1.742 2.119 1.930 0.266 13.809 
263 1.902 2.177 2.039 0.194 9.534 
Mean     9.974 
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9.4.4 Results and data analyses from chapter 6: 
 
9.4.4.1 VEGF level data 
 
Table 9.33 Example of intra-assay CV% of absorbance values for VEGF sandwich ELISA from 
a 96 well plate. CV% was calculated using the following formula: CV%= (Standard deviation 
(SD)/Mean) *100 
 
VEGF sandwich ELISA 
 
Sample Reading 1 Reading 2 Mean SD CV% 
72 1.421 1.434 1.427 0.009 0.643 
73 1.126 1.061 1.093 0.046 4.203 
74 1.19 1.218 1.204 0.019 1.644 
75 1.347 1.281 1.314 0.046 3.551 
79 1.161 1.089 1.125 0.051 4.525 
81 1.904 1.713 1.808 0.135 7.468 
84 1.077 1.048 1.062 0.020 1.929 
95 1.115 1.103 1.109 0.008 0.765 
98 1.158 1.157 1.157 0.001 0.061 
103 1.13 1.139 1.134 0.006 0.561 
106 0.902 0.921 0.911 0.013 1.474 
110 1.173 1.172 1.172 0.001 0.060 
112 1.011 1.026 1.018 0.011 1.041 
120 0.745 0.758 0.751 0.009 1.223 
122 1.442 1.311 1.376 0.092 6.729 
127 0.76 0.755 0.757 0.003 0.467 
128 1.151 1.121 1.136 0.021 1.867 
130 1.073 0.992 1.032 0.057 5.547 
141 1.236 1.178 1.207 0.041 3.397 
147 1.395 1.316 1.355 0.056 4.121 
223 2 1.98 1.99 0.014 0.711 
224 1.147 1.095 1.121 0.037 3.280 
241 1.878 1.726 1.802 0.108 5.964 
242 1.596 1.501 1.548 0.067 4.338 
243 1.159 1.088 1.123 0.050 4.468 
263 1.482 1.416 1.449 0.046 3.221 
278 0.911 0.88 0.895 0.022 2.448 
284 1.013 0.985 0.999 0.019 1.982 
287 1.697 1.632 1.664 0.046 2.761 
290 1.711 1.482 1.596 0.162 10.142 
291 0.79 0.782 0.786 0.005 0.719 
665 1.107 0.963 1.035 0.102 9.838 
326 1.049 0.902 0.975 0.104 10.655 
330 1.442 1.024 1.233 0.295 23.972 
341 1.316 0.996 1.156 0.226 19.574 
370 1.057 0.866 0.961 0.135 14.046 
378 1.045 0.857 0.951 0.133 13.978 
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400 1.418 1.041 1.229 0.266 21.681 




9.4.4.2 PLP1 level data 
 
Table 9.34 Example of intra-assay CV% of absorbance values for PLP1 sandwich ELISA from a 
96 well plate. CV% was calculated using the following formula: CV%= (Standard deviation 
(SD)/Mean) *100 
 
PLP1 sandwich ELISA 
 
Sample Reading 1 Reading 2 Mean SD CV% 
16 1.241 1.474 1.357 0.165 12.137 
50 1.403 1.354 1.378 0.035 2.513 
84 1.315 1.402 1.358 0.061 4.528 
141 1.419 1.383 1.401 0.025 1.816 
147 1.434 1.59 1.512 0.110 7.295 
150 1.328 1.345 1.336 0.012 0.899 
295 1.371 1.376 1.373 0.003 0.257 
336 1.285 1.349 1.317 0.045 3.436 
355 1.472 1.517 1.494 0.032 2.129 
714 1.327 1.399 1.363 0.051 3.735 
733 1.193 1.342 1.267 0.105 8.312 
190 1.239 1.19 1.214 0.034 2.853 
289 1.232 1.335 1.283 0.073 5.674 
541 1.293 1.401 1.347 0.076 5.669 
577 1.013 1.052 1.032 0.027 2.671 
579 1.282 1.196 1.239 0.061 4.908 
592 1.231 1.317 1.274 0.061 4.773 
601 1.153 1.257 1.205 0.073 6.102 
685 1.323 1.361 1.342 0.027 2.002 
687 1.105 1.136 1.120 0.022 1.956 
697 1.36 1.636 1.498 0.195 13.028 
713 1.268 1.323 1.295 0.039 3.001 
715 1.287 1.131 1.209 0.110 9.124 
725 1.274 1.321 1.297 0.033 2.561 
726 1.269 1.33 1.299 0.043 3.319 
737 1.381 1.41 1.395 0.020 1.469 
745 1.472 1.396 1.434 0.053 3.747 




9.4.5 Results and data analyses from chapter 7: 
 
9.4.5.1 Neurolysin level data 
 
Table 9.35 Example of intra-assay CV% of absorbance values for neurolysin competitive ELISA 
from a 96 well plate. CV% was calculated using the following formula: CV%= (Standard 
deviation (SD)/Mean) *100 
 
Neurolysin competitive ELISA 
 
Sample Reading 1 Reading 2 Mean SD CV% 
1 2.176 2.135 2.155 0.029 1.345 
36 1.431 1.811 1.621 0.269 16.576 
48 1.904 1.942 1.923 0.027 1.397 
57 1.979 1.859 1.919 0.085 4.422 
66 1.379 1.844 1.611 0.329 20.404 
69 2.098 2.157 2.128 0.042 1.961 
72 1.78 1.498 1.639 0.199 12.166 
73 1.943 1.889 1.916 0.038 1.993 
74 1.774 1.843 1.808 0.048 2.698 
75 1.85 1.902 1.876 0.037 1.959 
79 1.857 1.942 1.899 0.060 3.164 
81 1.667 1.875 1.771 0.147 8.305 
95 1.919 1.747 1.833 0.122 6.635 
128 1.634 1.796 1.715 0.114 6.679 
130 1.634 1.796 1.715 0.114 6.679 
141 1.686 1.631 1.658 0.039 2.345 
147 2.086 2.519 2.302 0.306 13.297 
150 2 2.329 2.164 0.232 10.748 
206 2.166 2.522 2.344 0.252 10.739 
259 2.378 2.303 2.340 0.053 2.266 
190 1.978 1.181 1.579 0.563 35.679 
196 2.082 2.173 2.127 0.064 3.024 
205 1.794 2.16 1.977 0.259 13.090 
212 2.179 2.078 2.128 0.071 3.355 
219 3.071 2.318 2.694 0.532 19.761 
224 2.618 2.025 2.321 0.419 18.062 
228 2.313 1.819 2.066 0.349 16.907 
243 2.677 2.291 2.484 0.273 10.988 
263 3.071 2.376 2.723 0.491 18.044 
278 3.091 2.351 2.721 0.523 19.230 
284 3.3 2.505 2.902 0.562 19.368 
289 2.188 2.043 2.115 0.102 4.847 
290 3.113 2.274 2.693 0.593 22.026 
541 2.092 2.079 2.085 0.009 0.441 
685 2.064 1.954 2.009 0.078 3.872 
687 2.38 2.45 2.415 0.049 2.049 
713 1.974 1.737 1.855 0.167 9.032 
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725 1.989 1.425 1.707 0.399 23.363 
726 2.183 2.106 2.144 0.054 2.538 
745 1.825 1.932 1.8785 0.076 4.027 




9.4.5.2 Neurotensin level data 
 
Table 9.36 Example of intra-assay CV% of absorbance values for neurotensin sandwich ELISA 
from a 96 well plate. CV% was calculated using the following formula: CV%= (Standard 
deviation (SD)/Mean) *100 
 
Neurotensin sandwich ELISA 
 
Sample Reading 1 Reading 2 Mean SD CV% 
1 0.39 0.335 0.362 0.039 10.728 
16 0.292 0.307 0.299 0.011 3.541 
36 0.418 0.397 0.407 0.014 3.644 
48 0.425 0.424 0.424 0.001 0.166 
50 0.563 0.544 0.553 0.013 2.427 
57 0.499 0.504 0.501 0.003 0.705 
66 0.502 0.508 0.505 0.004 0.840 
69 0.392 0.38 0.386 0.008 2.1982 
72 0.541 0.583 0.562 0.029 5.284 
73 0.551 0.564 0.557 0.009 1.649 
74 0.515 0.556 0.535 0.029 5.413 
75 0.566 0.569 0.567 0.002 0.374 
79 0.715 0.678 0.696 0.026 3.756 
81 0.307 0.317 0.312 0.007 2.266 
84 0.619 0.58 0.599 0.027 4.600 
95 0.48 0.435 0.457 0.031 6.955 
98 0.513 0.479 0.496 0.024 4.847 
103 0.593 0.532 0.562 0.043 7.668 
106 0.351 0.342 0.346 0.006 1.837 
110 0.463 0.42 0.441 0.030 6.887 
190 0.519 0.429 0.474 0.063 13.426 
196 0.526 0.474 0.5 0.037 7.354 
205 0.38 0.352 0.366 0.019 5.409 
212 0.467 0.504 0.485 0.026 5.389 
213 0.411 0.346 0.378 0.046 12.143 
219 0.584 0.517 0.550 0.047 8.606 
223 0.576 0.559 0.567 0.012 2.118 
224 0.334 0.34 0.337 0.004 1.259 
228 0.535 0.509 0.522 0.018 3.522 
241 0.441 0.449 0.445 0.005 1.271 
242 0.516 0.553 0.534 0.026 4.895 
243 0.485 0.463 0.474 0.015 3.282 
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263 0.469 0.505 0.487 0.025 5.227 
278 0.333 0.315 0.324 0.013 3.928 
284 0.395 0.384 0.389 0.007 1.997 
287 0.67 0.795 0.732 0.088 12.066 
289 0.362 0.34 0.351 0.015 4.432 
290 0.778 0.741 0.759 0.026 3.445 
302 0.342 0.377 0.3595 0.024 6.884 
326 0.407 0.405 0.406 0.001 0.348 




9.5 Appendix V: Relationships between measured proteins and confounding factors 
 
9.5.1 Results and data analyses of altered measured RAS proteins 
 
Table 9.37 Correlations between measured proteins and confounding factors 
 
Chapter 3 
ACE-1 N-domain immunocapture-based activity  




Age-at-death 0.117 0.209 No 
PMD - 0.059 0.525 No 
Gender - 0.326 No 
ACE-1 C-domain immunocapture-based activity  
(relative fluorescence units) 
 
Age-at-death 0.040 0.666    No 
PMD - 0.107 0.249  No 
Gender - 0.701 No 
Ang-I level (pg/ml) 
Age-at-death 0.008 0.925 No 
PMD 0.094 0.305 No 
Gender - 0.410 No 
Ang-I protein-adjusted level (pg/mg total protein) 
 
Age-at-death -0.118 0.199 No 
PMD -0.132 0.150 No 
Gender - 0.071 No 
Chapter 5 
IRAP activity (Abs) 
 
Age-at-death 0.155 0.093 No 
	 252 
PMD 0.036 0.695 No 
Gender - 0.712 No 
Chapter 7 
Neurolysin level (ng/ml) 
 
Age-at-death 0.008 0.934 No 
PMD 0.016 0.866 No 
Gender - 0.393 No 
Neurolysin protein-adjusted level (ng/mg total protein) 
 
Age-at-death -0.091 0.326 No 
PMD -0.083 0.371 No 
Gender - 0.009 Yes 
 
 
9.5.2 Relationship between ACE-1 N-domain activity, ACE-1 C-domain activity, Ang-I level, 
IRAP activity and APOE genotype 
 
Table 9.38 Relationship between ACE-1 N-domain activity, ACE-1 C-domain activity, Ang-I 














Presence or absence of 
APOE ε4 allelle 




ACE-1 C-domain activity 
0.428 No 
 
Ang-I level (pg/ml) Ang-I level (pg/mg total 
protein) 
p-value Significant p-value Significant 
0.020 
 
* 0.830 No 
IRAP activity (Abs) 
 




No 0.079 No 
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9.6 Appendix VI: Transformed data 
 
9.6.1 Log transformed data from chapter 3: 
 
9.6.1.1 Log transformed data for ACE-1 N-domain immunocapture activity 
 
Log transformation of ACE-1 N-domain activity was performed to attempt to reach normal 
distribution. The mean and standard error of mean (SEM) for controls was (4.108 ± 0.134) and for AD 
cases (3.920 ± 0.134). Unpaired samples t-test showed no significant difference between groups (p= 
0.165) (Figure 9.12). 
 
Figure 9.12. Measurement of log transformed ACE-1 N-domain activity compared between 
controls and AD cases.  
Bar chart showing changes of log transformed ACE-1 N-domain enzyme activity measured by 
immunocapture-based FRET activity assay in AD (n= 70) compared to age-matched controls (n= 48) 
in the mid-frontal cortex. Unpaired samples t-test showed no significant difference between groups (p= 




9.6.1.2 Log transformed data for Ang-I level 
 
 
Ang-I level data was not normally distributed and log transformation was performed to attempt to 
reach normal distribution. Similar pattern of reduction of Ang-I level in AD group was observed. 
Unpaired samples t-test showed a significant difference between groups (p= 0.043). The mean and 




















































Figure 9.13. Measurement of log transformed Ang-I level compared between controls and AD 
cases.  
Log transformed Ang-I level unadjusted to protein concentration was reduced in AD (n= 70) compared 
with age-matched control (n= 48) in mid-frontal cortex. Unpaired samples t-test revealed that Ang-I 




9.6.2 Log transformed data from chapter 4: 
 
9.6.2.1 Log transformed data for MasR level 
 
Log transformation was performed to normalise the data. The mean and SEM for controls was (1.726 
± 0.034) and for AD cases (1.741 ± 0.028) (Figure 10.14 A). MasR protein-adjusted level after log 
transformation was unchanged between AD cases (2.486 ± 0.053) and controls (2.567 ± 0.034) (Figure 



























Figure 9.14. Measurement of log transformed MasR level compared between controls and AD 
cases.  
A. Log transformed MasR level did not differ in AD cases compared to controls, Unpaired samples t-
test revealed no significant difference between AD and controls (p= 0.982). The bars indicate the mean 
± SEM. B. Log transformed MasR protein-adjusted level was unchanged in AD cases compared to 




9.6.2.2 Relationship between MasR and disease severity 
	
	
One-Way ANOVA test did not detect significant difference between the total MasR level and MasR 























































Figure 9.15. Log transformed MasR level in relation to Braak tangle stage. 
A. No significant variations were found for log transformed total MasR level measured by sandwich 
ELISA assay between Braak tangle stage groups (Braak stage 0-II (n= 36), Braak stage III-IV (n= 20), 
Braak stage V-VI (n= 61)), One-Way ANOVA test (p= 0.510). The bars indicate the mean  ± SEM. B. 
log transformed MasR protein-adjusted level was unchanged between Braak tangle stages groups 
(Braak stage 0-II (n= 36), Braak stage III-IV (n= 20), Braak stage V-VI (n= 61)), One-Way ANOVA 
test (p= 0.619). The bars indicate the mean  ± SEM.  
 
 
9.6.2.3 Relationship between MasR and AD pathology hallmarks 
 
Log transformed data for both total MasR level and MasR protein-adjusted level was not correlated 

























































Figure 9.16. Relationships between log transformed MasR level and AD pathological hallmarks 
(total insoluble Aβ and tau load).  
A. Scatterplots showing no correlation between log transformed total MasR level and total insoluble 
Aβ (measured by enzyme-linked immunosorbent assay), Pearson’s correlation coefficient test (r= 
0.025, p= 0.814). B. No significant correlation found between log transformed MasR protein-adjusted 
level and total insoluble Aβ, Pearson’s correlation coefficient test (r= 0.060, p= 0.574). C-D. No 
significant correlation found between both log transformed total MasR level and MasR protein-
adjusted level and tau load (measured by field fraction analysis), Pearson’s correlation coefficient test 
(r= 0.038, p= 0.706), Pearson’s r test (r= 0.032, p= 0.753). The solid inner line indicates the best-fit 




Similarly, no correlations were observed between Log transformed data for both total MasR level and 
























) r= 0.060p= 0.574






























































Figure 9.17. Relationships between log transformed MasR level and AD pathological hallmarks 
(insoluble Aβ40 and insoluble Aβ42).  
A and C. Scatterplots showing no correlation between log transformed total MasR level and both 
insoluble Aβ40 and insoluble Aβ42 (measured by enzyme-linked immunosorbent assay), Pearson’s 
correlation coefficient test (r= -0.163, p= 0.231), (r= -0.048, p= 0.726). B and D. No significant 
correlation found between log transformed MasR protein-adjusted level and both insoluble Aβ40 and 
insoluble Aβ42, Pearson’s correlation coefficient test (r= -0.199, p= 0.145), (r= -0.221, p= 0.108). The 
solid inner line indicates the best-fit linear regression and the outer lines the 95% confidence intervals. 




9.6.3 Log transformed data from chapter 5: 
 
9.6.3.1 Log transformed data for IRAP level 
 
Log transformation was performed to normalise the data. The mean and SEM for controls was (1.064 
± 0.021) and for AD cases (1.059 ± 0.024) (Figure 10.18 A). IRAP protein-adjusted level after log 
transformation was unchanged between AD cases (1.332 ± 0.026) and controls (1.332 ± 0.029) (Figure 


























































































Figure 9.18. Measurement of log transformed IRAP level compared between controls and AD 
cases.  
A. log transformed IRAP level unadjusted to protein concentration was unchanged in AD (n= 70) 
compared with age-matched control (n= 48) in mid-frontal cortex, Unpaired samples t-test (p= 0.892). 
The bars indicate mean ± SEM. B. log transformed protein-adjusted IRAP level did not differ in AD 






9.6.3.2 Comparison of IRAP activity in controls and AD 
 
The data was not normally distributed so square-root transformation for IRAP activity data was 
performed to attempt to reach normal distribution. Following square-root transformation, the data was 
normally distributed. The mean for square-root IRAP activity was significantly lower in AD cases, 






















































Figure 9.19. Measurement of square-rooted IRAP activity compared between controls and AD 
cases.  
Square-rooted IRAP activity in AD (n= 70) compared to age-matched controls (n= 48) in mid-frontal 
cortex. Unpaired samples t-test showed a significant difference between groups (p= 0.003). Bars 





9.6.3.3 IRAP activity in relation to disease severity 
 
Square-rooted IRAP activity was significantly reduced in cases with higher Braak tangle stage (V-VI) 
compared to Braak stage (0-II) (p= 0.043) and Braak stage (III-IV) (p= 0.023) using Dunn’s multiple 
comparisons test. One-Way ANOVA test detected a significant difference of the mean between all 






























Figure 9.20. Square-rooted IRAP activity in relation to disease severity. 
Square-rooted IRAP activity was significantly different between all groups (Braak stage 0-II (n= 36), 
Braak stage III-IV (n= 20), Braak stage V-VI (n= 61)) when analysed with One-Way ANOVA test (p= 
0.008). IRAP activity was found to be significantly lower in cases with higher Braak stage (V-VI) 
compared with cases in Braak stage (0-II) (post-hoc Dunn’s multiple comparisons test, p= 0.043) and 
Braak stage (III-IV) (post-hoc Dunn’s multiple comparisons test, p= 0.023) and. The bars indicate the 






























9.6.3.4 Relationship between IRAP activity and AD pathology hallmarks  
 





Figure 9.21. Relationships between square-rooted IRAP activity and AD pathological hallmarks 
(total insoluble Aβ, tau load, insoluble Aβ40 and insoluble Aβ42).  
A. Scatterplots showing significant inverse correlation between sqrt IRAP activity and total insoluble 
Aβ (measured by enzyme-linked immunosorbent assay), Spearman’s correlation coefficient test (r= -
0.269, p= 0.011). B. Scatterplots showing significant inverse correlations between sqrt IRAP activity 
and tau load (measured by field fraction analysis), Spearman’s correlation coefficient test (r= -0.269, 
p= 0.007). C. Scatterplots showing no correlation between sqrt IRAP activity and insoluble Aβ40 
(measured by enzyme-linked immunosorbent assay), Spearman’s correlation coefficient test (r= -
0.153, p= 0.261). D. Scatterplots showing no correlation between sqrt IRAP activity and insoluble 
Aβ42 (measured by enzyme-linked immunosorbent assay), Spearman’s correlation coefficient test (r= 
-0.134, p= 0.329). The solid inner line indicates the best-fit linear regression and the outer lines the 























































































9.6.4 Log transformed data from chapter 6: 
 
9.6.4.1 Relationship between MasR and marker of ischaemia in AD 
 
 
MasR unadjusted and protein-adjusted data were not normally distributed. Log transformation for 
unadjusted and protein-adjusted data was performed to attempt to reach normal distribution. 
Correlations between log transformed total MasR level, MasR protein-adjusted data and VEGF level 
were assessed using Pearson’s correlation coefficient. No significant correlations were observed 
between total MasR level and VEGF level (Pearson’s correlation coefficient test, r= 0.031, p= 0.828), 
MasR protein-adjusted level and VEGF level (Pearson’s correlation coefficient test, r= -0.267, p= 




Figure 9.22. Relationships between MasR level and ischemic marker (VEGF level). 
A-B. No significant correlations found between both log transformed total MasR level and log 
transformed MasR protein-adjusted level and VEGF level, Pearson’s correlation coefficient test (r= 
0.031, p= 0.828), Pearson’s correlation coefficient test (r= -0.267, p= 0.061). The solid inner line 
indicates the best-fit linear regression and the outer lines the 95% confidence intervals. Blue dots= 

























































9.6.4.2 Relationship between MasR and marker of brain tissue oxygenation in AD 
 
Log transformation for MasR unadjusted and protein-adjusted data was performed to attempt to reach 
normal distribution. Correlations between log transformed total MasR level, MasR protein-adjusted 
data and MAG:PLP1 ratio were assessed using Pearson’s correlation coefficient. A significant positive 
correlation was found between log transformed total MasR level and MAG:PLP1 ratio (Pearson’s 
correlation coefficient test, r= 0.309, p= 0.027) (Figure 10.23 A). While, no correlation was found 
between log transformed MasR protein-adjusted level and MAG:PLP1 ratio (Pearson’s correlation 





Figure 9.23. Relationships between MasR level and brain tissue oxygenation marker 
(MAG:PLP1 ratio). 
A. Significant positive correlation between log transformed total MasR level and MAG:PLP1 ratio, 
Pearson’s correlation coefficient test (r= 0.309, p= 0.027). B. No significant correlations found 
between log transformed MasR protein-adjusted level and MAG:PLP1 ratio, Pearson’s correlation 
coefficient test (r= 0.254, p= 0.072). The solid inner line indicates the best-fit linear regression and the 




















































9.6.4.3 Relationship between IRAP and marker of brain ischaemia in AD 
 
 
Both IRAP unadjusted to protein concentration and protein-adjusted data were not normally 
distributed. Log transformation for unadjusted and protein-adjusted data was performed to attempt to 
reach normal distribution. Correlations between log-transformed IRAP data and VEGF level and were 
assessed by the Pearson’s correlation coefficient. Both log transformed IRAP unadjusted level and 
protein-adjusted level showed significant inverse correlations with VEGF level, (Pearson’s correlation 
coefficient test, r= -0.329, p= 0.019) and (Pearson’s correlation coefficient test, r= -0.349, p= 0.013) 





Figure 9.24. Relationships between IRAP level and ischemic marker (VEGF level). 
A. Scatterplots showing significant inverse correlation between log transformed total IRAP level and 
VEGF level, Pearson’s correlation coefficient test (r= -0.329, p= 0.019). B. Scatterplots showing 
significant inverse correlations between log transformed IRAP protein-adjusted level and VEGF level, 
Pearson’s correlation coefficient test (r= -0.349, p= 0.013). The solid inner line indicates the best-fit 






9.6.4.4 Relationship between IRAP and marker of brain tissue oxygenation in AD 
 
 
Correlations between log-transformed IRAP data and MAG:PLP1 ratio were assessed by the Pearson’s 
correlation coefficient. Both log transformed IRAP unadjusted level and protein-adjusted level showed 
no significant correlations with MAG:PLP1 ratio, (Pearson’s correlation coefficient test, r= 0.146, p= 
A B






















































Figure 9.25. Relationships between IRAP level and brain tissue oxygenation marker 
(MAG:PLP1 ratio). 
A-B. No significant correlations between both log transformed total IRAP level and log transformed 
IRAP protein-adjusted level with MAG:PLP1 ratio, Pearson’s correlation coefficient test (r= 0.146, p= 
0.307) and  (r= -0.035, p= 0.808). The solid inner line indicates the best-fit linear regression and the 






















































9.7 Appendix VII: Data analysis after outliers removal 
 
9.7.1 Data analysis after outliers removal from chapter 3: 
 
9.7.1.1 ACE-1 N-domain immunocapture activity after removal of outliers  
 
 
ACE-1 N-domain activity data was re-analysed after removal of outliers detected by ROUT method. 
Eighteen outliers was removed and ACE-1 N-domain activity was significantly reduced in AD group 
compared to age-matched controls (p= 0.037) (Figure 9.26).  
 
Figure 9.26. Reduction in ACE-1 N-domain activity in Alzheimer’s disease. 
Bar chart showing changes of ACE-1 N-domain enzyme activity measured by immunocapture-based 
FRET activity assay in AD (n= 59) compared to age-matched controls (n= 41) in the mid-frontal 
cortex. Mann-Whiney test showed a significant difference between groups (p= 0.037). Bars show the 




9.7.1.2 ACE-1 C-domain immunocapture activity after removal of outliers  
 
ACE-1 C-domain activity data was re-analysed after removal of outliers detected by ROUT method. 
Six outliers was removed and ACE-1 C-domain activity was significantly increased in AD group 


















































Figure 9.27. Change of ACE-1 C-domain activity in control and AD cases.  
Bart chart showing changes of ACE-1 C-domain activity in mid-frontal cortex, measured by 
immunocapture-based FRET activity assay in AD (n= 68) and age-matched controls (n= 44). Mann-
Whitney test revealed that ACE-1C-domain activity was higher in AD compared to age-matched 




9.7.1.3 Relationships between ACE-1 C-domain immunocapture-based activity and AD pathological 
hallmarks 
 
ACE-1 C-domain activity data was re-analysed after removal of outliers detected by ROUT method. 
Ten outliers were removed in correlation between ACE-I C-domain activity and total insoluble Aβ 


















































Figure 9.28. Correlations between ACE-1 C-domain activity and AD pathological hallmark 
(total insoluble Aβ load). 
Scatterplots showing positive relationship between ACE-1 C-domain activity and insoluble total Aβ 
load (measured by enzyme-linked immunosorbent assay), Spearman’s correlation coefficient test (r= 
0.240, p= 0.024). The solid inner line indicates the best-fit linear regression and the outer lines the 




9.7.1.4 Ang-I level after removal of outliers  
 
 
Ang-I level data was re-analysed after removal of outliers detected by ROUT method. One outlier was 
removed and Ang-I level was significantly reduced in AD group compared to age-matched controls 




























Figure 9.29. Measurement of Ang-I level compared between controls and AD cases.  
Ang-I level unadjusted to protein concentration was reduced in AD (n= 69) compared with age-
matched control (n= 48) in mid-frontal cortex. Mann-Whitney test revealed that Ang-I level was lower 




9.7.1.5 Ang-I level in relation to disease severity 
 
Ang-I level data was re-analysed after removal of outliers detected by ROUT method. One outlier was 
removed and Ang-I level was assessed in relation to Braak tangle stage (Braak stage 0-II, Braak stage 
III-IV, Braak stage V-VI). Kruskal-Wallis test revealed a significant difference of the median between 
all groups (p= 0.003) (Figure 9.30).  
 
 
Figure 9.30. Ang-I level in relation to Braak tangle stage.  
Significant variations were found between all groups (Braak stage 0-II (n= 36), Braak stage III-IV (n= 











































found to be significantly lower in cases with higher Braak stage (V-VI) compared with cases in Braak 
stage (0-II) (post-hoc Dunn’s multiple comparisons test, p= 0.001). The bars indicate the median and 




9.7.1.6 Ang-II:Ang-I ratio in AD 
 
Ang-II:Ang-I ratio data was re-analysed after removal of outliers detected by ROUT method. One 
outlier was removed and Ang-II:Ang-I ratio level was significantly increased in AD group compared 
to age-matched controls (p< 0.0001) (Figure 9.31).  
 
 
Figure 9.31. The ratio of Ang-II to Ang-I in AD compared with age-matched controls.  
Reduced Ang-II:Ang-I ratio in AD (n= 70) compared to controls (n= 42) indicates an increase in ACE-
1 activity in AD in mid-frontal cortex. Differences between groups were compared using Mann-




9.7.1.7 Relationship between Ang-I level and ACE-1 activity 
 
Ang-I level data was re-analysed after removal of outliers detected by ROUT method. Four outliers 























Figure 9.32. Correlation between Ang-I level and ACE-1 activity.  
Scatterplots showing no correlation between Ang-I level unadjusted to protein concentration and ACE-
1 activity measured by FRET activity assay in mid-frontal cortex. Spearman’s correlation coefficient 
test (r= -0.18, p= 0.066). The solid inner line indicates the best-fit linear regression and the outer lines 




9.7.1.8 Relationship between Ang-II:Ang-I ratio and ACE-1 activity 
 
Ang-II:Ang-I ratio data was re-analysed after removal of outliers detected by ROUT method. Four 
outliers were removed in correlation between Ang-II:Ang-I ratio  and ACE-1 activity, (Figure 10.33). 
 

































Figure 9.33. Correlation between Ang-II:Ang-I ratio and ACE-1 activity.  
Scatterplots showing inverse correlation between Ang-II:Ang-I ratio and ACE-1 activity measured by 
FRET activity assay in mid-frontal cortex. Spearman’s correlation coefficient test (r= 0.168, p= 0.087). 
The solid inner line indicates the best-fit linear regression and the outer lines the 95% confidence 
intervals. Blue dots= controls, red dots= AD cases. 
 
 
9.7.2 Data analysis after outliers removal from chapter 4: 
 
9.7.2.1 The Ang-II:Ang (1-7) ratio is increased in AD 
 
Ang-II:Ang (1-7) ratio was re-analysed after removal of outliers detected by ROUT method. Tow 
outliers were removed and the mean ± SEM for Ang-II:Ang (1-7) ratio was significantly increased in 
AD compared to controls, Unpaired samples t-test detected a significant p value (p= 0.0008) (Figure  
9.34). 
 

































Figure 9.34. The ratio of Ang-II to Ang (1-7) in AD compared with age-matched controls.  
Increased Ang-II:Ang (1-7) ratio in AD (n= 67) compared to controls (n= 41) indicates a reduction in 
ACE-2 activity in AD in mid-frontal cortex. Differences between groups were compared using 




9.7.3 Data analysis after removal of outliers from chapter 6 
 
9.7.3.1 Relationship between MasR and marker of ischemia in AD 
 
MasR protein-adjusted data was inversely correlated with VEGF after removed four outliers  
(Spearman’s correlation coefficient r= -0.346, p= 0.018) (Figure 9.35). 
 
 
















































Significant inverse correlation found between MasR protein-adjusted level and VEGF level, 
Spearman’s correlation coefficient test (r= - 0.346, p= 0.018). The solid inner line indicates the best-fit 




9.7.3.2 Relationship between MasR and markers of brain tissue oxygenation in AD 
 
The association between both total unadjusted MasR level and protein-adjusted MasR measurement 
and the MAG:PLP1 ratio was examined after removed four outliers. No significant correlation was 
found between total MasR level and MAG:PLP1 ratio (Spearman’s correlation coefficient, r= -0.115, 
p= 0.437) (Figure 9.36 A). MasR protein-adjusted level was also not correlated with MAG:PLP1 ratio 





Figure 9.36. Relationship between MasR level and brain MAG:PLP1 ratio. 
A. Scatterplot showing no correlation between total MasR level and MAG:PLP1, Spearman’s 
correlation coefficient test (r= -0.115, p= 0.437). B. Scatterplot showing no significant correlation 
between MasR protein-adjusted level and MAG:PLP1 ratio, Spearman’s correlation coefficient test (r= 
-0.087, p= 0.559). The solid inner line indicates the best-fit linear regression and the outer lines the 


















































9.7.3.3 Relationship between Ang-IV and marker of brain ischaemia in AD 
 
Ang-IV protein-adjusted data was not correlated with VEGF after removed three outliers  (Spearman’s 




Figure 9.37. Relationship between Ang-IV level and ischemic marker (VEGF level). 
Scatterplots showing no correlation between Ang-IV protein-adjusted level and VEGF level (measured 
by sandwich enzyme-linked immunosorbent assay), Spearman’s correlation coefficient test (r= -0.259, 
p= 0.084). The solid inner line indicates the best-fit linear regression and the outer lines the 95% 
confidence intervals. Blue dots= controls, red dots= AD cases. 
 
9.7.3.4 Relationship between Ang-IV and markers of brain tissue oxygenation in AD 
 
Total unadjusted Ang-IV and Ang-IV protein-adjusted data were not correlated with MAG:PLP1 ratio 
after removed four outliers  (Spearman’s correlation coefficient, r= 0.017, p= 0.907) and (Spearman’s 

































Figure 9.38. Relationship between Ang-IV level and brain MAG:PLP1 ratio. 
A. Scatterplot showing no correlation between total Ang-IV level and MAG:PLP1, Spearman’s 
correlation coefficient test (r= 0.017, p= 0.907). B. Scatterplot showing no significant correlation 
between Ang-IV protein-adjusted level and MAG:PLP1 ratio, Spearman’s correlation coefficient test 
(r= 0.003, p= 0.982). The solid inner line indicates the best-fit linear regression and the outer lines the 




9.7.3.5 Relationship between IRAP and marker of brain ischaemia in AD 
 
IRAP protein-adjusted data was inversely correlated with VEGF after removed one outlier  
(Spearman’s correlation coefficient, r= -0.336, p= 0.018) (Figure 9.39). 
 
 
Figure 9.39. Relationship between IRAP level and ischemic marker (VEGF level). 
Scatterplots showing significant inverse correlations between IRAP protein-adjusted level and VEGF 
level, Spearman’s test (r= -0.398, p= 0.015). The solid inner line indicates the best-fit linear regression 
and the outer lines the 95% confidence intervals. Blue dots= controls, red dots= AD cases 






































































9.7.3.6 Relationship between IRAP and markers of brain tissue oxygenation in AD 
 
IRAP protein-adjusted data was not correlated with MAG:PLP1 ratio after removed one outlier 
(Spearman’s correlation coefficient, r= 0.023, p= 0.873) (Figure 9.40). 
 
 
Figure 9.40. Relationship between IRAP level and brain MAG:PLP1 ratio. 
Scatterplot showing no significant correlation between IRAP protein-adjusted level and MAG:PLP1 
ratio, Spearman’s correlation coefficient test (r= 0.023, p= 0.873). The solid inner line indicates the 
best-fit linear regression and the outer lines the 95% confidence intervals. Blue dots = controls, red 




9.7.4 Data analysis after outliers removal from chapter 7 
 
9.7.4.1 Neurolysin level after removal of outliers 
 
Neurolysin data was re-analysed after removal of outliers detected by ROUT method. In neurolysin 
unadjusted data, one outliers was removed and Neurolysin level was significantly reduced in AD group 
compared to age-matched controls (p= 0.007) (Figure 9.41 A). The median for neurolysin level was 
lower in AD group (median= 7.368 (ng/ml)) compared to control group (median= 8.086 (ng/ml)). 
When neurolysin level was adjusted to total protein concentration, ten outliers was removed and 
neurolysin level was unchanged in AD group compared to age-matched controls (p= 0.119). Mann-
Whitney test compared the median of AD group (median= 20.17 (ng/mg total protein)) to control 
group (median= 21.37 (ng/mg total protein)) (Figure 9.41 B).  
 


























Figure 9.41. Measurement of neurolysin level compared between controls and AD cases.  
A. Neurolysin level unadjusted to protein concentration was reduced in AD (n= 70) compared with 
age-matched control (n= 47) in mid-frontal cortex. Mann-Whitney test revealed that neurolysin level 
was lower in AD (p= 0.007) compared to controls. B. Neurolysin protein-adjusted measurement was 
unchanged in AD cases (n= 68) compared to age-matched controls (n= 40). Differences between 





9.7.4.2 Neurolysin level in relation to disease severity 
 
In neurolysin unadjusted data, one outliers was removed and Kruskal-Wallis test revealed a significant 
difference of the median between all Braak tangle stage groups (p= 0.003). A significant reduction of 
neurolysin level was observed in Braak stage (III-IV) compared to Braak stage (0-II) (p= 0.049) and 
between cases in Braak stage (V-VI) and Braak stage (0-II) (p= 0.004) using Dunn’s multiple 
comparisons test (Figure 9.42 A). For neurolysin protein-adjusted data, ten outliers removed and no 


























































Figure 9.42. Neurolysin level in relation to Braak tangle stage.  
A. Significant variations were found between all groups (Braak stage 0-II (n= 36), Braak stage III-IV 
(n= 20), Braak stage V-VI (n= 60)) when analysed with Kruskal-Wallis test (p= 0.003). Neurolysin 
level was found to be significantly lower in cases in Braak stage (III-IV) compared with cases in Braak 
stage (0-II) (p=0.049) and between cases in Braak stage (V-VI) and Braak stage (0-II) (p= 0.004) 
(post-hoc Dunn’s multiple comparisons test). The bars indicate the median and 95% confidence 
intervals. B. No significant difference was found for neurolysin protein-adjusted measurement between 
Braak tangle stage groups (Braak stage 0-II (n= 30), Braak stage III-IV (n= 19), Braak stage V-VI (n= 




9.7.4.3 Relationship between neurolysin level and APOE genotype 
 
There was no difference in both neurolysin unadjusted data and protein-adjusted neurolysin level in 
relation to the presence or absence of APOE ε4 allelle after removal of outliers in unadjusted data (n= 



























































Figure 9.43. Relationship between neurolysin level and APOE genotype 
A. Unchanged neurolysin level in presence of one or two APOE ε4 allelle compared to cases with 
absence of APOE ε4 allelle. Differences between groups were compared using Mann-Whitney test at 
p= 0.062. The bars indicate the median and 95% confidence intervals. B. No significant difference in 
neurolysin protein-adjusted measurement depending on the presence or absence of APOE ε4 allelle (p= 




9.7.4.4 Neurolysin level in relation to brain RAS markers 
 
The relationship between Ang-II level and neurolysin level was assessed after removal of outliers.  
Total neurolysin correlated inversely with Ang-II level after removed one outlier (Spearman’s 
correlation coefficient, r= -0.234, p= 0.013) and no correlation was observed between neurolysin 
protein-adjusted level and Ang-II level after removed ten outliers (Spearman’s correlation coefficient, 
r= -0.167, p= 0.093) (Figure 9.44 A and B). Unadjusted neurolysin correlated inversely with Ang-III 
level (Spearman’s correlation coefficient, r= -0.224, p= 0.030), no outliers detected. No significant 
correlation was found between neurolysin protein-adjusted data and Ang-III level after removed eight 




















































Figure 9.44. Relationships between neurolysin level and brain RAS markers (Ang-II and Ang-
III).  
A. Scatterplots showing significant inverse correlation between neurolysin level and Ang-II level 
(measured by enzyme-linked immunosorbent assay), Spearman’s correlation coefficient test (r= -
0.234, p= 0.013). B. No correlation found between neurolysin protein-adjusted level and Ang-II level, 
Spearman’s correlation coefficient test (r= -0.167, p= 0.093). C. Scatterplots showing no correlation 
between neurolysin protein-adjusted level and Ang-III level, Spearman’s correlation coefficient test 
(r= -0.013, p= 0.902). The solid inner line indicates the best-fit linear regression and the outer lines the 




Neurolysin unadjusted data was inversely correlated with Ang-II:Ang (1-7) ratio after removed one 
outlier  (Spearman’s c correlation coefficient, r= -0.194, p= 0.042) and protein-adjusted levels was not 
correlated with the Ang-II:Ang (1-7) ratio after removed ten outliers (Spearman’s correlation 




Figure 9.45. Relationship between neurolysin level and brain RAS markers (Ang-II:Ang (1-7) 
ratio).  
A. Scatterplots showing significant inverse correlation between neurolysin level and Ang-II:Ang (1-7) 
ratio, Spearman’s correlation coefficient test (r= -0.194, p= 0.042). B. No correlation found between 
neurolysin protein-adjusted level and Ang-II:Ang (1-7) ratio, Spearman’s correlation coefficient test 
A B C

























































































































(r= -0.182, p= 0.068). The solid inner line indicates the best-fit linear regression and the outer lines the 




9.7.4.5 Neurolysin level in relation to markers of brain tissue oxygenation and ischaemia 
 
No significant correlation was found between neurolysin protein-adjusted level and VEGF level after 
removed six outliers (Spearman’s correlation coefficient, r= 0.129, p= 0.369) (Figure 9.46). 
 
 
Figure 9.46. Relationship between neurolysin level and ischemic marker (VEGF) 
Scatterplots showing no significant correlation between neurolysin protein-adjusted level and VEGF 
level (measured by enzyme-linked immunosorbent assay), Spearman’s correlation coefficient test (r= -
0.148, p= 0.336). The solid inner line indicates the best-fit linear regression and the outer lines the 


































9.8 Appendix VIII: Summary statistics of all measured proteins  
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9.9 Appendix IX: Ang-I protein adjusted data 
 
9.9.1 Protein-adjusted data for Ang-I level  
 
I analysed Ang-I level after adjustment to total protein. Similar to Ang-I unadjusted data, the median 
for Ang-I protein adjusted level was lower in AD group (median= 4601 (pg/mg total protein)) 
compared to the control group (median= 4762 (pg/mg total protein)). The Mann-Whitney test showed 
a significant difference between AD and controls (p= 0.012) (Figure 9.47 A). Kruskal-Wallis test 
showed no significant difference in the median between all groups (p= 0.366) when was assessed in 






Figure 9.47. Measurement of Ang-I protein-adjusted level compared between controls and AD 
cases and in relation to Braak tangle stage. 
A. Ang-I protein-adjusted level was reduced in AD (n= 70) compared with age-matched control (n= 
48) in mid-frontal cortex. Mann-Whitney test revealed that Ang-I level was lower in AD (p= 0.012) 
compared to controls. The bars indicate the median and 95% confidence intervals. B. No variations 
were found between all groups (Braak stage 0-II (n= 36), Braak stage III-IV (n= 20), Braak stage V-VI 






























































9.9.2 Correlation between Ang-I protein-adjusted level and AD pathological hallmarks  
 
Ang-I protein-adjusted level was not correlated with both insoluble Aβ and tau load, Spearman’s 
correlation coefficient test found no significant correlation between Ang-I protein-adjusted level and 
insoluble Aβ (Spearman’s correlation coefficient, r= -0.2, p= 0.107) (Figure 9.48 A) and between tau 





Figure 9.48. Correlation between Ang-I protein-adjusted level and AD pathological hallmarks 
(Aβ load and tau load). A. Scatterplots showing no relationship between Ang-I level and insoluble 
Aβ load (measured by enzyme-linked immunosorbent assay), Spearman’s correlation coefficient test 
(r= -0.2, p= 0.107). B. Scatterplots showing no correlation between Ang-I protein-adjusted level and 
tau load (measured by field fraction analysis), Spearman’s correlation coefficient test (r= -0.016, p= 
0.296). The solid inner line indicates the best-fit linear regression and the outer lines the 95% 
confidence intervals. Blue dots= controls, red dots= AD cases. 
 
 
9.9.3 Relationship between Ang-I protein-adjusted level and ACE-1 activity 
 
 
Previous measurements of ACE-1 activity by FRET activity assay were available for controls (n= 43) 
and AD cases (n= 66). Spearman’s correlation coefficient test shoed no significant correlation between 
Ang-I protein-adjusted level and ACE-1 activity (Spearman’s correlation coefficient, r= -0.049, p= 


























































Figure 9.49. Correlation between Ang-I protein-adjusted level and ACE-1 activity.  
Scatterplots showing no correlation between Ang-I protein-adjusted level and ACE-1 activity 
measured by FRET activity assay in mid-frontal cortex. Spearman’s correlation coefficient test (r= -
0.049, p= 0.616). The solid inner line indicates the best-fit linear regression and the outer lines the 
95% confidence intervals. Blue dots= controls, red dots= AD cases. 
 
 
9.10 Appendix X: Piloting the effect of hypoxia on MasR expression in SH-SY5Y 
neuroblastoma cells  
	
We also modelled the effect of ischemia on MasR expression in neuronal SH-SY5Y cells cultured under 
hypoxic conditions (2% oxygen) for 24-hours. 
9.10.1 Cell culture  
	
SH-SY5Y neuroblastoma cells were cultured and maintained using standard conditions under aseptic 
conditions in T75 flasks as described previously in the method (section 2.11.2). Cells were seeded and 
cultured in T75 flasks until ~90% confluent. Prior to treatment of the cells with Aβ40 or Aβ42, the 
culture medium was replaced with serum-free medium and left to equilibrate for 4 hours, which was 
then replaced with SF medium containing either Aβ40 or Aβ42 (both at 1um), or serum-free (SF) 
medium alone (rPeptide). Aβ peptides stocks were dissolved in 35% acetonitrile at concentration of 
1mM and stored at -20 until being diluted in SF medium immediately prior to addition to the cells. 
Duplicate flasks were prepared and then incubated overnight under standard culture conditions  (5% 
CO2 at 37 °C) (Normoxia) or 2%	O2	(Hypoxia) (using a Ruskin hypoxic chamber). At the end of the 
treatment, cell lysates were prepared in cell lysis buffer (CelLytic M reagent (Sigma-Aldrich) for 
western blotting as described in the method (section 2.11.4). Total protein concentrations of the cell 
































lysates were measured using the Total Protein Assay Kit (Sigma-Aldrich) as described in detail in 
method (section 2.3). Expression of MasR was tested by western blot, the standard protocol used is 
described in detail in method (section 2.4 and 4.4.3.1).  
	
9.10.2 Expression of MasR in SH-SY5Y neuroblastoma cells 
	
To test the feasibility of this pilot study I initially determined whether MasR was expressed in SH-
SY5Y neuroblastoma cells. Western blot was used to probe SH-SY5Y cell lysates for the expression of 
MasR. A polyclonal rabbit antibody to MAS1 (Abcam, ab66030) was used to for the detection of 
MasR. A representative image showed three bands for MasR (Figure 9.50). One band between (35-37 
kDa) was at the expected MW for MasR protein (440) and a second unidentified lower band at 20 kDa 
that possibly represents a protein degradation product. The third faint higher bands at 40 kDa could be 
a heterodimer of MasR and AT2R that has been reported in previous studies (624, 625). Thus, MasR 
expression was detectable and levels were reduced in cell lysates that were diluted suggesting 
specificity of the antibody used.  
 
Figure 9.50 MasR western blot in SH-SY5Y neuroblastoma cell lysate. 
 
MasR expression in SH-SY5Y neuroblastoma cell lysate was studied by Western blotting: Line 9 
shows MasR expression in diluted sample (1:2) and (Line 8 to 2) show two fold serial dilution of cell 
lysates, bands intensity reduced with more diluted sample. Lines 1 and 5 include MW markers. The 
membrane was blotted with polyclonal rabbit antibody to MAS1 (Abcam, ab66030). The reported size 
of MasR was between (35-37 kDa). The smaller bands at MW 20 kDa are likely to be protein 
degradation products. The faint bands at MW 40 kDa, at a higher than the expected MW of MasR, 
could be a MasR/AT2R heterodimer. 
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9.11 Appendix XI: Pilot investigations into the specificity of antibodies against the 






The AT1R and AT2R are key components of the classical and regulatory axis of brain RAS. Activation 
of AT1R promotes neurotoxic effects including vasoconstriction, inflammation, fibrosis, and 
hypertrophy. On the other hand, activation of AT2R causes neuronal protective effects that counteract 
AT1R activation. In AD, there is hyperactivity of the cRAS resulting in overproduction of Ang-II that 
via activation of AT1R has been proposed to contribute to the pathogenesis of AD. Despite the 
suggested importance of these two receptors in AD, their expression remains poorly characterised in 
rodent models of AD and human brain tissue. It is therefore crucial to determine the expression of the 
AT1R and AT2R to better understand their role in AD. However, surprisingly, most commercially 
available AT1R and AT2R receptor antibodies have more recently been shown to be less specific than 
originally thought and do not to accurately discriminate between the two receptors. Therefore, accurate 
and specific characterisation of the two receptors in human brain tissue in AD is hampered and there is 
an urgent need for more specific antibodies within this area of research. In this chapter, I have begun to 
explore the specificity of several commercially available AT1R and AT2R antibodies to see if they hold 
potential for better characterisation of these receptors in AD.  
 
Three commonly used and widely reported AT1R antibodies (Alomone AAR-011; Santa Cruz sc-1173; 
Abcam 18801) have been found to be non-specific in the detection of AT1R as they all showed cross-
reactivity with AT2R (626). These antibodies were also tested in another study in conjunction with 
three additional AT1R antibodies (AT1 (306), rabbit polyclonal antibody, Santa Cruz sc-579; AT1, 
affinity purified rabbit polyclonal antibody, Millipore AB15552; (1E10-1A9) mouse monoclonal 
antibody, Abcam ab9391). Again, all of these antibodies showed cross-reactivity with AT2R i.e. were 
nonspecific for AT1R (627) despite the claims of the commercial providers.  
 
Similarly, three commercially available AT2R antibodies have been tested for specificity - two 
polyclonal antibodies (AT2 (H-143), rabbit Santa Cruz sc-9040; AT2, affinity purified rabbit Alomone 
AAR-012) and one monoclonal antibody (AT2, rabbit Epitomics Inc, 2818-1). Similar to the AT1R 
antibodies all three AT2R antibodies were unable to specifically detect AT2R (628).  
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In this study, I have sought to extend these studies and examine the specificity of additional AT1R and 
AT2R antibodies.  
These included three commercially available AT1R antibodies:  
a) Anti-AGTR1 polyclonal antibody (ThermoFisher, PA5-20812),  
b) Anti-AGTR1 (Sigma-Aldrich, SAB3500209),  
c) AT1 receptor polyclonal antibody (Enzo, BML-SA608))  
and two AT1aR antibodies (which are kindly gifted from Dr Atticus Hainsworth) 
d) AT1a non-selective receptor polyclonal antibody  
e) AT1a selective receptor polyclonal antibody  
I also investigated one AT2R antibody  
f) Anti-Angiotensin II Type 2 Receptor antibody (Abcam, ab92445))  
 
Specificity of these antibodies was determined in human embryo kidney (HEK) cells that were 
transfected to overexpress AT1aR, AT1bR and AT2R (gifted from the Jeremy Henley Lab, University 
of Bristol). I also tested the specificity of a commercially available AT2R sandwich ELISA kit (Human 
Angiotensin II Receptor 2 (AGTR2) ELISA, Cloud-Clone Corp.). 
 
In this study, I demonstrate that none of the additional AT1R antibodies tested were specific for AT1R 
or AT1aR as they showed cross-reactivity for AT2R. In contrast, the anti-AT2R antibody (Anti-
Angiotensin II Type 2 Receptor antibody (Abcam, ab92445)) appeared to exhibit preferential binding 
to AT2R in AT2R-overexpressing HEK cell lysate suggesting potential specificity.  
 
In conclusion, my studies indicate that the non-specific nature of all commercially available AT1R 
antibodies is likely to result in unreliable characterisation of these receptors in previous and future 
studies. In contrast the Abcam, ab92445 antibody, holds some promise, at least for related research 







The two major receptors in the brain RAS (AT1R and AT2R) have a crucial and contrasting role in the 
physiology and pathophysiology of AD. Ang-II mediates its effect mainly by binding to AT1R, 
overactivity of AT1R exacerbates tissue inflammation and oxidative stress (290), associated with 
hypertension and metabolic dysfunction (629, 630) and promotes cell death, neuronal injury and 
cognitive impairment (397). In contrast, activation of AT2R exerts protective effects that counteract the 
signalling of AT1R by inducing vasodilation, reducing inflammation and neuronal injury and inhibiting 
cellular growth, cell differentiation and apoptosis (631-634). Despite the great importance of these 
receptors, the exact role and balance of these receptors within the brain in AD remains unclear. This 
problem is mainly due to a lack of available antibodies that can successfully discriminate between 
AT1R and AT2R with genuine specificity.  
 
 
AT1R is a seven trans-membrane domain G-protein coupled receptor consisting of 359 amino acids 
with a molecular weight of approximately 41 kDa. There are two subtypes of AT1R in rodents (AT1aR 
and AT1bR) that have a sequence homology of around 95% (499). This high degree of homology 
between these subtypes may result in difficulty of differentiation between them. Ang-II, the central 
effector of the cRAS, has a very high affinity for AT1aR, which appears to be the main receptor for 
eliciting the effects of the cRAS (635).  
 
In brain tissue, AT1R is highly expressed in specific nuclei within the hypothalamus and brainstem 
areas, and is also expressed in neurons, astrocytes and microglia of the cortex, hippocampus and basal 
ganglia (246, 457). Dysregulation of AT1R expression has been implicated in several 
pathophysiological conditions such as stroke (559, 560, 578), anxiety (636), Alzheimer’s disease (366, 
637, 638) and epilepsy (639, 640). Despite these extremely important functions of AT1R, the accurate 
determination and localisation of this receptor in human post-mortem brain tissue and the potential 
dysregulation of its expression in relation to AD remains unclear. This issue is partly due to the lack of 
AT1R antibodies that are specific and can successfully allow the discrimination of AT1R from AT2R. 
To date, a number of commercially available AT1R antibodies originally proposed to be specific for 
AT1R and used in previous studies have since been found to lack specificity for AT1R– the authors of 
these studies strongly recommended the need to test the specificity of all antibodies against AT1R prior 
to conducting any future studies (626, 627). 
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AT2R is a seven trans-membrane domain G-protein coupled receptor consisting of 363 amino acids 
with a molecular weight of approximately 40 kDa. AT2R shares only about 32-34% similar amino acid 
sequence homology with AT1R (257). In addition to Ang-II, AT2R has a high affinity to Ang-III and 
Ang (1-7) (427, 499). Activation of AT2R elicits responses that counteract and help to regulate the 
actions of cRAS. AT1R and AT2R have been found to interact to form receptor complexes 
(heterodimer) both in vitro and in vivo regardless of Ang-II binding (641). This physiological cross-
talk mechanism could be the potential cause of cross-reactivity between antibodies. 
 
In brain tissue, expression of AT2R has been found in the vascular wall and high densities are localised 
in brain areas involved in learning and motor function such as the amygdala, caudate putamen and 
thalamus (247, 499). In addition, AT2R is expressed in neurons, astrocytes and microglia of the cortex, 
hippocampus and basal ganglia (246). 
 
AT1R and AT2R expression may be inter-dependent: in AT2R knockout mice for instance, there is 
increased expression of AT1R in the brain (642). In addition, previous studies have showed that 
dysfunction of AT2R detrimentally modulates brain morphology and is implicated in learning and 
memory dysfunction (385, 643). Together these studies highlight the regulatory role of AT2R in the 
brain and the importance of accurately characterising the expression of this receptor particularly in 
AD. However, as for AT1R, a previous study found that three of the commercially available antibodies 
against AT2R are also non-specific and cross-react with AT1R (628). Thus, testing the specificity of 
antibodies against AT2R is also very important for studies aimed to characterise AT2R receptor 
expression.    
 
 
9.11.3 Study aims and hypothesis 
 
 
The aims of the study described in this chapter were: 
 
(i) To investigate the specificity of previously untested commercially available antibodies against 
AT1R, AT1aR and AT2R. 
 
(ii) To explore the specificity of a commercially available AT2R sandwich ELISA kit. 
 
We wished to identify AT1R and AT2R specific antibodies that will be useful as research tools to allow 





9.11.4.1 Study Samples 
 
 
9.11.4.1.1 Transfected cell lysates 
 
HEK cells that had been stably transfected to overexpress AT1aR, AT1bR and AT2R were kindly 
provided by Prof. Jeremy Henley’s lab (University of Bristol). I tested the specificity of several 
commercially available AT1R and AT2R antibodies to specifically detect AT1R and AT2R in HEK cell 
lines that were transfected with Green fluorescent protein (GFP) tagged or un-tagged AT1aR, AT1bR, 




9.11.4.1.2 Exploration of AT1R antibody specificity  
 
In this study, three commercially available AT1R antibodies were tested by western blotting: rabbit 
AGTR1 polyclonal antibody (ThermoFisher, PA5-20812), rabbit anti-AGTR1 (Sigma-Aldrich, 
SAB3500209), and rabbit anti-AT1 receptor polyclonal antibody (Enzo, BML-SA608). In addition, 
two AT1aR antibodies were kindly gifted from Dr Atticus Hainsworth (St George’s University of 
London). These included the rodent versions of AT1R, a non-selective AT1a receptor polyclonal 
antibody and an AT1a selective receptor polyclonal antibody. Details of the primary and secondary 
antibodies are described previously in Appendix II: section 9.2.1 (Table 9.13 and Table 9.14 
respectively). Further information on the immunogen, specificity and applications of the commercially 
available AT1R antibodies is listed in Table 9.40. 
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Table 9.40 Characteristics of AT1R and AT2R antibodies used in this study 
 
Antibody Immunogen Specificity Application 
AGTR1 polyclonal antibody 
(ThermoFisher, PA5-20812) 
A 16 amino acid 
peptide near the centre 









Western Blot (WB) 
Anti-AGTR1(Sigma-
Aldrich, SAB3500209) 
AGTR1 antibody was 
raised against a 16 
amino acid peptide 
sequence near the 








Western Blot (WB) 
Indirect enzyme-linked 
immunosorbent assay  
(ELISA) 




corresponding to amino 






Western Blot (WB) 
Flow cytometry (FC) 
 
Anti-Angiotensin II Type 2 




angiotensin II Type 2 
Receptor amino acid 









9.11.4.2 Western blotting for AT1R 
 
A standard protocol of the western blot procedure is described in detail in chapter 2 (section 2.4). In 
summary, for the detection of AT1R in HEK cell lysate samples, the membrane was blocked in 10% 
milk/TBST buffer for 1 hour. After it had been washed with 0.05% TBST (3x 15 minutes) at room 
temperature on a shaker, the membrane was then incubated with either AGTR1 polyclonal antibody 
(ThermoFisher, PA5-20812) diluted 1:800, Anti-AGTR1 (Sigma-Aldrich, SAB3500209) diluted 1:800 
or AT1 receptor polyclonal antibody (Enzo, BML-SA608) diluted 1:500 in 5% milk/TBST antibody 
buffer overnight at 4°C (in the fridge) on a shaker. Following a wash step with 0.05% TBST (3x 15 
minutes) at room temperature on shaker, the membrane was incubated with a secondary antibody 
(peroxidase conjugated anti-Rabbit) diluted 1:5000 in 5% milk/TBST for 1 hour. After 3 x 15 minutes 
washing steps with 0.05% TBST, a chemiluminescent HRP substrate (ECL) (Millipore) was added to 
the membrane in a 1:1 ratio (5 ml of reagent 1 and 5 ml of reagent 2) for 5 minutes. The images then 
were acquired using ChemiDoc XRS+ and Image Lab software, version 0.5 (Bio-Rad).  
 
9.11.4.3 Western blotting for AT1aR 
 
For detection of AT1aR in HEK cell lysate samples, the membrane was blocked in 10% milk/TBST 
buffer for 1 hour. After it had been washed with 0.05% TBST (3x 15 minutes) at room temperature on 
a shaker, the membrane was then incubated with either AT1a non-selective receptor polyclonal 
antibody diluted 1:1000 or AT1a selective receptor polyclonal antibody diluted 1:1000 in 5% 
milk/TBST antibody buffer overnight at 4°C (in the fridge) on a shaker. Following a wash step with 
0.05% TBST (3x 15 minutes) at room temperature on a shaker, the membrane was incubated with a 
secondary antibody (peroxidase conjugated anti-Rabbit) diluted 1:5000 in 5% milk/TBST for 1 hour. 
After 3x 15 minutes wash steps with 0.05% TBST, a chemiluminescent HRP substrate (ECL) 
(Millipore) added to the membrane in a 1:1 ratio (5 ml of reagent 1 and 5 ml of reagent 2) for 5 
minutes. The images then were acquired using ChemiDoc	 XRS+	 and assessed using Image Lab 





9.11.4.4 Validation of AT2R antibody specificity 
 
A commercially available AT2R antibody (Anti-Angiotensin II Type 2 Receptor antibody (Abcam, 
ab92445)) was tested by western blot in HEK cell lysates that overexpressed AT1aR, AT1bR and 
AT2R. Details of the primary and secondary antibodies are described previously in Appendix II: 
section 9.2.1 (Table 9.13 and Table 9.14 respectively). Further information on immunogen, specificity 
and applications of the commercially available AT2R antibody is listed in Table 10-40.  
 
 
9.11.4.4.1 Western blotting for AT2R 
 
A standard protocol for western blotting is described in detail in the general methods (section 2.4). In 
summary, for detection of AT2R in HEK cell lysate samples, the membrane was blocked in 10% 
milk/TBST buffer for 1 hour. After it had been washed with 0.05% TBST (3x 15 minutes) at room 
temperature on a shaker, the membrane was then incubated with rabbit anti-angiotensin II type 2 
receptor antibody (Abcam, ab92445) diluted 1:800 in 5% milk/TBST antibody buffer overnight at 4°C 
(in the fridge) on a shaker. Following a wash step with 0.05% TBST (3x 15 minutes) at room 
temperature on shaker, the membrane was incubated with a secondary antibody (peroxidase 
conjugated anti-Rabbit) diluted 1:5000 in 5% milk/TBST for 1 hour. After 3x 15 minutes wash steps 
with 0.05% TBST, a chemiluminescent HRP substrate (ECL) (Millipore) was added to the membrane 
in a 1:1 ratio (5 ml of reagent 1 and 5 ml of reagent 2) for 5 minutes. The images then were acquired 
using ChemiDoc	XRS+	and assessed using Image Lab software, version 0.5 (Bio-Rad).  
 
9.11.4.4.2 Human Angiotensin II Receptor 2 (AGTR2) ELISA  
 
 
Recent studies have measured AT2R level in different tissues (heart and kidney) using a commercially 
available ELISA kit (644, 645). I tested the specificity of the same ELISA kit used previously in order 
to validate its specificity for AT2R in brain tissue. The concentration of AT2R was measured in HEK 
cell lysates transfected to overexpress AT1aR, AT1bR and AT2R using a commercially available 
quantitative sandwich ELISA kit for the detection of AT2R (Cloud-Clone Corp.) Following the 
manufacturer’s procedure, all reagents were allowed to reach room temperature before use. 
Recombinant AT2R (10-0.156 ng/ml) and diluted cell lysates (1:10) in PBS (all 100 µl) were added to 
a microplate pre-coated with an antibody specific to AT2R and incubated for 1 hour at 37°C. 
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Following five wash steps, 100 µl of detection reagent A was added to each well and incubated for 1 
hour at 37°C. After another five wash steps, 100 µl of detection reagent B was added to each well and 
incubated for 30 minutes at 37°C. After a further set of washes, 90 µl of TMB substrate was added to 
each well and incubated for 10 minutes at 37°C in the dark. The reaction was stop by adding 50 µl of 
stop solution and the absorbance was measured immediately at 450nm using a FLUOstar OPTIMA 




9.11.5.1 Specificity of AT1R antibodies 
 
The western blots shown in the representative images below (Figure 9.51) show a similar pattern of 
immunoreactivity between each of the three commercial AT1R antibodies tested: AGTR1 polyclonal 
antibody (ThermoFisher, PA5-20812); Anti-AGTR1 (Sigma-Aldrich, SAB3500209); AT1 receptor 
polyclonal antibody (Enzo, BML-SA608). For each antibody, a predominant band was observed at the 
anticipated approximate MW 50-60 kDa in HEK cell lysates that overexpressed AT1aR and AT1bR. In 
addition, several additional non-specific bands were identified at MW higher and lower than 50-60 
kDa.  
 
A similar pattern of bands was also identified in HEK cells that overexpressed AT2R for each of the 
AT1R targeting antibodies i.e. all three antibodies were unable to discriminate between AT1R and 
AT2R expression. We also used the antibody to probe for AT1R in human post-mortem brain tissue (1 
AD and 1 control). A dominant band was observed between 50-75 kDa as expected. There were 










Figure 9.51 Western blot of AT1R expression in HEK cell lysates and human post-mortem brain 
tissue. 
AT1R expression was studied by western blotting in HEK cell lysates transfected with GFP tagged 
AT2R, AT1bR, AT1aR (lane 3,4 and 6), un-tagged AT2R, AT1bR, AT1aR (lane 7,8,9) and human brain 
tissue from an AD case and non-disease control (lane 1 and 2). Lane (5) includes a MW marker. Each 
membrane was exposed to three different anti-AT1R antibodies respectively: A. (AGTR1 polyclonal 
antibody (ThermoFisher, PA5-20812), the reported size of AT1R was between 50-75 kDa and was 
detected in all samples. B. Anti-AGTR1 (Sigma-Aldrich, SAB3500209), the reported size of AT1R 
was between 50-75 kDa and detected in all samples. C. AT1 receptor polyclonal antibody (Enzo, 
BML-SA608), the reported size of the AT1R is about 50-75 kDa was detected in all samples. Several 
bands at different molecular sizes were also observed. 
 
 
9.11.5.2 Exploring the specificity of AT1aR antibodies 
 
The specificity of two generously gifted AT1aR antibodies was tested in HEK cells overexpressing 
AT1aR, AT1bR and AT2R. We compared an AT1a non-selective receptor polyclonal antibody and 
AT1a selective receptor polyclonal antibody. The western blot images shown below (Figure 9.52) 
indicate that both antibodies detected a single band at the anticipated MW 50-60 kDa. However, a 
similar pattern of immunoreactivity was observed in all three HEK cell lysates indicating that both 
antibodies were unable to discriminate between AT1aR and AT1bR, and between AT1aR and AT2R i.e. 




Figure 9.52 Western blot of AT1aR expression in HEK cell lysates. 
AT1aR expression was tested by western blotting in HEK cell lysates transfected with AT2R, AT1bR 
and AT1aR. The membranes were labelled with two different antibodies: A. AT1a non-selective 
receptor polyclonal antibody, the reported size of AT1R was between 50-60 kDa and detected in all 
samples (HEK cell lysates transfected with AT2R (lane 2), AT1bR (lane 3) and AT1aR (lane 4), lane 
(1) include MW marker. B. AT1a selective receptor polyclonal antibody, the reported size of AT1R 
was between 50-60 kDa and detected in all samples (HEK cell lysates transfected with AT2R (line 1), 
AT1bR (lane 2) and AT1aR (lane 3), lane (4) include MW marker. The AT1aR antibodies were kindly 
gifted from Dr Atticus Hainsworth. 
 
 
9.11.5.3 Exploration of the specificity of an AT2R antibody 
 
I also tested the specificity of a previously untested AT2R antibody (Anti-Angiotensin II Type 2 
Receptor antibody (Abcam, ab92445)).  The western blot image shown below in (Figure 9.53) shows 
that the antibody detects a distinct prominent band at approximately the correct predicted molecular 
weight of ~30 kDa in HEK cells that overexpressed AT2R-GFP tagged. The detected MW was lower 
than the expected MW of AT2R at approximately 40 kDa, however, the expression of this band was 
noticeably higher in HEK-AT2R cells compared to HEK-AT1aR and AT1bR cells. In addition, this 




tissue of control and AD case. Surprisingly no bands were observed in untagged HEK-AT2R, AT1aR 
and AT1bR cells – the reason for this is unclear. 
 
 
Figure 9.53 Western blot of AT2R expression in HEK cell lysates.  
AT2R expression was studied by western blotting in HEK cell lysates transfected with GFP tagged 
AT2R, AT1bR, AT1aR (lane 3,4 and 6), un-tagged AT2R, AT1bR, AT1aR (lane 7, 8, 9) and human 
brain tissue of AD case and control (lane 1 and 2), lanes (5 and 10) include MW markers. The 
membrane was exposed to AT2 receptor monoclonal antibody (Abcam, ab92445). The antibody 




9.11.5.4 Investigating the specificity of Human Angiotensin II Receptor 2 (AGTR2) ELISA 
	
	
The level of AT2R was measured in HEK cells that overexpressed AT1aR, AT1bR and AT2R using a 
commercially avaliable sandwich AT2R ELISA kit (Cloud-Clone Corp.). We predicted that levels of 
AT2R would be higher in HEK cells overexpressing AT2R compared to the AT1R (a and b) 
counterparts. However I detected a similar level of AT2R in all HEK cell lysates, despite only one line 
over-expressing AT2R. I found that the ELISA-measured AT2R level in HEK cells that overexpressed 
AT1aR= 2.473 ng/ml, HEK cell lysate that overexpressed AT1bR= 3.07 ng/ml and AT2R level in HEK 
cell lysate that overexpressed AT2R= 3.003 ng/ml (Figure 9.54). These data suggest that the 
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Figure 9.54 ELISA measured AT2R level in HEK cell lysate overexpressing AT1aR, AT1bR and 
AT2R. 
Bar chart represents the level of AT2R measured by sandwich ELISA kit (Cloud-Clone Corp. 
SEA973Hu) in HEK cell lysates transfected with either AT1aR, AT1bR or AT2R. The measurements 






In this chapter, I have investigated the specificity of three AT1R antibodies, two AT1aR antibodies 
(that are rodent sub-types of the human AT1R), one AT2R antibody, and a commercial AT2R ELISA 
kit, none of which have any reported testing for specificity with a view to being tools for the study of 
RAS in AD. None of the AT1R or AT1aR antibodies were found to be specific and were unable to 
discriminate between AT1R and AT2R, or between AT1aR and AT1bR respectively in human tissue 
and individual HEK cell lines over-expressing AT1aR, AT1bR and AT2R. The AT2R antibody 
provided some preliminary and encouraging evidence that it may have selectivity for AT2R, however, 
this needs further confirmation. In contrast the commercially available AT2R sandwich ELISA was 
non-specific and did not detect a difference in expression of AT2R compared to either AT1R sub-types 
in HEK overexpressing cells. Together these findings indicate, in support of previous research on 
























reagents are not specific and therefore using them to characterise these two important receptors may 
generate unreliable results.  
 
These findings have important implications for RAS research in general but particularly at this exciting 
time in AD research. Given the importance of AT1R as the main effector receptor of the cRAS and 
increased expression in several pathophysiological conditions, including AD (528), it has been 
surprising to find that the characterisation and selectivity of AT1R antibodies used in most of the 
studies undertaken have not been validated. AT1R expression has been reported to be increased in 
human brain tissue in AD using immunohistochemical staining (91) however, potential changes in the 
expression and distribution of the receptor has been limited by the lack of specific antibodies.  A 
previous study characterised six commercially available antibodies by western blotting and 
immunohistochemistry in tissue extracts from AT1aR knockout and wild-type mice and non-
transfected hypothalamic cultured 4B cells with or without AT1R expression. Their data revealed that 
none of the tested AT1R antibodies met the criteria of specificity (627). In this study, I examined the 
specificity of another three commercially available AT1R antibodies that have not been tested before.  
 
My findings from western blots of HEK cells transfected with AT1R, AT1aR, AT1bR and AT2R, 
showed that all AT1R antibodies tested recognised a major band at a higher MW between 50-75 kDa 
consistent with the expected molecular weight of AT1R. The MW of AT1R is influenced by the 
glycosylation level (626). In addition, the AT1R antibodies detected several additional bands at 
molecular sizes higher and lower than the major predominant band. Together these data indicate that 
these antibodies are non-specific and did not follow two of the characterised criteria for specificity of 
antibodies that state: (i) that antibodies immunoreactivity should correlate with the degree of receptor 
expression (646, 647), and (ii) that antibodies must detect single bands of appropriate molecular 
weight. The similar pattern of immunoreactivity of AT1R antibodies observed could be explained by 
similar immunogen properties of the antigen, which as seen in (Table 10.40) are all based on the centre 
area of AT1R involving the same region of overlapping residues, against which all the three antibodies 
are raised. My results extend and further support previous studies reporting that commercially 
available AT1R antibodies are non-specific and generate unreliable characterisation of this important 
receptor (626, 627, 648). Both AT1aR antibodies tested in my study recognized a distinct band at the 
approximate MW between 50-60 kDa in cells that individually overexpressed AT1aR, AT1bR and 
AT2R. These results indicate that these AT1aR antibodies are also non-specific and unfortunately did 
not discriminate between the two AT1R subtypes. This could be attributed to the high degree of 
homology (~95%) between AT1aR and AT1bR.  
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I tested one AT2R antibody (anti-Angiotensin II Type 2 Receptor antibody (Abcam, ab92445)) that has 
been used in several studies (649-653). Although, to our knowledge, the specificity of this antibody 
has not been tested (628), I found that it detected a single band only in cell lysates from HEK cells that 
overexpressed AT2R, suggesting that this antibody exhibited specificity against AT2R. However, the 
detected band was at a molecular size lower than the expected weight for AT2R (around 40 kDa) (499). 
The observed band at an unexpected lower MW could potentially result from cleavage of the GFP 
tagged protein - a weak fusion linker used in the transfection step (654, 655). In contrast, the 
commercially available AT2R sandwich ELISA tested failed to detect a significant difference in the 
expression of AT2R and AT1R in overexpressing HEK cells. This ELISA kit has been used in previous 
studies that have aimed to measure levels of AT2R in different tissues (644, 645) - our results indicate 
that such measurements may have been inaccurate and that there is a need for more rigorous testing 
and validation of commercially available AT1R and AT2R antibodies and kits prior to them being used 
in research studies. 
 
My results support previous reports suggesting that AT1R antibodies are non-specific. However, my 
investigations discussed in this chapter have some limitations which were due to limitations in the time 
available. This study was limited by characterising the specificity of AT1R and AT2R antibodies using 
just one methodological approach (western blot). Another limitation of this study was that the selected 
AT1R antibodies were raised against similar domains of the receptor. Further experimental 
investigations could be used to further test the specificity of the AT1R and AT2R antibodies, or at least 
of the AT2R antibody that showed some promising evidence of specificity. Additional and more 
sensitive methods that could be used are competitive radioligand binding assays and quantitative real-
time PCR of the gene within cells to verify whether there is the likelihood or receptor expression. The 
cross-reactivity between AT1R and AT2R is surprising given the low % sequence homology (~35%) 
but these receptors are now known to form homo- and heterodimers with each other and other RAS 
receptors (MasR and AT4R) which adds an additional level of complexity and difficulty to overcome. 
Perhaps, development of technology such as RNAscope together with immunofluorescence will be 
able to map the distribution on these receptors with confidence in future studies. 
 
In conclusion, this study highlights that there is ongoing need to identify more specific antibodies or 
alternative approaches to map the distribution and expression of AT1R and AT2R in AD and other 
diseases in which RAS is involved. These findings, along with previous studies highlight the need for 
cautious scepticism around the reported specificity of commercially available antibodies and kits to 
avoid generating unreliable results and the need for undertaking meaningful internal validation.  
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Are the commercially available AT1R and AT2R antibodies specific to detect these receptors?  
 
AT1R and AT2R are the main effector receptors of the cRAS axis, however, the expression and 
distribution of these major angiotensin receptors remains unclear within the brain due in part to a lack 
of specific antibodies (528, 626). In this thesis, I have undertaken pilot studies to examine the 
specificity of three new commercially available AT1R antibodies, two AT1aR antibodies, one AT2R 
antibody and one commercially available AT2R sandwich ELISA kit. I have used HEK cells that have 
been transfected to overexpress AT1aR, AT1bR and AT2R as the primary test source to explore the 
specificity of the receptor antibodies using Western blotting.  
 
My findings indicate that none of the tested AT1R antibodies tested were able to discriminate between 
AT1R, AT1aR and AT2R. In contrast, I present preliminary encouraging evidence that the AT2R 
antibody tested has potential selectivity for AT2R, however, this needs further confirmation. The AT2R 
ELISA kit was also unable to discriminate between HEK cells overexpressing AT2R and AT1R 
variants. Together my findings further support previous studies reporting that several other 
commercially available AT1R and AT2R antibodies are non-specific and thus potentially lead to 
unreliable and mis-leading characterisation of these important receptors in human and rodent brain 
tissue across different models of disease (626-628, 648). Some of problems with specificity could be 
attributed to the homology that exists between AT1R and AT2R or the dimerization between these 
receptors, and the high degree of homology between AT1aR and AT1bR (around 95%). My findings 
indicate that better tools are required to allow detailed characterisation of AT1R and AT2R - an urgent 
requirement in the field that needs more attention in future work. One potential method that could be 
used to provide some way of getting additional corroborating evidence would be the use of RNA scope 
and immunofluorescence labelling of receptors to discriminate between AT1R and AT2R expression in 
brain tissue. The characterisation of AT1R and AT2R in brain tissue in AD remains an ongoing issue 
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